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LIST OF ABBREVIATIONS 
Technical terms and abbreviations are used throughout this report. The meaning is usually clear 
from the context, but a glossary is provided for the non-specialist reader. 
AACC   American Association for Clinical Chemistry 
ACC   American College of Cardiology 
ACE   angiotensin converting enzyme 
ACS   acute coronary syndrome 
AHA   American Health Association 
AMI   acute myocardial infarction 
ARIF   aggressive Research Intelligence Facility 
CAD   coronary artery disease 
CADTH   Canadian Agency for Drugs and Technologies in Health 
CCT   controlled clinical trial 
CDSR   Cochrane Database of Systematic Reviews 
CEAC   cost-effectiveness acceptability curve 
CEAF   cost-effectiveness acceptability frontier 
CENTRAL  Cochrane Central Register of Controlled Trials 
CHD   coronary heart disease 
CI   confidence interval 
CTCA   computed tomography coronary angiography 
CV   co-efficient of variation 
DARE   Database of Abstracts of Reviews of Effects 
DTA   diagnostic test accuracy 
ECG   electrocardiography/electrocardiogram 
ECLIA   electrochemiluminescence immunoassay 
ED   emergency department 
EED   Economic Evaluations Database 
ESC   European Society of Cardiology 
ED   Emergency Department 
FN   false negative 
FP   false positive 
HES   Hospital Episode Statistics 
HF   heart failure 
H-FABP   heart fatty acid binding protein 
HES   hospital episode statistics 
HRQoL   Health-Related Quality of Life 
hs-cTn   high sensitivity cardiac troponin 
hs-cTnI    high sensitivity cardiac troponin I 
hs-cTnT   high sensitivity cardiac troponin T 
HSROC   hierarchical summary receiver operating characteristic 
HTA   Health technology Assessment 
ICER   incremental cost-effectiveness ratio 
INAHTA   International Network of Agencies for Health Technology Assessment 
IQR   interquartile range 
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LILACS   Latin American and Caribbean Health Sciences Literature 
LoB   limit of blank 
LoD   limit of detection 
LR+   Positive likelihood ratio 
LR-   Negative likelihood ratio 
LY   life year 
MACE   major adverse cardiac event 
MI   myocardial infarction 
NA   not applicable 
NHS   National Health Service 
NICE   National Institute for Health and Care Excellence 
NIH   National Institutes of Health 
NIHR   National Institute for Health Research 
NPV   negative predictive value 
NR   not reported 
NSTE-ACS  non-ST-segment-elevation ACS 
NSTEMI   non-ST segment elevation myocardial infarction 
ONS   Office for National Statistics 
PSA   probabilistic sensitivity analysis 
QALY   Quality-Adjusted Life Year 
RCT   randomised controlled trial 
ROC   receiver operating characteristic 
SCI   Science Citation Index 
SIGN   Scottish Intercollegiate Guidelines Network 
SROC   summary receiver operating characteristic 
STEMI   ST segment elevation myocardial infarction 
Tn   troponin 
TN   true negative 
TP   true positive 
UA   unstable angina 
WHF   World Heart Federation 
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GLOSSARY 
Cost-effectiveness 
analysis 
An economic analysis that converts effects into health terms and describes the 
costs for additional health gain. 
Decision modelling A mathematical construct that allows the comparison of the relationship 
between costs and outcomes of alternative healthcare interventions. 
False negative Incorrect negative test result  W number of diseased persons with a negative test 
result. 
False positive Incorrect positive test result  W number of non-diseased persons with a positive 
test result. 
Incremental cost-
effectiveness ratio 
(ICER) 
The difference in the mean costs of two interventions in the population of 
interest divided by the difference in the mean outcomes in the population of 
interest. 
Index test The test whose performance is being evaluated. 
Likelihood Ratio 
(LR) 
Likelihood ratios describe how many times more likely it is that a person with the 
target condition will receive a particular test result than a person without the 
target condition. 
Markov model An analytic method particularly suited to modelling repeated events, or the 
progression of a chronic disease over time. 
Meta-analysis Statistical techniques used to combine the results of two or more studies and 
obtain a combined estimate of effect. 
Meta-regression Statistical technique used to explore the relationship between study 
characteristics and study results. 
Opportunity costs The cost of forgone outcomes that could have been achieved through alternative 
investments. 
Publication bias Bias arising from the preferential publication of studies with statistically 
significant results. 
Quality of life ŶŝŶĚŝǀŝĚƵĂů ?ƐĞŵŽƚŝŽŶĂů ?ƐŽĐŝĂůĂŶĚƉŚǇƐŝĐĂůǁĞůů-being and their ability to 
perform the ordinary tasks of living. 
Quality-adjusted 
life year (QALY) 
A measure of health gain, used in economic evaluations, in which survival 
ĚƵƌĂƚŝŽŶŝƐǁĞŝŐŚƚĞĚŽƌĂĚũƵƐƚĞĚďǇƚŚĞƉĂƚŝĞŶƚ ?ƐƋƵĂůŝƚǇŽĨůŝĨĞĚƵƌŝŶŐƚŚĞƐƵƌǀŝǀĂů
period. 
Receiver Operating 
Characteristic 
(ROC) curve 
A graph which illustrates the trade-offs between sensitivity and specificity which 
result from varying the diagnostic threshold. 
Reference standard The best currently available method for diagnosing the target condition.  The 
index test is compared against this to allow calculation of estimates of accuracy. 
Sensitivity Proportion of people with the target disorder who have a positive test result. 
Specificity Proportion of people without the target disorder who have a negative test result. 
True negative Correct negative test result  W number of non-diseases persons with a negative 
test result. 
True positive  Correct positive test result  W number of diseased persons with a positive test 
result. 
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EXECUTIVE SUMMARY (2,043 WORDS) 
Background 
The primary indication for this assessment is the early rule-out of acute myocardial infarction (AMI) 
in people presenting with acute chest pain and suspected, but not confirmed, non-ST segment 
elevation myocardial infarction (NSTEMI).  
Cardiac troponins (Tn) I and T are used as markers of AMI. They are intended for use in conjunction 
with clinical history taking and electrocardiography monitoring. Elevated troponin levels are 
associated with an increased risk of adverse cardiac outcomes.  However, the optimal sensitivity of 
standard troponin assays for AMI occurs several (10-12) hours after the onset of symptoms. Two 
high-sensitivity troponin (hs-cTn) assays are currently available for use in the NHS in England and 
Wales, ARCHITECT high-sensitivity troponin I assay (Abbott Diagnostics) and the Elecsys troponin T 
high-sensitive assay (Roche).One additional assay, AccuTNI+3 troponin I assay (Beckman-Coulter), 
was included in the scope for this assessment pending CE marking; CE marking has now  been 
confirmed. These are able to detect lower levels of troponin in the blood with analytical sensitivities 
up to 100 times greater than conventional troponin assays. Use of high sensitivity assays enables the 
detection of small changes in troponin levels and may enable AMI to be ruled out at an earlier time 
after the onset of acute chest pain.  
This assessment considers hs-cTn assays used singly or in series, up to four hours after the onset of 
chest pain or up to four hours after presentation; for serial troponin measurements, both data on 
change in troponin levels and peak troponin are considered. 
Objectives 
To assess the clinical- and cost-effectiveness of high sensitivity troponin assays for the management 
of adults presenting with acute chest pain, in particular for the early (within four hours of 
presentation) rule-out of AMI. 
Methods 
Assessment of clinical effectiveness 
Sixteen databases, including MEDLINE and EMBASE, research registers and conference proceedings 
were searched to October 2013. Search results were screened for relevance independently by two 
reviewers.  Full text inclusion assessment, data extraction, and quality assessment were conducted 
by one reviewer and checked by a second. Study quality was assessed using QUADAS-2. The 
bivariate/hierarchical summary receiver operating characteristic (HSROC) model was used to 
estimate summary sensitivity and specificity with 95% confidence intervals (CIs) and prediction 
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regions around the summary points, and to derive hierarchical summary receiver operating 
characteristic curves for meta-analyses involving four or more studies. For meta-analyses with fewer 
than four studies we estimated separate pooled estimates of sensitivity and specificity, using 
random-effects logistic regression. Summary positive and negative likelihood ratios were derived 
from the summary estimates of sensitivity and specificity. Analyses were conducted separately for 
each of the three hs-cTn assays and were stratified according to whether the study evaluated the 
prediction of AMI or major adverse cardiac event (MACE), test timing, and the threshold used to 
define a positive hs-cTn result. Stratified analyses were used to investigate heterogeneity and the 
influence of risk of bias on summary estimates. 
Assessment of cost-effectiveness  
We considered the long-term costs and quality adjusted life years (QALYs) associated with different 
troponin testing methods, to diagnose or rule-out NSTEMI, for patients presenting at the emergency 
department (ED) with suspected non-ST-segment-elevation acute coronary syndrome (NSTE-ACS). 
The de novo model consisted of a decision tree and a Markov model. The decision tree was used to 
model the 30 day outcomes after presentation, based on test results and the accompanying 
treatment decision. The long-term consequences in terms of costs and QALYs were estimated using 
a Markov cohort model with a lifetime time horizon (60 years). The following strategies were 
included in the main economic analysis:  
x Standard troponin at presentation and at 10-12 hours (reference standard) 
x Roche Elecsys hs-cTnT at presentation: 99th centile threshold 
x Roche Elecsys hs-cTnT (optimal strategy): LoB threshold at presentation followed by 99th 
centile threshold peak within three ŚŽƵƌƐĂŶĚ ?Žƌȴ ? ?A? ?ĐŽŵƉĂƌĞĚƚŽƉƌĞƐĞŶƚĂƚŝŽŶƚĞƐƚ ?Ăƚ ?-
3 hours 
x Abbott ARCHITECT hs-cTnI at presentation: 99th centile threshold   
x Abbott ARCHITECT hs-cTnI (optimal strategy): LoD threshold at presentation, followed by 
99th centile threshold at three hours 
x Beckman Coulter hs-cTnI at presentation: 99th centile threshold 
In the base case, it was assumed that standard troponin testing had perfect sensitivity and specificity 
(reference case) for diagnosing AMI and that only patients testing positive on the reference standard 
(standard troponin), were at increased risk for adverse events and would benefit from immediate 
treatment. In a secondary analysis, a proportion of patients testing positive on an hs-cTn test were 
treated accordingly. These patients were assumed to be treated for the hs-cTn assays and left 
untreated for the standard troponin test and at increased risk for adverse events. In addition, a 
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number of sensitivity and subgroup analyses were performed. 
Results  
Assessment of clinical effectiveness 
Eighteen studies (38 publications) were included in the review. The main potential sources of bias in 
the included studies related to patient spectrum and patient flow. There were also concerns 
regarding the applicability of the patient population and the reference standard in some of the 
included studies.   
Diagnostic accuracy of the Roche Elecsys hs-cTnT assay (15 studies) 
The most commonly evaluated testing strategy was the 99th centile threshold in a blood sample 
taken on presentation. Studies (n=six) that excluded patients with ST segment elevation myocardial 
infarction (STEMI) gave a summary positive likelihood ratio (LR+) of 5.41 (95% CI: 3.40 to 8.63) and 
summary negative likelihood ratio (LR-) of 0.15 (0.08, 0.26) for this strategy. Estimates were similar 
when derived from all studies (n=13) that evaluated this strategy. The optimum strategy based on 
this assay appeared to be one based on the combination of a limit of blank (LoB) threshold in a 
presentation sample which could be used to rule out AMI (LR- 0.10, 95% CI: 0.05 to 0.18) but has 
limited potential to rule in an AMI (LR+ 1.83, 95% CI: 1.70, 1.97). Patients testing positive could then 
have a further sample taken at two hours, a result above the 99th centile on either the presentation 
or two hour sample and a delta of at least 20% has some potential for ruling in an AMI (LR+ 8.42, 
95% CI: 6.11 to 11.60) while a result below the 99th centile on both samples and a delta less than 
20% can be used to rule out an AMI (LR- 0.04, 95% CI: 0.02 to 0.10).   
Diagnostic accuracy of the Abbott ARCHITECT hs-cTnI assay (four studies) 
Three studies, all conducted in populations that included patients with STEMI, evaluated this assay 
at the 99th centile threshold in a blood sample taken on presentation. The summary LR+ was 11.47 
(95% CI: 9.04 to 16.19) and the summary LR- was 0.22 (95% CI: 0.16 to 0.27). The optimum strategy 
appeared to be one based on the combination of a limit of detection (LoD) threshold in a 
presentation sample which could be used to rule out AMI (LR- 0.01, 95% CI: 0.00 to 0.08) but has 
limited potential to rule in an AMI (LR+ 1.54, 95% CI: 1.47 to 1.62). Patients testing positive could 
then have a further sample taken at three hours, a result above the 99th centile on this sample has 
some potential for ruling in an AMI (LR+ 10.16, 95% CI: 8.38 to 12.31) while a result below the 99th 
centile can be used to rule out an AMI (LR- 0.02, 95% CI: 0.01 to 0.05).   
Diagnostic accuracy of the Beckman Coulter Access hs-cTnI (two studies) 
One study, conducted in a population that included patients with STEMI, evaluated this assay at the 
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99th centile threshold in a blood sample taken on presentation. The summary LR+ was 3.67 (95% CI: 
3.26 to 4.13) and the summary LR- was 0.11 (95% CI: 0.07 to 0.17). Data were not reported for the 
LoB/LoD threshold. There were insufficient data to determine the optimum testing strategy for this 
assay.   
Assessment of cost-effectiveness  
Base case analysis 
In the base case analysis, standard troponin testing was both most effective and most costly. 
Strategies considered cost-effective depending upon ICER thresholds were Abbott ARCHITECT hs-
cTnI 99th centile (thresholds below £6,597), Beckman Coulter hs-cTnI 99th centile (thresholds 
between £6,597 and £30,042), Abbott ARCHITECT hs-cTnI optimal strategy (LoD threshold at 
presentation, followed by 99th centile threshold at three hours) (thresholds between £30,042 and 
£103,194), and the standard troponin test (thresholds over £103,194). The Roche Elecsys hs-cTnT 
99th centile and the Roche Elecsys hs-cTnT optimal strategy (LoB threshold at presentation followed 
by 99th ĐĞŶƚŝůĞ ƚŚƌĞƐŚŽůĚ ĂŶĚ ?Žƌ ȴ ? ?A?  ?ĐŽŵƉĂƌĞĚ ƚŽ ƉƌĞƐĞŶƚĂƚŝŽŶ ƚĞƐƚ ? Ăƚ  ?-3 hours) were 
extendedly dominated in this analysis (one of the more effective strategies was better value in that 
the ICER was lower).    
Secondary analysis 
In the secondary analysis, which assumed that a proportion of false positives in the hs-cTn testing 
strategies had an increased risk of adverse events, standard troponin was least effective and most 
costly, and therefore a dominated strategy. The most effective strategy here was the Abbott 
ARCHITECT hs-cTnI optimal strategy. The Roche Elecsys hs-cTnT optimal strategy was extendedly 
dominated (one of the more effective strategies was better value in that the ICER was lower), as was 
the Beckman Coulter hs-cTnI 99th centile in this analysis. Strategies considered cost-effective were 
Abbott ARCHITECT hs-cTnI 99th centile (thresholds below £12,217), Roche Elecsys hs-cTnT 99th 
centile (thresholds between £12,217 and £14,992) and Abbott ARCHITECT hs-cTnI optimal strategy 
(thresholds over £14,992).     
Sensitivity and subgroup analyses 
Sensitivity analyses showed that assumptions regarding the difference between treated and 
untreated patients (e.g. mortality rate, risk of re-infarction) had the largest impact on relative cost-
effectiveness, as well as whether or not patients testing false positive were assigned treatment 
costs. In general, the base case analysis was affected more by varying these assumptions than the 
secondary analysis. Results from the subgroup analyses led to the conclusion that hs-cTn testing is 
likely to be more cost-effective in younger population, in populations with pre-existing coronary 
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artery disease (CAD), and for patients whose symptom onset was less than three hours ago. A no 
testing strategy can only be considered cost-effective in populations with a prevalence as low as 1%.  
Conclusions 
Implications for service provision 
There is evidence to suggest that undetectable levels of Tns (below the LoB/LoD of the assay) on 
presentation, measured using the Roche Elecsys hs-cTnT assay or the Abbott ARCHITECT hs-cTnI 
assay, may be sufficient to rule out NSTEMI in people presenting with symptoms suggestive of ACS. 
There is also evidence to suggest that, for the Roche Elecsys hs-cTnT assay and the Abbott 
ARCHITECT hs-cTnI assay, a further rule-out step may be possible within the four hour NHS 
emergency department target. There is insufficient evidence to determine an optimum testing 
strategy for the Beckman Coulter hs-cTnI assay. There is some limited evidence to suggest that a Tn 
level below the 99th centile on presentation, measured using the Roche Elecsys hs-cTnT assay, may 
be sufficient to rule out NSTEMI in some groups (people over 70 years old, people without pre-
existing CAD and people with a clinically determined high pre-test probability). 
The economic model does not provide strong evidence to prefer one hs-cTn testing strategy over 
another. Results do, however, indicate that hs-cTn testing in general may be cost-effective compared 
to standard troponin testing given that hs-cTn testing leads to cost-saving at a QALY loss. This 
becomes more likely if one assumes that hs-cTn testing detects some patients who require 
treatment despite their testing negative with standard troponin, as shown in the secondary analysis 
hs-cTn testing. In particular, the Abbott ARCHITECT hs-cTnI optimal strategy, which involves multiple 
testing and varying cutoff levels, may be promising. The main issue, with regard to service provision, 
if implementation of an hs-cTn testing strategy is considered, is the balance between the likely 
reduction in cost and the risk of a reduction in effectiveness, albeit possibly small. 
Suggested research priorities 
New studies are needed to fully evaluate the performance of our proposed optimal testing 
strategies in a clinical setting. Further research (diagnostic cohort studies or multivariable prediction 
modelling studies) is needed to fully explore possible variation in the performance of hs-cTn assays 
and the optimal testing strategies for these assays in relevant demographic and clinical subgroups 
(sex, age, ethnicity, renal function, previous CAD, previous AMI) and to investigate the effects of 
clinical judgement (assessment of pre-test probability) on test performance. As most of the 
uncertainties in the economic model were caused by assumptions relating to clinical effectiveness, 
this type of research would also facilitate economic analyses of hs-cTn testing. 
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PLAIN ENGLISH SUMMARY (232 WORDS) 
Heart disease is a leading cause of death in the UK, with myocardial infarction (MI) (heart attack) 
accounting for approximately 5% of all deaths recorded in 2011. Many people attend hospital with 
chest pain and suspected MI; chest pain has been reported as the most common cause of hospital 
admissions in the UK and 2011-2012 statistics showed that it accounted for approximately 5% of all 
emergency admissions. It is important to diagnose people who are suspected of having an MI as 
early as possible in order to ensure quick and effective treatment. However, only around 20% of 
emergency admissions for chest pain will actually have an MI and there are many other possible 
causes of chest pain (e.g. gastro-oesophageal disorders, muscle pain, anxiety, or stable ischaemic 
heart disease). Tests which can quickly tell which patients do not have MI could therefore avoid 
unnecessary hospital admissions and anxiety for many people. 
This assessment aimed to determine the clinical- and cost-effectiveness of high sensitivity troponin 
tests, used as single tests or repeated over a short time, for diagnosing or ruling-out MI in people 
who present to hospital with chest pain. We found that high sensitivity troponin tests may be able to 
rule-out MI within the four hour NHS emergency department target. Health economic analyses 
indicated that high sensitivity tests may be cost-effective compared to standard troponin tests, 
which require repeat testing at 10-12 hours. 
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1.   OBJECTIVE 
The overall objective of this project is to assess the clinical- and cost-effectiveness of high sensitivity 
troponin (Tn) assays for the management of adults presenting with acute chest pain, in particular for 
the early (within four hours of presentation) rule-out of acute myocardial infarction (AMI). The 
following research questions were defined to address the review objectives: 
x What is the clinical effectiveness of new, high sensitivity troponin (hs-cTn) assays (used 
singly or in series) compared with conventional diagnostic assessment, for achieving early 
discharge within four hours of presentation, where AMI is excluded without increase in 
adverse outcomes? 
x What is the accuracy of new, hs-cTn assays (used singly or in series, such that results are 
available within three hours of presentation) for the diagnosis of AMI in adults with acute 
chest pain? 
x What is the accuracy of new, hs-cTn assays (used singly or in series, such that results are 
available within three hours of presentation), for the prediction of major adverse cardiac 
events (MACE) (cardiac death, non-fatal AMI, revascularisation, or hospitalisation for 
myocardial ischemia) during 30 day follow-up in adults with acute chest pain? 
x What is the cost-effectiveness of using new, hs-cTn assays (used singly or in series, such that 
results are available within three hours of presentation), compared with the current 
standard of serial Tn T and/or I testing on admission and at 10-12 hours post-admission? 
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2.    BACKGROUND AND DEFINITION OF THE DECISION PROBLEM(S) 
2.1   Population 
The primary indication for this assessment is the early rule-out of AMI and consequent early 
discharge in people presenting with acute chest pain and suspected, but not confirmed, non-ST 
segment elevation myocardial infarction (NSTEMI). The assessment will also consider the potential 
effects of early diagnosis of AMI and of reduced specificity of testing. 
Acute coronary syndrome (ACS) is the term used to describe a spectrum of conditions caused by 
coronary artery disease (CAD) (also known as coronary heart disease or ischaemic heart disease).  
ACS arises when atheromatous plaque ruptures or erodes leading to vasospasm, thrombus 
formation and distal embolization, obstructing blood flow through the coronary arteries.  It 
incorporates three distinct conditions: unstable angina, ST segment elevation myocardial infarction 
(STEMI) and NSTEMI. CAD and AMI are  a significant health burden in the UK, with Office for National 
Statistics (ONS) mortality data for 2011 showing 23,705 deaths from AMI and 64,435 deaths from 
ischaemic heart disease; AMI accounted for approximately 5% of all deaths recorded in 2011 and 
ischaemic heart disease accounted for approximately 13%.1 
People with ACS usually present with chest pain and chest pain has been reported as the most 
common cause of hospital admissions in the UK;2 Hospital Episode Statistics (HES) for 2011-2012 
show 243,197 emergency admissions for chest pain, accounting for approximately 5% of all 
emergency admissions.3 However, many people presenting with acute chest pain will have non-
cardiac underlying causes, such as gastro-oesophageal disorders, muscle pain, anxiety, or stable 
ischaemic heart disease. A 2003 study on the impact of cardiology guidelines on the diagnostic 
classification of people with ACS in the UK reported that the majority of people admitted to hospital 
with chest pain have either no ischaemic heart disease or stable ischaemic heart disease.4 HES for 
2011-2012 are consistent with this observation, showing diagnoses of AMI in 47,783 emergency 
admissions and unstable angina in 32,369 admissions; this represents approximately 20% and 13% of 
emergency admissions with chest pain, respectively.3  Accurate and prompt differentiation of ACS (in 
particular AMI), stable CAD and other causes of chest pain is therefore vital to ensure appropriate 
and timely intervention where required and to avoid unnecessary hospital admissions. 
STEMI can usually be diagnosed on presentation by electrocardiogram (ECG), hence the main 
diagnostic challenge in the investigation of suspected ACS is the detection or rule-out of NSTEMI. 
Investigation of ACS can also involve identification of people with unstable angina (CAD with 
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worsening symptoms, but no evidence of myocardial necrosis).  
Since the development of protein biomarkers of myocardial damage in the 1980s, the number of 
biomarker assays available has proliferated, cardiac specificity has increased, and the role of 
biomarkers in the diagnostic work-up of acute chest pain has expanded. Cardiac biomarkers are 
becoming increasingly sensitive and recent European Society of Cardiology (ESC) and American 
College of Cardiology (ACC) guidelines enable AMI to be diagnosed with any rise and/or fall of Tn to 
above the laboratory reference range.5, 6  This has resulted in fewer people being classified as having 
unstable angina with no myocardial damage and more people being classified as having NSTEMI.7 
The most recent two years of HES show that the number of Emergency Department (ED) 
attendances where the first recorded investigation was a cardiac biomarker rose from 13,743 in 
2010-2011 to 28,379 in 2011-2012.3  Cardiac troponins I and T (cTnI and cTnT), together with cardiac 
troponin C, form the troponin-tropomyosin complex which is responsible for regulating cardiac 
muscle contraction. cTnI and cTnT are used clinically as markers of cardiomyocyte necrosis, 
indicative of AMI. Troponin assays are intended for use in conjunction with clinical history taking and 
ECG monitoring as, although specificity is high, troponins may also be elevated in many other 
conditions including myocarditis, congestive heart failure, severe infections, renal disease and 
chronic inflammatory conditions of the muscle or skin. Standard biochemical diagnosis of NSTEMI is 
based on elevation of the cardiac biomarker Tn above the 99th percentile of the reference range for 
the normal population.8  Elevated Tn levels have been shown to be associated with an increased risk 
of adverse cardiac outcomes.9  However, the optimal sensitivity of standard Tn assays for AMI occurs 
several hours after the onset of symptoms;10 this is reflected in current clinical guidelines, which 
recommend cTnI or cTnT testing at initial hospital assessment and again 10-12 hours after the onset 
of symptoms.11, 12 Since the majority of people presenting with chest pain do not have NSTEMI, 
where presentation is within a few hours of symptom onset delayed biomarker measurement may 
result in unnecessary periods of extended observation or hospitalisation and associated costs. The 
development of cardiac biomarkers which can be used at an earlier stage without reduction in 
sensitivity is, therefore, desirable. 
2.2   Intervention technologies 
The development of high-sensitivity cTn (hs-cTn) assays means that it is possible to detect lower 
levels of Tn in the blood. Current generations of commercially available assays have analytical 
sensitivities up to 100 times greater than was the case for early Tn assays (1 ng/L versus 100 ng/L).13 
Use of these high-sensitivity assays enable the detection of small changes in cTn levels, and may 
enable AMI to be ruled out at an earlier time after the onset of acute chest pain. Use of the hs-cTn 
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assays has the potential to facilitate earlier discharge for people with normal cTn levels and earlier 
intervention for those with elevated levels of cTn. The recommended definition of an hs-cTn assay 
uses two criteria:13, 14  
x The total imprecision, co-efficient of variation (CV ? ?ŽĨƚŚĞĂƐƐĂǇƐŚŽƵůĚďĞA? ? ?A?ĂƚƚŚĞ ? ?th 
percentile value for the healthy reference population. 
x The limit of detection (LoD) of the assay should be such as to allow measurable 
concentrations to be attainable for at least 50% (ideally >95%) of healthy individuals. 
A number of high-sensitivity cTnI and cTnT (hs-cTnI and hs-cTnT) assays are currently available for 
use in the NHS in England and Wales; all are designed for use in clinical laboratory settings.  
2.2.1   Abbott ARCHITECT high-sensitivity troponin I assay  
The ARCHITECT hs-cTnI STAT assay can be used with the Abbott ARCHITECT i2000SR and i1000SR 
analysers. The assay is a quantitative, chemiluminescent micro particle immunoassay (CMIA) for 
serum or plasma samples. Results are available within 16 minutes. The ARCHITECT hs-cTnI STAT 
assay can detect cTnI in 96% of the reference population, and has a recommended 99th percentile 
cut-off of 26.2ng/L with a CV of 4%.15 The assay is CE marked and available to the NHS. 
2.2.2   AccuTNI+3 troponin I assay (Beckman-Coulter) 
The AccuTnI+3 hs-cTnI assay is approved for use on both the Beckman Coulter Access 2 and DxI 
analysers and has recently received CE mark approval. The assay is a quantitative, two-site 
paramagnetic particle chemiluminescent sandwich immunoassay for serum or plasma samples. The 
AccuTnI+3 assay has a recommended 99th percentile cut-off of 40ng/L with a CV of <10%.16 A 
conference abstract, provided AiC ahead of 
publication*************************************************************************
**********************************************************************************
***********************************************17 
***********************************************************************************
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2.2.3   Roche Elecsys high-sensitive troponin T assay  
The Elecsys cTnT-hs and Elecsys cTnT-hs STAT assays can be used on the Roche Elecsys 2010 analyser 
and the cobas Modular Analytics e series immunoassay analysers. The assay is a quantitative, 
sandwich electrochemiluminescence immunoassay (ECLIA) for serum and plasma samples. Results 
are available within 18 minutes with the standard assay and within nine minutes if the STAT assay is 
used. Both versions of the assay can detect cTnT in 61% of the reference population and have a 
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recommended 99th percentile cut off of 14ng/L with a CV of <10%.18 Both versions of the assay are 
CE marked and available to the NHS. 
A summary of the product properties of hs-cTnI and hs-cTnT assays available as in the NHS in 
England and Wales is provided in Table 1. 
hs-cTn assays can be used as single diagnostic tests, or in combination with other cardiac 
biomarkers, e.g. heart fatty acid binding protein (H-FABP) and copeptin. The use of combinations of 
cardiac biomarkers may increase sensitivity, where a positive result on either test is considered to be 
indicative of AMI, although this increase may be achieved at the expense of decreased specificity. 
Conversely, if a positive result on both tests is required before AMI is diagnosed, increased 
specificity and reduced sensitivity are likely. It is currently unclear which, if any, of the available 
cardiac biomarkers could add clinical benefit if used in combination with hs-cTnI and hs-cTnT, 
compared to hs-cTnI and hs-cTnT alone. A recent systematic review reported some data for 
combination testing, but none of the identified studies of Tns combined with other biomarkers used 
high sensitivity methods.7 Retrospective analysis of data from one arm of a randomised controlled 
trial by the same authors provided some indication that the use of H-FABP in combination with hs-
cTn, on admission, may increase sensitivity for AMI without decreasing specificity.19 This increase 
was equivalent to the sensitivity achieved by serial hs-cTn testing on admission and at 90 minutes.19 
However, these tests are not readily available for analytical platforms in routine use in the NHS and 
discussions at the scoping stage of this assessment concluded that practical applications of H-FABP 
and copeptin assays and evidence for their effectiveness are not yet sufficiently developed to justify 
their inclusion. 
This assessment will consider hs-cTn assays used singly or in series, up to four hours after the onset 
of chest pain or up to four hours after presentation (as reported);  for serial Tn measurements, both 
data on change in Tn levels and peak Tn will be considered (as reported). 
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Table 1: Overview of cardiac biomarkers 
Manufacturer System Assay LoD (ng/L) LoB (ng/L) 99
th
 percentile 
(ng/L)
 *
 
CV at 99
th
 
percentile
*
 
Turnaround 
time (mins)
 *
 
CE marked 
Abbott Diagnostics ARCHITECT STAT 
hs-cTnI 
1.1 to 1.9 0.7 to 1.3 26.2 4% 16 9 
Beckman Coulter  Access and UniCel 
DxI 
AccuTnI+3 10 <10 40.0 <10% 13 9 
Roche Elecsys  cTnT-hs 5 3 14 <10% 18 9 
Roche Elecsys cTnT-hs STAT 5 3 14 <10% 9 9 
*
 Information supplied to NICE by the manufacturer 
LoD: limit of detection 
LoB: limit of blank 
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2.3   Comparator 
The comparator for this technology appraisal is the current UK standard of serial TnT and/or I testing 
(using any method not defined as a hs-cTn test) on admission and at 10-12 hours after the onset of 
symptoms.11 
2.4   Care pathway 
2.4.1   Diagnostic assessment 
The assessment of patients with suspected ACS is described in NICE clinical guideline 95 (CG95) 
 “ŚĞƐƚƉĂŝŶŽĨƌĞĐĞŶƚŽŶƐĞƚ PƐƐĞƐƐŵĞŶƚĂŶĚĚŝĂŐŶŽƐŝƐŽĨƌĞĐĞŶƚŽŶƐĞƚĐŚĞƐƚƉĂŝŶŽƌĚŝƐĐŽŵĨŽƌƚŽĨ
suspected cardiac ŽƌŝŐŝŶ ? ?11 The guideline specifies that initial assessment should include a resting 
12-lead ECG along with a clinical history, a physical examination and biochemical marker analysis. 
For people in whom a regional ST-segment elevation or presumed new left branch bundle block is 
seen on ECG, management should follow NICE clinical guideline 167 (CG167 ?  “dŚĞ ĂĐƵƚĞ
management of AMI with ST-segment elevation ? ?20 People without persistent ST-elevation changes 
on ECG, i.e. with suspected non-ST-segment-elevation ACS (NSTE-ACS), should receive further 
investigation using cardiac biomarkers with the aim of distinguishing NSTEMI from unstable angina. 
NICE CG95 makes the following recommendations on the use of cardiac biomarkers:11 
x Take a blood sample for cTnI or cTnT on initial assessment in hospital. These are the 
preferred biochemical markers to diagnose AMI. 
x Take a second blood sample for cTnI or cTnT measurement 10-12 hours after the onset of 
symptoms. 
x Do not use biomarkers such as natriuretic peptides and high sensitivity C-reactive protein to 
diagnose an ACS. 
x Do not use biomarkers of myocardial ischemia (such as ischemia modified albumin) as 
opposed to markers of necrosis when assessing people with acute chest pain. 
x Take into account the clinical presentation, from the time of onset of symptoms and the 
resting 12-lead ECG findings, when interpreting Tn measurements.  
CG95 recommends that a diagnosis of NSTEMI should be made using the universal definition of 
AMI.8 However, the third universal definition of AMI has been up-dated since the publication of 
CG95.21 The most recent version states that AMI is defined ĂƐ “dŚĞĚĞƚection of a rise and/or fall of 
cardiac biomarker values (preferably cardiac Tn) with at least one value above the 99th percentile 
upper reference limit and with at least one of the following: symptoms of ischemia, new or 
presumed new significant ST-segment-T wave changes or new left branch bundle block, 
development of pathological Q waves in the ECG, imaging evidence of new loss of viable 
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myocardium or new regional wall motion abnormality, or identification of an intracoronary 
thrombus by angiography or auƚŽƉƐǇ ? ? 
The Scottish Intercollegiate Guidelines Network guideline 93 (SIGN 93) provides similar 
recommendations on the diagnostic work-up of people with suspected ACS, stating that:12 
x Immediate assessment with a 12-lead ECG 
x Repeat 12-lead ECG if there is diagnostic uncertainty or change in clinical status, and at 
discharge 
x Serum Tn measurement on arrival at hospital 
x Repeat serum Tn measurement 12 hours after the onset of symptoms 
x Troponin concentrations should not be interpreted in isolation, but with regard to clinical 
presentation 
Guidelines from the ESC on the diagnostic assessment of people with a suspected NSTE-ACS are 
consistent with those of NICE and SIGN, but additionally acknowledge the use of high-sensitivity Tn 
assays and make recommendations on a fast track rule out protocol. The guidelines state that hs-cTn 
assays have a negative predictive value (NPV) of greater 95% for AMI on admission; including a 
second sample of hs-cTn at three hours can increase this to 100%.22  
2.4.2   Management/treatment 
NICE clinical guideline 94 (CG94) provides recommendations on the management of people with 
suspected NSTE-ACS  “hŶƐƚĂďle angina and NSTEMI: The early management of unstable angina and 
non-STEMI ? ?23  The guideline states that initial treatment should include a combination of 
antiplatelet (aspirin, clopidogrel and glycoprotein IIb/IIIa inhibitors) and antithrombin therapy, and 
should take into account contraindications, risk factors and the likelihood of percutaneous coronary 
intervention. SIGN 93 makes similar recommendations.12 It is recommended that people with a 
diagnosis of NSTEMI, who are assessed as being at low risk of future complications, receive 
conservative treatment with aspirin and/or clopidogrel, or aspirin in combination with ticagrelor. 
People at a higher risk of future complications should be offered coronary angiography (within 96 
hours of admission) with subsequent coronary revascularisation by percutaneous coronary 
intervention or coronary artery bypass grafting where indicated.23 Additional testing to quantify 
inducible ischemia may also be used, before discharge, to identify those who may need further 
intervention23 and SIGN 93 also recommends functional testing to identify people at higher risk.12 
SIGN 93 states that people in whom an elevated Tn level is not observed may be discharged for 
further follow up according to clinical judgement and, in some cases, the results of ischemia 
testing.12 
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Longer term follow-up of people who have had an AMI is described in full in NICE Clinical Guideline 
 ? ? ?' ? ? ? “^ĞĐŽŶĚĂƌǇƉƌĞǀĞŶƚŝŽŶŝŶƉƌŝŵĂƌǇĂŶĚƐĞĐŽŶĚĂƌǇĐ ĞĨŽƌƉĂƚŝĞŶƚƐĨŽůůŽǁŝŶŐĂŵǇŽĐĂƌĚŝĂů
ŝŶĨĂƌĐƚŝŽŶ ? ?dŚŝƐŝŶĐůƵĚĞƐƌĞĐŽŵŵĞŶĚĂƚŝŽns on lifestyle changes, cardiac rehabilitation programmes, 
drug therapy (including a combination of angiotensin converting enzyme (ACE) inhibitors, aspirin, 
beta-blockers and statins), and further cardiological assessment to determine whether coronary 
revascularisation is required.24 
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3.    ASSESSMENT OF CLINICAL EFFECTIVENESS 
A systematic review was conducted to summarise the evidence on the clinical effectiveness of hs-
cTn assays for the early rule-out or diagnosis of AMI in people with acute chest pain.  Systematic 
review methods followed the principles outlined in the Centre for Reviews and Dissemination (CRD) 
guidance for undertaking reviews in health care25 and NICE Diagnostics Assessment Programme 
manual.26, 27 
3.1   Systematic review methods 
3.1.1   Search strategy 
Search strategies were based on intervention (high-sensitivity Tn assays) and target condition, as 
recommended in the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews 
in health care25 and the Cochrane Handbook for Diagnostic Test Accuracy Reviews. 27 
Candidate search terms were identified from target references, browsing database thesauri (e.g. 
Medline MeSH and Embase Emtree), existing reviews identified during the rapid appraisal process 
and initial scoping searches. These scoping searches were used to generate test sets of target 
references, which informed text mining analysis of high-frequency subject indexing terms using 
Endnote reference management software. Strategy development involved an iterative approach 
testing candidate text and indexing terms across a sample of bibliographic databases, aiming to 
reach a satisfactory balance of sensitivity and specificity.  
The following databases were searched for relevant studies from 2005 to October 2013: 
x MEDLINE (OvidSP): 2005-2013/10/wk1 
x MEDLINE In-Process Citations and Daily Update (OvidSP): up to 2013/10/1 
x EMBASE  (OvidSP): 2005-2013/10/10 
x Cochrane Database of Systematic Reviews (CDSR) (Wiley): Cochrane Library Issue 10 2005-
2013/10/11 
x Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley): Cochrane Library Issue 9 
2005-2013/10/11 
x Database of Abstracts of Reviews of Effects (DARE) (Wiley): Cochrane Library Issue 3 2005-
July 2013 
x Health Technology Assessment Database (HTA) (Wiley): Cochrane Library Issue 3 2005-July 
2013 
x Science Citation Index (SCI) (Web of Science): 2005-2013/10/14 
x Conference Proceedings Citation Index  W Science (CPCI) (Web of Science): 2005-2013/10/14 
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x LILACS (Latin American and Caribbean Health Sciences Literature) (Internet): 2005-
2013/10/11 
http://regional.bvsalud.org/php/index.php?lang=en 
x International Network of Agencies for Health Technology Assessment (INAHTA) Publications 
(Internet): 2005-2013/10/15 
http://www.inahta.org/ 
x Biosis Previews (Web of Knowledge): 2005-2013/10/11 
x NIHR Health Technology Assessment Programme (Internet): 2005-2013/10/14 
x Aggressive Research Intelligence Facility (ARIF) database (Internet) : 2005-2013/10/16 
http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/ARIF/index.aspx 
x MEDION database (Internet): 2005-2013/10/16 
http://www.mediondatabase.nl/ 
x PROSPERO (International Prospective Register of Systematic Reviews) (Internet): up to 
2013/10/10 
http://www.crd.york.ac.uk/prospero/ 
Completed and on-going trials were identified by searches of the following resources (2005-present): 
x NIH ClinicalTrials.gov (Internet): up to 2013/10/1 
http://www.clinicaltrials.gov/ 
x Current Controlled Trials (Internet): up to 2013/10/10 
http://www.controlled-trials.com/ 
x WHO International Clinical Trials Registry Platform (ICTRP) (Internet): up to 2013/10/10 
http://www.who.int/ictrp/en/ 
No restrictions on language or publication status were applied.  Date restrictions were applied based 
on expert advice on the earliest appearance of literature of high sensitivity Tn assays. Searches took 
into account generic and other product names for the intervention. The main EMBASE strategy for 
each set of searches was independently peer reviewed by a second Information Specialist, using the 
CADTH Peer Review Checklist.28 Search strategies were developed specifically for each database and 
the keywords associated with high sensitivity Tn T/I were adapted according to the configuration of 
each database. Full search strategies are reported in Appendix 1. 
Electronic searches were undertaken for the following conference abstracts (selected based on 
advice from expert committee members): 
x American Heart Association (AHA) Scientific Sessions (Internet): 2009-2013 
http://my.americanheart.org/professional/Sessions/ScientificSessions/Archive/Archive-
Scientific-Sessions_UCM_316935_SubHomePage.jsp 
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x American Association for Clinical Chemistry (AACC) (Internet): 2009-2013 
http://www.aacc.org/resourcecenters/meet_abstracts_archive/abstracts_archive/annual_m
eeting/Pages/default.aspx# 
x European Society of Cardiology (ESC) (Internet): 2009-2013 
http://spo.escardio.org/abstract-book/search.aspx 
 
Identified references were downloaded in Endnote X4 software for further assessment and handling. 
References in retrieved articles were checked for additional studies. The final list of included papers 
were checked on PubMed for retractions, errata and related citations.29-31 
3.1.2   Inclusion and exclusion criteria 
Inclusion criteria for each of the clinical effectiveness questions are summarised in Table 2.  Studies 
which fulfilled these criteria were eligible for inclusion in the review. 
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Table 2: Inclusion criteria 
Question What is the accuracy of hs-cTn assays (used singly or in 
series, such that results are available within 3 hours of 
presentation) for the diagnosis of AMI in adults with acute 
chest pain? 
What is the effectiveness of hs-cTn assays (used singly or in 
series) compared with conventional diagnostic assessment, for 
achieving successful early discharge of adults with acute chest 
pain within 4 hours of presentation? 
Participants: ĚƵůƚƐ ?A䠃? ?ǇƌƐ ?ƉƌĞƐĞŶƚŝŶŐǁŝƚŚĂĐƵƚĞ ‘ƉĂin, discomfort or pressure in the chest, epigastrium, neck, jaw, or upper limb without an 
apparent non-ĐĂƌĚŝĂĐƐŽƵƌĐĞ ?32 due to a suspected, 
but not proven, AMI  
Setting: Secondary or tertiary care 
Interventions (index test): Any hs-cTnT or hs-cTnI test
*
, listed in Table 1
 
, hs-cTn assays (used singly or in series
**
, such that results were available within 3 hours of 
presentation) 
Comparators: Any other hs-cTn test, as specified above, or no comparator 
 
Troponin T or I measurement on presentation and 10-12 hours after 
the onset of symptoms 
Reference standard: Universal definition of AMI, including measurement of 
troponin T or I (using any method not defined as a hs-cTn 
test) on presentation and 10-12 hours after the onset of 
ƐǇŵƉƚŽŵƐŝŶA䠃? ?A?ŽĨƚŚĞƉŽƉƵůĂƚŝŽŶ$ or occurrence of MACE 
(any definition used in identified studies) during 30 day 
follow-up 
Not applicable 
Outcomes
$$
: Test accuracy  (the numbers of true positive, false negative, 
false positive and true negative test results)    
Early discharge (A?4 hrs after initial presentation) without MACE during 
follow-up, incidence of MACE during follow-up, re-attendance at or re-
admission to hospital during follow-up, time to discharge, patient 
satisfaction or health-related quality of life (HRQoL) measures 
Study design: Diagnostic cohort studies Randomised controlled trials (RCTs) (controlled clinical trials (CCTs) 
will be considered if no RCTs are identified) 
*
 A high sensitivity assay is defined as one which has a CV A?10% at the 99th percentile value for the healthy reference population, and where the LoD allows measurable 
concentrations to be attained for at least 50% of healthy individuals 
**
 For serial hs-cTn assays, both data on change in Tn levels and peak Tn values were be considered 
$
 Studies that used only new diagnostic ECG changes or outcome-based MACE (cardiac death, non-fatal AMI, revascularisation, or hospitalisation for myocardial ischemia) 
alongside a Tn-based reference standard were eligible for inclusion
7
 
$$ 
Any estimates of the relative accuracy/effectiveness of different hs-cTnT or hs-cTnI tests, were derived from direct, within study comparisons  
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3.1.3   Inclusion screening and data extraction 
Two reviewers (MW and PW) independently screened the titles and abstracts of all reports identified 
by searches and any discrepancies were discussed and resolved by consensus. Full copies of all 
studies deemed potentially relevant were obtained and the same two reviewers independently 
assessed these for inclusion; any disagreements were resolved by consensus. Details of studies 
excluded at the full paper screening stage are presented in Appendix 4. 
Studies cited in materials provided by the manufacturers of hs-cTn assays were first checked against 
the project reference database, in Endnote X4; any studies not already identified by our searches 
were screened for inclusion following the process described above.  
Data were extracted on the following: study details, inclusion and exclusion criteria, participant 
characteristics (demographic characteristics and cardiac risk factors), target condition (NSTEMI or 
AMI), details of the hs-cTnT or hs-cTnI test (manufacturer, timing, and definition of positive 
diagnostic threshold), details of reference standard (manufacturer, timing, diagnostic threshold for 
conventional Tn T or I testing, clinical and imaging components of the reference standard, method of 
adjudication (e.g. two independent clinicians)), and test performance outcome measures (numbers 
of true positive (TP), false positive (FP), false negative (FN) and true negative (TN) test results). Data 
were extracted by one reviewer, using a piloted, standard data extraction form and checked by a 
second (MW and PW); any disagreements were resolved by consensus. Full data extraction tables 
are provided in Appendix 2. 
3.1.4   Quality assessment 
The methodological quality of included diagnostic test accuracy (DTA) studies was assessed using 
QUADAS-2.33 Quality assessments was undertaken by one reviewer and checked by a second (MW 
and PW); any disagreements were resolved by consensus. 
The results of the quality assessments are summarised and presented in tables and graphs in the 
results of the systematic review and are presented in full, by study, in Appendix 3. 
3.1.5   Methods of analysis/synthesis 
Sensitivity and specificity were calculated for each set of 2u2 data and plotted in receiver operating 
characteristic space. The bivariate/hierarchical summary receiver operating characteristic (HSROC) 
model was used to estimate summary sensitivity and specificity with 95% confidence intervals (CIs) 
and prediction regions around the summary points, and to derive hierarchical summary receiver 
operating characteristic curves for meta-analyses involving four or more studies.34-36 This approach 
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allows for between-study heterogeneity in sensitivity and specificity, and for the trade-off (negative 
correlation) between sensitivity and specificity commonly seen in diagnostic meta-analyses. For 
meta-analyses with fewer than four studies we estimated separate pooled estimates of sensitivity 
and specificity, using random-effects logistic regression.37  Heterogeneity was assessed visually using 
summary receiver operating characteristic plots and statistically using the variance of logit 
(sensitivity) and logit (specificity)  ? ǁŚĞƌĞ  “ůŽŐŝƚ ? ŝŶĚŝĐĂƚĞƐ ƚŚĞ ůŽŐŝƐƚŝĐ ĨƵŶĐƚŝŽŶ P ƚŚĞ ƐŵĂůůĞƌ ƚŚĞƐĞ
values the less heterogeneity between studies. Summary positive and negative likelihood ratios 
were derived from the summary estimates of sensitivity and specificity. Analyses were performed in 
Stata 10 (StataCorp LP, College Station, Texas, USA), mainly using the metandi command. For 
analyses that would not run in Stata we used MetaDisc.38   
Analyses were conducted separately for each of the three hs-cTn assays. Analyses were stratified 
according to whether the study evaluated the prediction of AMI or MACE, timing of collection of 
blood sample for testing, and the threshold used to define a positive hs-cTn result. We investigated 
possible sources of heterogeneity using stratified analyses based on the following variables: 
x Population: studies included mixed populations compared to those that excluded patients 
with STEMI.   
x ŐĞAN ? ?ǇĞĂƌƐĐŽŵƉĂƌĞĚƚŽĂŐĞA? ? ?ǇĞĂƌƐ 
x Patients with pre-existing CAD at baseline compared to patients without pre-existing CAD 
x Time from symptom onset to presentation <3 hours compared to >3 hours 
x Time from symptom onset to presentation <6 hours compared to >6 hours 
x Low to moderate pre-test probability of disease compared to high pre-test probability of 
disease 
Stratified analyses were conducted for all time points and thresholds for which sufficient data were 
available. To investigate the influence of risk of bias on the studies we restricted analyses to studies 
conducted in patients at low or unclear risk of bias for the two QUADAS items considered to have 
the greatest potential to have introduced bias into these studies: the item on patient spectrum (1) 
and the item on patient flow (4). As the focus of this review was the diagnosis of NSTEMI, we 
conducted these analyses in studies that excluded patients with STEMI. We used summary receiver 
operating characteristic (ROC) plots to display summary estimates from the various primary and 
stratified analyses. 
We compared the accuracy of the three different hs-cTn assays by tabulating summary estimates 
from analyses for common time points and thresholds assessed for all assays.  Only one study 
provided a direct comparison of all three assays. Estimates of sensitivity, specificity, and positive and 
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negative likelihood ratio (LR+ and LR-) for each assay derived from this study were included in the 
summary tables. 
3.2   Results of the assessment of clinical effectiveness assessment 
The literature searches of bibliographic databases identified 6,766 references. After initial screening 
of titles and abstracts, 261 were considered to be potentially relevant and ordered for full paper 
screening; of these 35 were included in the review.39-73 All potentially relevant studies cited in 
documents supplied by the test manufacturers had already been identified by bibliographic 
database searches. One additional study was identified from hand searching of conference 
abstracts,74 and two additional studies were identified from information supplied by clinical 
experts.75, 76 Figure 1 shows the flow of studies through the review process, and Appendix 4 provides 
details, with reasons for exclusions, of all publications excluded at the full paper screening stage. 
3.2.1   Overview of included studies 
Based on the searches and inclusion screening described above, 38 publications 39-76 of 18 studies39, 
41, 43, 45, 47, 48, 50, 53, 54, 56, 57, 62, 63, 65, 67, 71, 74, 75 were included in the review; the results section of this report 
cites studies using the primary publication and, where this is different, the publication in which the 
referenced data were reported. Fifteen studies reported accuracy data for the Roche Elecsys hs-cTnT 
assay, 39, 41, 43, 45, 48, 50, 53, 54, 56, 57, 63, 65, 67, 71, 75 four studies reported accuracy data for the Abbott 
ARCHITECT hs-cTnI assay, 47, 57, 62, 75 and two studies reported accuracy data for the Beckman Coulter 
Access hs-cTnI assay;74, 75 two studies reported data for more than one assay.57, 75 No RCTs or CCTs 
were identified; no studies provided data on the effects on patient-relevant outcomes of 
management based on hs-cTn assays within 4 hours of presentation, compared to management 
based on standard cTn assays at presentation and after 10 to 12 hours. All studies included in the 
systematic review were diagnostic cohort studies, which reported data on the diagnostic or 
prognostic accuracy hs-cTn assays. 
Thirteen39, 41, 43, 47, 48, 50, 54, 56, 63, 65, 67, 74, 75 of the 18 included studies were conducted in Europe (two in 
the UK65, 67), four were conducted in Australia and New Zealand,45, 53, 57, 62 and one was conducted in 
the USA.71 Thirteen of the 18 included studies reported receiving some support from test 
manufacturers, including supply of assay kits; 39, 41, 45, 47, 48, 50, 53, 54, 56, 62, 63, 71, 75 two studies did not 
report any information on funding.57, 74 
Full details of the characteristics of study participants, study inclusion and exclusion criteria, and hs-
cTn assay used and reference standard, and detailed results are reported in the data extraction 
tables presented in Appendix 2 (Tables a,  b and c).  
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Figure 1: Flow of studies through the review process 
 
Information from clinical 
experts 
n = 2 
Titles and abstracts identified 
from bibliographic databases and 
screened for potential relevance 
n = 6766 
Excluded at title and 
abstract screening 
n = 6505 
Potentially relevant 
publications obtained for full 
text screening 
n = 261 
Total number of studies included in the 
review 
n = 18* studies (38 publications) 
*1 study assessed two tests and 1 study 
assessed all three tests 
Excluded at full paper 
screening 
n = 225 
Unobtainable studies 
n = 1 
Conference abstracts  
n = 1 
 
Roche hs-cTnT  
n = 15 studies (34 Publications) 
 
Abbott hs-cTnI 
n = 4 studies (5 Publications) 
 
Beckmann Coulter hs-cTnI 
n = 2 studies (3 Publications) 
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 3.2.2   Study quality 
The main potential sources of bias in the 18 studies included in this assessment relate to patient 
spectrum and patient flow.  There were also concerns regarding the applicability of the patient 
population and the reference standard in some of the included studies.  The results of QUADAS-2 
assessments are summarised in Table 3 and Figure 2; full QUADAS-2 assessments for each study are 
provided in Appendix 3.  A summary of the risks of bias and applicability concerns within each 
QUADAS-2 domain is provided below. 
3.2.2.1  Patient spectrum 
Three studies41, 45, 50 were rated as high risk of bias for patient selection and a further six were rated 
as unclear risk of bias.  Most studies rated as unclear risk of bias did not provide sufficient details to 
make a judgement on whether appropriate steps were taken to minimise bias when enrolling 
patients into the study.43, 57, 63, 67, 71 In one study a large number of patients were not enrolled due to 
'technical reasons' that were not fully defined and so it was not possible to judge whether these 
constituted inappropriate exclusions; this study was also judged as unclear risk of bias for this 
domain.54  One study only enrolled patients presenting between 05.30 and 20.00 and so patients 
who presented outside these hours were excluded; as these patients may differ in their presenting 
characteristics (e.g. time from symptom onset) this was considered to introduce a potential bias into 
the study.45  A further study stated that consecutive patients were enrolled except for temporary 
interruptions of the study due to high work load in the coronary care unit.50  This was also 
considered to have the potential to lead to the inclusion of a different spectrum of patients than if 
consecutive patients had been enrolled.  The last study judged at high risk of bias for patient 
enrolment excluded certain patient groups including those with a Tn elevation in any two serial 
determinations, a prior diagnosis of ischemic heart disease, structural heart disease, concomitant 
heart failure or significant bradyarrhythmia.41 
Although this assessment included studies that enrolled both mixed populations (i.e. when the 
target condition was any AMI) and studies restricted to populations where patients with STEMI were 
excluded (i.e. target condition NSTEMI), the primary focus was the population of patients with STEMI 
excluded.  Studies not restricted to this specific patient group were therefore considered to have 
high concerns regarding applicability.  Seven studies were restricted to patients in whom STEMI had 
been excluded39, 43, 45, 50, 54, 63, 65, an additional study enrolled a mixed population but also presented 
data for patients in whom STEMI had been excluded.75  Three of these studies43, 50, 54 were restricted 
to patients admitted to coronary care/chest patients units and so were considered to represent 
patients with more severe disease.  A further study had strict inclusion criteria which resulted in the 
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inclusion of a very low risk population.65  These four studies were not considered to be 
representative of patients with chest pain presenting to the emergency department who are the 
main focus of this assessment and so were also rated as having high concerns regarding applicability.  
Therefore only four studies39, 45, 75, 77 (one only for a subset of data75) were considered to have low 
concerns regarding the applicability of the included patients. 
3.2.2.2  Index test 
All but one of the studies were rated as low risk of bias for the index test as all reported data for at 
least one threshold that was pre-specified (generally the 99th centile threshold, LoD or LoB 
threshold).  The study that was rated as high risk of bias on this domain assessed the accuracy of the 
Beckman Coulter Access hs-cTnI assay at a single threshold which was derived from the ROC curve.74  
As the reference standard (diagnosis of AMI or MACE) was interpreted after the high sensitivity Tn 
test blinding was not considered important for these studies.   Inclusion criteria were very tightly 
defined in terms of the high sensitivity Tn assays that we were interested in and so all studies were 
considered to have low concerns regarding the applicability of the index test. 
3.2.2.3  Reference standard 
Six studies were rated as unclear risk of bias for reference standard.39, 41, 43, 54, 71, 74  In five this was 
because it was unclear whether the diagnosis of AMI/MACE was made without knowledge of the 
high sensitivity Tn results.39, 41, 43, 54, 56  Two studies reported as abstracts provided insufficient details 
on how the diagnosis of AMI was made, including whether adjudicators were blinded to the high 
sensitivity Tn results, to judge whether an appropriate reference standard had been used.71, 74  No 
studies were rated as high risk of bias for this domain as these would not have fulfilled the inclusion 
criteria for the review.  In our review question we specified that an appropriate reference standard 
had to include a standard Tn measurement at baseline and at 10-12 hours after the onset of 
symptoms in 80% of the population.11  Only five studies41, 50, 62, 65, 75 met this criteria for standard Tn 
measurement and were judged to have low concerns regarding the applicability of the reference 
standard; all but one of the remaining studies were judged at high risk of bias, the other study did 
not provide exact details on the timing of the standard Tn assay.39   
3.2.2.4  Patient flow 
Six studies were considered at high risk of bias for patient flow43, 47, 53, 63, 65, 75 and a further three 
were considered at unclear risk of bias.57, 71, 74  In all cases this was related to withdrawals from the 
study; verification bias was not considered to be a problem in any of the studies.  The four studies 
that were rated as unclear risk of bias were only reported as abstracts and did not provide sufficient 
details to judge whether there were any withdrawals in the study.  The studies judged at high risk of 
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bias on this domain generally excluded patients for whom samples or high sensitive Tn results were 
not available. 
Table 3: QUADAS-2 results for studies of hs-cTn assays 
Study RISK OF BIAS APPLICABILITY CONCERNS 
Patient 
selection 
Index 
test 
Reference 
standard 
Flow 
and 
timing 
Patient 
selection 
 
Index 
test 
Reference 
standard 
Aldous(2011)
53
 - - - / / - / 
Aldous(2012)
45
 / - - - - - / 
Body(2011)
67
 ? - - - / - / 
Christ(2010)
56
 - - ? - / - / 
Collinson(2013)
65
 - - - / / - - 
Cullen(2013)
62
 - - - - / - - 
Eggers(2012)
43
 ? - ? / / - / 
Freund(2011)
48
 - - - - / - / 
Hoeller(2013)
75
 - - - / //- - - 
Keller(2011)
47
 - - - / / - / 
Kurz(2011)
54
 ? - - - / - / 
Lippi(2012)
74
 - / ? ? / - / 
Melki(2011)
50
 1 - - - / - - 
Parsonage(2013)
57
 ? - - ? / - / 
Saenger(2010)
71
 ? - ? ? / - / 
Sanchis(2012)
41
 / - ? - / - - 
Santalo(2013)
39
 - - ? - - - ? 
Sebbane(2013)
63
 ? - - / - - / 
-Low Risk /High Risk   ? Unclear Risk  
 
 
Figure 2: Summary of QUADAS-2 results for studies of hs-cTn assays 
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3.2.3   Diagnostic accuracy of the Roche Elecsys hs-cTnT assay  
3.2.3.1  Study details 
Fifteen diagnostic cohort studies, 39, 41, 43, 45, 48, 50, 53, 54, 56, 57, 63, 65, 67, 71, 75 reported in 34 publications, 39-46, 
48-61, 63-68, 70-73, 75, 76 provided data on the diagnostic performance of the Roche Elecsys hs-cTnT assay. 
Fourteen of the 15 studies in this section assessed the accuracy of the Roche Elecsys hs-cTnT assay 
for the detection of AMI, and the remaining study assessed accuracy for the prediction of  MACE 
within 30 days of the index presentation.41 Eight studies provided data specific to the population of 
interest for this assessment; participants with STEMI were excluded, i.e. the target condition was 
NSTEMI rather than any AMI.39, 43, 45, 50, 54, 63, 65, 75  
All 14 of the studies which assessed accuracy for the detection of AMI reported data on the 
diagnostic performance of a single sample taken on presentation. All but one of the studies reported 
data for the 99th centile for the general population the remaining study reported data for a ROC-
derived threshold of 9.5 ng/L.54 Studies additionally assessed the diagnostic performance of a 
LoD/LoB threshold (5 ng/L or 3 ng/L) in a single sample taken on presentation,45, 52, 53, 67, 75 of a  single 
sample taken 1 to 3 hours after presentation,45, 50 and/or the diagnostic performance of a specified 
change in, or peak value of hs-cTnT level over the initial three hours from presentation.39, 45, 57, 71, 75  
Table 4 provides summary estimates of the diagnostic performance of all combinations of 
population, diagnostic threshold and hs-cTnT test timing which were assessed by more than one 
study.  For analyses based on NSTEMI patients only, where sufficient data were available sensitivity 
ĂŶĂůǇƐĞƐǁŚŝĐŚĞǆĐůƵĚĞĚƐƚƵĚŝĞƐƌĂƚĞĚĂƐ ‘ŚŝŐŚƌŝƐŬŽĨďŝĂƐ ?ŽŶŽŶĞŽƌŵŽƌĞYh^ĚŽŵĂŝŶƐ ? were 
also reported. Where combinations were assessed by a single study, diagnostic performance 
estimates derived from that study alone are provided. Key results used in the cost-effectiveness 
modelling conducted for this assessment are highlighted in bold. Full results (including numbers of 
TP, FP, FN and TN test results), for all studies and all datasets, are provided in Appendix 2 (Table c). 
3.2.3.2  Presentation samples 
The summary estimates of sensitivity and specificity, where the diagnostic threshold was defined as 
the 99th centile for the general population, were 89% (95% CI: 85 to 92%) and 82% (95% CI: 77 to 
86%), based on data from 13 studies; 39, 43, 45, 48, 50, 53, 56, 57, 63, 65, 67, 71, 75 the SROC curve for this analysis 
is shown in Figure 3. The LR+ and LR- were 4.96 (95% CI: 3.84 to 6.39) and 0.14 (95% CI: 0.10 to 
0.19), respectively. These estimates were similar when the analysis was restricted to studies which 
excluded participants with STEMI; summary estimates of sensitivity and specificity were 88% (95% 
CI: 78 to 93%) and 84% (95% CI: 74 to 90%), respectively (SROC curve shown in Figure 4) and the LR+ 
and LR- were 5.41 (95% CI: 3.40 to 8.63) and 0.15 (95% CI: 0.08 to 0.26), respectively, based on six 
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studies.39, 43, 45, 50, 63, 65 The only study, conducted in a population which excluded participants with 
^dD/ ?ǁŚŝĐŚǁĂƐƌĂƚĞĚĂƐ  ‘ůŽǁŽƌƵŶĐůĞĂƌƌŝƐŬŽĨďŝĂƐ ?ŽŶĂůůYh^ĚŽŵĂŝŶƐ,39 reported similar 
sensitivity and negative LR (see Table 4) to the summary estimates, but lower estimates of specificity 
(71% (95% CI: 66 to 76%)) and LR+ (3.11 (95% CI: 2.55 to 3.79)). Results were also similar when the 
analysis was restricted to eight studies with a mixed population (i.e. where the target condition was 
any AMI); summary estimates of sensitivity and specificity were 89% (95% CI: 86 to 91%) and 81% 
(95% CI: 76 to 85%), respectively (SROC curve shown in Figure 5) and the LR+ and LR- were 4.64 (95% 
CI: 3.73 to 5.76) and 0.14 (95% CI: 0.11 to 0.17), respectively. 40, 48, 53, 56, 57, 67, 71, 75 Based on these data, 
it is unlikely that hs-cTnT testing on a single admission sample, using the 99th centile diagnostic 
threshold, would be considered adequate for either rule-out or rule-in of any AMI or NSTEMI. 
Although there was little apparent variation in the estimates of test performance derived from the 
three meta-analyses described above, the results of the second analysis (studies which excluded 
participants with STEMI) was selected to inform our cost-effectiveness analyses, as it best matched 
the main population of interest for this assessment (i.e. the target condition was NSTEMI rather than 
any AMI). The approach of, where possible, selecting data based on a population which excluded 
STEMI rather than a mixed population to inform cost-effectiveness modelling was applied 
throughout. 
Figure 3: SROC for the Roche Elecsys hs-cTnT assay using the 99th centile threshold and a 
presentation sample (13 studies) 
0
.
2
.
4
.
6
.
8
1
0.2.4.6.81
Specificity
Study estimate
Summary point
HSROC curve
95% confidence
region
95% prediction
region
 
CONFIDENTIAL UNTIL PUBLISHED 
40 
Figure 4: SROC for the Roche Elecsys hs-cTnT assay using the 99th centile threshold and a 
presentation sample (6 studies which excluded participants with STEMI) 
 
Figure 5: SROC for the Roche Elecsys hs-cTnT assay using the 99th centile threshold and a 
presentation sample (8 studies with a mixed population, target condition any AMI) 
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Limited data were identified on additional clinical subgroups (age >70 years versus A? ? ?ǇĞĂƌƐ ?52, 75 
without pre-existing CAD versus with pre-existing CAD,46, 75 and high versus low to moderate pre-test 
probability (determined by clinical judgement based on cardiovascular risk factors, type of chest 
pain, physical findings, and ECG abnormalities)48). None of these studies excluded participants with 
STEMI. The study which stratified participants by age,52, 75 reported a higher estimate of sensitivity 
(97% (92% to 99%)) and a lower estimate of LR- (0.05 (95% CI: 0.02 or 0.18)) in participants >70 years 
of age thĂŶĨŽƌƉĂƚŝĞŶƚƐA? ? ?ǇĞĂƌƐŽĨĂŐĞ ? ? ?A? ? ? ?A?/ P ? ?ƚŽ ? ?A? ?ĂŶĚ ? ? ?   ? ? ?A?/ P ? ? ? ?ƚŽ ? ? ? ? ? ?
respectively); the estimates of sensitivity and LR- for people >70 years of age were also higher and 
lower, respectively, than the corresponding summary estimates derived from all 15 studies which 
used the 99th centile diagnostic threshold.  A similar pattern was apparent for people with a high 
pre-test probability compared to those with a low to moderate pre-test probability48 and for 
participants without pre-existing CAD compared to those with pre-existing CAD,46, 75 see Table 4. As 
with the age stratification, the estimates of sensitivity and LR- were higher and lower, respectively, 
than the corresponding summary estimates derived from all 15 studies which used the 99th centile 
diagnostic threshold, for people with a high pre-test probability and for people without pre-existing 
CAD. Figure 6 illustrates the variation in performance characteristics of a single admission sample, 
using the 99th centile diagnostic threshold, when used in different clinical subgroups. These data 
provide some indication that hs-cTnT testing on a single admission sample, using the 99th centile 
diagnostic threshold, may be adequate for rule-out of AMI in certain selected populations (older 
ƉĞŽƉůĞ  ?A? ? ?ǇĞĂrs), those without pre-existing CAD, and people classified by clinical judgement as 
having a high pre-test probability.  
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Figure 6: ROC space plot for the Roche Elecsys hs-cTnT assay using the 99th centile threshold and a 
presentation sample in different clinical subgroups 
 
Time from onset of chest pain to presentation was inconsistently reported across studies; where 
reported, the median time from onset ranged from 2.7 to 8.25 hours. Full details of all information 
reported is provided in Appendix 2 (Table a). Two studies specifically investigated variation in test 
performance according to time from symptom onset to presentation.67, 75 Both of these studies were 
conducted in a mixed population, i.e. the target condition was any AMI. Study participants were 
stratified by presentation before or after three hours,67, 75 and before or after six hours.67 Summary 
estimates for the three hour stratification indicated that a presentation sample, using the 99th 
centile threshold had higher sensitivity (94% (95% CI: 92 to 96%)) and lower specificity (77% (95% CI: 
75 to 79%)) for any AMI, when used to asses people presenting more than three hours after the 
onset of chest pain than when used to assess early presenters (sensitivity 78% (95% CI: 71 to 73%) 
and specificity 84% (95% CI: 81 to 86%)), see Table 4. The LR- was also lower when the test was used 
in people presenting after three hours from the onset of chest pain (0.08 (95% CI: 0.05 to 0.11)) than 
in early presenters (0.26 (95% CI: 0.178 to 0.39)). Test performance in people presenting after six 
hours from the onset of chest pain was similar to that observed in people presenting after three 
hours, see Table 4. Figure 7 illustrates the variation in performance characteristics of a single 
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admission sample, using the 99th centile diagnostic threshold, when used in people presenting at 
different times from the onset of chest pain. These data provide some indication that hs-cTnT testing 
on a single admission sample, using the 99th centile diagnostic threshold, may be adequate for rule-
out of AMI where people present after three hours from the onset of chest pain, but that longer 
delays in presentation did not appear to further improve rule-out performance. 
Figure 7: ROC space plot for the Roche Elecsys hs-cTnT assay using the 99th centile threshold and a 
presentation sample in people presenting at different times after symptom onset 
 
Five studies considered the performance of a presentation sample using a threshold equivalent to 
the LoD (5 ng/L) or LoB (3 ng/L) of the assay for the diagnosis of AMI.45, 52, 53, 56, 67, 75 Three studies 
reported data for the 5 ng/L threshold;45, 52, 53, 75 one of these studies only reported data at this 
threshold for participants over 70 years of age.52, 75 When this study was excluded, the summary 
estimates of sensitivity and specificity were 95% (95% CI: 92 to 97%) and 54% (95% CI: 51 to 58%), 
respectively, and the LR+ and LR- were 2.06 (95% CI: 1.40 to 2.64) and 0.09 (95% CI: 0.07 to 0.17), 
respectively (Table 4). Three studies reported data for the 3 ng/L threshold.41, 45, 67 The summary 
estimates of sensitivity and specificity derived from these studies were 98% (95% CI: 95 to 99%) and 
40% (95% CI: 38 to 43%), respectively, and the LR+ and LR- were 1.63 (95% CI: 1.24 to 1.86) and 0.05 
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(95% CI: 0.02 to 0.21), respectively (Table 4).  Only one study was conducted in a population which 
excluded people with STEMI,45 however, estimates of test performance from this study were similar 
to the summary estimates. For the 3 ng/L threshold, sensitivity and specificity derived from this 
study were 95% (95% CI: 92 to 98%) and 48% (95% CI: 44 to 51%), respectively, and the LR+ and LR- 
were 1.83 (95% CI: 1.70 to 1.97) and 0.10 (95% CI: 0.05 to 0.18), respectively, see Table 4.45 For the 5 
ng/L threshold, sensitivity and specificity derived from this study were 93% (95% CI: 89 to 96%) and 
58% (95% CI: 55 to 62%), respectively, and the LR+ and LR- were 2.20 (95% CI: 2.00 to 2.50) and 0.11 
(95% CI: 0.07 to 0.19), respectively, see Table 4.45 These data provide some indication that hs-cTnT 
testing on a single admission sample may be adequate to rule out any AMI or NSTEMI, where a 
lower diagnostic threshold (5 ng/L or 3 ng/L) is used.  
3.2.3.3  Subsequent samples 
The summary estimates of sensitivity and specificity, where the diagnostic threshold was defined as 
the 99th centile for the general population but the sample was taken 1 to 3 hours after presentation, 
were 95% (95% CI: 92 to 97%) and 80% (95% CI: 77 to 82%), based on data from two studies.45, 50 The 
LR+ and LR- were 4.75 (95% CI: 3.98 to 5.23) and 0.06 (95% CI: 0.00 to 0.63), respectively, see Table 
4. Both of these studies were conducted in populations which excluded people with STEMI. 
Unsurprisingly, these data indicate a similar improvement in rule-out performance to that seen 
when the test is used only in people presenting more than three hours after the onset of chest pain. 
3.2.3.4  Multiple samples 
Six studies (data reported in multiple publications) provided data on the performance of a variety of 
diagnostic strategies involving multiple sampling,39, 45, 49, 51, 57, 64, 71, 75 most commonly involving a 
combination of a peak hs-cTn value above the 99th centile diagnostic threshold and a 20% change in 
hs-cTnT over two or three hours following presentation, see Table 4. Figure 8 shows the results of 
these studies plotted in ROC space. One study reported data for this combination over two hours, in 
a population which excluded people with STEMI,45, 49 and this study was used in cost-effectiveness 
modelling. It is important to give full consideration to the optimal way of interpreting combination 
data of this type. As can be seen from the values reported in TabůĞ ? ?ĂƉŽƐŝƚŝǀĞƌĞƐƵůƚĨƌŽŵƚŚĞ ‘E ?
combination (defined as both a peak value above the 99th centile AND a change of >20% over two 
hours) provides the optimum rule-in performance (LR+ 8.42 (95% CI: 6.11 to 11.60)); conversely, a 
negative result from the  ‘KZ ?ĐŽŵďŝŶĂƚŝŽŶ  ?ĚĞĨŝŶĞĚĂƐďŽƚŚno value above the 99th centile AND a 
change of <20% over two hours) provides the optimum rule-out performance (LR- 0.04 (95% CI: 0.02 
to 0.10). Where a patient has a negative result from ƚŚĞ ‘E ?ĐŽŵďŝŶĂƚŝŽŶ ?ƉŽƐŝƚŝǀĞƌĞsult from the 
 ?KZ ?ĐŽŵďŝŶĂƚŝŽŶ ?ĚĞĨŝŶĞĚĂƐĞŝƚŚĞƌĂpeak value above the 99th centile OR a change of >20% over 
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two hours), further investigation is likely to be needed. This optimal interpretation strategy is 
illustrated in Figure 9, along with a potential initial rule-out step, based on a presentation sample 
below the LoB threshold (3 ng/L); this strategy is included in cost-effectiveness modelling. Figure 9 
shows the application of this two stage approach to a theoretical cohort of 1,000 people presenting 
with symptoms suggestive of ACS (STEMI excluded); the estimated number of people with AMI and a 
negative test result who would be erroneously discharged based on this testing strategy is 14 (nine 
at the first stage and five at the second stage). The prevalence of NSTEMI was estimated to be 17%, 
based on data from three studies conducted in populations which excluded people with STEMI.39, 45, 
63 Four studies were excluded from the estimate of prevalence because they were considered to 
have unrepresentative populations; three were conducted in coronary care unit populations, 43, 50, 54 
and one was conducted in a low risk population.78 It was assumed that the diagnostic performance 
of  ‘E ? ? ?KZ ? ĐŽŵďŝŶĂƚŝŽŶƐ ŽĨ ƉĞĂŬ values of hs-cTnT and change over two hours, using the 99th 
centile diagnostic threshold, are the same for people in whom NSTEMI is not ruled out by the initial 
test (hs-cTnT > LoB) as for the initial population; this was because no test performance data were 
available for the combination of initial hs-cTnT test using the LoB diagnostic threshold followed by 
combined peak hs-cTnT and change over two hours using the 99th centile threshold. 
3.2.3.5 Prognostic accuracy 
One study assed the performance of a presentation sample at the LoB (3 ng/L) threshold for the 
prediction of MACE within 30 days of the index presentation.41 The results of this study indicate that 
a positive test was a poor predictor of occurrence of MACE and a negative test was not adequate to 
rule out MACE within 30 days (Table 4). 
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Figure 8: ROC space plot of the Roche Elecsys hs-cTnT assay using multiple sampling strategies 
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Table 4: Accuracy of the Roche hs-cTnT assay: Summary estimates (95% confidence intervals) 
Grouping Population Risk of bias N Sensitivity (%) Specificity (%) LR+ LR- 
Presentation samples        
Any threshold* All Mixed 14 88 (84, 91) 82 (77, 86) 4.88 (3.84, 6.21) 0.14 (0.11, 0.19) 
 All Low/unclear risk of bias on 
patient spectrum 
13 86 (83, 89) 82 (77, 87) 4.89 (3.76, 6.35) 0.16 (0.14, 0.20) 
 All Low/unclear risk of bias on 
patient flow 
11 90 (87, 93) 80 (77, 84) 4.69 (3.88, 5.66) 0.12 (0.09, 0.16) 
 All Low/unclear risk of bias on 
patient spectrum and 
patient flow 
8 89 (85, 92) 80 (74, 85) 4.49 (3.47, 5.80) 0.14 (0.11, 0.18) 
99
th
 centile threshold All Mixed 13 89 (84, 91) 82 (77, 86) 4.96 (3.84, 6.69) 0.14 (0.10, 0.19) 
 Mixed Mixed 8 89 (86, 91) 81 (76, 85) 4.64 (3.74, 5.76) 0.14 (0.11, 0.17) 
 STEMI excluded Mixed 6 88 (78, 93) 84 (74, 90) 5.41 (3.40, 8.63) 0.15 (0.08, 0.26) 
 STEMI excluded Low/unclear risk of bias on 
patient spectrum 
4 81 (75, 86) 85 (70, 93) 5.33 (2.65, 10.72) 0.22 (0.17, 0.29) 
 STEMI excluded Low/unclear risk of bias on 
patient flow 
3 92 (88, 94) 79 (76, 82) 4.38 (3.02, 6.11) 0.10 (0.05, 0.22) 
 STEMI excluded Low/unclear risk of bias on 
patient spectrum and 
patient flow 
1
39
 89 (81, 94) 71 (66, 76) 3.11 (2.55, 3.79) 0.15 (0.08, 0.28) 
 ĂŐĞA䜃? ?ǇĞĂƌƐ High risk for patient flow 152, 75 88 (78, 94) 86 (83, 89) 6.24 (5.03, 7.74) 0.14 (0.07, 0.28) 
 age >70 years High risk for patient flow 1
52, 75
 97 (92, 99) 49 (44, 55) 1.91 (1.71, 2.14) 0.05 (0.02, 0.18) 
 patients with pre-existing CAD High risk for patient flow 1
46, 75
 93 (85, 97) 60 (55, 65) 2.32 (2.02, 2.68) 0.12 (0.05, 0.26) 
 patients without pre-existing CAD High risk for patient flow 1
46, 75
 94 (88, 97) 82 (79, 85) 5.18 (4.36, 6.16) 0.07 (0.04, 0.16) 
 Mixed; Low to moderate pre-test 
probability 
Low 1
48
 89 (70, 97) 85 (79, 89) 5.79 (4.16, 8.06) 0.13 (0.04, 0.41) 
 Mixed; High pre-test probability Low 1
48
 94 (77, 99) 66 (50, 79) 2.78 (1.75, 4.41) 0.09 (0.02, 0.45) 
 Symptom onset <3 hours 1 study high risk for 
patient flow 
2
67, 75
 78 (71, 83) 84 (81, 86) 4.88 (3.91, 5.74) 0.26 (0.18, 0.39) 
 Symptom onset >3 hours 1 study high risk for 
patient flow 
2
67, 75
 94 (92, 96) 77 (75, 79) 4.09 (3.33, 5.70) 0.08 (0.05, 0.11) 
 Symptom onset <6 hours Low 1
67
 83 (74, 89) 83 (79, 86) 4.80 (3.80, 6.08) 0.21 (0.14, 0.32) 
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Grouping Population Risk of bias N Sensitivity (%) Specificity (%) LR+ LR- 
 Symptom onset >6 hours Low 1
67
 94 (78, 99) 81 (75, 86) 4.99 (3.66, 6.81) 0.07 (0.02, 0.34) 
LoD (<5ng/L) All Mixed 3 96 (94, 98) 41 (39, 44) 1.63 (0.34, 7.07) 0.10 (0.07, 0.17) 
 All; Outlying study conducted in 
patients age>70 years removed 
Mixed 2 95 (92, 97) 54 (51, 58) 2.06 (1.40, 2.64) 0.09 (0.07, 0.17) 
 Age >70 years High risk for patient flow 1
52, 75
 100 (95, 100) 1 (0, 3) 1.01 (0.99, 1.03) 0.45 (0.02, 8.56) 
 STEMI excluded High risk for patient 
spectrum 
1
45
 93 (89, 96) 58 (55, 62) 2.20 (2.00, 2.50) 0.11 (0.07, 0.19) 
LoB (<3ng/L) All Mixed 3 98 (95, 99) 40 (38, 43) 1.63 (1.24, 1.86) 0.05 (0.02, 0.21) 
 STEMI excluded High risk for patient 
spectrum 
1
45
 95 (92, 98) 48 (44, 51) 1.83 (1.70, 1.97) 0.10 (0.05, 0.18) 
 Mixed; symptom onset <3 hours Low 1
67
 99 (94, 100) 64 (57, 69) 2.73 (2.31, 3.23) 0.01 (0.00, 0.16) 
 Mixed; symptom onset >3 hours Low 1
67
 99 (91, 100) 33 (28, 38) 1.47 (1.36, 1.59) 0.03 (0.00, 0.47) 
 Mixed; symptom onset <6 hours Low 1
67
 100 (96, 100) 34 (30, 39) 1.52 (1.41, 1.64) 0.01 (0.00, 0.22) 
 Mixed; symptom onset >6 hours Low 1
67
 100 (84, 100) 33 (27, 40) 1.47 (1.31, 1.65) 0.06 (0.00, 0.91) 
1-3 hours after 
presentation 
       
1-3 hours after 
presentation, 99
th
 
centile threshold 
STEMI excluded High risk for patient 
spectrum 
2
45, 50
 95 (92, 97) 80 (77, 82) 4.75 (3.98, 5.23) 0.06 (0.00, 0.63) 
Multiple samples 
99
th
 centile threshold 
(peak) ĂŶĚA? ? ?A? 
(presentation-3hrs) 
All High risk for patient 
spectrum 
1
45, 49
 50 (43, 56) 94 (92, 96) 8.40 (6.10, 11.60) 0.54 (0.47, 0.62) 
99
th
 centile (peak)  
ƚŚƌĞƐŚŽůĚŽƌA? ? ?A? 
(presentation-3hrs) 
All High risk for patient 
spectrum 
1
45, 49
 97 (94, 99) 65 (61, 68) 2.80 (2.50, 3.10) 0.04 (0.02, 0.10) 
99
th
 centile (peak)  
ƚŚƌĞƐŚŽůĚĂŶĚA? ? ?A? 
(presentation-2hrs)   
STEMI excluded Low 1
45, 49
 50 (43, 56) 94 (92, 96) 8.42 (6.11, 11.60) 0.54 (0.47, 0.62) 
99
th
 centile (peak)  
threshold or A? ? ?A? 
(presentation-2hrs)   
STEMI excluded Low 1
45, 49
 97 (94, 99) 65 (61, 68) 2.76 (2.50, 3.05) 0.04 (0.02, 0.10) 
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Grouping Population Risk of bias N Sensitivity (%) Specificity (%) LR+ LR- 
Peak above 99
th
 
centile 
All Mixed 2
45, 49, 57
 94 (91, 97) 84 (82, 86) 5.88 (3.56, 10.24) 0.07 (0.04, 0.11) 
On presentation (30 
minutes after arrival), 
and at 2, 4 and 6-8 
hours or until 
ĚŝƐĐŚĂƌŐĞ PA? ? ?A?
STEMI excluded Low 1
39
 99 (94, 100) 66 (61, 72) 2.94 (2.50, 3.47) 0.01 (0.00, 0.15) 
On presentation and 
at 1 hour PA? ? ?A?
STEMI excluded High risk for patient flow 1
64, 75
 60 (51, 69) 72 (69, 75) 2.15 (1.77, 2.60) 0.55 (0.44, 0.70) 
On presentation and 
at 2 hours PA? ? ?A?
STEMI excluded High risk for patient flow 1
51, 75
 64(52, 74) 84 (80, 87) 3.97(3.05, 5.17) 0.43 (0.31, 0.59) 
On presentation and 
Ăƚ ?ŚŽƵƌƐ Pȴ ?ŶŐ ?> 
Mixed Low 1
71
 95(89, 98) 95(91, 97) 19.19 (10.31, 35.72) 0.05 (0.02, 0.12) 
Prediction of MACE     
On presentation, LoB 
threshold 
STEMI excluded Low 1
41
 85 (74, 92) 46 (41, 51) 1.58 (1.37, 1.81) 0.33 (0.18, 0.59) 
*All but one study used the 99
th
 centile as the threshold, the remaining study used at threshold of 9.5ng/L 
Key results, used in cost-effectiveness modelling are highlighted in bold 
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 Figure 9: Testing pathway for the Roche Elecsys hs-cTnT assay used in cost-effectiveness modeling 
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3.2.4   Diagnostic accuracy of the Abbott ARCHITECT hs-cTnI assay for the rule-out and diagnosis 
of AMI 
3.2.4.1  Study details 
Four diagnostic cohort studies provided data on the diagnostic performance of the Abbott 
ARCHITECT hs-cTnI assay.47, 57, 62, 75 Three of these studies assessed the accuracy of the Abbott 
ARCHITECT hs-cTnI assay for the detection of AMI,47, 57, 75 and the remaining study assessed accuracy 
for the prediction of  MACE within 30 days of the index presentation.62 None of the studies in this 
section provided data specific to the population of interest for this assessment; participants with 
STEMI excluded, i.e. the target condition was NSTEMI rather than any AMI. All four studies were 
conducted in mixed populations. Full details of the baseline characteristics of study populations, 
including baseline cardiac risk factors are provided in Appendix 2 (Table a). 
Where a single diagnostic threshold was used to define a positive test result for AMI, all studies in 
this section reported data for the 99th centile for the general population and a single sample taken at 
presentation. Table 5 provides summary estimates of diagnostic performance for this testing 
strategy. All other combinations of diagnostic threshold and hs-cTnI test timing were assessed by 
only one study. Figure 10 shows the diagnostic performance of all testing strategies assessed plotted 
in ROC space. Diagnostic performance estimates derived from these studies are also provided. Key 
results used in the cost-effectiveness modelling conducted for this assessment are highlighted in 
bold. Full results (including numbers of true positive (TP), false positive (FP), false negative (FN) and 
true negative (TN) test results), for all studies and all datasets, are provided in Appendix 2 (Table c). 
3.2.4.2  Presentation samples 
Summary estimates of sensitivity and specificity based on a diagnostic threshold was defined as the 
99th centile for the general population were 80% (95% CI: 77 to 83%) and 93% (95% CI: 92 to 94%), 
based on data from three studies.47, 57, 75 The LR+ and LR- were 11.47 (95% CI: 9.04 to 16.19) and 0.22 
(95% CI: 0.16 to 0.27), respectively.  All three studies were conducted in a mixed population (i.e. 
where the target condition was any AMI). Based on these data, it is unlikely that hs-cTnI testing on a 
single admission sample, using the 99th centile diagnostic threshold, would be considered adequate 
for rule-out of any AMI, but a positive test result may be useful in ruling-in AMI. 
No studies reported clinical subgroup data, or data on the performance of the test in people 
presenting at different times after symptom onset for the Abbott ARCHITECT hs-cTnI assay. 
One study also considered the performance of a presentation sample using the LoD of the assay as 
the threshold for diagnosing AMI.47 This study provided estimates of sensitivity and specificity of 
CONFIDENTIAL UNTIL PUBLISHED 
52 
100% (95% CI: 98 to 100%) and 35% (95% CI: 32 to 38%), respectively, and the LR+ and LR- were 1.54 
(95% CI: 1.47 to 1.62) and 0.01 (95% CI: 0.00 to 0.08), respectively, see Table 5. These data provide 
some indication that hs-cTnI testing on a single admission sample may be adequate to rule out any 
AMI, where a lower diagnostic threshold (the LoD of the assay) is used.  
3.2.4.3  Subsequent samples 
One study assessed the performance of hs-cTnI testing on a sample taken three hours after 
presentation, where the diagnostic threshold was defined as the 99th centile for the general 
population.57 The summary estimates of sensitivity and specificity, derived from this study, were 
98% (95% CI: 96 to 99%) and 90% (95% CI: 88 to 92%). The LR+ and LR- were 10.16 (95% CI: 8.38 to 
12.31) and 0.02 (95% CI: 0.01 to 0.08), respectively, see Table 5. These data provide some indication 
that a sample taken at three hours after presentation may be informative, at the 99th centile 
threshold, for both rule-out and rule-in of AMI. 
3.2.4.4  Multiple samples 
Two studies provided data on the performance of a variety of diagnostic strategies involving multiple 
sampling (Table 5).47, 57 None of these strategies appeared to offer a performance advantage over 
testing based on a single sample. Figure 11 illustrates our proposed optimal testing pathway for the 
Abbott ARCHITECT hs-cTnI assay; this strategy is included in cost-effectiveness modelling.  As with 
Figure 9, which presents the Roche Elecsys hs-cTnT optimal strategy, Figure 11 shows the application 
of this two stage approach to a theoretical cohort of 1,000 people presenting with symptoms 
suggestive of ACS (STEMI excluded), with a prevalence of NSTEMI of 17%; the estimated number of 
people with AMI and a negative test result who would be erroneously discharged based on this 
testing strategy is three (zero at the first stage and three at the second stage). It was assumed that 
the diagnostic performance of hs-TnI using the 99th centile diagnostic threshold on a sample taken 
three hours after presentation is the same for people in whom NSTEMI is not ruled out by the initial 
test (hs-cTnI > LoD) as for the initial population; this was because no test performance data were 
available for the combination of initial hs-cTnI test using the LoD diagnostic threshold followed by 
three hour hs-cTnI and using the 99th centile threshold. 
3.2.4.5 Prognostic accuracy 
One study assed the performance of a presentation sample at the 99th centile for the prediction of 
MACE within 30 days of the index presentation.62, 75 The results of this study indicate that a positive 
test may be helpful in predicting the occurrence of MACE, whilst a negative test was not adequate to 
rule out MACE within 30 days, see Table 5. 
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Figure 10: ROC space plot of the Abbott ARCHITECT hs-cTnT assay  
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Table 5: Accuracy of the Abbott ARCHITECT hs-cTnI assay: Summary estimates (95% confidence intervals) 
Grouping Population Risk of bias N Sensitivity (%) Specificity (%) LR+ LR- 
Prediction of AMI 
Presentation samples, 99
th
 centile 
threshold 
Mixed Mixed 3
47, 57, 75
 80 (77, 83) 93 (92, 94) 11.47 (9.04, 
16.19) 
0.22 (0.16, 0.27) 
Presentation sample, LoD 
threshold 
Mixed High risk for patient 
flow 
1
47
 100(98, 100) 35 (32, 38) 1.54 (1.47, 1.62) 0.01 (0.00, 0.08) 
3 hours after presentation, 99
th
 
centile threshold 
Mixed High risk for patient 
flow 
1
47
 98 (96, 99) 90 (88, 92) 10.16 (8.38, 
12.31) 
0.02 (0.01, 0.05) 
Presentation and 2-3 hours, peak 
above 99
th
 centile threshold 
Mixed Unclear risk for patient 
spectrum and flow 
1
57
 91 (81, 96) 93 (91, 95) 12.94 (9.74, 
17.19) 
0.09 (0.04, 0.23) 
Above LoD threshold on admission 
ĂŶĚȴ ? ?A? 
Mixed High risk for patient 
flow 
1
47
 82 (78, 86) 52 (49, 55) 1.73 (1.59, 1.88) 0.34 (0.26, 0.43) 
On presentation and at 3 hours, ȴ
20% 
Mixed High risk for patient 
flow 
1
47
 77 (72, 82) 26 (23, 29) 1.04 (0.97, 1.12) 0.87 (0.69, 1.11) 
Prediction of MACE        
Presentation samples, 99
th
 centile 
threshold 
Mixed High risk for patient 
flow for 1 study 
2
62, 75
 88 (85, 91) 93 (91, 94) 12.57 (8.88, 
15.35) 
0.13 (0.06, 0.28) 
Key results, used in cost-effectiveness modelling are highlighted in bold 
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Figure 11: Testing pathway for the Abbott ARCHITECT hs-cTnI assay used in cost-effectiveness modeling 
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3.2.5   Diagnostic accuracy of the Beckman Coulter Access hs-cTnI assay  
3.2.5.1  Study details 
Two diagnostic cohort studies,74, 75 reported in three publications,64, 74, 75 provided data on the 
diagnostic performance of the Beckman Coulter Access hs-cTnI assay. Both studies assessed a pre-
commercial version of the assay and both reported accuracy data for the diagnosis of AMI (any 
AMI,64, 74 or NSTEMI75). No study assessed the performance of the Beckman Coulter Access hs-cTnI 
assay for the prediction of MACE within 30 days of the index admission. The diagnostic performance 
estimates, for all combinations of diagnostic threshold and test timing assessed by in cluded studies, 
are summarised in Table 6. Figure 12 shows the diagnostic performance of all testing strategies 
assessed, plotted in ROC space. 
3.2.5.2  Presentation samples 
Both studies assessed the diagnostic performance of a single sample taken at presentation. One 
study used the 99th centile for the general population as the diagnostic threshold.75 This study was 
considered the most relevant to our assessment and was used to inform cost effectiveness analyses; 
this was the only testing strategy modelled for the Beckman Coulter Access hs-cTnI assay and, for a 
theoretical cohort of 1,000 people presenting with symptoms suggestive of ACS (STEMI excluded) 
with a prevalence of NSTEMI of 17%, the estimated number of people with AMI and a negative test 
result who would be erroneously discharged based on this testing strategy is 14. However, it should 
be noted that the Beckman Coulter hs-cTnI assay evaluated in the this ƐƚƵĚǇǁĂƐĚĞƐĐƌŝďĞĚĂƐ  ‘ĂŶ
ŝŶǀĞƐƚŝŐĂƚŝŽŶĂůƉƌŽƚŽƚǇƉĞ ? ?75 the 99th ĐĞŶƚŝůĞ  ? ?ŶŐ ?> ? ?ĚĞƐĐƌŝďĞĚĂƐ  ‘ĂĐŽƌĚŝŶŐ ƚŽ ƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ? ?
differs from the 99th centile given in the current product information leaflet (40 ng/L).16 The 
estimates of sensitivity and specificity derived from this study were 92% (95% CI: 88 to 95%) and 
75% (95% CI: 72 to 78%) respectively, and the LR+ and LR- were 3.67 (95% CI: 3.26 to 4.13) and 0.11 
(95% CI: 0.07 to 0.17), respectively, see Table 6. The summary estimates, for the two studies 
combined, were very similar (Table 6). 
No studies reported clinical subgroup data, or data on the performance of the test in people 
presenting at different times after symptom onset, for the Beckman Coulter Access hs-cTnI assay. 
3.2.5.3 Subsequent samples 
Neither of the studies reported data for single samples taken at time points other than presentation. 
3.2.5.4 Multiple samples 
One study assessed the diagnostic performance of a >27% change in hsTnI from presentation to one 
hour.75 This testing strategy produced results indicating a decline in both rule-in and rule-out 
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performance compared to the single presentation sample described above (Table 6). 
Figure 12: ROC space plot of the Beckman Coulter Access hs-cTnT assay  
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Table 6: Accuracy of the Beckman Coulter Access hs-cTnI assay: Summary estimates (95% confidence intervals) 
Grouping Population Risk of bias N Sensitivity (%) Specificity (%) LR+ LR- 
Prediction of AMI 
Presentation sample,  9ng/L and 
18 ng/L 
All High risk for 
patient flow 
on 1 study 
2
74, 75
 92 (88, 95) 75 (72, 77) 3.68 (2.46, 4.48) 0.11 (0.07, 0.16) 
Presentation sample, 99
th
 
centile (9ng/L) 
Mixed High risk for 
patient flow 
1
75
 92 (88, 95) 75 (72, 78) 3.67 (3.26, 4.13) 0.11 (0.07, 0.17) 
On pƌĞƐĞŶƚĂƚŝŽŶĂŶĚĂƚ ?ŚŽƵƌ Pȴ
27% 
STEMI excluded High risk for 
patient flow 
1
64, 75
 63 (53, 71) 66 (63, 69) 1.85 (1.55, 2.21) 0.56 (0.44, 0.72) 
Key results, used in cost-effectiveness modelling are highlighted in bold 
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3.2.6  Comparative diagnostic accuracy of the Roche Elecsys hs-TnT assay, the Abbott ARCHITECT 
hs-TnI assay  and the Beckman Coulter Access hs-TnI assay 
Only one study provided data for a direct comparison of the diagnostic performance of all thee hs-
cTn assays in the same polulation.75 These data were for the use of the 99th centile threshold in a 
sample taken at presentation.  This was also the only time point and threshold assessed for each 
study by individual included studies. As can be seen from Tables 7 and 8 below, the summary 
estimates of the performance of each test, derived from all studies reporting data for this threshold, 
were similar to estimates derived from the direct comparison study alone. 
Table 7: Comparison between assays (Presentation samples, 99th centile threshold): Sensitivity and 
specificity (95% CI) 
 Indirect comparison Direct comparison
75
 
Assay N Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Beckman Coulter 
Access hs-cTnI 
2 92 (88, 95) 75 (72, 77) 92 (88, 98) 75 (72, 78) 
Abbott ARCHITECT 
hs-cTnI 
3 80 (77, 83) 93 (92, 94) 77 (72, 82 93 (91, 94) 
Roche Elecsys hs-
cTnT 
15 88 (85, 91) 82 (78, 86) 90 (86, 92) 78 (76, 79) 
 
Table 8: Comparison between assays (Presentation samples, 99th centile threshold):  Likelihood 
ratios (95% CI) 
 Indirect comparison Direct comparison
75
 
Assay N LR+ LR- LR+ LR- 
Beckman Coulter 
Access hs-cTnI 
2 3.32 (2.46, 4.48) 0.11 (0.07, 0.16) 3.68 (3.27, 4.14) 0.11 (0.07, 0.17) 
Abbott ARCHITECT 
hs-cTnI 
3 12.10 (9.04, 16.19) 0.21 (0.16, 0.27) 10.42 (8.49, 12.79) 0.25 (0.20, 0.30) 
Roche Elecsys hs-
cTnT 
15 5.02 (4.02, 6.28) 0.14 (0.11, 0.18) 4.02 (3.65, 4.43) 0.13 (0.10, 0.18) 
 
3.2.7 Selection of diagnostic strategies for inclusion in cost-effectiveness modeling 
Diagnostic strategies, for each hs-cTn assay, were selected for inclusion in cost-effectiveness 
modeling based on optimal diagnostic performance as indicated by data from the systematic review. 
In addition, wherever possible data from studies which excluded patients with STEMI (i.e. where the 
target condition was NSTEMI) were preferentially selected. 
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4.  ASSESSMENT OF COST-EFFECTIVENESS 
This chapter explores the cost-effectiveness of hs-cTn assays (used singly or in series, up to four 
hours from the onset of chest pain/presentation), compared with the current standard of serial 
troponin T and/or I testing on admission and at 10-12 hours after the onset of symptoms for the 
early rule out of AMI in people with acute chest pain.  
4.1  Review of economic analyses of hs-cTn assays 
4.1.1   Search strategy 
Searches were undertaken to identify cost-effectiveness studies of high sensitivity TnT/I. As with the 
clinical effectiveness searching, the main EMBASE strategy for each set of searches was 
independently peer reviewed by a second Information Specialist, using the CADTH Peer Review 
Checklist.28 Search strategies were developed specifically for each database and keywords associated 
with high sensitivity TnT/I were adapted according to the configuration of each database. Full search 
strategies are reported in Appendix 1. 
The following databases were searched for relevant studies from 2005-October 2013: 
x MEDLINE (OvidSP): 2005-2013/10/wk1 
x MEDLINE In-Process Citations and Daily Update (OvidSP): up to 2013/10/1 
x EMBASE  (OvidSP): 2005-2013/10/17 
x NHS Economic Evaluation Database (NHS EED) (Wiley): Cochrane Library Issue 3 2005-July 
2013 
x Health Economic Evaluation Database (HEED) (Wiley): 2005-2013/10/18 
x EconLit (EBSCO): 2005-2013/09/01 
x Science Citation Index (SCI) (Web of Science): 2005-2013/10/21 
x Conference Proceedings Citation Index  W Science (CPCI) (Web of Science): 2005-2013/10/21 
x Research Papers in Economics (REPEC) (Internet): up to 2013/10/21 
x http://repec.org/ 
Identified references were downloaded in Endnote X4 software for further assessment and handling.  
References in retrieved articles were checked for additional studies. 
4.1.2  Inclusion criteria 
Studies reporting a full economic analysis, which related explicitly to the cost-effectiveness of hs-cTn 
or standard cTn (with cTn implying either cTnI or cTnT) testing, with survival and/or Quality-Adjusted 
Life Years (QALYs) as an outcome measure, were eligible for inclusion. Specifically, one of the 
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strategies had to include cTn testing. Studies that only reported a cost-analysis of cTn testing were 
not included in the review. 
4.1.3  Quality assessment 
Full cost-effectiveness studies were appraised using the Drummond checklist.79 
4.1.4  Results 
The literature search identified 152 reports. After initial screening of titles and abstracts, five reports 
were considered potentially relevant: two full papers, and three HTA reports. Two additional reports 
were identified provided by a clinical expert: a Canadian optimal use report (comparable to an HTA 
report) and an abstract which was referred to in this report.  All seven identified reports fulfilled 
inclusion criteria based on full text assessment.  The seven publications related to five studies. Figure 
13 shows the flow of studies through the review process, Table 9 lists the study details and the 
results of the quality assessment are shown in Table 10. 
4.1.4.1  Goodacre (2011)
80
 and Fitzgerald (2011)
81
 
This study was based on the multicentre ƉƌĂŐŵĂƚŝĐ ĐŽŶƚƌŽůůĞĚ ƚƌŝĂů  ?ZĂŶĚŽŵŝƐĞĚ ƐƐĞƐƐŵĞŶƚ ŽĨ
dƌĞĂƚŵĞŶƚ ƵƐŝŶŐ WĂŶĞů ƐƐĂǇ ŽĨ ĂƌĚŝĂĐ DĂƌŬĞƌƐ ?  ?ZdW ? ?80 An economic evaluation was 
undertaken to assess the cost-effectiveness of management based on testing with a panel of point-
of-care cardiac markers compared with management without point-of-care panel assessment. The 
included population consisted of patients presenting to hospital with chest pain due to suspected, 
but not proven, AMI and no other potentially serious alternative pathology or co-morbidity. The 
analysis was performed from an NHS perspective using trial data to estimate the mean costs per 
patient of chest pain-related care and the mean number of QALYs accrued by patients in each arm of 
the trial, with a time horizon of three months. In addition, a decision-analytic model was constructed 
to duplicate (validate) trial results and extrapolate results to a longer time horizon.   
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Figure 13: Flow of studies through the review process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA=conference abstract; JA=journal article; HTA=health technology assessment 
 
Information from clinical 
experts 
n = 2 
Titles and abstracts identified 
from bibliographic databases and 
screened for potential relevance 
n = 152 
Excluded at title and 
abstract screening 
n = 145 
Potentially relevant 
publications obtained for full 
text screening 
n = 7 
Total number of studies included in the 
review 
n = 5 studies (9 publications) 
Excluded at full paper 
screening 
n = 0 
Unobtainable studies 
n = 0 
Goodacre (2011) 
(1 HTAs, 1 JA) 
Vaidya (2012) 
(1 CA) 
Goodacre (2013) 
(1 HTA, 1 JA) 
CADTH (2013) 
(1 HTA) 
Collinson (2013) 
(1 HTA) 
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Resource use data were collected for all patients. Cost and outcome data were collected using 
patient notes and self-completed questionnaires. Unit prices were based partly on a micro-costing 
study on a sample of patients, partly on a study previously undertaken by the investigators, and 
partly on purchase price and national unit costs. QALYs were calculated based on EQ-5D 
measurements. In a sensitivity analysis, productivity costs were included as reported by the patients.  
As it was anticipated that the trial would have limited power to detect a difference in major adverse 
events, the decision-analytic model was intended to explore whether uncertainty around the effect 
of the intervention upon the major adverse event rate could influence the potential cost-
effectiveness of the intervention. The model used trial data to estimate costs and QALYs up to three 
months. Beyond this, lifetime cost and QALYs were estimated from a previous study.82 It was 
assumed that patients who had died at three months would accrue no further costs or QALYs. Those 
who had survived non-fatal myocardial infarction (MI) would accrue costs and QALYs associated with 
coronary heart disease (CHD) (estimated at £10,079 and 6.829, respectively). Those without CHD 
were assigned zero costs and 20 QALYs.   
Empirical results showed that the point-of-care test strategy was dominated by standard care, which 
delivered slightly more QALYs at a lower cost. The probability that point-of-care testing would be 
more cost-effective than standard care at a willingness to pay threshold of £20,000 per QALY was 
less than 1%. The decision-analytic model again resulted in higher costs and less effect for the point-
of-care panel assay compared to standard care, also when extrapolated to lifetime survival. The 
probability of the point-of-care panel assay being cost-effective for the three month and lifetime 
model was 22.3% and 33.6%, respectively. 
The main conclusion was that point-of-care panel assay testing is unlikely to be considered cost-
effective in the NHS, with an 89% probability that standard care was dominant. Cost-effectiveness 
was mainly driven by differences in mean cost, with point estimates suggesting that, per patient, 
point-of-care panel assessment was £211 more expensive than standard care. 
4.1.4.2   Vaidya (2012)
83
 
This study aimed to assess the cost-effectiveness of an hs-TnT assay, alone or in combination with 
the H-FABP assay in comparison with the conventional cTnT assay for the diagnosis of AMI in 
patients presenting to hospital with chest pain.  A decision analytic model was developed to perform 
both a cost-utility analysis (cost per QALY gained) and a cost-effectiveness analysis (cost per life year 
(LY) gained and cost per AMI averted), using a health care perspective and a lifetime time horizon. 
One way and probabilistic sensitivity analyses were conducted.  
CONFIDENTIAL UNTIL PUBLISHED 
64 
The incremental cost-effectiveness ratio (ICER) for hs-TnT compared to conventional cTnT was 
 ? ? ? ? ? ? per QALY gained. For hs-cTnT in combination with H-FABP compared to conventional cTnT 
ƚŚĞ /Z ǁĂƐ  ? ? ? ? ? ? ƉĞƌ Y>z ŐĂŝŶĞĚ ? &Žƌ >z ĂŶĚ D/ ĂǀĞƌƚĞĚ ? ŶŽ /ZƐ ǁĞƌĞ ƌĞƉŽƌƚĞĚ ŝŶ ƚŚĞ
abstract. The probabilistic sensitivity analysis showed the hs-TnT assay to be the preferable strategy 
ǁŝƚŚĂƉƌŽďĂďŝůŝƚǇŽĨŽǀĞƌ ? ?A? ?ĂƚĂĐĞŝůŝŶŐƌĂƚŝŽŽĨ ? ? ? ? ? ?ƉĞƌY>z ?dŚŝƐůĞĚƚŽƚŚĞĐŽŶĐůƵƐŝŽŶƚŚĂƚ
the hs-TnT assay is very cost-effective relative to the conventional cTnT assay. Combining hs-TnT 
with H-FABP did not seem to offer any additional economic or health benefit over the hs-TnT test 
alone.  
4.1.4.3   Goodacre (2013)
7
 and Thokala(2012)
84
 
This study aimed to estimate the cost-effectiveness of using alternative biomarker strategies to 
diagnose MI, and using biomarkers, computed tomography coronary angiography (CTCA) and 
exercise ECG to risk-stratify troponin-negative patients. As the second aim was outside the scope of 
this review, we have only summarised the analysis which compares the biomarker strategies for 
ĚŝĂŐŶŽƐŝŶŐ D/ ? ƌĞĨĞƌƌĞĚ ƚŽ ŝŶ ƚŚĞ ,d ƌĞƉŽƌƚ ĂƐ  ‘ƚŚĞ ĚŝĂŐŶŽƐƚŝĐ ƉŚĂƐĞ ŵŽĚĞů ? ?  dŚĞ ĚŝĨĨĞƌĞŶƚ
diagnostic strategies were applied to a hypothetical cohort of patients attending the ED with 
suspected, but not proven, ACS. Patient characteristics were defined using data from the RATPAC 
trial, 85 ĂƐǁĞůůĂƐƉĂƚŝĞŶƚƐ ?ĂƌƌŝǀĂůƚŝŵĞƐĚƵƌŝŶŐƚŚĞĚĂǇĂƚƚŚĞ ?dŚĞŵŽĚĞůĂƐƐŝŐŶĞĚĞĂĐŚƉĂƚŝĞŶƚĂ
probability of re-infarction or death depending on their characteristics and whether or not they had 
treatment.  The model took a lifetime time horizon. The economic perspective was that of the NHS 
in England and Wales. 
The following strategies were applied to each patient: 
x No testing: discharge all patients without treatment (hypothetical) 
x Standard troponin assay measured at presentation using the 10% coefficient of variation 
as the threshold for positivity 
x Standard troponin assay measured at presentation using the 99th percentile threshold 
x High-sensitivity troponin assay measured at presentation using the 99th percentile 
threshold 
x Standard troponin  assay measured at presentation and 10 hours after symptom onset 
using the 99th percentile threshold 
Blood tests at presentation were assumed to be taken in the ED and so a decision could be made 
within one hour of the test results becoming available. For the 10-12 hours troponin measurement, 
three different scenarios were tested: 
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x  ‘ĚŽĐƚŽƌ-on-ĚĞŵĂŶĚ ? ƐĐĞŶĂƌŝŽ ? ǁŝƚŚ ŵĞĚŝĐĂů ƐƚĂĨĨ ĂǀĂŝůĂďůĞ  ? ? Śours a day to make a 
disposition decision within one hour of the results being available 
x twice-daily ward round scenario, with medical staff only available at twice daily ward 
rounds to make disposition decisions 
x once-daily ward round scenario, with medical staff only available at a once daily ward 
round to make disposition decisions 
Sensitivity and specificity estimates for the presentation troponin tests were obtained by performing 
meta-analysis of estimates from individual primary studies included in the accompanying review. 
The 10 hour troponin test was assumed to have perfect sensitivity and specificity as it was the 
reference standard for the review. This implies that false-positives of the hs-Tn testing at 
presentation will still be discharged home after the 10-12 hour troponin test, but false negatives will 
be dischargĞĚŚŽŵĞǁŝƚŚŽƵƚƚƌĞĂƚŵĞŶƚ ?dŚĞ  ‘ĚŝƐĐŚĂƌŐĞǁŝƚŚŽƵƚƚĞƐƚŝŶŐŽƌƚƌĞĂƚŵĞŶƚ ?ďǇĚĞĨŝŶŝƚŝŽŶ
has perfect specificity, but a sensitivity of 0%.  
The risk of re-infarction and death for patients with MI was based on a study by Mills et al.86 Life 
expectancy of patients with MI and MI with re-infarction was estimated from Polanczyk et al,87 while 
the utility of patients with MI was based on Ward et al.88 The utility of patients with re-infarction 
was estimated by using a multiplicative factor of 0.8 for patients with MI (expert opinion). Patients 
without MI were assigned the life expectancy and utility scores of the general population. Lifetime 
costs for patients with MI were based on Ward et al.88 One-way sensitivity analyses were performed, 
as well as a probabilistic sensitivity analysis. In a secondary analysis, a strategy was added that 
involved alternative biomarkers in combination with the presentation troponin testing.  
The results showed that measuring a 10 hour troponin level in all patients was the most effective 
strategy (ICER £27,546-103,560).  However, at a threshold of £30,000 per QALY, the optimal strategy 
in all but one scenario was measurement of high-sensitivity troponin at presentation, with a 10 hour 
troponin test if positive and discharge home if negative (ICER £7,487 W£17,191 per QALY). The 
exception was a scenario involving patients without known CAD and doctor available on demand to 
discharge the patient, where, using the £30,000 per QALY threshold, the strategy of measuring a 10 
hour troponin level in all patients was optimal (ICER of £27,546 per QALY). Sensitivity analyses 
showed the optimal strategy to vary with different levels of sensitivity and timing of the tests. 
The report concluded that the additional costs that are likely to be incurred by measuring a 10 hour 
troponin level, compared with a presentation high-sensitivity troponin level, are unlikely to 
represent a cost-effective use of NHS resources in most of the scenarios tested.  
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4.1.4.4   CADTH optimal use report
89
 
This report aimed to determine the cost-effectiveness of hs-cTnT and hs-cTnI assays compared with 
each other as well as with cTnI assays in patients with suspected ACS symptoms in the ED. For this 
purpose, three comparators were considered: hs-cTnT, hs-cTnI, and cTnI. As cTnT is no longer 
available in Canada, it was not taken into account in the analysis. The target population consisted of 
65-year old patients presenting to the ED, without ST-segment elevation, who required cTn testing 
for diagnosis of NSTEMI. For the economic evaluation, a decision tree was constructed which 
calculated lifetime cost per QALY from the perspective of a publicly funded health care system.  
The model consisted of a short-term part, which had a time horizon of one year, and a long-term 
part. The short-term part incorporated the testing and treatment procedures and short-term 
outcomes. Patients were tested at presentation at the ED and, if they were not admitted to hospital 
after the first test, they were tested again after six hours. When the patient was admitted after the 
first test, treatment was said to be initiated early, and when a patient was admitted after the second 
test, treatment was late. One year mortality depended on whether a patient had NSTEMI and 
whether they were treated early, treated late, or untreated (in the case of false negative test 
results). Those not suffering from NSTEMI were further stratified into unstable angina (UA) or not 
having acute coronary syndrome (non-ACS). The annual probability of death in the long-term part of 
the model was dependent on patient age, gender, and whether they had suffered an NSTEMI, UA, or 
did not have any type of ACS in the short-term part of the model.  
The sensitivity and specificity for each cTn test at presentation to the ED was derived from the 
systematic review which was also part of this study. In the model, patients with a negative cTn test 
at presentation were assumed to be observed and have a second cTn test six hours later. After the 
second cTn test, 90% of these false negatives were assumed to become true positives.  
Short-term mortality rates and relative risks for treated/non-treated were taken from published 
clinical studies and one non-referenced study. The relative risk for late versus early treatment was 
derived from expert opinion.  Long-term mortality rates were taken from published clinical studies, 
and one non-referenced study. QALYs were calculated by incorporating an age-specific utility 
decrement for patients with NSTEMI. A number of one-way sensitivity analyses were performed, as 
well as a probabilistic sensitivity analysis.  
The base-case results indicated that hs-cTnI was dominated by hs-cTnT, when compared to cTnI, at 
an ICER of $119,377 per QALY. The probabilistic sensitivity analysis showed that, for willingness-to-
pay thresholds up to $124,000, cTnI had the highest probability of being cost-effective. For 
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thresholds over $124,000, hs-cTnT had the highest probability of being cost-effective. The hs-cTnI 
test was not likely to be cost-effective for any value of the threshold.  
The authors concluded that hs-cTnT would be considered the most cost-effective testing strategy if 
willingness to pay for a QALY is $119,377 or more, otherwise cTnI would be the most cost-effective 
test. However, there was a lot of uncertainty in results when model assumptions were changed.  
4.1.4.5  Collinson (2013)
65
 
This study used the decision tree developed in the related HTA by Goodacre et al7 to compare the 
cost-effectiveness of five diagnostic strategies to a hypothetical cohort of patients presenting to 
hospital with symptoms suggestive of myocardial infarction but with no diagnostic ECG changes, no 
known history of coronary heart disease and no major co-morbidities requiring inpatient treatment. 
Essentially, this was a sub-study of the point-of-care arm of the RATPAC trial. All methods and model 
inputs were identical to the study by Thokala et al 84 and the HTA report by Goodacre et al,7 but with 
slightly different strategies applied to the cohort of patients: 
x No testing: ĚŝƐĐŚĂƌŐĞĂůůƉĂƚŝĞŶƚƐǁŝƚŚŽƵƚƚƌĞĂƚŵĞŶƚ ?ƚŚĞŽƌĞƚŝĐĂů ‘ǌĞƌŽ ?ŽƉƚŝŽŶ ? 
x High-sensitivity cTnT at presentation: discharge home if test is negative or admit to 
hospital for troponin-testing at 10-12 hours if positive 
x High-sensitivity cTnT and H-FABP at presentation: discharge home if both tests are 
negative or admit to hospital for troponin testing at 10-12 hours if either test is positive 
x High-sensitivity cTnT at presentation and at 90 minutes as in the RATPAC protocol: 
discharge home if both tests are negative or admit to hospital testing at 10-12 hours if 
either test is positive 
x Standard troponin testing at 10-12 hours (current standard as per NICE guidelines) 
The difference with the other studies is in the addition of H-FABP in the 3rd strategy and in the 
second high-sensitive troponin test at 90 minutes in the 4th strategy. In a secondary analysis, cTnT 
was replaced by cTnI. Sensitivity and specificity of presentation biochemical testing were estimated 
using data from within the study (RATPAC). Standard troponin testing at 10-12 hours was assumed 
to have perfect sensitivity and specificity as this was again the reference standard.    
At the £20,000 per QALY threshold, 10 hour troponin testing was cost-effective (£12,090 per QALY) 
in the doctor-on demand scenario, but not in the other scenarios (once-daily ward round and twice-
daily ward rounds), when high-sensitivity cTnT and H-FABP measurement at presentation was cost-
effective. At the £30,000 per QALY threshold, 10 hour troponin testing was cost-effective in the 
doctor-on-demand scenario and twice-daily ward rounds scenario (£24,600 per QALY), whereas the 
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troponin T and H-FABP measurement at presentation strategy was cost-effective (£14,806 per QALY) 
in the once-daily ward round scenario. Secondary analysis using cTnI instead of cTnT showed that 
cTnI testing at presentation and at 90 minutes was cost-effective in all three scenarios at the 
£20,000 per QALY threshold and in two of the scenarios at the £30,000 per QALY threshold, with 10 
hour troponin being cost-effective only in the doctor-on-demand scenario (£24,327 per QALY). The 
overall conclusion was that 10 hour troponin testing is likely to be cost-effective compared with 
rapid rule-out strategies only if patients can be discharged as soon as a negative result is available 
and a £30,000 per QALY threshold is used.  
4.1.4.6   Summary of studies included in the cost-effectiveness review 
Most of the studies identified in this review have found that the question whether hs-Tn testing is 
cost-effective cannot be answered unequivocally. In favour of hs-Tn testing, the abstract by Vaidya 
et al83 concluded ƚŚĂƚŚƐdŶd ƚĞƐƚŝŶŐ ŝƐ  ‘ǀĞƌǇĐŽƐƚĞĨĨĞĐƚŝǀĞ ?ĂŶĚ ƚŚĞ ƐƚƵĚǇďǇ Goodacre7 concluded 
ƚŚĂƚ ‘ƚŚĞŽƉƚŝŵĂůƐƚƌĂƚĞŐǇŝŶĂůůďƵƚŽŶĞƐĐĞŶĂƌŝŽǁĂƐŚŝŐŚ-sensitivity troponin at presentation, with a 
10 hour troponin test if positive and dischĂƌŐĞŚŽŵĞŝĨŶĞŐĂƚŝǀĞ ? ?Ɖ ?ǆǀ ? ?The other papers reported 
ICERs that were considerably higher and with substantial uncertainty. The accuracy of high-sensitive 
tests and the efficiency of decision-making based on test results were important drivers of cost-
effectiveness. 
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Table 9: Summary of included full papers 
Study details Goodacre et al (2011)
80
 
Fitzgerald et al
81
 
Vaidya et al
83
 Thokala et al
84
 Goodacre et al 
(2013)
7
 
CADTH report
89
 Collinson et al
65
 
Population People presenting to hospital 
with chest pain due to 
suspected but not proven 
AMI, and no other potentially 
serious alternative  pathology 
or comorbidity 
Patients presenting to the 
hospital with chest pain 
Patients attending hospital 
with symptoms suggesting MI, 
but a normal or non-diagnostic 
ECG, and no major 
comorbidities requiring 
hospital treatment 
65-year-old patients 
presenting to an ED with 
ischemic chest pain, 
without ST-segment 
elevation ECG who 
require cTn testing for 
diagnosis of NSTEMI 
Patients presenting to hospital with 
symptoms suggestive of myocardial 
infarction but with no diagnostic 
ECG changes (ST deviation >1 mm 
or T-wave inversion > 3mm), no 
known history of coronary heart 
disease and no major 
comorbidities requiring inpatient 
treatment  
Time horizon Lifetime Lifetime Lifetime Lifetime Lifetime 
Objective  Estimate the cost-
effectiveness of the point-of-
care panel in terms of mean 
costs and QALYs accrued 
compared with standard care 
Assess the cost-
effectiveness of a high-
sensitive troponin T assay 
(hs-cTnT), alone or 
combined with the H-
FABP assay in comparison 
with the conventional 
cardiac troponin (cTnT) 
assay for the diagnosis of 
AMI 
Estimate the incremental cost 
per QALY of delayed troponin 
testing compared with 
presentation testing and no 
testing to determine which 
diagnostic strategy should be 
recommended   
To investigate the cost-
effectiveness of hs-cTnT 
and hs-cTnI assays 
compared with each 
other as well as with cTnI 
assays in patients with 
suspected ACS symptoms 
in the ED 
Assess the cost-effectiveness of 
measuring a combination of 
biomarkers compared with 
measurement of cardiac troponin 
alone 
Source of 
effectiveness 
information 
Data from within the trial up 
to 3 months, and beyond this, 
lifetime costs and QALY 
estimates were used from a 
previous economic 
evaluation.  
No information Sensitivity and specificity were 
taken from the meta-analysis 
as reported in the 2013 
Goodacre report
7
, the RATPAC 
trial
65
 was used for sampling 
patient characteristics, Mills
86
 
for risk of re-infarction and 
death, Polanczyk
90
 for life 
expectancy of patients with MI 
and re-MI  
Sensitivity and specificity 
from review performed in 
same report. Proportion 
UA and mortality 
estimated based on 
published studies, and 
one unpublished study. 
Utility decrements based 
on published study 
Sensitivity and specificity data 
derived from data from the HTA 
(RATPAC) itself, short-term survival 
and probability of re-infarction 
based on Mills et al
86
. Source for 
long-term survival and QALYs not 
specified  
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Study details Goodacre et al (2011)
80
 
Fitzgerald et al
81
 
Vaidya et al
83
 Thokala et al
84
 Goodacre et al 
(2013)
7
 
CADTH report
89
 Collinson et al
65
 
Comparators  Diagnostic assessment using 
the point-of-care biochemical 
marker panel 
 
Conventional diagnostic 
assessment without the panel 
Conventional cTnT 
 
hs-cTnT 
 
hs-cTnT combined with H-
FABP 
no biochemical testing: 
discharge all patients without 
treatment (hypothetical) 
 
standard troponin assay 
measured at presentation 
using the 10% coefficient of 
variation as the threshold for 
positivity 
 
standard troponin assay 
measured at presentation 
using the 99
th
 percentile 
threshold 
 
high-sensitivity troponin assay 
measured at presentation 
using the 99
th
 percentile 
threshold 
 
standard troponin assay 
measured at presentation and 
10h after symptom onset using 
the 99
th
 percentile threshold 
hs-cTnT 
 
hs-cnI 
 
cTnI 
no testing: discharge all patients 
without treatment 
 
hs-cTn at presentation: discharge 
home if test is negative or admit to 
hospital for troponin testing at 10-
12 hours if positive 
 
hs-cTn and a combination of 
cytoplasmic or neurohormone 
biomarkers at presentation: 
discharge home if both tests are 
negative or admit to hospital for 
troponin testing at 10-12 hours if 
either test is positive 
 
hs-cTn at presentation and at 90 
minutes as in the RATPAC protocol: 
discharge home if both tests are 
negative or admit to hospital for 
troponin testing at 10-12 hours if 
either test is positive 
 
standard troponin testing at 10-12 
hours 
Unit costs  Microcosting study within 
RATPAC; PSSRU unit costs 
No information Admission and treatment were 
based on the national tariff. 
Lifetime costs for MI patients 
were taken from Ward
88
. The 
price of a troponin test was 
taken from the 2011 Goodacre 
Costs of hospital 
admission were based on 
the Ontario Case Costing 
Initiative database and 
the Ontario Schedule of 
Benefits for Physician 
Hospital stay and treatment for MI 
based on NHS reference cost, 
biochemical testing based on 
Goodacre et al
80
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Study details Goodacre et al (2011)
80
 
Fitzgerald et al
81
 
Vaidya et al
83
 Thokala et al
84
 Goodacre et al 
(2013)
7
 
CADTH report
89
 Collinson et al
65
 
report
80
 Services. Costs of ED visits 
were based on a hospital 
in Soutwestern Ontario 
and the Ontario Schedule 
of Benefits. Unit prices of 
cTn tests were based on 
information provided by 
the manufacturers.  
Measure of 
benefit  
QALY AMI survivor QALY QALY QALYs 
Study type Trial-based economic 
evaluation up to 3 months, 
decision tree lifetime. Cost-
utility analysis. 
Model-based cost-
effectiveness and cost-
utility study 
Model-based cost-utility 
analysis 
Model-based cost-utility 
analysis 
Model-based cost-utility study 
Model 
assumptions 
2-hour delay between 
sampling and results available 
4 hours after presentation at 
ED patients moves to 
inpatient dept 
1 hour delay between 
presentation and start 
biomarker sampling 
After short term (test-
treatment-outcome), progress 
only depends on whether or 
not patient had MI, and 
whether or not this was 
treated 
No information 10h troponin testing has 
perfect sensitivity and 
specificity (since it is the 
reference standard) 
2h delay from the time at 
which sampling could be 
performed to results available 
For presentation testing 
strategies: decision made 
within 1h of results available 
For 10h testing strategies: 
decision made according to 
scenario applied 
Diagnostic strategy only 
non-NSTEMI patients are 
further classified into 
Unstable Angina (UA) or 
non-ACS, with 
consequences for costs 
and outcome 
there is a small survival 
benefit (RR 1.01) of 
treating early compared 
to treating late 
(presentation testing vs. 
standard testing) 
- 10h troponin testing has 
perfect sensitivity and 
specificity (since it is the 
reference standard) 
- presentation blood tests 
taken in ED and results 
available and decision 
made within 2h of 
sampling 
- for testing at 10-12h 
delays according to 
scenario used 
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Study details Goodacre et al (2011)
80
 
Fitzgerald et al
81
 
Vaidya et al
83
 Thokala et al
84
 Goodacre et al 
(2013)
7
 
CADTH report
89
 Collinson et al
65
 
influences outcomes among 
patients with MI 
Perspective  NHS Healthcare NHS Publicly funded health 
care system 
NHS in England and Wales 
Discount rate  Not mentioned No information Nothing mentioned 5% discount rate applied 
to costs and QALYs 
Nothing mentioned 
Uncertainty 
around cost-
effectiveness 
ratio expressed  
iCE plane, probability of 
strategy being 
dominated/cost-effective 
Cost-effectiveness 
acceptability curves (not 
shown in abstract) 
Cost-effectiveness acceptability 
curves for probabilistic 
sensitivity analysis (PSA) 
results, per scenario 
as reported in outcomes 
of one-way sensitivity 
analyses, and also (for 
PSA) In cost-effectiveness 
acceptability curves 
Cost-effectiveness acceptability 
curves 
Sensitivity 
analysis 
Probabilistic sensitivity 
analysis 
One way and probabilistic One-way sensitivity analyses, 
scenario analyses (doctor on 
demand, twice-daily ward 
round, and once daily ward-
round), and PSA 
 Secondary  analysis using  cTnI 
instead of cTnT, scenario analysis 
(doctor-on-demand, once-daily 
ward round, twice-daily ward 
round), and PSA 
Outcome (cost 
and Lys/QALYs) 
per comparator  
Empirical 3 months 
PoC £ 1217 QALY 0.158 
SC £ 1006 QALY 0.161 
For the model, no outcomes 
per comparator were 
reported 
No information For doctor-on-demand 
scenario, per 1000 patients 
without known CAD: 
No testing £ 965,994 QALY 
26,227 
Pres standard trop, 10% CV £ 
1,560,361 QALY 26,345 
Pres standard trop, 99th perc £ 
1,609,760 QALY 26,352 
Pres hs-trop, 99th perc £ 
1,806,910 QALY 26,279 
10h troponin £ 2,016,540 QALY 
26,286 
cTnI $ 2,018 QALY 8.1385 
hs-cTnI $ 2,082 QALY 
3.1389 
hs-cTnT $ 2,186 QALY 
8.1399 
For doctor-on-demand scenario, 
per 1000 patients: 
No testing £ 965,994 QALY 26,227 
hs-cTnT at presentation £ 
1,581,263 QALY 26,349 
hs-cTnT at presentation and 90 min 
£ 1,715,526 QALY 26,354 
hs-cTnT and H-FABP at 
presentation £ 1,682,362 QALY 
26,359 
10-hour troponin £ 2,016,540 QALY 
26,386 
Summary of Empirical 3 months: hsTnT vs cTnT: incr 111 For doctor-on-demand cTnI reference No testing  W reference strategy 
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Study details Goodacre et al (2011)
80
 
Fitzgerald et al
81
 
Vaidya et al
83
 Thokala et al
84
 Goodacre et al 
(2013)
7
 
CADTH report
89
 Collinson et al
65
 
incremental 
analysis 
Increment PoC vs SC £211 
QALY -0.00282 
Probability PoC cost-effective 
at £20,000/QALY = 0.4% 
Decision model 3 months: 
Increment PoC vs SC £169 
QALY -0.002 
Probability PoC cost-effective 
at £20,000/QALY = 22.3%  
Decision model lifetime: 
Increment PoC vs SC £329 
QALY -0.087 
Probability PoC cost-effective 
at £20,000/QALY = 33.6%  
Euros and 16-17 lives per 
1,000 AMI ICER 3,748 
Euro/QALY 
hsTnT + H-FABP vs cTnT: 
incr 178 Euros ICER 5,717 
Euro /QALY   
scenario: 
Pres standard trop. 10% CV vs 
no testing: £ 5030/QALY 
Pres standard trop 99
th
 perc vs 
pres standard trop 10% CV: £ 
6518/QALY 
Pres hs-trop 99
th
 perc vs pres 
standard trop 99
th
 perc: £ 
7487/QALY 
10h trop vs pres hs-trop 99
th
 
perc: £  27,546/QALY  
hs-cTnI incr costs $64 incr 
QALYs 0.000352 
dominated (by extension) 
hs-cTnT incr costs $168 
incr QALYs 0.001408 ICER 
$119,377/QALY 
hs-cTnT compared to no testing 
ICER £ 5012/QALY 
hs-cTnT at presentation and at 90 
minutes: dominated 
hs-cTnT and H-FABP compared to 
hs-cTnT at presentation: ICER 
£11,026/QALY (as reported bu t 
correct number should be 10,871) 
10-hour troponin compared to Hs-
cTnT and H-FABP: ICER 
£12,090/QALY 
Conclusion: if a rapid-rule out 
strategy with a sensitivity of 95% 
(and specificity of around 90%) 
would be available, then a 10-hour 
troponin strategy does not seem 
cost-effective  
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Table 10: Checklist of study quality for full papers included 
  
Goodacre et al. 
2011 
80
 & 
Fitzgerald et al 
81
 
Vaidya et al 
83
 
Thokala et al 
84
 
& Goodacre et 
al 2013 
7
 
CADTH report 
89
 Collinson et al 
65
 
Study design       
The research question is stated A? A? A? A? A? 
The economic importance of the research question is stated A? X A? A? A? 
The viewpoint(s) of the analysis are clearly stated and justified A? A? A? A? A? 
The rationale for choosing alternative programmes or interventions compared 
is stated 
A? X A? A? A? 
The alternatives being compared are clearly described A? A? A? A? A? 
The form of economic evaluation used is stated A? A? A? A? A? 
The choice of form of economic evaluation is justified in relation to the 
questions addressed 
A? A? A? A? A? 
Data collection      
The source(s) of effectiveness estimates used are stated A? X A? A? A? 
Details of the design and results of effectiveness study are given (if based on a 
single study) 
A? X A? A? A? 
Details of the methods of synthesis or meta-analysis of estimates are given (if 
based on a synthesis of a number of effectiveness studies) 
A? X A? A? A? 
The primary outcome measure(s) for the economic evaluation are clearly 
stated 
A? A? A? A? A? 
Methods to value benefits are stated A? X A? A? x 
Details of the subjects from whom valuations were obtained were given A? X x x x 
Productivity changes (if included) are reported separately NA X NA NA NA 
The relevance of productivity changes to the study question is discussed NA X NA NA NA 
Quantities of resource use are reported separately from their unit costs A? X x x x 
Methods for the estimation of quantities and unit costs are described A? X A? A? A? 
Currency and price data are recorded A? X A? A? A? 
Details of currency of price adjustments for inflation or currency conversion are 
given 
A? X x x x 
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Goodacre et al. 
2011 
80
 & 
Fitzgerald et al 
81
 
Vaidya et al 
83
 
Thokala et al 
84
 
& Goodacre et 
al 2013 
7
 
CADTH report 
89
 Collinson et al 
65
 
Details of any model used are given A? X A? A? A? 
The choice of model used and the key parameters on which it is based are 
justified 
A? X A? A? A? 
Analysis and interpretation of results      
Time horizon of costs and benefits is stated A? A? A? A? A? 
The discount rate(s) is stated x X x A? x 
The choice of discount rate(s) is justified NA X NA A? NA 
An explanation is given if costs and benefits are not discounted x X x NA x 
Details of statistical tests and confidence intervals are given for stochastic data A? X A? A? A? 
The approach to sensitivity analysis is given A? X A? A? A? 
The choice of variables for sensitivity analysis is justified A? X A? A? A? 
The ranges over which the variables are varied are justified A? X A? A? A? 
Relevant alternatives are compared A? A? A? A? A? 
Incremental analysis is reported A? X A? A? A? 
Major outcomes are presented in a disaggregated as well as aggregated form A? X A? A? A? 
The answer to the study question is given A? A? A? A? A? 
Conclusions follow from the data reported A? A? A? A? A? 
Conclusions are accompanied by the appropriate caveats A? X A? A? A? 
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4.2   Model structure and methodology 
4.2.1 Troponin tests considered in the model 
The health economic analysis will estimate the cost-effectiveness of different troponin testing 
methods for diagnosing or ruling-out NSTEMI, in patients presenting at the ED with suspected NSTE-
ACS, who have no major comorbidities requiring hospitalisation (e.g. as heart failure (HF) or 
arrhythmia) and in whom STEMI has been ruled out. Those diagnosed with NSTEMI will then be 
admitted to the hospital for AMI treatment and those diagnosed as without NSTEMI can be 
discharged without AMI treatment and further hospital stay. AMI treatment might include aspirin, 
statins and angiotensin converting enzyme inhibitors and consideration of coronary 
revascularisation for high-risk cases.7 Initiating AMI treatment for NSTEMI will reduce the probability 
of major adverse cardiac events, particularly cardiac death and re-infarction.  
Standard serial troponin testing, for patients with acute chest pain due to possible ACS, does not 
achieve optimal sensitivity in detecting AMI until 10-12 hours after onset of symptoms. Waiting for 
10-12 hours after symptoms onset is burdensome for patients and induces additional health care 
costs. Therefore, various alternatives have been proposed, using more sensitive troponin tests, for 
the early rule-out of NSTEMI (within the four hour NHS emergency department target).91 
Two hs-cTn assays (Roche Elecsys hs-cTnT and Abbott ARCHITECT hs-cTnI) are currently used in NHS 
laboratories in England and Wales. One additional assay (Beckman Coulter hs-cTnI) was listed in the 
scope for this assessment, pending CE marking. However, each of these tests can be used at 
different time points and with different diagnostic thresholds, resulting in multiple possible 
strategies for each test. Whether or not a test strategy was included in the economic model was 
decided based on optimal diagnostic performance given the available evidence on accuracy for a 
population with STEMI ruled out, and on applicability in clinical practice (see section 3.2). The test 
strategies evaluated in the model are: 
x Standard troponin at presentation and at 10-12 hours (reference standard) 
x Roche Elecsys hs-cTnT at presentation: 99th centile threshold 
x Roche Elecsys hs-cTnT (optimal strategy): LoB threshold at presentation followed by 99th 
centile threshold peak within three ŚŽƵƌƐĂŶĚ ?Žƌȴ ? ?A? ?ĐŽŵƉĂƌĞĚƚŽƉƌĞƐĞŶƚĂƚŝŽŶƚĞƐƚ ?
at 1-3 hours (Figure 9) 
x Abbott ARCHITECT hs-cTnI at presentation: 99th centile threshold   
x Abbott ARCHITECT hs-cTnI (optimal strategy): LoD threshold at presentation, followed by 
99th centile threshold at three hours (Figure 11) 
x Beckman Coulter hs-cTnI at presentation: 99th centile threshold 
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x No testing, discharge all patients without testing or treatment (only in sensitivity 
analyses). A troponin test may not be indicated when clinical judgment assesses the 
probability that a patient is experiencing an AMI as low. Therefore, consistent with the 
protocol, this hypothetical strategy, is included in sensitivity analyses wherein the AMI 
prevalence is varied. 
In the base case, it was assumed that standard troponin had perfect sensitivity and specificity 
(reference case) for diagnosing AMI.  Using this assumption, all patients testing positive on an hs-cTn 
test but negative on the standard troponin would be classified as false positives. This implies that 
their risk for adverse events would be the same as for those patients testing negative on both the 
hs-cTn test and the standard troponin and that they ought to be discharged home without further 
immediate treatment. However, recent evidence has shown that patients with a negative standard 
troponin, but a positive hs-cTn, may be at higher risk for adverse events than patients who test 
negative on both the standard and the high-sensitive troponin.92 A secondary analysis was therefore 
performed, which attributed a higher risk of adverse events to a proportion of patients testing false 
positive with the hs-cTn test.  
Based on the available evidence, two analyses were performed: 
x Base case analysis 
x Secondary analysis, assuming that false positives in the hs-cTn testing strategies do not 
have the same risk for adverse events as true negatives. Instead, these patients were 
assigned a higher risk for (re-)infarction and death, to reflect the idea that when the 
hs-cTn test gives a positive result, in some cases this must be caused by a disease 
process, whether or not the strict definition of AMI is met. The risk of adverse events 
in patients with positive hs-cTn but a negative standard troponin is higher than the 
patients testing negative on both the hs-cTn test and the standard troponin, but lower 
than risk of adverse events in patients diagnosed with NSTEMI (i.e. both positive hs-
cTn and standard troponin). 
4.2.2 Model structure 
This assessment uses the HTA report by Goodacre et al7 as a starting point for cost-effectiveness 
modelling. The Goodacre report compared the cost-effectiveness of several diagnostic strategies for 
ACS. The assessment group received the health economic model (in Simul8; SIMUL8 Corporation) 
that this HTA was based on and this model was used as a starting point to develop a de novo model 
(in Microsoft Excel) adapted to better fit the scope of the current assessment. In the health 
economic model the mean expected costs and quality adjusted life years (QALYs) were calculated for 
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each alternative strategy. These long-term consequences were estimated based on the accuracy of 
the different testing strategies followed by AMI treatment or discharge from the hospital without 
AMI treatment for patients presenting at the emergency department with suspected NSTE-ACS, 
ŝŶĐůƵĚŝŶŐƉĂƚŝĞŶƚƐǁŝƚŚE^dD/ĂŶĚƉĂƚŝĞŶƚƐǁŝƚŚŽƵƚE^dD/ ?ǁŚŽĂƌĞ ĨƵƌƚŚĞƌƐƵďĚŝǀŝĚĞĚ ŝŶƚŽ  ‘Ŷo 
ACS ?ŶŽh ?ĂŶĚ  ‘h ? ?For this purpose a decision tree and a Markov model were developed. The 
decision tree was used to model the 30-day outcomes after presentation, based on test results and 
the accompanying treatment decision. These outcomes consisted of  ‘Ŷo ACS ?ŶŽh ?,  ‘h ?,  ‘Non-fatal 
AMI (untreated) ?,  ‘Non-fatal AMI (treated) ? and  ‘Death ?. The decision tree is shown in Figure 14. 
The long-term consequences in terms of costs and QALYs were estimated using a Markov cohort 
model (Figure 15) with a lifetime time horizon (60 years). The cycle time was one year, except for the 
first cycle which was adjusted to 335.25 days (365.25-30) to ensure that the decision tree period (30 
days) and the first cycle combined summed to one year. The following health states were included: 
x No acute coronary syndrome and no unstable angina (no ACS, no UA) 
x Unstable angina 
x Post AMI (treated and untreated) 
x Post AMI with re-infarction 
x Death 
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Figure 14: Decision tree structure 
 
Patients with
suspect NSTE-ACS 
presenting at ED
POPULATION
Single/serial
hs Troponin test A
ALTERNATIVES
Serial Troponin T/I
(comparator)
Single/serial
hs Troponin test C
AMI treatment
TREATMENT 
(based on test result)
Discharge
OUTCOME
(short term)
No ACS, no UA
Death
Non-fatal AMI
(untreated)
As above
As above
As above
Unstable angina
Non-fatal AMI 
(treated)
Single/serial
hs Troponin test B As above
 
Figure 15: Markov model structure 
No ACS, no UA
Post-AMIa
Death
Post-AMI with
re-infarction
Unstable
angina
a
 During the first year post-AMI a distinction is made between treated and untreated AMI. 
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4.2.3 Model parameters  
Estimates for the model input parameters were retrieved from the literature and by consulting 
experts for unpublished data. Accuracy estimates were derived from the systematic review 
component of this assessment (see section 3.2). 
4.2.3.1  Transition probabilities 
An overview of transition probabilities is provided in Table 11. 
Table 11: Transition probabilities 
 Estimate Se / 95% CI Distribution Source 
Decision tree (short term)     
NSTEMI prevalence
a
 0.170 0.028 Beta Santalo (2013),
39
 
Aldous (2012),
45
 
Sebbane 
(2013),
63
 
APACE
75
 
Proportion of UA (of all non-NSTEMI 
patients) 
0.160 0.038 Beta CADTH (2013)
89
 
Decision tree (30-day) probabilities 
Mortality (30-day) treated AMI 0.097 0.012 Beta Pope (2000)
93
 
Mortality (30-day) untreated AMI 0.105 0.069 Beta Pope (2000)
93
 
Mortality (30-day) treated UA 0.021 0.005 Beta Pope (2000)
93
 
Mortality (30-day) no ACS 
b 
- Fixed ONS
94
) 
     
Markov model (long term)     
AMI incidence 
c 
- Fixed British Heart 
Foundation
95
 
     
Annual re-infarction (treated)
d
 0.023 0.001 Beta Smolina (2012)
96
 
RR re-infarction (untreated versus treated)
e
 2.568 1.366 - 5.604 LogNormal Mills (2011)
86
 
     
Annual mortality no ACS 
b 
- Fixed ONS
94
 
Annual mortality post-MI
d
 0.066 0.000 Beta Smolina (2012)
96
 
Annual mortality post re-infarction
d
 0.142 0.002 Beta Smolina (2012)
96
 
HR mortality (UA versus NSTEMI) 0.781 0.581 - 1.053 LogNormal Allen (2006)
97
 
RR mortality (untreated versus treated)
d
 1.877 0.951 - 4.239 LogNormal Mills (2011)
86
 
     
Secondary analysis (adjusted relative risk 
for patients tested false positive) 
    
OR AMI
f
  ***** ************* LogNormal personal 
communication
92
 
OR Death
f
 ***** ************* LogNormal personal 
communication
92
 
Proportion of AMI
g
 ***** ***** Beta personal 
communication
92
 
Proportion of Death
g
 ***** ***** Beta personal 
communication
92
 
RR AMI
f, h
  ***** ************* LogNormal personal 
communication
92
 
RR Death
f, h
 ***** ************* LogNormal personal 
communication
92
 
a
 Prevalence was used to calculate the proportions of true/false positives/negatives based on test accuracy. Prevalence was 
calculated using identified studies that included NSTEMI data (see section 3.2.3.4).  
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b
 Based on age dependent mortality from the general population. 
c
 Age dependent incidence from the general population. 
d
 Weighted average based on gender (58.1% males 
7
). 
e
 Increased re-infarction and mortality risk for untreated (versus treated) was assumed for the 1
st
 year after presentation at 
ED, after which no increased risk was assumed (RR = 1.0). 
f
 For patients with both positive high sensitivity and standard troponin tests versus patients with positive high sensitivity 
and negative standard troponin tests. 
g
 Proportion for patients with both positive high sensitivity and standard troponin tests. This proportion is only used to 
covert odds ratios to relative risks. 
h
 ORs were converted to RRs using the method described by Zhang and Yu.
98
 
4.2.3.2  Decision tree 
The proportions of patients testing positive or negative (and thus commencing AMI treatment or 
being discharged from the hospital) were based on the estimated accuracy of the testing strategies 
considered (Table 12) and the estimated prevalence of NSTEMI in the UK (17.0% with standard error 
2.8%; Table 11).39,, 45,, 63,, 75 This prevalence was higher than that derived from the RATPAC trial99 and 
used in the Goodacre model,7 because the RATPAC study population was a low risk population.81,, 85 
The proportion of true positives (TP), false positive (FP), false negative (FN) and true negatives (TN) 
were calculated as follows:  
x TP = NSTEMI prevalence × sensitivity  
x FP = (1  W NSTEMI prevalence) × (1  W specificity) 
x FN = NSTEMI prevalence × (1  W sensitivity)  
x TN = (1  W NSTEMI prevalence) × specificity  
Subsequently, the proportions of patients who receive AMI treatment (TP + FP), and who are 
discharged without AMI treatment (TN + FN) were calculated. These results are listed in Table 13. 
Table 12: Test accuracy  
 Sensitivity (Se)a Specificity (Se)a Distribution Source 
Serial standard troponin 
testing 
1.00 (-) 1.00 (-) Fixed Assumption 
Roche Elecsys hs-cTnT (99th 
centile at presentation) 0.88 (0.04) 0.84 (0.04) 
Multivariate 
normal 
Chapter 3 
Roche Elecsys hs-cTnT 
(optimal strategy)
b
 0.93 (0.02)
c
 0.82 (0.01)
C
 
Multivariate 
normal 
Chapter 3 
Abbott ARCHITECT hs-cTnI 
(99th centile at 
presentation) 0.80 (0.02) 0.93 (0.00) 
Multivariate 
normal 
Chapter 3 
Abbott ARCHITECT hs-cTnI 
(optimal strategy)
d
 0.98 (0.01)
c
 0.94 (0.01)
c
 
Multivariate 
normal 
Chapter 3 
Beckmann Coulter hs-cTnI 
(99th centile) 0.92 (0.02) 0.75 (0.01) 
Multivariate 
normal 
Chapter 3 
No troponin test
e
 0.00 (-) 1.00 (-) Fixed Assumption 
a
 Correlation between sensitivity and specificity was calculated to be -0.262 based on the covariance matrix from the 
metandi output for the Roche Elecsys hs-cTnT (99th centile at presentation) test (see also Chapter 3). This correlation was 
assumed to be equal for other tests as it was not possible to obtain the covariance matrix for the other tests included in 
the economic analyses (a minimum of 4 studies is required). 
b
 Calculated based on accuracy data for the Roche Elecsys hs-cTnT optimal testing strategy 
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c
 Standard error based on probabilistic sensitivity analysis 
d
 Calculated based on accuracy data for the Abbott ARCHITECT optimal testing strategy 
e
 The no testing strategy is only considered in sensitivity analyses. 
 
Table 13: Test outcomes 
 TP FP FN TN PPV NPV LR+ LR- 
Serial standard troponin testing 0.17 0.00 0.00 0.83 1.00 1.00 1.00 0.00 
Roche Elecsys hs-cTnT (99th 
centile at presentation)  0.15 0.13 0.02 0.70 0.53 0.97 5.41 0.15 
Roche Elecsys hs-cTnT (optimal 
strategy) 0.16 0.15 0.01 0.68 0.51 0.98 5.05 0.09 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) 0.14 0.06 0.03 0.77 0.70 0.96 11.47 0.21 
Abbott ARCHITECT hs-cTnI 
(optimal strategy) 0.17 0.05 0.00 0.78 0.76 1.00 15.67 0.02 
Beckman Coulter hs-cTnI (99th 
centile) 0.16 0.21 0.01 0.62 0.43 0.98 3.67 0.11 
No troponin test
a
 0.00 0.00 0.17 0.83 0.00 0.83 0.00 1.00 
a
 The no testing strategy is only considered in sensitivity analyses, the FN rate represents the prevalence of NSTEMI 
After treatment, TP patients in the decision tree weƌĞĂůůŽĐĂƚĞĚƚŽ ‘EŽŶ-ĨĂƚĂůD/ ?ƚƌĞĂƚĞĚ ? ?ĂŶĚ&W
patients weƌĞĨƵƌƚŚĞƌƐƵďĚŝǀŝĚĞĚďĞƚǁĞĞŶ ‘ŶŽ^ ?ŶŽh ?ĂŶĚ ‘h?(based on the proportion of UA 
among non-NSTEMI patients; Table 11). After being discharged, TN patients were also subdivided 
ďĞƚǁĞĞŶ  ‘ŶŽ ^ ? ŶŽ h ? ĂŶĚ  ‘h ? ? ǁŚĞƌĞĂƐ &E ƉĂƚŝĞŶƚƐweƌĞ ĂůůŽĐĂƚĞĚ ƚŽ  ‘EŽŶ-fatal AMI 
 ?ƵŶƚƌĞĂƚĞĚ ? ? ?dŚĞƉƌŽƉŽƌƚŝŽŶƐŽĨ&E ?Ɛ ?ƌĞƉŽrted in Table 13, can be considered as the proportions of 
AMIs that would have been missed when assuming that standard troponin testing has perfect 
accuracy. Finally, to calculate the total number of deaths in the decision tree, the probability of 30 
day mortality was assigned based on above mentioned subdivision (Table 11). It was assumed that 
UA is always correctly diagnosed, hence the mortality probability for treated UA was used. 
4.2.3.3  Markov model 
The age-dependent AMI incidence in the UK95 was used to model the occurrence of AMI for patients 
ŝŶ ƚŚĞ ŚĞĂůƚŚ ƐƚĂƚĞƐ  ‘ŶŽ ^ ? ‘ ĂŶĚ  ‘h ? ? /ƚ ǁĂƐ ĂƐƐƵŵĞĚ ƚŚĂƚ Ăůů D/Ɛ ŝŶ ƚŚĞ DĂƌŬŽǀ ƚƌĂĐĞ ĂƌĞ
diagnosed correctly and thus receive treatment. For paƚŝĞŶƚƐ ŝŶ ƚŚĞ  ‘WŽƐƚ-D/ ? ŚĞĂůƚŚ ƐƚĂƚĞ ? ƚŚĞ
probability of re-infarction after treated AMI was retrieved from a UK record linkage study, 
(n=387,452) which assessed long-term survival and recurrence after AMI.96 For the current 
assessment the probabilities for females and males were weighted according to the estimated 
proportion of females and males in the population (males = 58.1%7). The re-infarction probability for 
ƚŚĞ ‘Post-MI with re-ŝŶĨĂƌĐƚŝŽŶ ?ŚĞĂůƚŚƐƚĂƚĞŝƐĞƋƵĂůƚŽƚŚĞƌĞ-ŝŶĨĂƌĐƚŝŽŶƉƌŽďĂďŝůŝƚǇĨŽƌƚŚĞ ‘Post-MI ?
health state. The re-infarction RR for people with untreated versus treated AMI was calculated from 
a recent study by Mills et al86 based on patients with a troponin concentration of 5 to 19 ng/L. This 
RR was assumed only for the first year after presentation at ED, after which no increased risk was 
assumed (i.e. RR = 1.0 for untreated versus treated AMI after year 1).  
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Age-ĚĞƉĞŶĚĞŶƚŵŽƌƚĂůŝƚǇĨƌŽŵƚŚĞŐĞŶĞƌĂůƉŽƉƵůĂƚŝŽŶǁĂƐƵƐĞĚĨŽƌƉĂƚŝĞŶƚƐŝŶƚŚĞ ‘ŶŽ^ ?ŶŽh ‘
health state.94 &Žƌ ƚŚĞ  ‘WŽƐƚ-D/ ? ĂŶĚ  ‘WŽƐƚ-MI with re-ŝŶĨĂƌĐƚŝŽŶ ? ŚĞĂůƚŚ ƐƚĂƚĞƐ ? ŵŽƌƚĂůŝƚǇ ǁĂƐ
extracted from the record linkage study.96 Again the study by Mills et al86 was used to calculate the 
mortality RR for untreated versus treated AMI for the first year, after which an RR of 1.0 was used. 
Finally, a multivariate adjusted mortality hazard ratio for UA versus NSTEMI was retrieved from a 
study by Allen et al97 to calculate mortality after UA. 
All input parameters for the Markov model are reported in Table 11.  
4.2.3.4  Health state utilities 
Age-ĚĞƉĞŶĚĞŶƚƵƚŝůŝƚǇƐĐŽƌĞƐ ?ĨƌŽŵƚŚĞh<ŐĞŶĞƌĂůƉŽƉƵůĂƚŝŽŶ ?ǁĞƌĞĐĂůĐƵůĂƚĞĚĨŽƌƉĂƚŝĞŶƚƐŝŶƚŚĞ ‘ŶŽ
^ ?ŶŽh ‘Śealth state based on a linear regression model.88 These age-dependent utility scores 
from the general population, were combined with age-dependent disutilities for AMI89 to calculate 
ƵƚŝůŝƚŝĞƐ ĨŽƌ ƚŚĞ  ‘WŽƐƚ-D/ ? ŚĞĂůƚŚ ƐƚĂƚĞƐ  ?ǁŝƚŚ Žƌ ǁŝƚŚŽƵƚ ƌĞ-infarction). Utility scores for the  ‘h ?
health state were calculated based on Post-MI utility scores and a utility increment of 0.010 (Table 
14).88 
Table 14: Utility scores 
 Estimate Se Distribution Source 
No ACS, no UA     
Intercept 1.060 0.029 Normal 
88
 
Disutility for age 0.004 0.001 Normal 
88
 
     
Post-MI (disutility compared to no 
ACS by age) 
    
Age = 45 0.060 0.001 Normal 
89
 
Age = 55 0.051 0.001 Normal 
89
 
Age = 65 0.025 0.001 Normal 
89
 
Age = 75 0.007 0.001 Normal 
89
 
     
UA     
Utility increment compared to AMI 0.010 0.042 Normal 
88
 
 
4.2.3.5  Resource use and costs 
Test specific resource use consisted of the number of tests performed and the duration of hospital 
stay (hours) before discharge / AMI treatment (see Table 15). 
Table 15: Resource use (test specific) 
 Estimate Se / Range Distribution Source 
Number of tests     
Serial standard troponin testing 2.00 - Fixed Assumption 
Roche Elecsys hs-cTnT (99th centile at 
presentation)  
1.00 - Fixed Assumption 
Roche Elecsys hs-cTnT (optimal 1.60 0.02 Beta
a
 Chapter 3 
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strategy) 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) 
1.00 - Fixed Assumption 
Abbott ARCHITECT hs-cTnI (optimal 
strategy) 
1.71 0.02 Beta
a
 Chapter 3 
Beckman Coulter hs-cTnI (99th 
centile) 
1.00 - Fixed Assumption 
No troponin test
b
 0.00 - Fixed Assumption 
     
Hospital stay (hours) before 
discharge / AMI treatment
b
 
    
Serial standard troponin testing 14 13 - 15 Beta PERT Assumption 
Roche Elecsys hs-cTnT (99th centile at 
presentation) 
3 - Fixed Assumption 
Roche Elecsys hs-cTnT optimal 
strategy (patients with AMI ruled-out 
on first test) 
3 - Fixed Assumption 
Roche Elecsys hs-cTnT optimal 
strategy (patients receiving both tests) 
5 4 - 6  Assumption 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) 
3 - Fixed Assumption 
Abbott ARCHITECT hs-cTnI optimal 
strategy (patients with AMI ruled-out 
on first test) 
3 - Fixed Assumption 
Abbott ARCHITECT hs-cTnI optimal 
strategy (patients receiving both tests) 
6 - Fixed Assumption 
Beckman Coulter hs-cTnI (99th centile 
at presentation) 
3 - Fixed Assumption 
No troponin test
b
 0 - Fixed Assumption 
a
 Beta distribution is used to estimate the probability of patients receiving a second test (all patients receive the 
presentation test). 
b
 The no testing strategy is only considered in sensitivity analyses. 
c
 Includes delay from the time at which sampling could be performed to the time at which results became available (2 
hours) and delay between arrival at hospital and troponin assessment commencing (1 hour).  
Health state costs (Table 16) were mainly retrieved from previous economic evaluations conducted 
in the UK.88, 100 ,ĞĂůƚŚƐƚĂƚĞĐŽƐƚƐĨŽƌƚŚĞ ‘h ? ? ‘WŽƐƚ-D/ ?ĂŶĚ ‘WŽƐƚ-MI with re-ŝŶĨĂƌĐƚŝŽŶ ?ĐŽŶƐŝƐƚĞĚŽĨ
costs for three 15 minute GP consultations and medication costs.88 For the first year in the  ‘h ? 
health state, costs for clopidogrel (for 60%) and hospitalisation (for 50%) were added to this. The 
ĨŝƌƐƚǇĞĂƌĐŽƐƚƐĨŽƌďŽƚŚ ‘WŽƐƚ-D/ ?ŚĞĂůƚŚƐƚĂƚĞƐǁĞƌĞďĂƐed on resource data from the Nottingham 
Heart Attack Register. 100 
Additionally, costs of fatal events, retrieved from a UK economic evaluation,88 were accumulated for 
ĂůůĨĂƚĂůD/ ?Ɛ ?&ŽƌƚŚŝƐƉƵƌƉose, it was assumed that all 30 ĚĂǇĚĞĂƚŚƐĂĨƚĞƌ ‘ƚƌƵĞ ?E^dD/ǁĞƌĞĚƵĞ
to a fatal AMI event. In addition, AMI treatment costs were calculated based on the national tariff 
for non-elective AMI without complications (HRG code: EB10Z).101 To calculate the hospital stay costs 
for patients, based on the number of hours before the test results become available, non-elective 
NHS reference costs for the general medical ward were used (HRG code: EB01Z).101 For this purpose, 
it was assumed that doctors were available on demand and the time to discharge was delayed due 
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to time between arrival at the emergency department and start of first sampling (one hour) and the 
time between sampling and the results being available (two hours). In the case of multiple testing, 
the one hour delay between arrival at the emergency department and start of sampling was only 
applied to the first test, however, this also affected the timing of the second test if applicable. The 
two hour delay before test results become available applies to all tests performed. Incorporating 
these time delays effectively implies that only tests at presentation and tests performed one hour 
after presentation could inform decisions within the NHS four hour emergency department target. 
All other multiple testing strategies, as well as standard troponin testing at 10-12 hours, would 
require a transfer from emergency department to the general ward (patients are transferred to the 
general ward four hours after presentation at the emergency department). Finally, the test costs 
includes panel (including reagent, machine and maintenance), calibration and quality control costs. 
Depending on the annual number of panels, the test costs varied between £16.18 and £21.33, for 
annual rates of testing of 1,500 and 3,000 respectively.99 Based on clinical expert input, the average 
test costs were estimated to be £20 (2011 price level).7, 84  
Table 16: Health state costs, event costs and unit prices 
 Estimate (£) Se / range (£) Distribution Source 
Health state costs     
No ACS, no UA first year 0 - Fixed Assumption 
No ACS, no UA subsequent year 0 - Fixed Assumption 
UA first year
a
 548 - Fixed 
88
 
UA subsequent year
a
 213 - Fixed 
88
 
Post-MI first year
a, b
 5,835 488 Gamma 
100
 
Post-MI subsequent years
a, b
 213 - Fixed 
88
 
     
Event costs     
Costs of fatal AMI
a
 1,451 - Fixed 
88
 
AMI treatment costs 3,436 - Fixed 
101
 
     
Unit prices     
Hospital stay costs (per hour)
c
 27 - Fixed 
101
 
Test costs
a
 20 18 - 26 Beta PERT 
7, 84
 
a
 Price inflated to the 2012-2013 price level based on price indices from The Hospital & Community Health Services 
index.
102
 
b
 Post-MI with or without re-infarction. 
c
 NHS reference costs was divided by 24 to obtain the hourly costs
 
4.2.4 Overview of main model assumptions 
The main assumptions in the health economic analyses were: 
x Serial troponin testing (comparator) has perfect accuracy (sensitivity = 1.0 and specificity = 
1.0). 
x For the Roche Elecsys hs-cTnT and Abbott ARCHITECT hs-cTnI optimal strategies it was 
assumed that the sensitivity and specificity for the subpopulation not discharged after the 
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presentation test is equal to the sensitivity and specificity for the initial group (presenting at 
the emergency department). 
x The life expectancy, quality of life and costs for false positive patients is, in the base case 
analysis, equal to the life expectancy, quality of life and costs of true negative patients. This 
assumption was amended in the secondary and sensitivity analyses. 
x In contrast with AMIs occurring during the decision tree period, all AMIs (either first or re-
infarction) occurring in the Markov trace are diagnosed correctly and thus treated.  
x UA is always correctly diagnosed and thus treated.  
x The re-infarction probability for ƚŚĞ ‘WŽƐƚ-MI with re-infarction ? health state is equal to the 
re-infarction probability for the  ‘WŽƐƚ-D/ ?ŚĞĂůƚŚƐƚĂƚĞ ? 
x The increased Post-MI re-infarction and mortality probabilities for untreated AMI were 
assumed to last one year: afterwards a RR of 1.0 was applied (for untreated versus treated 
AMI). 
x There is no additional benefit of starting treatment early, so treatment effect for high-
sensitive strategies is equal to treatment effect for standard troponin strategy. 
x All 30 day deaths (after presentation at the emergency department) are due to fatal AMI 
events and will receive the associated costs.  
4.3  Model analyses 
Expected costs, life years (LYs) and QALYs were estimated for all troponin testing methods. Discount 
rates of 3.5% and a half-cycle correction were applied for both costs and effects. Incremental cost 
and QALYs for each strategy versus standard troponin and versus the next best alternative were 
calculated. The ICER was then calculated by dividing the incremental costs by the incremental QALYs. 
Probabilistic sensitivity analyses (10,000 simulations) were performed, and cost-effectiveness 
acceptability curves (CEACs) and cost-effectiveness acceptability frontiers (CEAFs) were constructed. 
Although CEACs can be used to illustrate decision uncertainty, the option with the highest 
probability of being cost-effective may not necessarily be the most cost-effective option according to 
the expected values. Moreover, CEAFs can be used to illustrate the decision uncertainty surrounding 
the most cost-effective option 103. 
4.3.1 Secondary analysis 
For the base case it was assumed that patients who tested negative on standard troponin and 
positive on hs-cTn tests would experience life expectancy and quality of life equal to true negative 
patients. This assumption is, however, debatable. As unpublished data92 show that patients with a 
negative standard troponin test and positive hs-cTn test have an increased risk of (re-)infarction and 
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mortality compared to those who test negative on both standard troponin and hs-cTn tests. 
Although this risk was not as high as in patients with both positive standard troponin and positive hs-
cTn tests, it could still be considered prognostically important. Therefore, in this secondary analysis 
the risk of re-infarction and mortality was adjusted for patients who tested false positive (Table 11). 
It was assumed that for this proportion of patients, the relative treatment benefit would be equal to 
that for true positive patients. ƐƚŚĞƉƌĞǀĂůĞŶĐĞŽĨƚŚŝƐ ‘ŚŝŐŚĞƌƌŝƐŬƐƵďŐƌŽƵƉ ?ŝƐůŬely to be the same 
for all comparators, it was assumed that this proportion was equal to the lowest proportion of FP 
patients for all hs-ĐdŶƚĞƐƚƐ ?dĂďůĞ ? ? ? ?dŚŝƐ ‘ŚŝŐŚĞƌƌŝƐŬƐƵďŐƌŽƵƉ ?ǁĂƐĂƐƐƵŵĞĚƚŽďĞƚƌĞĂƚĞĚĨŽƌĂůů
hs-cTn tests (since they tested positive with these tests) and untreated for the standard troponin 
test (since they tested negative with this test), thus affecting the probability of adverse outcomes 
and treatment costs. In addition, the post-MI utility and health state costs were used for ƚŚŝƐ ‘ŚŝŐŚĞƌ
ƌŝƐŬƐƵďŐƌŽƵƉ ? ? 
4.3.2 Sensitivity analysis 
For both the base case and the secondary analysis, the following one-way sensitivity analyses were 
performed to assess the impact of model assumptions and input parameters on the estimated 
outcomes: 
Model assumptions: 
x The assumption that the increased post AMI re-infarction and mortality probabilities for 
untreated AMI only lasts for one year was replaced by the assumption that these 
probabilities would remain elevated for a lifetime. 
x The assumption that a doctor will be available on demand and thus that a decision could 
be made immediately (as in the base case) was replaced with an assumed delay (one, 
two or three hours) before a doctor is available and a decision could be made.  
x As for the previous sensitivity analysis except that the delay (one, two or three hours) 
only applies once patients are transferred to the general ward four hours after 
presentation; (no delay in the emergency department).  
x A total delay of 1.5 hours is assumed (includes delay from the time at which sampling 
could be performed to the time at which results became available and delay between 
arrival at hospital and troponin assessment commencing) rather than assuming a total 
delay of three hours (base case). 
x AMI treatment costs are applied for patients who tested false positive rather than using 
no treatment costs, as assumed in the base case analysis.  
x In addition to the health state costs of UA during the first year, the AMI treatment costs 
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are also applied for patients with UA (during the first year), rather than assuming no 
additional treatment costs.  
Model input parameters (varied to lower and upper boundary of the 95% CI unless stated 
otherwise): 
x Test costs (test costs was varied over a wider range (£5-£40) than the 95% confidence 
interval) 
x AMI treatment costs (- / + 25%) 
x Post-MI first year health state costs 
x Utility increment for UA compared to AMI 
x Post-MI disutility compared to no ACS 
x Mortality (30 day) treated AMI (decision tree) 
x Mortality (30 day) untreated AMI (decision tree) 
x Annual re-infarction (after initial AMI) 
x RR re-infarction (untreated versus treated AMI) 
x Annual Post-MI mortality 
x Annual Post-MI mortality after re-infarction 
x HR mortality (UA versus NSTEMI) 
x RR mortality (untreated versus treated AMI) 
4.3.3 Subgroup analysis 
For both the base case and the secondary analysis, a number of subgroup analyses were performed. 
The main subgroup analyses were based on age- and gender-dependent re-infarction probabilities, 
mortality probabilities (for all health states), AMI incidence and quality of life, and could be applied 
to all test strategies. Accuracy was thus assumed to be subgroup independent (equal to the base 
case values). The following subgroups were identified:   
x Gender 
x Age (45, 55, 65, 75 and 85) 
x People with a history of previous NSTEMI. For this purpose, a proportion of 0% UA was 
ĂƐƐƵŵĞĚĂŶĚƚŚĞƉƌŽďĂďŝůŝƚŝĞƐĨŽƌƚŚĞŝŶŝƚŝĂů ‘WŽƐƚ-D/ ?ŚĞĂůƚŚƐƚĂƚĞǁĞƌĞƵƐĞĚĨŽƌƚŚĞ ‘ŶŽ^ ?
ŶŽh ?ŚĞĂůƚŚƐƚĂƚĞĂŶĚƚŚĞƉƌŽďĂďŝůŝƚŝĞƐĨŽƌ ‘Post-MI with re-ŝŶĨĂƌĐƚŝŽŶ ?ǁĞƌĞƵƐĞĚĨŽƌƚŚĞ 
 ‘Post-MI ? ĂŶĚ  ‘Post-MI with re-ŝŶĨĂƌĐƚŝŽŶ ? ŚĞĂůƚŚ ƐƚĂƚĞƐ ? dŚŝƐ ƐƵďŐƌŽƵƉ ĂŶĂůǇƐŝƐ ǁĂƐ ŽŶůǇ
performed for the base case as for the secondary analysis this would lead to lower mortality 
probabilities for false positive patients compared with true negative patients (which seems 
implausible). 
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x Subgroups with varying AMI prevalence (1%, 5%, 10%, 20%, 30%). In these analyses the no 
testing strategy was included as a comparator since a troponin test may not be indicated 
when clinical judgment assesses that the probability that a patient is experiencing an AMI is 
low. For the no testing strategy it is assumed that patients will be discharged immediately. 
It should be noted that the main subgroup analyses (described above) differ from the subgroups 
described in the systematic review component of this assessment (see section 3.2.3.2), for which 
specific accuracy and prevalence data were available. Additional subgroup analyses were performed 
based on these subgroup-specific accuracy data. However, these analyses could only be performed 
for the Roche Elecsys hs-cTnT assayat presentation sample, using the 99th centile diagnostic 
threshold, compared with standard troponin testing; no subgroup-specific accuracy data were 
available for the other two hs-cTn assays. The following subgroups were considered: 
x ŐĞA? ? ?ĂŶĚĂŐĞAN ? ? 
x Patients with pre-existing CAD and patients without pre-existing CAD 
x ^ǇŵƉƚŽŵ ŽŶƐĞƚ AM ? ŚŽƵƌƐ ďĞĨŽƌĞ ƉƌĞƐĞŶƚĂƚŝŽŶ ĂŶĚ ƐǇŵƉƚŽŵ ŽŶƐĞƚ A? ? ŚŽƵƌƐ ďĞĨŽƌĞ
presentation 
The subgroups with high pre-test probability and low to moderate pre-test probability were not 
considered as the prevalence data for these subgroups was unknown. 
4.4  Results of cost-effectiveness analyses 
This section describes the results using probabilistic analyses for the base case analysis and the 
secondary analysis. In addition the sensitivity analyses (deterministic) and subgroup analyses are 
described (these deterministic analyses are also presented in tabulated form in Appendices 5 to 9. 
4.4.1 Base case analysis 
The base case analysis includes six test strategies. Tables 17 and 18 show the probabilistic results of 
this analysis. Standard troponin testing was both most effective (15.101 life years, 11.730 QALYs) 
and most expensive (£2,697). The Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th 
centile diagnostic threshold, was least effective (15.076 life years, 11.712 QALYs) and least expensive 
(£2,253). Compared to standard troponin testing, hs-cTn testing resulted in ICERs ranging between 
£90,725 and £24,019 savings per QALY lost.   
Comparisons based on the next best alternative showed that for willingness to pay values below 
£6,600 per QALY, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile 
diagnostic threshold, would be cost-effective. For thresholds between £6,600 and £30,631 per QALY, 
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the Beckmann Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was 
cost-effective; above £30,631 per QALY the Abbott ARCHITECT hs-cTnI optimal strategy was cost-
effective. Standard troponin becomes cost-effective at a threshold of £90,725 or higher (Table 18). 
Table 17: Probabilistic results for base case analysis: life years  
Strategy Life years 
Compared to Standard 
troponin 
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 
15.076 
(95% CI: 14.321 - 15.764) -0.024 
Roche Elecsys hs-cTnT (99th centile at presentation) 
15.085 
(95% CI: 14.332 - 15.770) -0.016 
Beckman Coulter hs-cTnI (99th centile at presentation) 
15.090 
(95% CI: 14.338 - 15.774) -0.010 
Roche Elecsys hs-cTnT optimal strategy 
15.091 
(95% CI: 14.340 - 15.776) -0.009 
Abbott ARCHITECT hs-cTnI optimal strategy 
15.098 
(95% CI: 14.351 - 15.780) -0.003 
Standard troponin 
15.101 
(95% CI: 14.356 - 15.781) 
 
 
At a willingness to pay threshold of £20,000 and £30,000 per QALY, the Beckmann Coulter hs-cTnI 
assay at presentation, using the 99th centile diagnostic threshold, had a probability of being cost-
effective of 47% and 35% respectively. Although the Beckmann Coulter hs-cTnI assay at 
presentation, using the 99th centile diagnostic threshold, was cost-effective at a willingness to pay 
threshold of £30,000 per QALY, the Abbott ARCHITECT hs-cTnI optimal strategy had the highest 
probability of being cost-effective (35%) at this threshold (Figure 16 and 17). 
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Table 18: Probabilistic results for base case analysis: costs and QALYs  
Strategy   
Compared to Standard 
troponin 
Compared to next best strategy 
 Costs (95% CI) QALYs (95% CI) A?ŽƐƚƐ A?Y>zƐ 
A?ŽƐƚƐ ?
A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ 
A?ŽƐƚƐ ?
A?Y>zƐ 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) 
£2,253 
(95% CI: £1,702 - 
£2,877) 
11.712 
(95% CI: 10.312 - 
13.157) -£444 -0.018 £24,019     
Roche Elecsys hs-cTnT (99th 
centile at presentation) 
£2,296 
(95% CI: £1,731 - 
£2,936) 
11.718 
(95% CI: 10.319 - 
13.165) -£401 -0.012 £33,247 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) £42 0.006 
Extendedly 
dominated 
Beckmann Coulter hs-cTnI (99th 
centile at presentation) 
£2,324 
(95% CI: £1,755 - 
£2,971) 
11.723 
(95% CI: 10.323 - 
13.172) -£373 -0.008 £48,337 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) £71 0.011 £6,600 
Roche Elecsys hs-cTnT (optimal 
strategy) 
£2,422 
(95% CI: £1,846 - 
£3,077) 
11.723 
(95% CI: 10.326 - 
13.171) -£275 -0.007 £38,528 
Beckmann Coulter hs-cTnI (99th 
centile at presentation) £98 0.001 
Extendedly 
dominated 
Abbott ARCHITECT hs-cTnI 
(optimal strategy) 
£2,491 
(95% CI: £1,908 - 
£3,148) 
11.728 
(95% CI: 10.328 - 
13.177) -£206 -0.002 £90,725 
Beckmann Coulter hs-cTnI (99th 
centile at presentation) £167 0.005 £30,631 
Standard troponin 
£2,697 
(95% CI: £2,113 - 
£3,359) 
11.730 
(95% CI: 10.334 - 
13.179) 
   Abbott ARCHITECT hs-cTnI 
(optimal strategy) £206 0.002 £90,725 
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Figure 16: Cost-effectiveness acceptability curve and incremental cost-effectiveness plane 
(incremental costs and QALYs compared to standard troponin) for base case analysis 
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Figure 17: Cost-effectiveness acceptability frontier for base case analysis 
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4.4.2 Secondary analysis 
The secondary analysis includes the same six test strategies. This analysis assumed that in a 
proportion of patients with a false positive hs-cTn test (i.e. positive hs-cTn test and a negative 
standard troponin test), there is prognostic significance (i.e. it is associated with an increased risk of 
adverse events (mortality and re-infarction)).  
Standard troponin testing was least effective (14.785 life years, 11.464 QALYs) and most expensive 
(£3,058). The Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic 
threshold was the least effective hs-cTn test strategy (14.833 life years, 11.501 QALYs) and overall 
the least expensive strategy (£2,781). The Abbott ARCHITECT hs-cTnI optimal strategy was most 
effective (14.855 life years, 11.518 QALYs). Standard troponin testing was dominated by all hs-cTn 
testing strategies. 
Comparisons based on the next best alternative showed that for willingness to pay values below 
£13,623 per QALY, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile 
diagnostic threshold, was cost-effective. For thresholds between £13,623 and £14,562 per QALY, the 
Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, was cost-
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effective; above £14,562 per QALY the Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective 
(Tables 19 and 20).  
Table 19: Probabilistic results for secondary analysis: life years  
Strategy Life years 
Compared to 
Standard troponin 
Abbott ARCHITECT hs-cTnI (99th centile at presentation) 
14.833 
(95% CI: 14.104 - 15.487) 0.048 
Roche Elecsys hs-cTnI (99th centile at presentation) 
14.837 
(95% CI: 14.111 - 15.491) 0.052 
Beckman Coulter hs-cTnI (99th centile at presentation) 
14.839 
(95% CI: 14.114 - 15.488) 0.054 
Roche Elecsys hs-cTnT (optimal strategy) 
14.843 
(95% CI: 14.119 - 15.494) 0.058 
Abbott ARCHITECT hs-cTnI (optimal strategy) 
14.855 
(95% CI: 14.129 - 15.502) 0.070 
Standard troponin 
14.785 
(95% CI: 14.061 - 15.436)  
 
At a willingness to pay threshold of £20,000 and £30,000 per QALY, the Abbott ARCHITECT hs-cTnI 
optimal strategy had the highest probability of being cost-effective (53% and 67% respectively; 
Figures 18 and 19). 
CONFIDENTIAL UNTIL PUBLISHED 
95 
Table 20: Probabilistic results for secondary analysis: costs and QALYs 
Strategy   
Compared to Standard 
troponin 
Compared to next best strategy 
 Costs (95% CI) QALYs (95% CI) 
A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ 
A?ŽƐƚƐ ?
A?Y>zƐ 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) 
£2,781 
(95% CI: £2,247 
- £3,388) 
11.501 
(95% CI: 10.087 
- 12.918) -£277 0.037 
Dominant     
Roche Elecsys hs-cTnT (99th 
centile at presentation) 
£2,823 
(95% CI: £2,271 
- £3,442) 
11.504 
(95% CI: 10.092 
- 12.920) -£235 0.040 
Dominant 
Abbott ARCHITECT hs-cTnI (99th 
centile at presentation) 
£42 0.003 £13,623 
Beckmann Coulter hs-cTnI (99th 
centile at presentation) 
£2,851 
(95% CI: £2,299 
- £3,477) 
11.506 
(95% CI: 10.093 
- 12.923) -£207 0.042 
Dominant 
Roche Elecsys hs-cTnT (99th 
centile at presentation) 
£28 0.001 
Extendedly 
dominated 
Roche Elecsys hs-cTnT (optimal 
strategy) 
£2,949 
(95% CI: £2,390 
- £3,579) 
11.509 
(95% CI: 10.095 
- 12.926) -£109 0.045 
Dominant 
Roche Elecsys hs-cTnT (99th 
centile at presentation) 
£126 0.004 
Extendedly 
dominated 
Abbott ARCHITECT hs-cTnI 
(optimal strategy) 
£3,018 
(95% CI: £2,446 
- £3,659) 
11.518 
(95% CI: 10.103 
- 12.936) -£39 0.054 
Dominant 
Roche Elecsys hs-cTnT (99th 
centile at presentation) 
£196 0.013 £14,562 
Standard troponin 
£3,058 
(95% CI: £2,485 
- £3,708) 
11.464 
(95% CI: 10.053 
- 12.869)   
 
Abbott ARCHITECT hs-cTnI 
(optimal strategy) 
£39 -0.054 Dominated 
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Figure 18: Cost-effectiveness acceptability curve and incremental cost-effectiveness plane 
(incremental costs and QALYs compared to standard troponin) for secondary analysis 
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Figure 19: Cost-effectiveness acceptability frontier for secondary analysis 
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4.4.3 Sensitivity analysis 
The deterministic analysis for the base case analysis is presented in Appendix 5. When it was 
assumed that the Post-MI re-infarction and mortality probabilities would remain elevated for 
untreated AMI for a life-time period, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 
99th centile diagnostic threshold, was cost-effective for thresholds below £1,642 per QALY, at which 
point the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, 
became cost-effective up to a threshold of £7,602 per QALY. The Abbott ARCHITECT hs-cTnI optimal 
strategy was cost-effective for thresholds between £7,602 and £26,532 per QALY. Standard troponin 
testing was cost-effective for thresholds above £26,532 per QALY. Consistent with the base case 
analysis, all  ‘ŶŽĚŽĐƚŽƌŽŶĚĞŵĂŶĚ ?ƐĞŶƐŝƚŝǀŝƚǇĂŶĂůǇƐĞƐ  ?one, two or three hours) showed that the 
Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-
effective for thresholds between approximately £8,000 and £40,000 per QALY. Similarly, where the 
total delay decreased to 1.5 hours (and assuming availability of a doctor on demand), the Beckman 
Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-effective 
for thresholds between £7,778 and £29,653 per QALY at which point the ARCHITECT hs-cTnI optimal 
strategy became cost-effective. Adding AMI treatment costs for the patients with a false positive test 
substantially impacted the results: standard troponin testing was cost-effective for all threshold 
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values above £16,050 per QALY. Adding AMI treatment costs to the UA health state for the first year 
had a negligible impact on the incremental outcomes.  
The following input parameters had a noticeable impact on the estimated cost-effectiveness: 30 day 
mortality for treated and untreated AMI (decision tree) and the mortality RR for treated versus 
untreated AMI (Markov trace). Varying the remaining parameters did not have a substantial impact 
on the results (i.e. the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile 
diagnostic threshold, was cost-effective for thresholds between approximately £10,000 and £35,000 
per QALY). 
The deterministic analysis for the secondary analysis is presented in Appendix 6. When assuming 
that the post AMI re-infarction and mortality probabilities would remain elevated for untreated AMI 
for a life-time period, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile 
diagnostic threshold, was cost-effective for thresholds below £1,853 per QALY, at which point the 
Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, became 
cost-effective up to a threshold of £2,017 per QALY. The Beckman Coulter hs-cTnI assay at 
presentation, using the 99th centile diagnostic threshold, was cost-effective for thresholds between 
£2,017 and £5,889 per QALY. The Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for 
thresholds above £5,889 per QALY. For all  ‘ŶŽ ĚŽĐƚŽƌ ŽŶ ĚĞŵĂŶĚ ? ƐĞŶƐŝƚŝǀŝƚǇ ĂŶĂůǇƐĞƐ, the Abbott 
ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-
effective for thresholds below £18,000 per QALY for one, two and three hours delay. The Roche 
Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, was cost-effective 
for thresholds between £18,000 and £19,000, £20,000 and £22,000 per QALY in case of one, two and 
three hours delay respectively. The Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective 
for higher thresholds. Similarly to the deterministic base case, where the total delay decreased to 
1.5 hours (assuming availability of a doctor on demand), the Abbott ARCHITECT hs-cTnI assay at 
presentation, using the 99th centile diagnostic threshold, was cost-effective for thresholds below 
£14,956 at which point the ARCHITECT hs-cTnI optimal strategy became cost-effective. Adding AMI 
treatment costs for all patients with a false positive test gave comparable results to the deterministic 
analysis: the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic 
threshold, was cost-effective for all threshold values below £15,508 per QALY at which point the 
Abbott hs-cTnI optimal strategy became the preferred option. Adding AMI treatment costs to the UA 
health state for the first year had a negligible impact on the incremental outcomes. 
The following input parameters had a noticeable impact on the estimated cost-effectiveness of the 
secondary analysis: increased test cost (of £40 per test), 30 day mortality for treated and untreated 
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AMI (decision tree), and the re-infarction and mortality RR for treated versus untreated AMI 
(Markov trace). Varying the remaining parameters did not have a substantial impact on the results. 
4.4.4 Subgroup analysis 
Additional analyses were performed for subgroups based on age, gender, people with a history of 
previous NSTEMI, and AMI prevalence. These deterministic subgroup analyses (for the base case) 
analysis are presented in Appendix 7. Consistent with the base case analyses, analyses based on age 
and gender subgroups indicated that, up to an age of 75 year, the Beckman Coulter hs-cTnI assay at 
presentation, using the 99th centile diagnostic threshold, was cost-effective for thresholds between 
approximately £10,000 and £35,000 per QALY. The Abbott ARCHITECT hs-cTnI optimal strategy was 
cost-effective for higher thresholds up to £115,000-£170,000, at which point standard troponin 
testing became cost-effective. For females aged over 85 years, the Beckman Coulter hs-cTnI assay at 
presentation, using the 99th centile diagnostic threshold, was cost-effective for thresholds between 
£15,793 and £74,597 per QALY; the Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective 
for thresholds between £74,597 and £259,592 per QALY and standard troponin testing was cost-
effective for thresholds of £259,592 per QALY and higher. For males aged over 85 years, the Abbott 
ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, was cost-
effective for thresholds below £28,711 per QALY; the Beckman Coulter hs-cTnI assay at presentation, 
using the 99th centile diagnostic threshold, was cost-effective for thresholds between £28,711 and 
£143,225 per QALY and the Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for 
thresholds between £143,225 and £503,476 per QALY, at which point standard troponin testing 
became cost-effective. The results for the subgroup with a history of previous NSTEMI were almost 
identical to the base case analysis. 
For subgroup analyses considering AMI prevalence, no testing was included as additional 
comparator. For an AMI prevalence of 1%, the no testing strategy was cost-effective up to 
thresholds of £27,409 per QALY at which the Beckmann Coulter hs-cTnI (99th centile) test became 
cost-effective up to a threshold of £447,934 per QALY. For an AMI prevalence of 5%-20%, the no 
testing strategy was cost-effective up to thresholds of £8,759-£11,703 per QALY at which point the 
Beckmann Coulter hs-cTnI (99th centile) test became cost-effective up to thresholds of £32,042-
£97,709 per QALY. For an AMI prevalence of 30%, the no testing strategy was cost-effective up to a 
threshold of £8,431 per QALY at which point the Beckmann Coulter hs-cTnI (99th centile) test became 
cost-effective up to a threshold of £24,745 per QALY. The Abbott ARCHITECT hs-cTnI optimal 
strategy was cost-effective for thresholds between £24,745 and £70,942 per QALY. 
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In addition, cost-effectiveness estimates for the subgroups, described in section 3.2.3.2, based on 
subgroup-specific accuracy and prevalence are reported in Appendix 9 (only comparing the Roche 
Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, and standard 
troponin testing). The results of these analyses indicated that differences in accuracy and AMI 
prevalence between subgroups had a substantial impact on the cost-effectiveness of the Roche 
Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, compared with 
standard troponin testing (ICER range: £22,111-£355,571; deterministic base case: £41,233). 
The deterministic subgroup analyses for the secondary analysis are presented in Appendix 8. For 
females aged 45 and males aged 45 or 55, the Abbott ARCHITECT hs-cTnI assay at presentation, 
using the 99th centile diagnostic threshold, was cost-effective for thresholds below £16,023-£17,836 
per QALY. The Abbott ARCHITECT hs-cTnI optimal strategy became cost-effective for higher 
thresholds. For females aged 55 or 65 and males aged 65 or 75, the Abbott ARCHITECT hs-cTnI assay 
at presentation, using the 99th centile diagnostic threshold, was cost-effective for thresholds below 
£13,064-£16,994 per QALY. From this threshold up to £18,999-£25,149 per QALY the Roche Elecsys 
hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, was most cost-effective. 
The Abbott ARCHITECT hs-cTnI optimal strategy was cost-effective for higher thresholds. For females 
aged 75 or 85, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic 
threshold, was cost-effective up to thresholds of £12,392-£21,140 per QALY, at which point the 
Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, became 
cost-effective up to thresholds of £16,407-£26,911 per QALY. The Abbott ARCHITECT hs-cTnI optimal 
strategy became cost-effective for thresholds higher than £24,020-£45,709 per QALY. For males 
aged 85, the Abbott ARCHITECT hs-cTnI assay at presentation, using the 99th centile diagnostic 
threshold, was cost-effective for thresholds below £66,418 per QALY. The Abbott ARCHITECT hs-cTnI 
optimal strategy became cost-effective for higher thresholds. 
For subgroup analyses considering AMI prevalence, no testing was included as additional 
comparator. For an AMI prevalence of 1%, the no-testing strategy was cost-effective up to a 
threshold of £4,563 per QALY at which point the Abbott ARCHITECT hs-cTnI assay at presentation, 
using the 99th centile diagnostic threshold, became cost-effective up to a threshold of £109,991 per 
QALY where the Abbott ARCHITECT hs-cTnI optimal strategy became cost-effective.  Similarly, for an 
AMI prevalence of 5% and 10% the thresholds were £5,209 and £35,574 and £5,820 and £22,684 
respectively. For an AMI prevalence of 20% and 30%, the Abbott ARCHITECT hs-cTnI optimal strategy 
was cost-effective for thresholds above £16,319 and £15,410 respectively. 
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In contrast with the base case analysis (described above), the subgroup Wspecific accuracy and 
prevalence (only comparing the Roche Elecsys hs-cTnT assay at presentation, using the 99th centile 
diagnostic threshold, and standard troponin testing) did not have an important impact on the cost-
effectiveness (Appendix 9). The Roche Elecsys hs-cTnT assay at presentation, using the 99th centile 
diagnostic threshold, was dominant for all subgroups. 
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5. DISCUSSION 
5.1 Statement of principal findings 
5.1.1 Clinical effectiveness 
All 18 studies (37 publications) included in the systematic review assessed the accuracy of one or 
more hs-cTn tests for the diagnosis of any AMI or for NSTEMI. There were no controlled trials 
comparing clinical outcomes in people assessed using hs-cTn tests to those assessed using 
conventional Tn assays. The majority (15/18) of the included studies reported data for the Roche 
Elecsys hs-cTnT assay; four studies reported data for the Abbott ARCHITECT hs-cTnI assay and two 
reported data for pre-commercial versions of the Beckman Coulter Access hs-cTnI assay. Not all of 
the included studies reported data on accuracy for the diagnosis of NSTEMI (i.e. for a population 
which excluded people with STEMI), which was the target population for this assessment. However, 
where data were available for both any AMI (population with symptoms suggestive of ACS) and 
NSTEMI (population which excluded people with STEMI), estimates of test performance were 
generally similar, see Table 4 section 3.2.3 and Table 6 section 3.2.5. 
When diagnosis was based on a single sample taken at presentation, using the 99th centile for the 
general population as the diagnostic threshold, positive LRs derived from summary estimates of 
sensitivity and specificity indicated that neither the Roche Elecsys hs-cTnT assay or the Beckman 
Coulter Access hs-cTnI would be adequate to rule-in a diagnosis of NSTEMI. The LR+ for the Roche 
Elecsys hs-cTnT assay was 5.41 (95% CI: 3.40 to 8.63) and the LR+ for the Beckman Coulter Access hs-
cTnI was 3.67 (95% CI: 3.26 to 4.13). By contrast, the LR+ for the Abbott ARCHITECT hs-cTnI assay, in 
a population which did not exclude STEMI, was 11.47 (95% CI: 9.04 to 16.19), indicating that a 
positive test using this assay may have some utility in confirming a diagnosis of AMI. The 
corresponding LR-s indicated that a negative test result on a single sample taken at presentation, 
using the 99th centile for the general population as the diagnostic threshold, would not be adequate 
to rule-out NSTEMI using any of the three assays assessed. LR- was 0.15 (95% CI: 0.08 to 0.26) for the 
Roche Elecsys hs-cTnT, 0.11 (95% CI: 0.07 to 0.17) for the Beckman Coulter Access hs-cTnI, and 0.22 
(95% CI: 0.16 to 0.27), for the Abbott ARCHITECT hs-cTnI assay.  Although, these LRs are fairly low, 
the consequences of missing an  AMI are so great that a test needs to be able to rule out an AMI 
with a very high degree of certainty.  It should be noted that the Beckman Coulter hs-cTnI assay 
ĞǀĂůƵĂƚĞĚ ŝŶ ƚŚĞWƐƚƵĚǇǁĂƐĚĞƐĐƌŝďĞĚĂƐ  ‘ĂŶ ŝŶǀĞƐƚŝŐĂƚŝŽŶĂůƉƌŽƚŽƚǇƉĞ ? ?75 the 99th centile (9 
ŶŐ ?> ? ?ĚĞƐĐƌŝďĞĚĂƐ ‘ĂĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ? ?ĚŝĨĨĞƌƐĨƌŽŵƚŚĞ ? ?th centile given in the current 
product information leaflet (40 ng/L),16 
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hypothetical cohort of 1,000 people is considered, assuming a prevalence of NSTEMI of 17% (derived 
from studies included in our systematic review, see section 3.2.3.2), the estimated number of people 
with AMI and a negative test result who would be erroneously discharged based on this testing 
protocol is 20 for the Roche Elecsys hs-cTnT assay, 14 for the Beckman Coulter Access hs-cTnI assay 
and 34 for the Abbott ARCHITECT hs-cTnI assay. 
Some limited data were available on the diagnostic performance of the Roche Elecsys hs-cTnT assay 
in clinical subgroups, using a single sample taken at presentation and the 99th centile diagnostic 
threshold. These data indicated a lower LR- when the test is used in certain population groups, (e.g. 
people over 70 years of age LR- 0.05, 95% CI: 0.02 to 0.18, people without pre-existing CAD LR- 0.07, 
95% CI: 0.04 to 0.16) and with a high pre-test probability (determined by clinical judgement based 
on cardiovascular risk factors, type of chest pain, physical findings, and ECG abnormalities; LR- 0.09,  
95% CI: 0.02 to 0.45). Using the hypothetical cohort of 1,000 people described above, the estimated 
number of people with AMI and a negative test result who would be erroneously discharged if the 
test were used to rule-out AMI in these selected populations is five for people over 70 years of age, 
10 for people without pre-existing CAD, and 10 for people with a clinical assessment of high pre-test 
probability. When the performance of the Roche Elecsys hs-cTnT assay was assessed in a population 
restricted to people who presented more than three hours after the onset of symptoms, a similar fall 
in the LR- was observed (LR- 0.08, 95% CI: 0.05 to 0.11); the estimated number of people with AMI 
and a negative test result who would be erroneously discharged if the test were used to rule-out 
AMI in this populations is 10. 
We constructed optimal testing strategies for the Roche Elecsys hs-cTnT assay (Figure 9, section 
3.2.3.4) and for the Abbott ARCHITECT hs-cTnI assay (Figure 11, section 3.2.4.4). Both strategies 
employ a two step process, which provides two potential oportunities to rule-out AMI and hence to 
discharge patients within the four hour window specified in the scope for this assessment. This 
potential is conditional upon the acheivement of short (<1 hour) turnarround times for hs-cTn 
testing, as recommended by the joint National Academy of Clinical Biochemistry and IFCC guidelines 
on troponin testing104 and in line with clinical opinion; a study of 1,355 emergency department 
physicians in the USA indicated that 75% believed that the results of troponin testing should be 
available to them within 45 minutes.105 The initial step for both the Abbott ARCHITECT hs-cTnI 
optimal strategy and Roche Elecsys hs-cTnT optimal strategy was based on the use of an LoB (3 ng/L) 
diagnostic threshold in a sample taken at presentation and was selected for optimal rule-out 
potential (low negative LR), regardless of poor rule-in performance. For the Roche Elecsys hs-cTnT 
optimal strategy, the second step involves an additional sample taken two to three hours after 
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admission and was selected to provide the best possible combination of rule-out and rule-in 
performance. Using the hypothetical cohort of 1,000 people, previously described, the intial step of 
the prososed Roche Elecsys hs-cTnT optimal strategy would result in discharge of 407 people, nine of 
whom would have been erroneously discharged with AMI. The second step of this strategy involves 
a combination of testing on admission and after two hours, where a negative result is defined as 
both no sample above the 99th centile AND a change of <20% over two hours and provides the 
optimum rule-out performance (LR- 0.04, 95% CI: 0.02 to 0.10); conversely, a positive result is 
defined as both a peak  value above the 99th centile AND a change of >20% over two hours and 
provides the optimum rule-in performance (LR+ 8.42 (95% CI: 6.11 to 11.60)). Application of the rule-
out component of the second step would result in discharge of a further 286 people, five of whom 
would have been erroneously discharged. For the proposed Abbott ARCHITECT hs-cTnI optimal 
strategy, the initial rule-out step would result in discharge of 291 people all of whom would have 
been appropriately discharged. The second step of this strategy involves repeat testing on a sample 
taken three hours after admission, using the 99th centile diagnostic threshold. Application of the 
rule-out component of the second step would result in discharge of a further 489 people, three of 
whom would have been erroneously discharged. Available data on the Beckman Coulter hs-TnI assay 
were insufficient to support construction of an optimal testing strategy. 
5.1.2 Cost-effectiveness 
The review of economic analyses of hs-cTn (i.e. either hs-cTnI or hs-cTnT) testing for the early rule-
out of AMI in people with acute chest pain found four HTA reports, two full papers and one abstract. 
Based on all of these publications, it can be said that, in general, the question of whether hs-cTn 
testing is cost-effective cannot yet be answered unequivocally. The majority of papers reported 
substantial ICERs, with considerable uncertainty. In particular, the accuracy of high-sensitive tests as 
well as the efficiency of decision-making based on test results were found to be important drivers of 
cost-effectiveness. 
In our health economic analysis, the cost-effectiveness of different testing strategies involving hs-cTn 
for the early rule-out of AMI in people with acute chest pain presenting to the ED with suspected 
ACS and STEMI ruled out was assessed. All analyses had the same comparator: standard troponin 
testing at 10-12 hours, which is considered the reference standard and therefore was assumed to 
have perfect sensitivity and specificity.  In addition to the base case analysis, given some evidence 
that false positives versus this reference standard also have a poor prognosis, a secondary analysis 
was conducted which assumed an increased adverse event risk for patients with false positive hs-cTn 
tests. A number of subgroup and sensitivity analyses were also performed.  
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In the base case analysis, standard troponin testing was both most effective and most costly. 
Strategies considered cost-effective depending upon ICER thresholds were Abbott ARCHITECT hs-
cTnI assay at presentation, using the 99th centile diagnostic threshold,(thresholds below £6,597), 
Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, 
(thresholds between £6,597 and £30,042), Abbott ARCHITECT hs-cTnI optimal strategy (LoD 
threshold at presentation, followed by 99th centile threshold at three hours) (thresholds between 
£30,042 and £103,194), and the standard troponin test (thresholds over £103,194). The Roche 
Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold and the Roche 
Elecsys hs-cTnT optimal strategy (LoB threshold at presentation followed by 99th centile threshold 
ĂŶĚ ?Žƌ ȴ ? ?A?  ?ĐŽŵƉĂƌĞĚ ƚŽ ƉƌĞƐĞŶƚĂƚŝŽŶ ƚĞƐƚ ? Ăƚ  ?-3 hours) were extendedly dominated in this 
analysis (one of the more effective strategies was better value in that the ICER was lower). 
In the secondary analysis, which assumed a proportion of false positives in the hs-cTn testing 
strategies had an increased risk of adverse events, standard troponin was least effective and most 
costly, and therefore a dominated strategy. The most effective strategy here was the Abbott 
ARCHITECT hs-cTnI optimal strategy. The Roche Elecsys hs-cTnT optimal strategy was extendedly 
dominated (one of the more effective strategies was better value in that the ICER was lower), as was 
the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, in this 
analysis. Strategies considered cost-effective were Abbott ARCHITECT hs-cTnI assay at presentation, 
using the 99th centile diagnostic threshold, (thresholds below £12,217), Roche Elecsys hs-cTnT assay 
at presentation, using the 99th centile diagnostic threshold,(thresholds between £12,217 and 
£14,992) and Abbott ARCHITECT hs-cTnI optimal strategy (thresholds over £14,992).     
Sensitivity analyses showed that in general, there were no major changes in the relative cost-
effectiveness of strategies. That is, dominancy and order of relative cost-effectiveness were 
comparable, although the ICERs were different. Exceptions included assuming that the increased 30 
day mortality for treated versus untreated MI applied to a lifetime (instead of only during the first 
year after presentation at ED), which meant that standard troponin could be cost-effective from a 
threshold of £26,352 or higher. The same assumption applied to the secondary analysis meant that 
the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, 
strategy was no longer extended dominated but was considered cost-effective at thresholds 
between £2,017 and £5,889. Another sensitivity analysis that resulted in substantial changes was 
assigning AMI treatment costs to patients who tested false positive. In the base case, under this 
assumption, standard troponin became cost-effective at an ICER threshold of £20,000 (ICER £16,050 
as compared to the Abbott ARCHITECT hs-cTnI optimal strategy). In the secondary analysis, however, 
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assigning treatment costs to false positive patients did not impact the position of standard troponin; 
it was still dominated by another strategy i.e. less effective and more costly.   
Subgroup analyses (with non-subgroup specific accuracy data) for the base case showed that ICERs 
compared to the next best strategy were slightly higher for males at all ages. Also, for both females 
and males, ICERs increased with age. In addition, from ages 55 upwards (base case 53), the Roche 
Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold, became 
extendedly dominated. In the subgroup with previous NSTEMI, again the Roche Elecsys hs-cTnT 
assay at presentation, using the 99th centile diagnostic threshold, was extendedly dominated and 
ICERs are slightly higher as compared to the whole group. Subgroup analysis based on MI prevalence 
(including a no testing strategy) indicated that only when MI prevalence is as low as 1% (base case 
17%) was the no testing strategy considered cost-effective up to an ICER threshold of £27,409 after 
which the Beckman Coulter hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, 
strategy takes over. The higher the prevalence, the lower the point at which the Beckman Coulter 
hs-cTnI assay at presentation, using the 99th centile diagnostic threshold, strategy became cost-
effective (i.e. £11,703 for prevalence 5%, £9,740 for prevalence 10% and £6,597 for 17%).  
For the secondary analysis, again, the ICERS for males were slightly higher than for females. For the 
various age categories, results were rather diffuse, but as in the base case ICERs appeared to 
increase with age. There did not appear to be a substantial difference between the MI prevalence 
subgroups, that is, the no testing strategy was only cost-effective up to rather modest ICER 
thresholds (£4,563-£7,109) for all values of prevalence. 
The subgroup analyses using subgroup-specific accuracy and prevalence could only be performed for 
the Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic threshold as there 
were no subgroup data on Beckman Coulter hs-cTnI and Abbott ARCHITECT hs-cTnI assays. The 
comparator was the standard troponin at 10-12 hours, which was assumed to have perfect 
sensitivity and specificity. For the base case, the Roche Elecsys hs-cTnT assay at presentation, using 
the 99th centile diagnostic threshold, was always less costly and less effective, but ICERs were more 
favorable for the following subgroups as compared to their counterparts: Age A? ? ? ?ǁŝƚŚƉƌĞ-existing 
CAD, and symptom onset <3 hours. For the secondary analysis, the standard troponin was 
dominated by the Roche Elecsys hs-cTnT assay at presentation, using the 99th centile diagnostic 
threshold, overall, as this test was both less costly and more effective. However, the subgroups 
which rendered the highest savings per QALY gained were consistent with the base case analysis i.e. 
Age A? ? ?, with pre-existing CAD, and symptom onset <3 hours. Although data are lacking, it seems 
likely that these differences between subgroups can be extrapolated, at least partly, to the other 
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tests considered in the base case analysis.  
5.2   Strengths and limitations of assessment 
5.2.1   Clinical effectiveness 
Extensive literature searches were conducted in an attempt to maximise retrieval of relevant 
studies. These included electronic searches of a variety of bibliographic databases, as well as 
screening of clinical trials registers and conference abstracts to identify unpublished studies. 
Because of the known difficulties in identifying test accuracy studies using study design-related 
search terms,106 search strategies were developed to maximise sensitivity at the expense of reduced 
specificity. Thus, large numbers of citations were identified and screened, relatively few of which 
met the inclusion criteria of the review.  
The possibility of publication bias remains a potential problem for all systematic reviews. 
Considerations may differ for systematic reviews of test accuracy studies. It is relatively simple to 
define a positive result for studies of treatment, e.g. a significant difference between the treatment 
and control groups which favours treatment. This is not the case for test accuracy studies, which 
measure agreement between index test and reference standard. It would seem likely that studies 
finding greater agreement (high estimates of sensitivity and specificity) will be published more often. 
In addition, test accuracy data are often collected as part of routine clinical practice, or by 
retrospective review of records; test accuracy studies are not subject to the formal registration 
procedures applied to randomised controlled trials and are therefore more easily discarded when 
results appear unfavourable. The extent to which publication bias occurs in studies of test accuracy 
remains unclear, however, simulation studies have indicated that the effect of publication bias on 
meta-analytic estimates of test accuracy is minimal.107 Formal assessment of publication bias in 
systematic reviews of test accuracy studies remains problematic and reliability is limited.27  We did 
not undertake a statistical assessment of publication bias in this review. However, our search 
strategy included a variety of routes to identify un-published studies and resulted in the inclusion of 
a number of conference abstracts.  
Clear inclusion criteria were specified in the protocol for this review, a copy of which is provided in 
Appendix 6. The eligibility of studies for inclusion is therefore transparent. In addition, we have 
provided specific reasons for exclusion for all of the studies which were considered potentially 
relevant at initial citation screening and were subsequently excluded on assessment of the full 
publication (Appendix 4). The review process followed recommended methods to minimise the 
potential for error and/or bias;25 studies were independently screened for inclusion by two 
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reviewers and data extraction and quality assessment were done by one reviewer and checked by a 
second (MW and PW). Any disagreements were resolved by consensus.  
Studies included in this review were assessed for risk of bias and applicability using the QUADAS-2 
tool developed by the authors33 and recommended by the Cochrane Collaboration.27 QUADAS-2 is 
structured into four key domains covering participant selection, index test, reference standard, and 
the flow of patients through the study (including timing of tests). Each domain is rated for risk of bias 
(low, high, or unclear); the participant selection, index test and reference standard domain are also, 
separately rated for concerns regarding the applicability of the study to the review question (low, 
high, or unclear). The results of the QUADAS-2 assessment are reported, in full, for all included 
studies in Appendix 3 and are summarised in section 3.2.2. The main potential sources of bias in the 
studies included in this assessment were related to patient spectrum and patient flow (QUADAS 
domains 1 and 4). Reporting of the participant selection process was frequently unclear; a further 
study was rated as unclear for this domain as a large number of patients were not enrolled due to 
'technical reasons' that were not fully defined and so it was not possible to judge whether these 
constituted inappropriate exclusions.54 dŚĞ ŵŽƐƚ ĐŽŵŵŽŶ ĨĞĂƚƵƌĞŽĨ ƐƚƵĚŝĞƐ ƌĂƚĞĚ ĂƐ  ‘ŚŝŐŚ ƌŝƐŬŽĨ
ďŝĂƐ ? ĨŽƌ ƉĂtient selection was the inclusion of participants based on staffing or work flow 
considerations, e.g. participants were excluded if they presented at night or during busy periods.41, 45, 
50 ůůƌĂƚŝŶŐƐŽĨ ‘ŚŝŐŚƌŝƐŬŽĨďŝĂƐ ?ĨŽƌƉĂƚŝĞŶƚĨůŽǁǁĞƌĞĚƵĞƚŽŚŝŐŚƉroportions of withdrawals. There 
were also concerns regarding the applicability of the patient population and the reference standard 
in some of the included studies. The main area of concern, with respect to population, was for 
studies that enrolled mixed populations (i.e. when the target condition was any AMI); because the 
primary focus of this assessment was the diagnosis of NSTEMI in populations where patients with 
STEMI were excluded (i.e. target condition NSTEMI), the primary focus was the population of 
patients with STEMI excluded, mixed population studies which were not restricted to this specific 
patient group were considered to have high concerns regarding applicability. However, as noted 
above (section 5.1.1), where data were available for both any AMI (mixed population) and NSTEMI 
(population which excluded people with STEMI), estimates of test performance were generally 
similar. In accordance with current NICE guidance,11 our review question specified that an 
appropriate reference standard had to include a standard Tn measurement at baseline and at 10-12 
hours after the onset of symptoms in 80% of the population. Although studies generally included a 
baseline and a second, later standard Tn measurement, only five41, 50, 62, 65, 75 met the specific timing 
criterion for the second standard Tn measurement; studies which did not meet this criterion were 
classified as having high concerns regarding applicability. 
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We identified one recently published systematic review which included an assessment of the 
accuracy of hs-cTn assays for the diagnosis of AMI and prediction of MACE.7 This review, by 
Goodacre et al, also evaluated standard cTn assays (alone and in combination with other cardiac 
biomarkers) and the diagnostic accuracy of other cardiac biomarkers, as well as including prediction 
modelling studies, all of which were outside the scope of this assessment. Our systematic review 
represents an advance on Goodacre et al as it provides a more up-to-date and comprehensive 
assessment of the performance of hs-cTn assays. Although the Goodacre review was published in 
2013, search dates were reported as 1995 to November 2010; hence it only included two studies, 
which met the definition of an hs-cTn assay used in our assessment.56, 73 Both of these studies 
assessed the diagnostic performance of the Roche Elecsys hs-cTnT assay when applied to a single 
sample taken at presentation, using the 99th centile diagnostic threshold, and neither excluded 
participants with STEMI. Both studies were also included in our systematic review and one56 
contributed data to our summary estimates (based on a total of 15 studies) of the performance of 
the Roche Elecsys hs-cTnT assay for the diagnosis of any AMI at this threshold studies; the other was 
an early publication of the APACE study,73 the most recent publication from which contributed data 
to our main analysis (accuracy for the diagnosis of NSTEMI), which included a total of six studies.75 
The summary estimate of sensitivity derived from our systematic review was lower (88% for both 
any AMI or NSTEMI analyses) than that reported by the Goodacre review (96% for any AMI),7 and 
our summary estimate of specificity was higher (82% for any AMI and 84% for NSTEMI) than that 
reported by the Goodacre review (72% for any AMI).7 A pre-publication copy of a more recent 
systematic review, provided by the authors as academic-in-confidence material, 
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Our assesment represents an advance on both of these systematic reviews in that we provide up-to-
date estimates of the diagnostic performance of assays meeting a strict definintion for hs-cTn, which 
are stratified by hs-cTn assay type, diagnostic threshold and timing of the Tn test. 
CONFIDENTIAL UNTIL PUBLISHED 
110 
We believe that our assessment provides information of direct relevance to UK clinical practice as 
we focus on the performance of hs-cTn within the four hour time window corresponding to the 
target for NHS emergency departments, which specifies that µno one should be waiting more than 
four hours in the emergency department from arrival to admission, transfer or ĚŝƐĐŚĂƌŐĞ ? ?91 
Furthermore, we have used the data from our systematic review to propose strategies for how hs-
cTn assays might be applied and interpreted in order to maximise diagnostic performance. These 
strategies were devised with consideration to test timing, diagnostic threshold and interpretation of 
combinations of multiple test results. One limitation of this approach is that our estimates of the 
effectiveness and cost-effectiveness of the proposed two step strategies require the assumption that 
the diagnostic performance of the second step is the same when used in people in whom NSTEMI is 
not ruled out by the first step as it is when used in the whole population (see sections 3.2.3.4 and 
3.2.4.4). This assumption was necessary because no combined test performance data were available 
for the proposed strategies. However, it can be argued that the assumption is reasonable as the first 
step in both strategies focuses on rule-out performance and thus has a low positive LR. This means 
that there is a relatively small change in the prevalence of AMI between the first and second steps 
(17% to 27% for the Roche Elecsys hs-cTnT optimal strategy and 17% to 24% for the Abbott 
ARCHITECT hs-cTnI optimal strategy). 
Our assessment was less comprehensive for the Abbott ARCHITECT hs-cTnI assay and the Beckman 
Coulter hs-cTnI assay than for the Roche Elecsys hs-cTnT, because available data were limited for 
these two assays. 
5.2.2   Cost-effectiveness 
Our cost-effectiveness analysis is the most comprehensive to date in terms of the number of 
relevant hs-cTn test strategies for the early rule-out of AMI in people presenting to the ED with 
acute chest pain and suspected ACS.  Moreover, the de novo probabilistic model was based on one 
previously developed for a published and peer reviewed HTA.84 This model was also used in a later 
assessments on the cost-effectiveness of biomarkers in patients with suspected ACS.65 For the 
present analysis, a number of adjustments were made to the model, but most of the assumptions 
were maintained.  
The model was also informed by a comprehensive, high quality systematic review of diagnostic test 
accuracy. Additional parameters were either those from the original HTA model, or any of the 
further assessments, or, where necessary, were based on a pragmatic literature review. Such a 
review is standard practice in economic modeling given the large number of parameters required 
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and we expect that the review has delivered the most relevant information given that it focused on 
identifying the most recent large UK based studies. 
As in any economic model, a number of major and minor assumptions had to be made. It is 
important to understand the impact of these assumptions in order to correctly interpret the results 
of the model. The impact of most assumptions has been explored in sensitivity and secondary 
analyses. However, one major assumption that was maintained throughout all analyses was the 
conservative assumption of no health benefit of early treatment in the hs-cTn strategies as 
ĐŽŵƉĂƌĞĚƚŽ ‘ůĂƚĞ ?ƚƌĞĂƚŵĞŶƚŝŶƚŚĞƐƚĂŶĚĂƌĚĐdŶƐƚƌĂƚĞŐǇ ?ůƚŚŽƵŐŚŵĂŶǇĞǆƉĞƌƚƐďĞůŝĞǀĞƚŚĂƚƚŚĞƌĞ
must be a benefit, at least to some extent, of treating patients early, there is no evidence to support 
or quantify a timing effect, as yet. In addition, there may well also be adverse effects associated with 
early treatment also, (e.g. the risk of bleeding, unnecessary PCIs, etc.). The Canadian HTA report89 
identified in the economic review (section 4.1.4.4) did include an advantage for early versus late 
treatment, based on one study, which investigated the effect of a 36 hour treatment delay.109 The 
RR found in this study was then recalculated, assuming a constant effect of timing on treatment 
benefit, to a RR of 1.035 of mortality for a treatment delay of six hours versus early treatment, was 
again adjusted to 1.01 based on expert opinion. Any possible adverse effect of early treatment was 
not considered in this analysis. A similar approach would have been possible in the present model, 
but in our view, this would not be informative, given the level of uncertainty underlying this final 
estimate. Therefore, it was decided to leave out a possible effect of timing of treatment. This could 
be considered a conservative approach, but even this is uncertain.  
The assumption that standard troponin, as the reference standard, has perfect sensitivity and 
specificity was also maintained throughout all analyses. Although a simplification, given that the 
actual reference standard is standard troponin plus clinical information, this approach is consistent 
with previous modeling and incorporation of the effect of clinical information to the hs-cTn test 
would be very difficult, given the current lack of data. To some extent, clinical judgment might 
already be incorporated into the modeling because, for the effect of treatment (RR for re-infarction 
and mortality), the study performed by Mills et al was used.86  In this study not all patients with 
negative tests results were left untreated; we might therefore speculate that, where patients who 
tested negative were treated, this was because of clinical judgment. However, we cannot be certain 
that the observations from this trial reflect the true contribution of clinical judgment. On the other 
hand, there is recent evidence that the prognostic performance of standard troponin testing may be 
imperfect. For example, a negative troponin test might assess correctly that a patient is not 
experiencing a NSTEMI, but some patients with negative test results may still benefit from 
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treatment. To take this possibility into account, a secondary analysis was performed, which resulted 
in the standard troponin strategy being dominated by the hs-cTn testing strategies. In other words, it 
seems reasonable to conclude that not only might hs-cTn be cost effective, it might also be more 
effective than standard troponin.    
Another assumption, which was varied in sensitivity analysis, with a rather substantial impact on 
results, was how to attribute costs of treatment to patients testing false positive in the hs-cTn 
treatment strategies. In the base case analysis, false positive patients were assigned survival, quality 
of life, and costs of true negative patients, i.e. they were basically assumed not to be treated. 
However, if hs-cTn assays were incorporated in clinical practice, patients with a positive result would 
be treated, at least up to the point where it is discovered they were false positive. Therefore, in a 
sensitivity analysis, false positive patients were assigned treatment costs as if they were true 
positive, but mortality and quality of life as if they were true negative. For the base case, this would 
change results quite dramatically, as the hs-cTn strategies would become more expensive but not 
more effective, whereas for the standard troponin nothing would change. For the secondary analysis 
(some hs-cTn false positives need and get treatment) things are different, since in this case 
treatment costs would be incurred for a proportion of patients (5%), but these patients would also 
receive the benefits of treatment. This approach had a very limited effect on results, in terms of 
strategies that were cost-effective. In our opinion, the secondary analysis, which assigns treatment 
costs to all false positives, but also assumes that some of these patients benefit treatment, is the 
most plausible scenario.    
5.3   Uncertainties 
5.3.1   Clinical effectiveness 
The performance of any test that uses the 99th centile for the general population as the diagnostic 
threshold will be dependent upon the characteristics of the reference population from which this 
value was derived. Although the product information leaflet for the Abbott ARCHITECT hs-cTnI assay 
ƌĞĐŽŵŵĞŶĚƐƚŚĂƚ ‘ĞĂĐŚůĂďŽƌĂƚŽƌǇƐŚŽƵůĚǀerify that the 99th centile is transferable to its population 
or establish its own 99th ĐĞŶƚŝůĞ ? ?15 test accuracy data included in the assessment are predominantly 
based on the 99th centiles for the three assays (Roche Elecsys hs-cTnT, Abbott ARCHITECT hs-cTnI, 
Beckman Coulter hs-cTnI) as reported by their respective manufacturers.15, 16, 18  The 99th centile for 
the Roche Elecsys hs-cTnT was reported as being derived from a study population of 616 apparently 
healthy volunteers and blood donors, with an age range of 20 to 71 years and equal proportions of 
males and females;110 no further details were reported. The 99th centile for the Abbott ARCHITECT 
hs-cTnI  asssay was described being derived from a study of  ‘1,531 apparently healthy individuals in 
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a US population with normal levels of BNP, HbA1c, and estimated GFR values ?.15 AůƚŚŽƵŐŚĂ ? ? ? ? ‘ŝŶ
ƉƌĞƐƐ ? ƌĞĨĞƌĞŶĐĞ ĨŽƌ ƚŚŝƐ ƐƚƵĚǇ ǁĂƐ ŐŝǀĞŶ ŝŶ ƚŚĞ WƐƚƵĚǇ ?75 we were not able to identify any 
corresponding publication. It should also be noted that the Beckman Coulter hs-cTnI assay evaluated 
ŝŶ ƚŚĞ W ƐƚƵĚǇ ǁĂƐ ĚĞƐĐƌŝďĞĚ ĂƐ  ‘ĂŶ ŝŶǀĞƐƚŝŐĂƚŝŽŶĂů ƉƌŽƚŽƚǇƉĞ ? ?75 the 99th centile (9 ng/L), 
ĚĞƐĐƌŝďĞĚ ĂƐ  ‘ĂĐcŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ? ? ĚŝĨĨĞƌƐ ĨƌŽŵ ƚŚĞ99th centile given in the current 
product information leaflet (40 ng/L).16 The product information leaflet describes this value as being 
derived from general practice samples obtained from London, UK, and the surrounding area; 
samples were from 1,000 people over 40 years of age, with approximately equal numbers of males 
and females, and samples from people with abnormal urea and electrolytes, liver function tests, 
glucose, or NT-proBNP, were excluded.16 Expected values, and hence diagnostic thresholds derived 
from groups of healthy volunteers may have limited applicability to the population in whom hs-cTn 
testing would be applied in practice, e.g. with respect to age range. Data provided in the product 
information leaflets for the Roche Elecsys hs-cTnT assay and the Abbott ARCHITECT hs-cTnI  asssay 
both indicated that 99th centile values differed between males and females; the Abbott ARCHITECT 
hs-cTnI assay reported values of 15.6 ng/L and 34.2 ng/L for females and males, respectively,15 and 
the Roche Elecsys hs-cTnT assay reported values of 10.0 ng/L and 14.2 ng/L for females and males, 
respectively.18 Despite this we were unable to identify any data on whether the diagnostic 
performance of tests varies according to sex, when a single common diagnostic threshold is used for 
both males and females; the effectiveness of using sex-specific diagnostic thresholds therefore 
remains uncertain. Similarly, we were unable to identify any data on the diagnostic performance of 
hs-cTn assays when used in people with impaired renal function. 
Differences in the populations used to derive the 99th centile diagnostic threshold, and hence in the 
Tn level at which this threshold set, may also affect the ability of an assay to acheive the first point of 
the accepted definition of a hs-cTn assay, i.e. a CV ŽĨ A? ? ?A? Ăƚ ƚŚĞ99th centile for the general 
population. A standardised definition of the required reference population would be useful in 
ĞŶƐƵƌŝŶŐ Ă  ‘ůĞǀĞů ƉůĂǇŝŶŐ ĨŝĞůĚ ? ĨŽƌ ĐůĂƐƐŝĨŝĐĂƚŝŽŶ ŽĨ ĂƐƐĂǇƐ ĂƐ  ‘ŚŝŐŚ ƐĞŶƐŝƚŝǀĞ ? ĂŶĚ ǁŽƵůĚ ĂŝĚ
comparisons between tests. 
We identified some data on the diagnostic performance of hs-cTn testing in clinically important 
subgroups (older people,52, 75 and people with and without pre-existing CAD).46, 75 However, these 
data were very limited and were only available for the Roche Elecsys hs-cTnT assay. Therefore, there 
remains some uncertainty about how the diagnostic performance of individual hs-cTn assays may 
vary in clinically relevant subgroup, as well as what may constitute the optimal testing strategy in 
these groups. 
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A significant limitation of this assessment follows from the design of the primary studies included in 
the systematic review. The objective of these studies was to evaluate the diagnostic performance of 
hs-cTn assays when compared to a reference standard based on the universal definition of AMI 
endorsed the European Cardiology Society, the American Colledge of Cardiology, the American 
Health Association and the World Heart Federation.8, 21, 22  The scope for this assessment did not 
include studies which evaluated the use of hs-cTn testing in combination with other tests, thus, 
studies which assessed the combined accuracy of a clinical risk score and a hs-cTn test used together 
would have been excluded, however, we did not identify any studies which were excluded on this 
basis. Studies assessing the diagnostic performance of a hs-cTn test alone, where participants were 
subgrouped by clinical risk, met our inclusion criteria and were included in the systematic review. 
We identified only one study of this type,48 which, as described in section 5.1.1, indicated that the 
rule-out performance of hs-cTnT testing may be improved if the test is used in a population with 
high clinically determined pre-test probability. There remains uncertainty arround how hs-cTn 
testing would perform if used, as it would be in clinical practice, in combination with a clinical 
assessment of pre-test probaility (with or without formal risk scoring). Full assessment of the 
independent predictive value of hs-cTn testing requires multivariable prediction modelling. 
ĨŝŶĂůĂƌĞĂŽĨƵŶĐĞƌƚĂŝŶƚǇĞǆŝƐƚƐǁŝƚŚƌĞƐƉĞĐƚƚŽƚŚĞĐůŝŶŝĐĂůƐŝŐŶŝĨŝĐĂŶĐĞŽĨĂ  ‘ĨĂůƐĞƉŽƐŝƚŝǀĞ ?ŚƐ-cTn 
result, i.e. does a positive hs-cTn result imply a clinically important change in cardiac risk, where a 
diagnosis of AMI is not confirmed (based on standard Tns and the universal definition)? Re-
adjudication of the final diagnosis, using later hs-cTn measurements in place of the conventional Tn 
results, can provide some insight into this issue. The most recent publication from the APACE study 
reported that when hs-cTnT results (including a six hour time point) were included in the reference 
standard diagnosis, this resulted in 131 participants being classified as having had a small AMI, which 
ǁŽƵůĚŚĂǀĞďĞĞŶĐůĂƐƐŝĨŝĞĚĂƐ ‘ŶŽAMI ?ǁŚĞƌĞĂĚũƵĚŝĐĂƚŝŽŶǁĂƐďĂƐĞĚŽŶƐƚĂŶĚĂƌĚTn results.75  
5.3.2  Cost-effectiveness 
The main uncertainties for the cost-effectiveness analysis lie in the model assumptions, particularly 
regarding the effect of actual clinical practice in terms of both other diagnostic information and 
treatment given this information. Although many of these assumptions have been varied in one-way 
sensitivity analysis, the precise implication of false negative test results, where patients are 
discharged without essential treatment or of false positive test results, where patients stay in 
hospital and may receive unnecessary interventions, is unknown.   
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It should also be emphasised that the uncertainty resulting from the above mentioned assumptions 
was not parameterised in the model and is therefore not reflected in the probabilistic sensitivity 
analyses or in the cost-effectiveness acceptability curves.   
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6.   CONCLUSIONS 
6.1   Implications for service provision 
We propose the use of two step testing strategies to optimise the diagnostic performance of hs-cTn 
testing. There is evidence to suggest that undetectable levels of Tns (below the LoB/LoD of the 
assay) on presentation, measured using the Roche Elecsys hs-cTnT assay or the Abbott ARCHITECT 
hs-cTnI assay, may be sufficient to rule out NSTEMI in people presenting with symptoms suggestive 
of ACS. There is also evidence to suggest that a further rule-out step may be possible, within the four 
hour NHS emergency department target. For the Abbott ARCHITECT hs-cTnI assay, this second rule-
out step would be based on a Tn level below the 99th centile in a sample taken three hours after 
presentation. For the Roche Elecsys hs-cTnT assay, the second rule-out step would be based on a Tn 
level below the 99th centile in all samples AND a change in Tn level of <20% between presentation 
and two hours. There is insufficient evidence to determine an optimal testing strategy for the 
Beckman Coulter hs-cTnI assay. There is some limited evidence to suggest that a Tn level below the 
99th centile on presentation, measured using the Roche Elecsys hs-cTnT assay, may be sufficient to 
rule out NSTEMI in some groups (people over 70 years old, people without pre-existing CAD and 
people with a clinically determined high pre-test probability). 
When considering the base case analysis it appears that the Beckman Coulter hs-cTnI assay at 
presentation, using the 99th centile diagnostic threshold, would be the cost-effective strategy, given 
an ICER threshold of £20,000 - £30,000. However, both cost and QALY differences between the 
strategies were small. This means that within the hs-cTn testing strategies, ICERs can change 
substantially especially with small changes in either costs or QALYs. Therefore, it is difficult to be 
confident that other hs-cTn strategies might not be cost effective. 
Overall, the model does not provide strong evidence to prefer one hs-cTn testing strategy over 
another. Results do however indicate that hs-cTn testing in general may be cost-effective compared 
to standard troponin testing. This becomes more likely if one assumes that hs-cTn testing detects 
some patients who require treatment despite their testing negative with standard troponin, as 
shown in the secondary analysis. In particular, the Abbott ARCHITECT hs-cTnI optimal strategy, which 
involves multiple testing and varying diagnostic thresholds, may be promising. The main issue, with 
regard to service provision, if implementation of an hs-cTn testing strategy is considered, is the 
balance between the likely reduction in cost and the risk of a reduction in effectiveness, albeit 
possibly small. 
6.2   Suggested research priorities 
Diagnostic cohort studies are needed to fully evaluate the performance of our proposed optimal 
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testing strategies in a clinical setting. 
If adoption of the Beckman Coulter hs-cTnI is to be considered, further studies are needed to fully 
evaluate the diagnostic accuracy of this test at the thresholds currently recommended by the 
manufacturer and to inform the development of an optimal testing strategy. 
Further diagnostic cohort studies, or subgroup analyses of existing data sets, are needed to fully 
explore possible variation in the accuracy of hs-cTn assays and the optimal testing strategies for 
these assays in relevant demographic and clinical subgroups: sex; age; ethnicity; renal function; 
previous CAD; previous AMI. 
It is important to further explore the effects of clinical judgement (assessment of pre-test 
probability) on the diagnostic performance of hs-cTn testing. This could be achieved by assessing the 
combined diagnostic accuracy of risk scoring tools, such as TIMI or GRACE, and hs-cTn tests, or by 
assessing the accuracy of hs-cTn testing in subgroups stratified by pre-test probability. 
Multivariable prediction modelling studies may be useful to assess the independent prognostic value 
of a positive hs-cTn test result, in the context of other clinical risk factors and tests. 
As most of the uncertainties in the economic model were caused by assumptions relating to clinical 
effectiveness, this type of research would also facilitate economic analyses of hs-cTn testing. 
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APPENDIX 1: LITERATURE SEARCH STRATEGIES 
Clinical effectiveness search strategies 
Medline (OvidSP): 1946 to 2013/10/Week 1 
Searched: 11.10.13 
1     (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (229) 
2     (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or 
accu-tni).ti,ab,ot. (99) 
3     ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (563) 
4     ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (349) 
5     (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high 
performance or ultrasensitive)).ti,ab,ot. (769) 
6     (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (66) 
7     or/1-6 (1215) 
8     troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (8642) 
9     (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or 
ultrasensitive).ti,ab,ot. (4878300) 
10     8 and 9 (4209) 
11     7 or 10 (4559) 
12     chest pain/ (9293) 
13     ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. 
(28602) 
14     exp myocardial ischemia/ (357748) 
15     (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (16495) 
16     (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (285) 
17     Unstable angina$.ti,ab,ot. (10718) 
18     ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ 
or occlusion$ or isch?emia$)).ti,ab,ot. (194088) 
19     (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI).ti,ab,ot. (53168) 
20     or/12-19 (444673) 
21     11 and 20 (2503) 
22     animals/ not (animals/ and humans/) (3957888) 
23     21 not 22 (2336) 
 
Medline In-Process & Other Non-Indexed Citations  (OvidSP): up to 2013/10/01 
Medline Daily Update: up to 2013/10/01 
Searched: 11.10.13 
1     (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (32) 
2     (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or 
accu-tni).ti,ab,ot. (9) 
3     ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (62) 
4     ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (29) 
5     (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high 
performance or ultrasensitive)).ti,ab,ot. (99) 
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6     (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (3) 
7     or/1-6 (125) 
8     troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (5) 
9     (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or 
ultrasensitive).ti,ab,ot. (388942) 
10     8 and 9 (3) 
11     7 or 10 (127) 
12     chest pain/ (13) 
13     ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. 
(1742) 
14     exp myocardial ischemia/ (170) 
15     (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (1544) 
16     (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (3) 
17     Unstable angina$.ti,ab,ot. (378) 
18     ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ 
or occlusion$ or isch?emia$)).ti,ab,ot. (8220) 
19     (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI).ti,ab,ot. (4224) 
20     or/12-19 (12386) 
21     11 and 20 (76) 
22     animals/ not (animals/ and humans/) (1462) 
23     21 not 22 (76) 
 
Embase (OvidSP): 1974 to 2013/10/10 
Searched: 11.10.13 
1     "high sensitivity cardiac troponin T"/ or high sensitivity troponin t assay/ (12) 
2     "high sensitivity cardiac troponin I"/ or high sensitivity troponin i assay/ (3) 
3     (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (565) 
4     (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or 
accu-tni).ti,ab,ot. (190) 
5     ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (1052) 
6     ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (598) 
7     (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high 
performance or ultrasensitive)).ti,ab,ot,hw. (1478) 
8     (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (106) 
9     or/1-8 (2142) 
10     troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (18661) 
11     (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or 
ultrasensitive).ti,ab,ot,hw. (6591905) 
12     10 and 11 (9505) 
13     9 or 12 (10097) 
14     thorax pain/ (44504) 
15     ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. 
(64208) 
16     acute coronary syndrome/ (24295) 
17     (acute adj2 coronary adj2 syndrome$).ti,ab,ot,hw. (34428) 
18     exp heart muscle ischemia/ (73551) 
19     exp heart infarction/ (266027) 
20     exp Unstable-Angina-Pectoris/ (16552) 
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21     (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot,hw. (374) 
22     Unstable angina$.ti,ab,ot. (14593) 
23     ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ 
or occlusion$ or isch?emia$)).ti,ab,ot,hw. (406203) 
24     (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI).ti,ab,ot,hw. (85655) 
25     or/14-24 (498902) 
26     13 and 25 (6007) 
27     animal/ (1890932) 
28     animal experiment/ (1720343) 
29     (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or 
pigs or porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or 
sheep or ovine or monkey or monkeys).ti,ab,ot,hw. (5825865) 
30     or/27-29 (5825865) 
31     exp human/ (15014990) 
32     human experiment/ (317206) 
33     or/31-32 (15016431) 
34     30 not (30 and 33) (4642837) 
35     26 not 34 (5642) 
36     limit 35 to yr="2005 -Current" (4374) 
37     remove duplicates from 36 (4282) 
 
Cochrane Database of Systematic Reviews (CDSR) (Wiley). Issue 10/October: up to 2013/10/11 
Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley). Issue 9/September: 2013 
Database of Abstracts of Reviews of Effects (DARE) (Wiley). Issue 3/July:2013 
Health Technology Assessment Database (HTA) (Wiley). Issue 3/July:2013 
NHS Economic Evaluation Database (NHS EED) (Wiley). Issue 3/July:2013 
Searched 11.10.13 
#1 (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs):ti,ab,kw  5 
#2 (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or 
accutni or accu-tni):ti,ab,kw  5 
#3 ((troponin t or tnt or ctnt or tropt or trop t) near/2 (sensitiv* or hs or early or initial or rapid 
or present* or ultra or high performance or ultrasensitive)):ti,ab,kw  12 
#4 ((troponin I or tni or ctni or tropI or trop I) near/2 (sensitiv* or hs or early or initial or rapid 
or present* or ultra or high performance or ultrasensitive)):ti,ab,kw  10 
#5 (troponin* near/2 (sensitiv* or hs or early or initial or rapid or present* or ultra or high 
performance or ultrasensitive)):ti,ab,kw  27 
#6 (troponin* near/5 (architect or elecsys or accutni or accu-tni or access or unicel)):ti,ab,kw 
 2 
#7 #1 or #2 or #3 or #4 or #5 or #6  42 
#8 MeSH descriptor: [Troponin T] this term only 265 
#9 MeSH descriptor: [Troponin I] this term only 309 
#10 #8 or #9  543 
#11 (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or 
ultrasensitive):ti,ab,kw  170016 
#12 #10 and #11  236 
#13 #7 or #12  249 
#14 MeSH descriptor: [Chest Pain] this term only 335 
#15 ((chest or thorax or thoracic) near/2 (pain* or discomfort or tight* or pressure)):ti,ab,kw 
 1793 
#16 (acute near/2 coronary near/2 syndrome*):ti,ab,kw  1678 
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#17 MeSH descriptor: [Myocardial Ischemia] explode all trees 20427 
#18 (preinfarc* Angina* or pre infarc* Angina*):ti,ab,kw  90 
#19 (Unstable angina*):ti,ab,kw  1818 
#20 ((heart* or myocardi* or cardiac or coronary) near/2 (preinfarc* or infarc* or attack* or 
arrest* or occlusion* or isch?emia*)):ti,ab,kw  16156 
#21 (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI):ti,ab,kw  4740 
#22 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21  28923 
#23 #13 and #22 from 2005 to 2013 114 
 
CDSR search retrieved 0 references 
CENTRAL search retrieved 108 references 
DARE search retrieved 2 references 
HTA search retrieved 1 references 
(NHS EED search retrieved 3 references) 
 
Science Citation Index  ? Expanded (SCI) (Web of Science): 1970-2013/10/14 
Conference Proceedings Citation Index (CPCI-S) (Web of Science): 1990-2013/10/14 
Searched 14.10.13 
Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=2005-2013 
# 1 228 TS=(Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs) 
# 2 90 TS=(Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or 
accutni or accu-tni) 
# 3 1,438 TS=((troponin* or tnt or ctnt or tropt or tni or ctni or tropI or "trop t" or "trop I") NEAR/2 
(sensitiv* or hs or early or initial or rapid or present* or ultra or "high performance" or 
ultrasensitive)) 
# 4 1,470 #3 OR #2 OR #1 
# 5 13,963 TS=((chest or thorax or thoracic) NEAR (pain* or discomfort or tight* or pressure)) 
# 6 19,298 TS=(acute NEAR/2 coronary NEAR/2 syndrome*) 
# 7 393 TS=(preinfarc* angina* or pre infarc* angina) 
# 8 5,481 TS=unstable angina* 
# 9 115,395 TS=((heart* or myocard* or cardiac or coronary) NEAR/2 (preinfarc* or infarc* or 
attack* or arrest* or occlusion* or isch?emia*)) 
# 10 40,133 TS=(MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP 
or OMI) 
# 11 155,342 #10 OR #9 OR #8 OR #7 OR #6 OR #5 
# 12 835 #11 AND #4 
LILACS (Latin American and Caribbean Health Sciences): 1982-2013/09/24 
http://regional.bvsalud.org/php/index.php?lang=en 
Searched 14.10.13 
Terms  Records 
(Troponin$ or MH:D05.750.078.730.825.925 or MH:D12.776.210.500.910.925 or 
MH:D12.776.220.525.825.925 or MH:D05.750.078.730.825.962 or 
MH:D12.776.210.500.910.962 or MH:D12.776.220.525.825.962 or 
MH:D05.750.078.730.825 or MH:D12.776.210.500.910 or 
MH:D12.776.220.525.825 or Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths 
or ctnths or ctnt-hs or Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or 
ctnihs or ctni-hs or ctni-ultra or accutni or accu-tni) 
247 
Total  247 
CONFIDENTIAL UNTIL PUBLISHED 
150 
 
Spanish and Portuguese translations of MeSH terms identified using the DECS (Health Sciences 
Descriptors) thesaurus: http://decs.bvs.br/I/homepagei.htm 
 
INAHTA (International Network of Agencies for Health Technology Assessment): up to 2013/10/15 
http://www.inahta.org/Search2/?pub=1 
Searched 15.10.13 
Search Term Results 
Troponin 9 
Elecsys 2 
Architect 0 
Accutni 0/1 
unicel 0 
Total 11 
 
Biosis Previews (Web of Knowledge): 1956-2013/10/11 
Searched 14.10.13 
Databases=BIOSIS Previews Timespan=2005-2013 
# 1 266 TS=(Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs) 
# 2 114 TS=(Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or 
accutni or accu-tni) 
# 3 1,055 TS=((troponin* or tnt or ctnt or tropt or tni or ctni or tropI or "trop t" or "trop I") NEAR/2 
(sensitiv* or hs or early or initial or rapid or present* or ultra or "high performance" or 
ultrasensitive)) 
# 4 1,095 #3 OR #2 OR #1 
# 5 7,468 TS=((chest or thorax or thoracic) NEAR (pain* or discomfort or tight* or pressure)) 
# 6 11,149 TS=(acute NEAR/2 coronary NEAR/2 syndrome*) 
# 7 196 TS=(preinfarc* angina* or pre infarc* angina) 
# 8 3,025 TS=unstable angina* 
# 9 62,717 TS=((heart* or myocard* or cardiac or coronary) NEAR/2 (preinfarc* or infarc* or attack* 
or arrest* or occlusion* or isch?emia*)) 
# 10 28,931 TS=(MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP 
or OMI) 
# 11 83,999 #10 OR #9 OR #8 OR #7 OR #6 OR #5 
# 12 628 #11 AND #4 
NIHR HTA (Internet) 
http://www.hta.ac.uk/ up to 2013/10/14 
Searched 14.10.2013 
 
Browsed with Troponin terms  W 6 results 
 
ARIF (Internet): 1996-2013/10/16 
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http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/ARIF/databases/inde
x.aspx 
Searched 16.10.13 
 
Search terms Quick Search 
Troponin* 21 
Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs 0 
Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or 
ctni-ultra or accutni or accu-tni 
0 
Total 21 
 
MEDION database: up to 2013/10/16 
http://www.mediondatabase.nl/ 
Searched 16.10.13 
 
^ĞĂƌĐŚĞĚŝŶ ‘tŚŽůĞĂƚĂďĂƐĞ ?
^ĞĂƌĐŚdĞƌŵŝŶ ?dŽƉŝĐƐ ? Results 
Troponin 0 
Troponins 0 
Total 0 
 
PROSPERO (International Prospective Register of Systematic Reviews) (Internet): up to 
2013/10/10 
http://www.crd.york.ac.uk/prospero/ 
Searched 10.10.13 
 
^ĞĂƌĐŚĞĚŝŶ ‘ůůĨŝĞůĚƐ ? 
 
Terms Records 
Troponin* 8 
Total  8 
 
 
Clinicaltrials.gov (Internet) 
http://clinicaltrials.gov/ct2/search/advanced 
Searched 14.10.13 
 
Advanced search option  W search terms box 
 
Search terms Condition Intervention Records 
troponin% AND (sensitiv% OR hs 
OR early OR initial OR rapid OR 
present% OR ultra OR high 
performance OR ultrasensitive 
OR elecsys OR architect OR 
accutni OR access OR unicel) 
  186 
  Troponin% 109 
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(Hstnt OR hs-tnt OR hsctnt Or 
hs-ctnt OR tnt-hs OR tnths OR 
ctnths OR ctnt-hs OR Hstni OR 
hs-tni OR hsctni OR hs-ctni OR 
tni-hs OR tnihs OR ctnihs OR 
ctni-hs OR ctni-ultra OR accutni 
OR accu-tni) 
  17 
Total    312 
 
 
mRCT  ? metaRegister of Controlled Trials (Internet) 
http://www.controlled-trials.com/ Up to 10.10.13 
Searched 10.10.13 
 
Search terms Results 
(troponin* AND (sensitiv* or hs or early or initial or rapid or present* or ultra or 
high performance or ultrasensitive)) 
333 
TOTAL 333 
 
WHO International Clinical Trials Registry Platform (ICTRP) (Internet) 
http://www.who.int/ictrp/en/ 
Searched 10.10.2013 
 
Advanced search option 
Date of registration limited to 01/01/2005  W 10/10/2013 
 
Title Condition Intervention Records 
Troponin OR Troponins   67 
  Troponins 2 
  Troponin This search does not work  W 
the results are irrelevant and 
do not contain the word 
troponin in the intervention 
field 
Total    69 
 
American Heart Association  ? Scientific Sessions 
http://my.americanheart.org/professional/Sessions/ScientificSessions/Archive/Archive-Scientific-
Sessions_UCM_316935_SubHomePage.jsp 
Searched: 29.10.13 
2013  W Conference not yet taken place at time of searching 
2012: http://circ.ahajournals.org/content/vol126/21_MeetingAbstracts 
2011: http://circ.ahajournals.org/content/vol124/21_MeetingAbstracts 
2010: http://circ.ahajournals.org/content/vol122/21_MeetingAbstracts 
2009: http://circ.ahajournals.org/content/120/21/2152.full.pdf 
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Keyword 2013 2012 2011 2010 2009 Total 
Troponin* N/A 138 131 109 1 379 
       
 
American Association for Clinical Chemistry 
http://www.aacc.org/resourcecenters/meet_abstracts_archive/abstracts_archive/annual_meeting/
Pages/default.aspx# 
Searched: 29.10.13 
2013 Abstracts from: Clinical Chemistry, 59(S10):A1-295 
http://www.aacc.org/events/Annual_Meeting/abstracts/Documents/AACC_13_AbstractBook_Comp
lete.pdf 
2012 Abstracts from: Clinical Chemistry, 58(S10):a1-A264 
http://www.aacc.org/events/annualmtgdirectory/Documents/AACC_12_AbstractBook-Final-
Complete.pdf 
2011 Abstracts from: Clinical Chemistry, 57 (S10): A1-A235 
http://www.aacc.org/events/annualmtgdirectory/documents/AACC_11_FullAbstract.pdf 
2010 Abstracts from: Clinical Chemistry, 57 (6 Suppl): A1-276  
http://www.aacc.org/events/annualmtgdirectory/Pages/2010PosterAbstracts.aspx# 
2009 19-23 July, Chicago, Ill, 
http://www.abstractsonline.com/viewer/searchAdvanced.asp?MKey={CA6D749E-BE20-4F85-899B-
8A84E2268F72}&AKey={B08F832C-9D23-4F0B-96C3-3FA22F3D94A1} 
Keyword 2013 2012 2011 2010 2009 Totals 
Troponin 48 21 32 40 29 170 
       
 
European Society of Cardiology 
http://spo.escardio.org/abstract-book/search.aspx 
Searched: 29.10.13 
Keyword 2013 2012 2011 2010 2009 Total 
Troponin 52 51 61 51 25 240 
Troponins 2 1 2 1 2 8 
      248 
Additional searches 
Results sorted by Link Ranking 
http://www.ncbi.nlm.nih.gov/pubmed/ 
Searched 10.12.13 
 
Nine of the included publications were not indexed on PubMed. Indexed publications were checked 
for errata and comments. For each reference, the first 20 references were retrieved by carrying out 
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downloaded for screening. All related citations were checked against the Endnote Library to remove 
duplicates, and only new unique references were imported and screened = 58 records 
 
Reference PMID Result retrieved 
Santalo39 23764266 20/131 
Aldous40 22109535 20/145 
Sanchis41 22877804 20/203 
Haaf42 22623715 20/203 
Eggers43 22456003 20/145 
Reiter44 22044927 20/280 
Aldous45 22291171 20/277 
Potocki46 22337952 20/304 
Keller47 22203537 20/300 
#403 Meune 22014790 20/252 
Freund48 21663627 20/142 
Aldous49 21784766 20/254 
Melki50 21428843 20/210 
Reichlin51 21709058 20/162 
Reiter52 21362702 20/261 
Aldous53 21441390 20/251 
Kurz54 20852870 20/207 
Hochholzer55 21138939 20/138 
Christ56 20932502 20/201 
Parsonage57 Not in pubmed  
Collinson58 Not in pubmed  
Body59 Not in pubmed  
Melki60 Not in pubmed  
Aldous61 Not in pubmed  
Cullen62 23583250 20/133 
Sebbane63 23816196 20/131 
Irfan64 23870791 20/134 
Collinson65 23597479 20/275 
Reiter66 23514979 20/155 
Body67 21920261 20/192 
Aldous68 21441393 20/174 
Keller69 Not in pubmed  
Collinson70 Not in pubmed  
Saenger71 Not in pubmed  
Lippi74 Not in pubmed  
Hoeller75 23604180 20/107 
Total 640 
Following duplicate removal, number of records screened 58 
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Cost-effectiveness searches 
Medline (OvidSP): 1946 to 2013/10/Week 1 
Searched: 18.10.13 
1     economics/ (27116) 
2     exp "costs and cost analysis"/ (182544) 
3     economics, dental/ (1866) 
4     exp "economics, hospital"/ (19403) 
5     economics, medical/ (8578) 
6     economics, nursing/ (3879) 
7     economics, pharmaceutical/ (2605) 
8     (economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. (427344) 
9     (expenditure$ not energy).ti,ab. (17552) 
10     (value adj1 money).ti,ab. (22) 
11     budget$.ti,ab. (17208) 
12     or/1-11 (551693) 
13     ((energy or oxygen) adj cost).ti,ab. (2752) 
14     (metabolic adj cost).ti,ab. (798) 
15     ((energy or oxygen) adj expenditure).ti,ab. (16662) 
16     or/13-15 (19503) 
17     12 not 16 (547348) 
18     letter.pt. (803396) 
19     editorial.pt. (334975) 
20     historical article.pt. (299710) 
21     or/18-20 (1423597) 
22     17 not 21 (519320) 
23     (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (229) 
24     (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni 
or accu-tni).ti,ab,ot. (99) 
25     ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (563) 
26     ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (349) 
27     (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high 
performance or ultrasensitive)).ti,ab,ot. (769) 
28     (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (66) 
29     or/23-28 (1215) 
30     troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (8642) 
31     (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or 
ultrasensitive).ti,ab,ot. (4878300) 
32     30 and 31 (4209) 
33     29 or 32 (4559) 
34     chest pain/ (9293) 
35     ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. 
(28602) 
36     exp myocardial ischemia/ (357748) 
37     (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (16495) 
38     (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (285) 
39     Unstable angina$.ti,ab,ot. (10718) 
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40     ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ 
or occlusion$ or isch?emia$)).ti,ab,ot. (194088) 
41     (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI).ti,ab,ot. (53168) 
42     or/34-41 (444673) 
43     33 and 42 (2503) 
44     animals/ not (animals/ and humans/) (3957888) 
45     43 not 44 (2336) 
46     limit 45 to yr="2005 -Current" (1457) 
47     22 and 46 (43) 
 
Costs filter: 
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search 
York: Centre for Reviews and Dissemination; 2010  
 
Medline In-Process & Other Non_Indexed Citations  (OvidSP): up to 2013/10/01 
Medline Daily Update: up to 2013/10/01 
Searched: 18.10.13 
1     economics/ (2) 
2     exp "costs and cost analysis"/ (87) 
3     economics, dental/ (0) 
4     exp "economics, hospital"/ (8) 
5     economics, medical/ (0) 
6     economics, nursing/ (0) 
7     economics, pharmaceutical/ (1) 
8     (economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. (39821) 
9     (expenditure$ not energy).ti,ab. (1172) 
10     (value adj1 money).ti,ab. (4) 
11     budget$.ti,ab. (1822) 
12     or/1-11 (41689) 
13     ((energy or oxygen) adj cost).ti,ab. (218) 
14     (metabolic adj cost).ti,ab. (67) 
15     ((energy or oxygen) adj expenditure).ti,ab. (911) 
16     or/13-15 (1160) 
17     12 not 16 (41354) 
18     letter.pt. (24293) 
19     editorial.pt. (14525) 
20     historical article.pt. (68) 
21     or/18-20 (38878) 
22     17 not 21 (40906) 
23     (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (32) 
24     (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni 
or accu-tni).ti,ab,ot. (9) 
25     ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (62) 
26     ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot. (29) 
27     (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high 
performance or ultrasensitive)).ti,ab,ot. (99) 
28     (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. (3) 
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29     or/23-28 (125) 
30     troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (5) 
31     (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or 
ultrasensitive).ti,ab,ot. (388942) 
32     30 and 31 (3) 
33     29 or 32 (127) 
34     chest pain/ (13) 
35     ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. 
(1742) 
36     exp myocardial ischemia/ (170) 
37     (acute adj2 coronary adj2 syndrome$).ti,ab,ot. (1544) 
38     (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot. (3) 
39     Unstable angina$.ti,ab,ot. (378) 
40     ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ 
or occlusion$ or isch?emia$)).ti,ab,ot. (8220) 
41     (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI).ti,ab,ot. (4224) 
42     or/34-41 (12386) 
43     33 and 42 (76) 
44     animals/ not (animals/ and humans/) (1462) 
45     43 not 44 (76) 
46     limit 45 to yr="2005 -Current" (75) 
47     22 and 46 (4) 
 
Costs filter: 
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search . 
York: Centre for Reviews and Dissemination; 2010  
Embase (OvidSP): 1974 to 2013/10/17 
Searched: 18.10.13 
1     health-economics/ (33273) 
2     exp economic-evaluation/ (205882) 
3     exp health-care-cost/ (197503) 
4     exp pharmacoeconomics/ (169588) 
5     or/1-4 (471813) 
6     (econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. (590127) 
7     (expenditure$ not energy).ti,ab. (23360) 
8     (value adj2 money).ti,ab. (1320) 
9     budget$.ti,ab. (23595) 
10     or/6-9 (613918) 
11     5 or 10 (885833) 
12     letter.pt. (844056) 
13     editorial.pt. (449323) 
14     note.pt. (587506) 
15     or/12-14 (1880885) 
16     11 not 15 (799169) 
17     (metabolic adj cost).ti,ab. (876) 
18     ((energy or oxygen) adj cost).ti,ab. (3163) 
19     ((energy or oxygen) adj expenditure).ti,ab. (19981) 
20     or/17-19 (23208) 
21     16 not 20 (794101) 
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22     "high sensitivity cardiac troponin T"/ or high sensitivity troponin t assay/ (12) 
23     "high sensitivity cardiac troponin I"/ or high sensitivity troponin i assay/ (3) 
24     (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs).ti,ab,ot. (571) 
25     (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni 
or accu-tni).ti,ab,ot. (193) 
26     ((troponin t or tnt or ctnt or tropt or trop t) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (1059) 
27     ((troponin I or tni or ctni or tropI or trop I) adj2 (sensitiv$ or hs or early or initial or rapid or 
present$ or ultra or high performance or ultrasensitive)).ti,ab,ot,hw. (602) 
28     (troponin$ adj2 (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high 
performance or ultrasensitive)).ti,ab,ot,hw. (1489) 
29     (troponin$ adj5 (architect or elecsys or accutni or accu-tni or access or unicel)).ti,ab,hw,ot. 
(106) 
30     or/22-29 (2155) 
31     troponin t/ or troponin I/ or (60304-72-5 or 77108-40-8).rn. (18726) 
32     (sensitiv$ or hs or early or initial or rapid or present$ or ultra or high performance or 
ultrasensitive).ti,ab,ot,hw. (6601404) 
33     31 and 32 (9548) 
34     30 or 33 (10144) 
35     thorax pain/ (44662) 
36     ((chest or thorax or thoracic) adj2 (pain$ or discomfort or tight$ or pressure)).ti,ab,ot,hw. 
(64388) 
37     acute coronary syndrome/ (24412) 
38     (acute adj2 coronary adj2 syndrome$).ti,ab,ot,hw. (34558) 
39     exp heart muscle ischemia/ (73666) 
40     exp heart infarction/ (266475) 
41     exp Unstable-Angina-Pectoris/ (16570) 
42     (preinfarc$ Angina$ or pre infarc$ Angina$).ti,ab,ot,hw. (374) 
43     Unstable angina$.ti,ab,ot. (14604) 
44     ((heart$ or myocardi$ or cardiac or coronary) adj2 (preinfarc$ or infarc$ or attack$ or arrest$ 
or occlusion$ or isch?emia$)).ti,ab,ot,hw. (406847) 
45     (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI).ti,ab,ot,hw. (85913) 
46     or/35-45 (499787) 
47     34 and 46 (6035) 
48     animal/ (1890937) 
49     animal experiment/ (1721607) 
50     (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or 
pigs or porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or 
sheep or ovine or monkey or monkeys).ti,ab,ot,hw. (5828979) 
51     or/48-50 (5828979) 
52     exp human/ (15032575) 
53     human experiment/ (317393) 
54     or/52-53 (15034016) 
55     51 not (51 and 54) (4644866) 
56     47 not 55 (5669) 
57     limit 56 to yr="2005 -Current" (4401) 
58     remove duplicates from 57 (4309) 
59     21 and 58 (129) 
 
Costs filter: 
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Centre for Reviews and Dissemination. NHS EED Economics Filter: Embase (Ovid) weekly search. 
York: Centre for Reviews and Dissemination; 2010 
NHS Economic Evaluation Database (NHS EED) (Wiley) Issue 3/July:2013 
Searched 11.10.13 
#1 (Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs):ti,ab,kw  5 
#2 (Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or 
accutni or accu-tni):ti,ab,kw  5 
#3 ((troponin t or tnt or ctnt or tropt or trop t) near/2 (sensitiv* or hs or early or initial or rapid 
or present* or ultra or high performance or ultrasensitive)):ti,ab,kw  12 
#4 ((troponin I or tni or ctni or tropI or trop I) near/2 (sensitiv* or hs or early or initial or rapid 
or present* or ultra or high performance or ultrasensitive)):ti,ab,kw  10 
#5 (troponin* near/2 (sensitiv* or hs or early or initial or rapid or present* or ultra or high 
performance or ultrasensitive)):ti,ab,kw  27 
#6 (troponin* near/5 (architect or elecsys or accutni or accu-tni or access or unicel)):ti,ab,kw 
 2 
#7 #1 or #2 or #3 or #4 or #5 or #6  42 
#8 MeSH descriptor: [Troponin T] this term only 265 
#9 MeSH descriptor: [Troponin I] this term only 309 
#10 #8 or #9  543 
#11 (sensitiv* or hs or early or initial or rapid or present* or ultra or high performance or 
ultrasensitive):ti,ab,kw  170016 
#12 #10 and #11  236 
#13 #7 or #12  249 
#14 MeSH descriptor: [Chest Pain] this term only 335 
#15 ((chest or thorax or thoracic) near/2 (pain* or discomfort or tight* or pressure)):ti,ab,kw 
 1793 
#16 (acute near/2 coronary near/2 syndrome*):ti,ab,kw  1678 
#17 MeSH descriptor: [Myocardial Ischemia] explode all trees 20427 
#18 (preinfarc* Angina* or pre infarc* Angina*):ti,ab,kw  90 
#19 (Unstable angina*):ti,ab,kw  1818 
#20 ((heart* or myocardi* or cardiac or coronary) near/2 (preinfarc* or infarc* or attack* or 
arrest* or occlusion* or isch?emia*)):ti,ab,kw  16156 
#21 (MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP or 
OMI):ti,ab,kw  4740 
#22 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21  28923 
#23 #13 and #22 from 2005 to 2013 114 
 
NHS EED search retrieved 3 references 
Health Economic Evaluation Database (HEED) (Internet): up to 2013/10/18 
http://onlinelibrary.wiley.com/book/10.1002/9780470510933 
Searched 18.10.13 
 
Compound search, (all data), unable to limit by date 
 
Troponin* 
AND 
sensitiv* OR hs OR early OR initial OR rapid OR present OR ultra OR high performance OR 
ultrasensitive OR elecsys OR architect OR accutni OR access OR unicel 
N=20 
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Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs or Hstni or hs-tni or hsctni 
or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra 
N=0 
 
Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni or 
accu-tni 
N=0 
EconLit (EBSCO) 1990-2013/09/01 
Searched: 18.10.13 
 
Search modes - Boolean/Phrase 
S1 TX Troponin* (0) 
S2 TX Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs (0) 
S3 TX Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or accutni 
or accu-tni (0) 
 
 
Science Citation Index  ? Expanded (SCI) (Web of Science): 1970-2013/10/21 
Conference Proceedings Citation Index (CPCI-S) (Web of Science): 1990-2013/10/21 
Searched 21.10.13 
# 1 622,444 TS=(economic* or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic* or budget*) 
# 2 10,144 TS=(expenditure* not energy) 
# 3 952 TS=(value NEAR money) 
# 4 626,873 #3 OR #2 OR #1 
# 5 22,383 TS=((energy or oxygen) NEAR cost) 
# 6 1,804 TS=(metabolic NEAR cost) 
# 7 12,974 TS=((energy or oxygen) NEAR expenditure) 
# 8 35,684 #7 OR #6 OR #5 
# 9 602,398 #4 NOT #8 
# 10 230 TS=(Hstnt or hs-tnt or hsctnt or hs-ctnt or tnt-hs or tnths or ctnths or ctnt-hs) 
# 11 91 TS=(Hstni or hs-tni or hsctni or hs-ctni or tni-hs or tnihs or ctnihs or ctni-hs or ctni-ultra or 
accutni or accu-tni) 
# 12 1,442 TS=((troponin* or tnt or ctnt or tropt or tni or ctni or tropI or "trop t" or "trop I") NEAR/2 
(sensitiv* or hs or early or initial or rapid or present* or ultra or "high performance" or 
ultrasensitive)) 
# 13 1,474 #12 OR #11 OR #10 
# 14 14,001 TS=((chest or thorax or thoracic) NEAR (pain* or discomfort or tight* or pressure)) 
# 15 19,324 TS=(acute NEAR/2 coronary NEAR/2 syndrome*) 
# 16 393 TS=(preinfarc* angina* or pre infarc* angina) 
# 17 5,486 TS=unstable angina* 
# 18 115,562 TS=((heart* or myocard* or cardiac or coronary) NEAR/2 (preinfarc* or infarc* or 
attack* or arrest* or occlusion* or isch?emia*)) 
# 19 40,195 TS=(MI or ACS or STEMI or NSTE-ACS or NSTEACS or nonSTEMI or NSTEMI or AMI or UAP 
or OMI) 
# 20 155,582 #19 OR #18 OR #17 OR #16 OR #15 OR #14 
# 21 839 #20 AND #13 
# 22 32 #21 AND #9 
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Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC Timespan=2005-2013 
Research Papers in Economics (REPEC) up to 2013/10/21 
http://econpapers.repec.org/scripts/search/search.asp?pg=-1 
Searched: 21.10.13 
Advanced search 
Free text search Results Total 
Troponin 0/2 0 
Troponins 0/1 0 
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APPENDIX 2: DATA EXTRACTION TABLES 
a.  Baseline study details 
Study Details Selection criteria Participant details Test 
Manufacturer 
Aldous(2012)
40, 45, 49
 
 
Country: New Zealand 
 
Funding: Funded by the National Heart Foundation 
of New Zealand and assay reagents were provided 
by the manufacturer (Roche). One author declared 
personal funding from Abbott 
 
Recruitment: November 2007 - December 2010 
 
Number of participants: 939,
45
 385
40
 
Inclusion criteria: 
ĚƵůƚƐ ?A䠃? ?ǇĞĂƌƐ ?ǁŝƚŚƐǇŵƉƚŽŵƐƐƵŐŐĞƐƚŝǀĞŽĨĐĂƌĚŝĂĐŝƐĐŚĞŵŝĂ ?ĂĐƵƚĞ
chest, epigastric, neck, jaw or arm pain or discomfort or pressure without 
an apparent noncardiac source) 
 
Exclusion criteria: 
ST-segment elevation on ECG
45
; unable to provide informed consent; 
would not be available to follow-up  
 
Patient category: 
NSTEMI
45
 
Mixed
40
 
 
Median age (IQR):  65( 56, 76) 
Male (%): 60 
White (%): 89 
Previous CAD (%): 52 
Previous Family History (%): 60 
Previous Revascularisation (%): 30 
Diabetes (%): 17 
Smoking (%): 61  
Hypertension (%): 61 
Dyslipidaemia (%): 58 
Median BMI (IQR): 28(25, 31) 
Median (IQR) time to presentation 
(hours): 6.3 (3.3, 13.3) 
Roche  
Aldous(2011)
53, 61, 68
 
 
Country: New Zealand 
 
Funding: Manufacturers (Roche and Abbott) 
supplied assays. The study was funded by a New 
Zealand National Heart Foundation grant 
 
Recruitment: November 2006 - April 2007 
 
Number of participants: 332 
Inclusion criteria: 
Consecutive patients presenting to the emergency department with chest 
pain; participants were eligible for inclusion if the attending clinician had 
sufficient suspicion of ACS that serial troponins and ECGs were considered 
necessary 
 
Exclusion criteria: 
<18 years; samples not stored for both time points (on admission and at 
6-24 hours)  
 
Patient category: 
Mixed 
Median age (IQR):  64( 53, 74) 
Male (%): 60 
White (%): 85 
Previous CAD (%): 54 
Previous Family History (%): 40 
Diabetes (%): 16 
Smoking (%): 45  
Hypertension (%): 46 
Dyslipidaemia (%): 38 
Median (IQR) time to presentation 
(hours): 4.0 (2.0 to 8.6) 
Roche  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Body(2011)
59, 67, 76
 
 
Country: UK 
 
Funding: Central Manchester NHS Trust 
 
Recruitment: January 2006 - February 2007 
 
Number of participants eligible (enrolled):  
1004(703) 
Inclusion criteria: 
Presenting to ED with chest pain; age >25 years and chest pain within 
previous 24h that initial treating physician suspected may be cardiac in 
nature. 
 
Exclusion criteria: 
renal failure requiring dialysis, trauma with suspected myocardial 
contusion, or another medical condition mandating hospital admission or 
if they did not consent to and provide a blood sample for use by the 
research team  
 
Patient category: 
Mixed 
Mean age (sd):  59(14) 
Male (%): 61 
Kidney Disease (%):1 
Previous AMI (%): 24 
Previous Family History (%): 48 
Previous Revascularisation (%): 20 
Diabetes (%): 18 
Smoking (%): 31  
Dyslipidaemia (%): 48  
Median time to presentation 
(hours): 3.5 hours 
 
Roche  
Christ(2010)
56
 
 
Country: Germany 
 
Funding: hsTnT test kits were provided by Roche 
 
Recruitment: 7/9/2009 - 21/9/2009 
 
Number of participants: 137 
Inclusion criteria: 
Consecutive patients with acute chest pain of possible coronary origin 
presenting to the emergency department 
 
Exclusion criteria: NR 
 
Patient category: 
Mixed 
 
 
Mean age (SD):  66(16) 
Male (%): 64 
Previous AMI (%): 32 
Previous CAD (%): 34 
Previous Family History (%): 12 
Previous Revascularisation (%): 24 
Diabetes (%): 22 
Smoking (%): 22  
Hypertension (%): 66 
Dyslipidaemia (%): 35 
Mean BMI (SD): 28(5) 
Time to presentation:  
0-2h 36%; 2-6h 22%; 6-24 h 33%; 
>24h 20% 
Roche  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Collinson(2013)
58, 65, 70
 
 
Country: UK 
 
Funding: UK Health Technology Assessment 
Programme 
 
Study Name: Point of care arm of the RATPAC study 
 
Recruitment: February 2007 - June 2008 
 
Number of participants: 850 
Inclusion criteria: 
Patients presenting to the emergency department with chest pain due to 
suspected, but not proven AMI 
 
Exclusion criteria: 
ECG changes diagnostic for AMI or high risk ACS (>1 mm ST deviation, or 
>3 mm inverted T waves); known CAD with prolonged (>1 hr) or recurrent 
typical cardiac-type pain; proven or suspected serious non-cardiac 
pathology (e.g. PE); co-morbidity or social problems requiring hospital 
admission even if AMI ruled out; obvious non-cardiac cause of chest pain 
(e.g. pneumothorax or muscular pain); presentation >12 hrs after most 
significant episode of pain 
 
Patient category: NSTEMI 
Median age (IQR):  54( 44, 64) 
Male (%): 60 
Previous AMI (%): 40 
Previous Family History (%):  
Previous Revascularisation (%): 1 
Diabetes (%): 8 
Smoking (%): 28  
Hypertension (%): 35 
Dyslipidaemia (%): 24 
Median (IQR) time to presentation 
(hours): 8.25 (5.17 to 12.30) 
Roche  
Cullen(2013)
62
 
 
Country: New Zealand and Australia 
 
Funding: The manufacturers (Abbott, Roche and 
Siemens) provided partial funding 
 
Study Name: ADAPT study 
(ACTRN12611001069943) 
 
Recruitment: November 2007 - February 2011 
 
Number of participants: 1635 
Inclusion criteria: 
Prospectively recruited adults with at least 5 min of 
possible cardiac symptoms in accordance with the American 
Heart Association case definitions (acute chest, epigastric, neck, jaw, or 
arm pain; or discomfort or pressure without a clear non-cardiac so 
 
Exclusion criteria: 
Pregnancy; unable or unwilling to consent; recruitment inappropriate (e.g. 
terminal illness); transfer from another hospital; follow-up considered 
impossible (e.g. homeless patients)  
 
Patient category: 
Mixed 
Mean age (SD):  59(13) 
Male (%): 60 
Previous AMI (%): 24 
Previous Family History (%): 57 
Previous Revascularisation (%): 8 
Diabetes (%): 15 
Smoking (%): 18  
Hypertension (%): 52 
Dyslipidaemia (%): 57 
Mean (SD) time to presentation 
(hours): 22.3 (60.5) 
 
Abbott  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Eggers(2012)
43
 
 
Country: Sweden 
 
Funding: Swedish Society of Medicine and the 
Selander Foundation 
 
Study Name: FASTER 1-study and FAST II study 
 
Recruitment: May 2000 (FAST II), October 2002 
(FASTER I) - March 2001 (FAST II), August 2003 
(FASTER I) 
 
Number of participants eligible (enrolled):  
495(360) 
Inclusion criteria: 
ŚĞƐƚƉĂŝŶǁŝƚŚA䠃? ?ŵŝŶĚƵƌĂƚŝŽŶǁŝƚŚŝŶƚŚĞůĂƐƚ ? ?Ś ?&^d//-study), or 
the last 8 h (FASTER I-study).  Analysis restricted to patients with symptom 
onset <8h. 
 
Exclusion criteria: 
ST-segment elevation on the admission 12-lead ECG leading to immediate 
reperfusion therapy or its consideration was used as exclusion criterion.  
 
Patient category: 
NSTEMI 
 
Median age (IQR):  67( 58, 76) 
Male (%): 66 
Previous AMI (%): 38 
Previous Revascularisation (%): 18 
Diabetes (%): 18 
Smoking (%): 18  
Hypertension (%): 43 
Dyslipidaemia (%): 38 
Delay <4 hours (%): 40 
Roche  
Freund(2011)
48, 72
 
Country: France 
 
Funding: Assay kits for the study were provided by 
the manufacturers (Roche) 
 
Study Name:  
 
Recruitment: August 2005 - January 2007 
 
Number of participants: 317 
Inclusion criteria: 
Consecutive adults (>18 years) presenting to the emergency department 
with chest pain suggestive of ACS (onset or peak within the previous 6 hrs) 
 
Exclusion criteria: 
Patients with acute kidney failure requiring dialysis were excluded  
 
Patient category: 
Mixed (13 were STEMI and 32 NSTEMI) 
Mean (SD):  57(17) 
Male (%): 65 
Previous CAD (%): 26 
Previous Family History (%): 32 
Diabetes (%): 14 
Smoking (%): 40  
Hypertension (%):  
Dyslipidaemia (%): 36 
 
Roche  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Hoeller(2011)
42, 44, 46, 51, 52, 55, 62, 64, 66, 73, 75
 
Country: Switzerland, Spain, USA and Germany 
 
Funding: Swiss National Science Foundation, Swiss 
Heart Foundation, Department of Internal Medicine 
of the University Hospital Basel, Roche, Siemens, 
Abbott, Brahms, nanosphere, and 8sense 
 
Study Name: APACE trial (NCT00470587) 
 
Recruitment: April 2006 - August 2011 
 
Number of participants: 2245 
Inclusion criteria: 
Consecutive adults presenting to the ED with symptoms suggestive of AMI 
(e.g. acute chest pain, angina pectoris at rest, other thoracic sensations) 
within an onset or peak within the last 12 hours 
 
Exclusion criteria: 
Terminal kidney failure requiring dialysis  
 
Patient category: 
Mixed 
 
 
Median age (IQR):  62( 50, 75) 
Male (%): 69 
Previous AMI (%): 24 
Previous CAD (%): 34 
Previous Family History (%): 43 
Previous Revascularisation (%): 24 
Diabetes (%): 18 
Smoking (%): 61  
Hypertension (%): 64 
Dyslipidaemia (%): 45 
Median BMI (IQR): 27(24, 30) 
Presenting <3 hours from 
symptom onset (%): 24 
Roche , 
Abbott, 
Beckman 
Coulter  
Keller(2011)
47, 69
 
 
Country: Germany 
 
Funding: Abbott Diagnostics provided study funding 
 
Recruitment: January 2007 - December 2008 
 
Number of participants: 1818 
Inclusion criteria: 
Consecutive adults (18-85 years) presenting to three chest pain units with 
chest pain suggestive of ACS 
 
Exclusion criteria: 
Major surgery or trauma within the previous 4 weeks; pregnancy; 
intravenous drug abuse; anaemia (haemoglobin <10 g/dL)  
 
Patient category: 
Mixed 
Mean age (sd):  61(14) 
Male (%): 66 
Previous CAD (%): 36 
Previous Family History (%): 32 
Diabetes (%): 16 
Smoking (%): 24  
Hypertension (%): 74 
Dyslipidaemia (%): 73 
Mean BMI (sd): 28(5) 
Abbott  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Kurz(2011)
54
 
 
Country: Germany 
 
Funding: Investigators were supported by Roche 
diagnostics and assay kits were also provided by the 
manufacturer 
 
Recruitment: May 2008 - December 2008 
 
Number of participants: 94 
Inclusion criteria: 
Consecutive patients admitted to a chest pain unit with symptoms 
suggestive of ACS 
 
Exclusion criteria: 
ST-segment elevation; severe kidney dysfunction(GFR <60 mL/min/1.73 
m
2
); patients undergoing PCI during follow-up sampling  
 
Patient category: 
NSTEMI 
 
Mean age (sd):  66(11) 
Male (%): 71 
Previous AMI (%): 37 
Previous CAD (%): 50 
Previous Family History (%): 32 
Previous Revascularisation (%): 17 
Diabetes (%): 31 
Smoking (%): 22  
Hypertension (%): 78 
Dyslipidaemia (%): 65 
Median symptom onset (IQR, 
minutes): 358 (152, 929) 
BMI (95% CI/range/IQR): 28(4) 
Roche  
Lippi(2012)
74
 
 
Country: Italy 
 
Funding: NR 
 
Recruitment: NR  
 
Conference abstract only 
 
Number of participants: 57 
Inclusion criteria: 
Consecutive patients presenting to the emergency department with chest 
pain, within 3 hours of the onset of pain 
 
Exclusion criteria: 
None reported  
 
Patient category: 
Mixed 
 
 
No participant details reported 
 
Beckman  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Melki(2011)
50, 60
 
Country: Sweden 
 
Funding: Partially supported by a grant from Roche 
Diagnostics, who also provided reagents. Also 
supported by the Swedish Heart and Lung 
Foundation and National Board of Health and 
Welfare 
 
Recruitment: August 2006 - January 2008 
 
Number of participants: 233 
Inclusion criteria: 
Patients admitted to a coronary care unit with chest pain or other 
symptoms suggestive of ACS within 12 hours of admission 
 
Exclusion criteria: 
Patients with persistent ST-segment elevation  
 
Patient category: 
NSTEMI 
 
 
Median age (IQR):  65( 55, 76) 
Male (%): 67 
Previous AMI (%): 30 
Previous Revascularisation (%): 21 
Diabetes (%): 23 
Smoking (%): 17  
Hypertension (%): 50 
Mean symptom onset (95% 
CI/range/IQR, hours): 5 (3, 8) 
 
Roche  
Parsonage(2013)
57
 
 
Country: Australia 
 
Funding: Not reported 
 
Recruitment: NR  
 
Conference abstract only 
 
Number of participants: 737 
Inclusion criteria: 
Patients with symptoms of possible ACS 
 
Exclusion criteria: 
None reported  
 
Patient category: 
Mixed 
 
Mean age (IQR):  54( 44, 65) 
Male (%): 60 
 
Abbott, Roche 
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Study Details Selection criteria Participant details Test 
Manufacturer 
Saenger(2010)
71
 
Country: USA 
 
Funding: Two authors declared individual funding 
from manufacturers (one from Roche diagnostics 
and one from Beckman Coulter and Abbott) 
 
Study Name:  
 
Recruitment: NR - NR 
 
Conference abstract only 
 
Number of participants: 288 
Inclusion criteria: 
Patients presenting to the emergency department with symptoms 
suggestive of AMI 
 
Exclusion criteria: 
None reported  
 
Patient category: 
Mixed 
 
Details: 
NSTEMI 19%, STEMI 15% 
 
No further participant details 
reported 
 
Roche  
Sanchis(2012)
41
 
Country: Spain 
 
Funding: Supported by a grant from Roche 
Diagnostics 
 
Study Name: PITAGORAS study 
 
Recruitment: NR  
 
Number of participants: 446 
Inclusion criteria: 
Patients presenting to the emergency department with chest pain of 
possible coronary origin and onset of pain within the previous 24 hrs 
 
Exclusion criteria: 
Exclusion criteria: persistent ST-segment elevation on ECG; troponin 
elevation in any of 2 serial determinations (at arrival and 6-8 hours later); 
prior diagnosis of ischemic heart disease by either the finding of 
significant stenosis in a prior coronary angiogram or previously 
documented AMI;  left bundle-branch block or other non-interpretable 
ECG or inability to performance exercise test; structural heart disease 
different to ischemic heart disease; concomitant heart failure or 
significant bradyarrhythmia (<55 beat/min) or tachyarrythmia (>110 
beat/min) at admission.  
 
Patient category: 
NSTEMI 
Mean age (sd):  60(12) 
Male (%): 59 
Previous Family History (%): 14 
Diabetes (%): 20 
Smoking (%): 25  
Hypertension (%): 54 
Dyslipidaemia (%): 46 
 
Roche  
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Study Details Selection criteria Participant details Test 
Manufacturer 
Santaló(2013)
39
 
 
Country: Spain 
 
Funding: Reagents and logistical support were 
provided by Roche diagnostics 
 
Study Name: TUSCA study 
 
Recruitment: NR  
 
Number of participants: 358 
Inclusion criteria: 
Adult (>18 years) described as presenting with acute coronary syndromes 
ĂŶĚƐǇŵƉƚŽŵĚƵƌĂƚŝŽŶA䠃?ŵŝŶ ?ƉŽƉƵůĂƚŝŽŶŝŶĐůƵĚĞĚ ? ? ?ƉĞŽů ǁŝƚŚĂ
final diagnosis of non-acute coronary syndromes. 
 
Exclusion criteria: 
Exclusion criteria: ST-segment elevation; new left bundle branch block; 
pre-admission thrombolytic therapy; defibrillation or cardioversion before 
sampling; pregnancy; renal failure requiring dialysis; unstable angina 
within 2 months; CABG within 3 month  
 
Patient category: 
NSTEMI 
Mean age (range):  69( 27, 93) 
Male (%): 68 
Previous CAD (%): 35 
Diabetes (%): 26 
Hypertension (%): 62 
Presentation within 3 hours: 
46.2%  
 
Roche  
Sebbane(2013)
63
 
 
Country: France 
 
Funding: Study funded by the hospital, with assay 
reagents supplied by the manufacturers 
 
Recruitment: December 2009 - November 2011 
 
Number of participants: 248 
Inclusion criteria: 
Adults presenting to the emergency department with chest pain  of recent 
(within 12 hrs of presentation) 
 
Exclusion criteria: 
Traumatic causes of chest pain.  STEMI was defined by the persistent 
elevation of the ST segment of at least 1 mm in 2 contiguous ECG leads or 
by the presence of a new left bundle-branch block with positive cardiac 
enzyme results.  Patients with STEMI were excluded from the analysis for 
our review.  
 
Patient category: 
NSTEMI (Data also reported for mixed AMI but not extracted) 
 
Median age (IQR):  61( 48, 75) 
Male (%): 63 
 
Roche  
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b.  Index test and reference standard details 
Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Aldous 
(2012)
40, 45, 49
 
Roche 
Elecsys hs-
cTnT 
5  14  <10% at 13  NSTEMI NR ACC
111
 Conventional troponins were 
measured using Abbott Diagnostics TnI 
(LoD 10 ng/L, 99th centile 28 ng/L, CV 
<10% at 32 ng/L, decision threshold 30 
ng/L) 
 
Timing: On presentation, and at 2 
hours and 6-12 hours 
Diagnoses on admission and at 
follow-up were independently 
adjudicated by one cardiologist, who 
was blinded to hs-TnT results 
Aldous 
(2011)
53, 61, 68
 
Roche 
Elecsys hs-
cTnT 
5  14  <10% at 13  AMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
Conventional troponins were 
measured using Abbott Diagnostics TnI 
2 (LoD 10 ng/L, 99th centile 28 ng/L, CV 
<10% at 32 ng/L) 
Change (rise or fall) in TnI 2, or no 
change but no clear alternative cause 
of troponin elevation, were considered 
indicative of AMI. 
 
Timing: On presentation and at follow-
up (6-24 hours) 
Final diagnoses were adjudicated 
independently by cardiologists, 
blinded to patient history and hs-TnT 
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Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Body (2011)
59, 
67, 76
 
Roche 
Elecsys hs-
cTnT 
NR 14  <10% at 9  AMI 12 
hours 
Joint ESC, 
ACC, AHA 
and World 
Heart 
Federation 
(WHF)
8
 
Rise or fall of cTnT, or both, above the 
99th percentile (10 ng/l) in the 
appropriate clinical context.  For 
patients with modest elevations of 
cTnT (<0.1 ng/ml) at baseline, an 
absolute difference of at least 20 ng/l 
on serial sampling was considered to 
represent a significant rise, fall, or both 
based on the analytical performance of 
the cTnT assay. 
 
Timing: at least 12 h after the onset of 
the most significant symptoms. 
2 independent investigators who had 
all clinical, laboratory, and imaging 
data available for review, but who 
were blinded to hs-CTnT levels. 
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Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Christ 
(2010)
56
 
Roche 
Elecsys hs-
cTnT 
3  14  <10% at 13  AMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
Myocardial necrosis was diagnosed on 
the basis of a rising and/or falling cTnT 
pattern >20% or <20% compared to the 
cTnT levels admission) with at least one 
value above the 99th percentile and an 
imprecision of <10%.  Myocardial 
necrosis not related to AMI was 
defined as a typical rise and fall of cTnT 
levels without clinical evidence of 
coronary artery disease, and cardiac 
pain without necrosis was defined as a 
typical patient history and clinical signs 
of cardiac pain without increased levels 
of cTnT.  Unstable angina was 
diagnosed when a patient had normal 
troponin levels and typical angina at 
rest or exercise, or a cardiac 
catheterization result compatible with 
the diagnosis.  cTnT cut-off level of  
0.04 ug/L, 
 
Timing: At presentation and about 6 
hours at discretion of physician 
Two independent consultants 
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Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Collinson 
(2013) 
58, 65, 70
 
Roche 
Elecsys hs-
cTnT 
3  14  <10% at 13  NSTEMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
Conventional troponins were 
measured using one of the following 
methods: Siemens cTnI Ultra (LoD 6 
ng/L, 99th centile 40 ng/L, CV 10% at 
30 ng/L; Abbott cTnI (LoD 10 ng/L, 99th 
centile 12 ng/L, CV 10% at 32 ng/L; 
Beckman AccuTnI (LoD 10 ng/L, 99th 
centile 40 ng/L, CV 10% at 60 ng/L; 
Roche cTnT (LoD 10 ng/L, 99th centile 
10 ng/L, CV 10% at 30 ng/L 
 
Timing: On presentation and at 10 to 
12 hours 
An initial working diagnosis was 
recorded by the senior emergency 
department clinician and reviewed by 
two independent clinicians; all were 
blind to hs-TnT results 
Cullen 
(2013)
62
 
Abbott 
ARCHITECT 
hs-cTnI STAT 
1.2  26.2  <5% at 26.2  MACE 30 days MACE NR 
 
Adjudication of all cardiac endpoints 
was made by two cardiologists, with 
consultation of a third cardiologist in 
case of disagreement 
Eggers 
(2012)
43
 
Roche 
Elecsys hs-
cTnT 
3  14  <10% at 13  NSTEMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
cTnI (Stratus CS, Siemens Healthcare 
Diagnostics, Deerfield, IL, USA).  Non-
STEMI defined as:  cTnI above the 99th 
ƉĞƌĐĞŶƚŝůĞŽĨ ? ? ? ?ʅŐ ?>ĂƚůĞĂƐƚĂƚŽŶĞ
measuremeŶƚƚŽŐĞƚŚĞƌǁŝƚŚĂA䠃? ?A?
rise and/or fall and an absolute change 
A? ? ? ? ?ʅŐ ?>ǁŝƚŚŝŶ ? ?Ś ?dŽĂůůŽǁĨŽƌƚŚĞ
calculation of relative changes, cTnI 
ǁĂƐƐĞƚƚŽ ? ? ? ?ʅŐ ?> ?ŝ ?Ğ ?Ă
concentration below the lowest level 
of detection) when reported as 0.00 or 
 ? ? ? ?ʅŐ ?L. 
 
Timing: eight time points during the 
first 24 h following enrolment 
Not reported 
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Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Freund 
(2011)
48, 72
 
Roche 
Elecsys hs-
cTnT 
3  14  <10% at 14  AMI 30 days Joint ESC, 
ACC, AHA 
and WHF
8
 
cTnI (Siemens Healthcare Diagnostica 
Inc., NewaRK, USA or Access analyser 
Beckman Coulter Inc., Brea, USA). 
Threshold for Siemens assay 140 ng/L, 
sA䜃? ?A? 
Threshold for  Beckman assay 60 ng/L, 
CV 10% 
 
Timing: On presentation and at 3-9 
hours if needed 
Two independent emergency 
department physicians, who were 
blinded to hs-TnT results. 
Disagreements were adjudicated by a 
third emergency department 
physician. 
Hoeller (2011) 
APACE
46, 51, 52, 
55, 64, 75
 
Roche 
Elecsys hs-
cTnT 
5  14  <10% at 13  AMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
Conventional troponins were 
measured using Roche cTnT 4th 
generation assay (CV <10% at 35 ng/L), 
Beckman Coulter Accu cTnI (CV <10% 
at 60 ng/L), or Abbott Axsym cTnI ADV 
(CV <10% at 160 ng/L). A positive test 
ǁĂƐĚĞĨŝŶĞĚĂƐĐŚĂŶŐĞA? ? ?A?ŽĨ ? ?ƚŚ
centile or 10% CV level, within 6 to 9 
hours. 
 
Timing: On presentation and at 6 to 9 
hours 
Final diagnoses were adjudicated by 
two independent cardiologists blind 
to hsTnT results. Where there was 
disagreement a third cardiologist was 
consulted. 
APACE
73
 2 
APACE
64, 75
 Beckman 
(pre-
commercial 
assay) 
2 9 <10% at 9  AMI and 
NSTEMI 
30 days 
APACE
62
 Abbott 
ARCHITECT 
hs-cTnI STAT 
1.2  26.2  <5% at 26.2  AMI 30 days 
APACE
75
 MACE NA 
 
 
Adjudication of all cardiac endpoints 
was made by two cardiologists, with 
consultation of a third cardiologist in 
case of disagreement 
Keller 
(2011)
47
 
Abbott 
ARCHITECT 
hs-cTnI STAT 
3.4  24-30 
for this 
study 
popul-
ation 
10% at 5.2  AMI 30 days Joint ESC, 
ACC, AHA 
and WHF
8
 
Conventional serial troponin T or I (no 
further details) 
 
Timing: On presentation and at 3 and 6 
hours 
Final diagnosis adjudicated by two 
independent cardiologists, with 
disagreements referred to a third 
cardiologist; all three were blinded to 
hs-TnI results 
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Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Kurz (2011)
54
 Roche 
Elecsys hs-
cTnT 
3  13.5  8% at 10  NSTEMI 24 
hours 
Joint ESC, 
ACC, AHA 
and WHF
8
 
4th generation cTnT (Roche Elecsys, 
Mannheim, Germany) LoD 10 ng/L, 
diagnostic threshold 30 ng/L 
Diagnosis of NSTEMI required elevated 
cTnT concentration in at least one of 
the consecutive samples collected 
within 24 hours of the index event 
 
Timing: On presentation, at 6 hours 
and at least one sample between 
presentation and 6 hours 
NR 
Lippi (2012)
74
 Beckman 
Coulter 
prototype 
hs-cTnI (hs-
Accu-TnI) 
2.1  8.6  NR AMI NR AMI (unclear 
method) 
NR 
 
 
NR 
Melki 
(2011)
50, 60
 
Roche 
Elecsys hs-
cTnT 
2  14  <10% at 13  NSTEMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
Conventional troponin Roche 4th 
generation TnT (LoD 10 ng/L, 10% CV at 
35 ng/L), or Beckman Coulter Access 
AccuTnI (LoD 10 ng/L, 99th centile 40 
ng/L, CV <10% at 60 ng/L 
 
Timing: On presentation and 9 to 12 
hours later 
Final diagnosis determined by the 
individual cardiologist, then 
adjudicated by two independent 
evaluators; all three were blinded to 
hs-TnT results 
Parsonage 
(2013)
57
 
Abbott 
ARCHITECT 
hs-cTnI STAT 
NR 26.2  NR AMI NR AMI (unclear 
method) 
NR 
 
Timing: On admission and >6 hours 
after presentation 
Final diagnosis was adjudicated by 
two independent cardiologists 
Saenger 
(2010)
71
 
Roche 
Elecsys hs-
cTnT 
NR 14  NR AMI NR AMI (unclear 
method) 
NR 
 
 
NR 
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Study Details High sensitivity troponin details (ng/L) Reference standard details 
Manu-
facturer 
LoD 99
th
 
Centile  
Coefficient 
of variation 
Target 
Condition 
Time 
frame 
Reference 
standard 
Standard troponin  Observer  
Sanchis 
(2012)
41
 
Roche 
Elecsys hs-
cTnT 
3  14  <10% at 14  MACE 30 days MACE NR NR 
Santaló 
(2013)
39
 
Roche 
Elecsys hs-
cTnT 
NR 14  10% at 9.3  NSTEMI NR National 
Academy of 
Clinical 
Biochemistr
y and 
International
Federation 
of Clinical 
Chemistry 
Committee
10
4
 
Roche cTnT; NSTEMI was defined as 
ĐdŶdAN ? ?ŶŐ ?>ĂŶĚȴĐdŶdAN ? ?A? 
 
Timing: 30 minutes after arrival and at 
2,4 and 6-8 hours or until discharge 
Final diagnosis was made by an 
adjudication committee 
Sebbane 
(2013)
63
 
Roche 
Elecsys hs-
cTnT 
5  14  <10% at 13  NSTEMI NR Joint ESC, 
ACC, AHA 
and WHF
8
 
cTnI measured using the Access2 
analyser (Access Immunosystem, 
Beckman Instruments, France). The 
LoD was <10 ng/L and the decision 
threshold was 40 ng/L 
 
Timing: Convention cardiac troponin 
(cTnI) on presentation, 6 hrs later and 
beyond as needed 
Two independent emergency 
department physicians, blinded to hs-
cTnT results 
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c.  Study results 
Study Details Troponin 
Assay 
Timing Threshold 
(ng/L) 
Target 
Condition 
TP FP FN TN Sens 
(95% CI) 
Spec 
(95% CI) 
LR+ (95% CI) LR- (95% CI) 
Aldous (2011)
53
 Roche On presentation 14 AMI 92 36 18 186 83 (75, 89) 84 (78, 88) 5.1 (3.7, 6.9) 0.2 (0.13, 0.3) 
5 106 131 4 91 96 (90, 98) 41 (35, 48) 1.6 (1.4, 1.8) 0.1 (0.04, 0.25) 
13 92 38 18 184 83 (75, 89) 83 (77, 87) 4.8 (3.6, 6.5) 0.2 (0.13, 0.31) 
15 93 29 17 193 84 (76, 90) 87 (82, 91) 6.4 (4.5, 9) 0.18 (0.12, 0.28) 
             
Aldous (2012)
40
 Roche On presentation 14 AMI 74 54 8 249 90 (81, 95) 82 (77, 86) 5 (3.9, 6.4) 0.12 (0.07, 0.24) 
0-1 hours after 
presentation 
14 77 63 5 240 93 (86, 97) 79 (74, 83) 4.5 (3.6, 5.6) 0.08 (0.04, 0.19) 
0-2 hours after 
presentation 
14 78 67 4 236 95 (87, 98) 78 (73, 82) 4.3 (3.4, 5.3) 0.07 (0.03, 0.17) 
On presentation 
and at 2 hours 
14 and no 
change 
78 74 4 229 95 (87, 98) 75 (70, 80) 3.9 (3.1, 4.7) 0.07 (0.03, 0.18) 
AM ? ?ĂŶĚȴ ? ?A? 49 81 33 222 60 (49, 70) 73 (68, 78) 2.2 (1.7, 2.9) 0.55 (0.42, 0.72) 
 ? ?ĂŶĚȴ ? ?A? 46 23 36 280 56 (45, 66) 92 (89, 95) 7.2 (4.7, 
11.2) 
0.48 (0.37, 0.61) 
 ? ?Žƌȴ ? ?A? 81 131 1 172 98 (93, 100) 57 (51, 62) 2.3 (2, 2.6) 0.03 (0.01, 0.16) 
Aldous (2012)
45
 Roche On presentation 14 NSTEMI 181 134 24 600 88 (83, 92) 82 (79, 84) 4.8 (4.1, 5.7) 0.15 (0.1, 0.21) 
On presentation 5 192 305 13 429 93 (89, 96) 58 (55, 62) 2.2 (2, 2.5) 0.11 (0.07, 0.19) 
On presentation 3 196 383 9 351 95 (92, 98) 48 (44, 51) 1.8 (1.7, 2) 0.1 (0.05, 0.18) 
2 hours after 
presentation 
14 189 149 16 585 92 (87, 95) 80 (77, 82) 4.5 (3.9, 5.2) 0.1 (0.06, 0.16) 
5 196 340 9 394 95 (92, 98) 54 (50, 57) 2.1 (1.9, 2.2) 0.09 (0.05, 0.16) 
3 201 424 4 310 98 (95, 99) 42 (39, 46) 1.7 (1.6, 1.8) 0.05 (0.02, 0.13) 
Data from: 
Aldous (2011)
49
 
0-2 hours after 
presentation 
Peak 14 189 149 11 590 94 (90, 97) 80 (77, 83) 4.7 (4, 5.4) 0.07 (0.04, 0.13) 
14 ĂŶĚȴ ? ?A? 99 43 101 696 50 (43, 56) 94 (92, 96) 8.4 (6.1, 
11.6) 
0.54 (0.47, 0.62) 
14 Žƌȴ ? ?A? 195 260 5 479 97 (94, 99) 65 (61, 68) 2.8 (2.5, 3.1) 0.04 (0.02, 0.1) 
Body (2011)
67
 Roche On presentation 3 AMI 130 378 0 195 100 (96, 100) 34 (30, 38) 1.5 (1.4, 1.6) 0.01 (0, 0.18) 
On presentation 14 111 101 19 472 85 (78, 90) 82 (79, 85) 4.8 (4, 5.8) 0.18 (0.12, 0.27) 
On presentation: 
Symptom onset 
<3h 
3 79 89 0 156 99 (94, 100) 64 (57, 69) 2.7 (2.3, 3.2) 0.01 (0, 0.16) 
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Study Details Troponin 
Assay 
Timing Threshold 
(ng/L) 
Target 
Condition 
TP FP FN TN Sens 
(95% CI) 
Spec 
(95% CI) 
LR+ (95% CI) LR- (95% CI) 
On presentation:  
Symptom onset 
<3h 
14 63 42 13 203 82 (72, 89) 83 (78, 87) 4.8 (3.6, 6.4) 0.21 (0.13, 0.35) 
On presentation:  
Symptom onset 
>3h 
3 51 221 0 107 99 (91, 100) 33 (28, 38) 1.5 (1.4, 1.6) 0.03 (0, 0.47) 
On presentation: 
Symptom onset 
>3h 
14 47 59 4 269 91 (81, 96) 82 (77, 86) 5.1 (4, 6.5) 0.11 (0.04, 0.26) 
On presentation: 
Symptom onset 
<6h 
3 105 253 0 133 100 (96, 100) 34 (30, 39) 1.5 (1.4, 1.6) 0.01 (0, 0.22) 
On presentation: 
Symptom onset 
<6h 
14 87 66 18 320 83 (74, 89) 83 (79, 86) 4.8 (3.8, 6.1) 0.21 (0.14, 0.32) 
On presentation: 
Symptom onset 
>6h 
3 25 125 0 62 98 (84, 100) 33 (27, 40) 1.5 (1.3, 1.6) 0.06 (0, 0.91) 
On presentation: 
Symptom onset 
>6h 
14 24 35 1 152 94 (78, 99) 81 (75, 86) 5 (3.7, 6.8) 0.07 (0.02, 0.34) 
Christ (2010)
56
 Roche On presentation 14 AMI 19 45 1 72 93 (74, 98) 61 (52, 70) 2.4 (1.9, 3.1) 0.12 (0.02, 0.55) 
Christ (2010)
56
 Roche On presentation 14 AMI 20 92 0 25 100 (81, 100) 22 (15, 30) 1.25 (1.11, 
1.40) 
0.11 (0.01, 1.74) 
Collinson 
(2013)
65
 
Roche On presentation 14 NSTEMI 53 33 14 733 79 (68, 87) 96 (94, 97) 18 (12.6, 
25.7) 
0.22 (0.14, 0.35) 
On presentation 
and at 1.5 hours 
Peak 14 NSTEMI 57 43 11 736 83 (73, 90) 94 (93, 96) 14.9 (11, 
20.3) 
0.18 (0.1, 0.3) 
Cullen (2013)
62
 Abbott On presentation 
and at 2 hours 
26.2 on 
admission and 
at 2 hours 
MACE 227 96 20 129
2 
92 (88, 95) 93 (92, 94) 13.2 (10.9, 
16.1) 
0.09 (0.06, 0.13) 
Eggers (2012)
43
 Roche On presentation 14 NSTEMI 101 59 27 173 79 (71, 85) 74 (68, 80) 3.1 (2.4, 3.9) 0.29 (0.2, 0.4) 
45.7 NSTEMI 65 11 63 221 51 (42, 59) 95 (91, 97) 10.3 (5.7, 
18.5) 
0.52 (0.43, 0.62) 
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Study Details Troponin 
Assay 
Timing Threshold 
(ng/L) 
Target 
Condition 
TP FP FN TN Sens 
(95% CI) 
Spec 
(95% CI) 
LR+ (95% CI) LR- (95% CI) 
Freund (2011)
48
 Roche On presentation 14 AMI 42 48 3 224 92 (81, 97) 82 (77, 86) 5.2 (4, 6.8) 0.09 (0.03, 0.25) 
On presentation: 
Low/moderate 
pre-test 
probability  
20 36 2 200 89 (70, 97) 85 (79, 89) 5.8 (4.2, 8.1) 0.13 (0.04, 0.41) 
On presentation: 
High pre-test 
probability 
22 12 1 24 94 (77, 99) 66 (50, 79) 2.8 (1.7, 4.4) 0.09 (0.02, 0.45) 
Hoeller (2011)
75
 Roche On presentation 14 AMI 398 363 46 126
5 
90 (86, 92) 78 (76, 80) 4 (3.6, 4.4) 0.13 (0.1, 0.18) 
On presentation: 
Symptom onset 
<3h 
14 79 63 28 335 74 (65, 81) 84 (80, 87) 4.6 (3.6, 6) 0.31 (0.23, 0.43) 
On presentation:  
Symptom onset 
A? ?Ś 
14 318 300 18 931 95 (92, 96) 76 (73, 78) 3.9 (3.5, 4.3) 0.07 (0.05, 0.11) 
Beckman On presentation 9 209 231 18 693 92 (88, 95) 75 (72, 78) 3.7 (3.3, 4.1) 0.11 (0.07, 0.17) 
Abbott 26.2 240 93 71 116
3 
77 (72, 81) 93 (91, 94) 10.4 (8.4, 
12.7) 
0.25 (0.2, 0.3) 
Data from: 
 Reichlin (2009)
73
 
Roche On presentation 2 123 512 0 83 100 (97, 100) 14 (11, 17) 1.2 (1.1, 1.2) 0.03 (0.00, 0.46) 
Abbott 10 116 77 7 518 94 (89, 98) 87 (84, 90) 7.3 (5.9, 9.0) 0.07 (0.03, 0.13) 
Data from: 
 Reiter (2011)
52
 
Roche On presentation: 
>70 years only 
5 98 305 0 3 99 (95, 100) 1 (0, 3) 1 (1, 1) 0.45 (0.02, 8.56) 
On presentation: 
>70 years only 
14 96 157 2 151 97 (92, 99) 49 (44, 55) 1.9 (1.7, 2.1) 0.05 (0.02, 0.18) 
On presentation: 
A? ? ?ǇĞĂƌƐ 
14 54 87 7 533 88 (78, 94) 86 (83, 88) 6.2 (5, 7.7) 0.14 (0.07, 0.28) 
Data from: 
Potocki (2012)
46
 
On presentation: 
with pre-existing 
CAD 
14 73 142 5 213 93 (85, 97) 60 (55, 65) 2.3 (2, 2.7) 0.12 (0.05, 0.26) 
On presentation: 
without pre-
existing CAD 
14 100 114 6 517 94 (88, 97) 82 (79, 85) 5.2 (4.4, 6.2) 0.07 (0.04, 0.16) 
Data from: On presentation 11 129 177 3 454 97 (93, 99) 72 (68, 75) 3.5 (3.1, 3.9) 0.04 (0.01, 0.1) 
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Study Details Troponin 
Assay 
Timing Threshold 
(ng/L) 
Target 
Condition 
TP FP FN TN Sens 
(95% CI) 
Spec 
(95% CI) 
LR+ (95% CI) LR- (95% CI) 
Hochholzer 
(2011)
55
 
On presentation 11 NSTEMI 90 177 3 454 96 (90, 99) 72 (68, 75) 3.4 (3, 3.9) 0.05 (0.02, 0.14) 
Data from: 
Irfan (2013)
64
 
On presentation 
and at 1 hour 
ȴ17% 65 202 43 520 60 (51, 69) 72 (69, 75) 2.1 (1.8, 2.6) 0.55 (0.44, 0.7) 
Beckman ȴ ? ?A? 68 245 40 477 63 (53, 71) 66 (63, 69) 1.9 (1.6, 2.2) 0.56 (0.44, 0.72) 
Data from: 
Reichlin (2011)
51
 
Roche On presentation 
and at 2 hours 
ȴ ? ?A? 43 84 24 439 64 (52, 74) 84 (80, 87) 4 (3, 5.2) 0.43 (0.31, 0.59) 
Data from: 
Cullen (2013)
62
 
Abbott 26.2 on 
admission and 
at 2 hours 
MACE 129 62 27 691 82 (76, 88) 92 (90, 93) 10 (7.8, 
12.8) 
0.19 (0.14, 0.27) 
Keller (2011)
47
 Abbott On presentation 3.4 AMI 282 633 0 345 100 (98, 100) 35 (32, 38) 1.5 (1.5, 1.6) 0.01 (0, 0.08) 
30 AMI 232 77 50 901 82 (77, 86) 92 (90, 94) 10.4 (8.3, 
12.9) 
0.19 (0.15, 0.25) 
3 hours after 
presentation 
3.4 AMI 282 959 0 19 100 (98, 100) 2 (1, 3) 1 (1, 1) 0.09 (0.01, 1.46) 
30 AMI 277 94 5 884 98 (96, 99) 90 (88, 92) 10.2 (8.4, 
12.3) 
0.02 (0.01, 0.05) 
On presentation 
and at 3 hours 
ȴ ? ?A? AMI 218 723 64 255 77 (72, 82) 26 (23, 29) 1 (1, 1.1) 0.87 (0.69, 1.11) 
3.4 on 
admission and 
ȴ ? ?A? 
AMI 254 454 54 498 82 (78, 86) 52 (49, 55) 1.7 (1.6, 1.9) 0.34 (0.26, 0.43) 
30 after 3 hrs 
ĂŶĚȴ ? ?A? 
AMI 187 34 110 929 63 (57, 68) 96 (95, 97) 17.6 (12.5, 
24.7) 
0.38 (0.33, 0.45) 
30 after 3 hrs 
ĂŶĚȴ ? ?A? ?ŝŶ
patients 
<30ng/L on 
admission 
AMI 52 26 4 869 92 (82, 97) 97 (96, 98) 31.1 (21.2, 
45.7) 
0.08 (0.03, 0.2) 
Kurz (2011)
54
 Roche On presentation 9.5 NSTEMI 38 11 8 37 82 (69, 90) 77 (63, 86) 3.5 (2.1, 5.9) 0.24 (0.13, 0.44) 
14 NSTEMI 16 7 10 24 61 (42, 77) 77 (60, 88) 2.6 (1.3, 5.2) 0.51 (0.3, 0.85) 
within 3 hours of 
presentation 
14 NSTEMI 26 7 0 23 98 (84, 100) 76 (58, 87) 4.1 (2.2, 7.6) 0.02 (0, 0.38) 
On presentation 
and within 3 
hours 
14 ĂŶĚȴ ? ?A? NSTEMI 11 27 15 3 43 (26, 61) 11 (4, 27) 0.5 (0.3, 0.8) 5.08 (1.8, 14.37) 
Lippi (2012)
74
 Beckman On presentation 18 AMI 9 17 0 31 95 (66, 99) 64 (50, 76) 2.7 (1.8, 4) 0.08 (0.01, 1.17) 
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Study Details Troponin 
Assay 
Timing Threshold 
(ng/L) 
Target 
Condition 
TP FP FN TN Sens 
(95% CI) 
Spec 
(95% CI) 
LR+ (95% CI) LR- (95% CI) 
Melki (2011)
50
 Roche On presentation 14 NSTEMI 112 21 2 98 98 (93, 99) 82 (74, 88) 5.5 (3.7, 8) 0.03 (0.01, 0.09) 
2 hours after 
presentation 
14 NSTEMI 114 25 0 94 100 (96, 100) 79 (71, 85) 4.7 (3.3, 6.6) 0.01 (0, 0.09) 
Parsonage 
(2013)
57
 
Abbott On presentation 26.2 AMI 45 34 6 652 88 (76, 94) 95 (93, 96) 17.4 (12.4, 
24.5) 
0.13 (0.06, 0.27) 
On presentation 
and at 2 hours 
26.2 peak AMI 47 48 4 638 91 (81, 96) 93 (91, 95) 12.9 (9.7, 
17.2) 
0.09 (0.04, 0.23) 
Roche On presentation 14 AMI 44 75 7 611 86 (74, 93) 89 (86, 91) 7.8 (6.1, 9.9) 0.16 (0.08, 0.31) 
On presentation 
and at 2 hours 
14 peak AMI 48 82 3 604 93 (83, 98) 88 (85, 90) 7.8 (6.3, 9.6) 0.08 (0.03, 0.21) 
Saenger( 2010)
71
 Roche On presentation 14 AMI 92 38 6 152 93 (87, 97) 80 (74, 85) 4.6 (3.5, 6.2) 0.08 (0.04, 0.17) 
On presentation 
and at 3 hours 
ȴ ? AMI 94 9 4 181 95 (89, 98) 95 (91, 97) 19.2 (10.3, 
35.7) 
0.05 (0.02, 0.12) 
Sanchis (2012)
41
 Roche On presentation 3 MACE 53 207 9 177 85 (74, 92) 46 (41, 51) 1.6 (1.4, 1.8) 0.33 (0.18, 0.59) 
On presentation 
and 6-8 hours  
3 MACE 57 234 5 150 91 (82, 96) 39 (34, 44) 1.5 (1.3, 1.7) 0.22 (0.1, 0.5) 
14 MACE 21 42 41 342 34 (24, 46) 89 (85, 92) 3.1 (2, 4.8) 0.74 (0.62, 0.89) 
Santaló (2013)
39
 Roche On presentation  14 NSTEMI 71 80 8 199 89 (81, 94) 71 (66, 76) 3.1 (2.5, 3.8) 0.15 (0.08, 0.28) 
On presentation 
and at 2, 4 and 6-
8 hours or until 
discharge 
ȴ ? ?A? NSTEMI 79 94 0 185 99 (94, 100) 66 (61, 72) 2.9 (2.5, 3.5) 0.01 (0, 0.15) 
Sebbane (2013)
63
 Roche On presentation, 
or sample taken 
during pre-
hospital 
management 
14 NSTEMI 19 25 6 142 75 (56, 88) 85 (79, 89) 4.9 (3.2, 7.5) 0.29 (0.15, 0.58) 
18 NSTEMI 19 17 6 150 75 (56, 88) 90 (84, 93) 7.2 (4.4, 
11.8) 
0.28 (0.14, 0.54) 
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APPENDIX 3: QUADAS-2 ASSESSMENTS 
Study: Aldous (2011)53 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutive adults presenting to the emergency department with chest pain were eligible for inclusion. 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT on admission and after 6 hrs. Data reported for admission, for four thresholds 
No details of interpretation reported. One threshold was derived from ROC analysis; primary analysis based on 
99th centile 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Unclear 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI based on joint European Cardiology Society an American College of Cardiology 
criteria and included serial conventional cTnI (10-12 hour time point not specified) 
Determination of diagnosis was made blind to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
Participants for whom stored samples were not available at both time points were excluded. 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? No 
Could the patient flow have introduced bias? RISK: High 
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 Study: Aldous (2012)45 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Patients presenting to the emergency department between 05:30 h and 20:00 h, and with chest pain 
Was a consecutive or random sample of patients enrolled? No 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: High 
B. APPLICABILITY 
Patients with ST-segment elevation excluded 
Do the included patients match the question? Concerns: Low 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hsTnT 
Data reported for multiple thresholds based on pre-determined properties of the assay 
Frozen samples used, unclear whether interpretation of index test was blind to reference standard 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard final diagnosis of AMI, based on ACC criteria and including the results of serial conventional 
cTnI (10-12 hour time point not specified), but blinded to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
All participants appear to have been included in the analyses 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
 
CONFIDENTIAL UNTIL PUBLISHED 
185 
Study: Body (2011)67 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Prospective enrolment of patients; unclear if consecutive 
Was a consecutive or random sample of patients enrolled? Unclear 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Unclear 
B. APPLICABILITY 
Mixed chest pain 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys HsTnT.  Threshold 99th percentile cut point and limit of detection.  Blinding not reported; objective 
test interpreted prior to reference standard so unlikely to have been influenced by knowledge of reference 
standard. 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Thorgeson criteria; time point not specified.  Clinicians were blinded to Hs-Tn. 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
301 patients were excluded prior to enrolment; all patients enrolled included in 2x2 table. 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Christ (2010)56 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Retrospective analysis of consecutive patients presenting to ED with chest pain 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Patients with general chest pain symptoms, includes participants with a final diagnosis of STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys HsTnT.  Threshold 99th percentile cut point.  Blinding not reported; retrospective analysis and so 
disease status may have been known when interpreting results.  However, objective test and so unlikely to have 
been influenced by knowledge of disease state. 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Unclear 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Joint European Cardiology Society an American College of Cardiology criteria; time point not specified.  Unclear 
whether clinicians were blinded to Hs-Tn.  A second consensus diagnosis incorporating Hs-Tn was also made and so 
clinicians may have been aware of the result for the first consensus diagnosis based only on standard troponin. 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
No dropouts reported, all included patients accounted for in flow diagram and numbers suggest that troponin 
results were available for all. 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Collinson (2013)65 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Participants with chest pain and suspected AMI; Study uses subgroup of one arm of an RCT.  Patients at high risk of 
NSTEMI excluded 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Chest pain patients excluding those with diagnostic ECG changes 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT on admission and at 90 minutes 
Reference standard (final diagnosis) determined after hs-TnT 
Threshold based on assay characteristics including 99th centile 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI based on joint European Cardiology Society an American College of Cardiology 
criteria and included serial conventional cTnT or cTnI (10-12 hour time point specified) 
Determination of diagnosis was made blind to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: Low 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
1125 enrolled, 25 no samples collected, 250 samples taken but study samples not collected. 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? No 
Could the patient flow have introduced bias? RISK: High 
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Study: Cullen (2013)62 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutively recruited adults presenting to the emergency department with cardiac symptoms 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Abbott ARCHITECT hs-STAT TnI; Threshold was 99th centile 
Frozen samples were used, but laboratory technicians were blinded to patient data 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
30 day MACE, adjudicated blind to index tests, but with access to clinical records, ECG and conventional troponin 
results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: Low 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
No patients were lost to 30 day follow-up.  Procedure for adjudication of 30 day MACE was the same in all cases, 
but investigations undergone by individual patients varied 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? No 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Eggers (2012)43 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Unclear whether consecutive or random patients were enrolled. 
Was a consecutive or random sample of patients enrolled? Unclear 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Unclear 
B. APPLICABILITY 
Non-STEMI patients with chest pain presenting to coronoary care/chest pain unit 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys HsTnT.  Threshold 99th percentile cut point and 95% specificity value.  Blinding not reported; 
objective test interpreted prior to reference standard so unlikely to have been influenced by knowledge of 
reference standard. 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Unclear 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Joint European Cardiology Society an American College of Cardiology criteria; time point not specified.  Unclear 
whether clinicians were blinded to Hs-Tn.  A second consensus diagnosis. 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
Only 360 patients out of 495 who fulfilled inclusion criteria had all biochemical tests performed and were included 
in the analysis; reasons for not performing tests were not reported. 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? No 
Could the patient flow have introduced bias? RISK: High 
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Study: Freund (2011)48 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutive adults presenting to the emergency department with chest pain (onset or peak within previous 6 hrs). 
Patients with acute kidney failure requiring dialysis were excluded 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Unselected emergency department chest pain population, includes participants with a final diagnosis of STEMI; 
data also presented for subgroups with low-moderate and with high pre-test probability 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT on admission and at 3-9 hours if available. Reference standard (final diagnosis) adjudicated by 
two independent physicians after acute episode. Threshold was 99th centile 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard final diagnosis, based on joint European Cardiology Society an American College of Cardiology 
criteria and included conventional cTnI on admission and at 3-9 hours if needed (10-12 hour time point not 
specified). Clinicians adjudicating final diagnosis were blind to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
All participants appear to have been included in the analyses 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Hoeller (2013)75 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Patients presenting to the ED with symptoms suggestive of AMI. Consecutive patients with hs-TnT measurements 
available were included. 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Hs-TnT, Beckman Coulter Hs-AccuTnI and Abbott ARCHITECT HsTnI on admission 
Reference standard probably made later than admission. 99th Centiles for assays used as diagnostic thresholds 
(some publications also reported data for ROC derived thresholds). 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard final diagnosis of AMI, European Cardiology Society criteria and included cTn assays (0 and 6 
hours). Unclear whether those adjudicating final diagnosis were blind to hs-TnI/hsTnT results in all cases, some 
publications reported blinding 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes/No 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: Low 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
2245 participants were included in the trial, 2072 were included in the hsTnT analysis, 1151 were included in the 
hsTnI (Beckman) analysis, and 1567 were included in the hsTnI (Abbott) analysis 
Most exclusions were because hsTn measurements were not available 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? No 
Could the patient flow have introduced bias? RISK: High 
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Study: Keller (2011)47 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutive patients presenting to chest pain units  
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
General chest pain populations, some participants had a final diagnosis of STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Abbott Architect STAT hs-TnI, on admission and at 3 hrs. Reference standard (final diagnosis) was adjudicated after 
hs-TnI testing. Thresholds based on test properties, appeared to be pre-specified 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI based on joint European Cardiology Society an American College of Cardiology 
criteria and included serial conventional cTnT (10-12 hour time point not specified) 
Determination of diagnosis was made blind to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
None of the analyses included all study participants (558 or 867 participants missing) 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? No 
Could the patient flow have introduced bias? RISK: High 
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Study: Kurz (2011)54 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutive patients admitted to a chest pain unit. 206 Patients not included due to 'technical reasons' ( not fully 
defined, e.g. venipuncture not possible) 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Unclear 
Could the selection of patients have introduced bias? RISK: Unclear 
B. APPLICABILITY 
Appears to be an unselected chest pain population, STEMI excluded. Second publication
112
 is for a retrospectively 
selected subgroup of participants with a diagnosis of NSTEMI or unstable angina.  Patients were admitted to chest 
pain units. 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT, data reported for admission, 3 hr and 6 hr samples (6 hrs data not extracted) 
Reference standard troponin testing occurred after hs-TnT. Threshold was pre-specified for data extracted from 
112
, 
but not from 
54
 (low risk of bias for
112
 data) 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI based on joint European Cardiology Society and American College of 
Cardiology criteria and included serial conventional cTnT (10-12 hour time point not specified) 
Unclear whether determination of diagnosis was made blind to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
All participants appear to have been included in the analyses 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Lippi (2012)74 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutive patients presenting to the emergency department with chest pain of recent onset (<3 hrs) 
No exclusion criteria reported 
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Unclear 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Beckman Coulter HS-AccuTnI on admission. Reference standard final diagnosis (AMI); probably made later than 
admission hs-TnI. Threshold derived from ROC analysis 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  No 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: High 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard final diagnosis of AMI, criteria for diagnosis not reported 
Unclear whether those adjudicating final diagnosis were blind to hs-TnI 
Is the reference standard likely to correctly classify the target condition? Unclear 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
No withdrawals reported 
Did all patients receive a reference standard? Unclear 
Did patients receive the same reference standard? Unclear 
Were all patients included in the analysis? Unclear 
Could the patient flow have introduced bias? RISK: Unclear 
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Study: Melki (2011)50 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Recruitment described as "consecutive except for temporary interruptions of the study due to high work load in 
the coronary care unit" 
Was a consecutive or random sample of patients enrolled? No 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: High 
B. APPLICABILITY 
Chest pain patients admitted to chest pain unit, excluding ST-segment elevation 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT on admission and at 2 hrs. Reference standard (final diagnosis) determined after hs-TnT 
testing. Threshold based on assay characteristics, appears pre-determined 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI based on joint European Cardiology Society an American College of Cardiology 
criteria and included serial conventional cTnT or cTnI (9-12 hour time point specified) 
Determination of diagnosis was made blind to hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: Low 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
All participants appear to have been included in the analyses 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Parsonage (2013)57 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Prospective studies; no further details on recruitment 
Was a consecutive or random sample of patients enrolled? Unclear 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Unclear 
Could the selection of patients have introduced bias? RISK: Unclear 
B. APPLICABILITY 
Unselected chest pain population AMI diagnoses may have included both NSTEMI and STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hsTnT and Abbott ARCHITECT hs-STAT TnI. Threshold was 99th centile 
Index test occurred before adjudication of final diagnosis 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI (criteria unclear) and included serial conventional cTnI (10-12 hour time point 
not specified). Determination of diagnosis was made blind to hs-TnT  and hs-TnI results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
Patients appear to be missing from the analyses, as 2x2 data (derived from reported sensitivity and specificity 
estimates and total number of AMI) do not match reported number of test positives 
Did all patients receive a reference standard? Unclear 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Unclear 
Could the patient flow have introduced bias? RISK: Unclear 
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Study: Saenger (2010)71 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
No details on how patients were selected.  No exclusion criteria reported. 
Was a consecutive or random sample of patients enrolled? Unclear 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Unclear 
Could the selection of patients have introduced bias? RISK: Unclear 
B. APPLICABILITY 
No exclusion criteria reported, reference standard was AMI (diagnosis method not specified),diagnoses included 
STEMI 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT on admission and after 3 ŚƌƐ ?ĂƚĂƌĞƉŽƌƚĞĚĨŽƌĂĚŵŝƐƐŝŽŶĂŶĚȴ ?-3 hrs. No details of 
ŝŶƚĞƌƉƌĞƚĂƚŝŽŶƌĞƉŽƌƚĞĚ ?dŚƌĞƐŚŽůĚĨŽƌȴǀĂůƵĞĚĞƌŝǀĞĚĨƌŽŵZKĂŶĂůǇƐŝƐ ? ? ?ƚŚĐĞŶƚŝůĞĂůƐŽƵƐĞĚ 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Unclear 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Reference standard diagnosis of AMI (no details reported) 
Is the reference standard likely to correctly classify the target condition? Unclear 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
No withdrawals reported 
Did all patients receive a reference standard? Unclear 
Did patients receive the same reference standard? Unclear 
Were all patients included in the analysis? Unclear 
Could the patient flow have introduced bias? RISK: Unclear 
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Study: Sanchis (2012)41 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Patients excluded due to troponin elevation in any of 2 serial determinations (at arrival and 6-8 hours later) and 
prior diagnosis of ischemic heart disease.  No details on how patients were selected for the study. 
Was a consecutive or random sample of patients enrolled? Unclear 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? No 
Could the selection of patients have introduced bias? RISK: High 
B. APPLICABILITY 
Selected low risk population 
Do the included patients match the question? Concerns: High 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hs-TnT on admission and at 6-8 hrs (data reported for admission and peak values). Reference 
standard (30 day composite) occurred after testing. Thresholds were reported as pre-specified 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Composite 30 day end point of AMI, death and revascularisation 
Not clear whether those adjudicating AMI were aware of hs-TnT results 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: Low 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
All participants appeared to have been included in the analyses 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Santalo (2013)39 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
Consecutive adult patients presenting to the emergency department  
Was a consecutive or random sample of patients enrolled? Yes 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Low 
B. APPLICABILITY 
Appears to be an unselected emergency department chest pain population 
Do the included patients match the question? Concerns: Low 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hsTnT on admission and at 2, 4, and 6- ?ŚŽƵƌƐŽƌƵŶƚŝůĚŝƐĐŚĂƌŐĞ ?ĚĂƚĂƌĞƉŽƌƚĞĚĨŽƌĂĚŵŝƐƐŝŽŶĂŶĚȴ
values). Unclear whether hs-TnT interpreted blind to cTnT 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Unclear 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Final diagnosis adjudicated by committee, based on Roche cTnT at admission and 2, 4 and 6-8 hours or until 
discharge (10-12 hr time point not specified). NSTEMI deĨŝŶĞĚĂƐĐdŶdAN ? ?ŶŐ ?>ĂŶĚȴĐdŶdAN ? ?A? ?ĂůƐŽ ? ?ƚŚĐĞŶƚŝůĞ ?
Unclear whether adjudicators were blinded to hs-TnT 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Unclear 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Unclear 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: Unclear 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
All participants appear to have been included in the analyses 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? Yes 
Could the patient flow have introduced bias? RISK: Low 
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Study: Sebbane (2013)63 
DOMAIN 1:  PATIENT SELECTION   
A. RISK OF BIAS 
No details on how patients were selected for inclusion.    
Was a consecutive or random sample of patients enrolled? Unclear 
Was a case-control design avoided? Yes 
Did the study avoid inappropriate exclusions? Yes 
Could the selection of patients have introduced bias? RISK: Unclear 
B. APPLICABILITY 
Unselected cohort of adult patients presenting with chest pain of recent onset (within 12 hours) 
Do the included patients match the question? Concerns: Low 
 
DOMAIN 2:  INDEX TEST(S)  
A. RISK OF BIAS 
Roche Elecsys hsTnT on admission or from sample taken during pre-hospital management. Final Diagnosis 
adjudicated one month after acute episode. Optimal diagnostic thresholds were determined using within study 
ROC analyses; 99th centile also reported 
Were the index test results interpreted without knowledge of the results of 
the reference standard? 
Yes 
If a threshold was used, was it pre-specified?  Yes 
Could the conduct or interpretation of the index test have 
introduced bias?  
RISK: Low 
B. APPLICABILITY 
Are there concerns that the index test, its conduct, or interpretation 
differ from the review question? 
Concerns: Low 
 
DOMAIN 3: REFERENCE STANDARD 
A. RISK OF BIAS 
Diagnosis determined by two independent emergency department physicians, based on Joint European Cardiology 
Society an American College of Cardiology criteria. Reference standard included cTnI taken on admission, at 6 hrs 
and beyond, as needed (10-12 hr time point not specified). Physicians had access to serial cTnI results, but were 
blinded to hs-TnT results. 
Is the reference standard likely to correctly classify the target condition? Yes 
Were the reference standard results interpreted without knowledge of the 
results of the index test? 
Yes 
Could the reference standard, its conduct, or its interpretation have 
introduced bias?   
RISK: Low 
B. APPLICABILITY 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
Concerns: High 
 
DOMAIN 4: FLOW AND TIMING 
A. RISK OF BIAS 
54 patients were excluded from the analyses because of missing data, including lack of copeptin, hs-cTnT, and cTnI 
measurements 
Did all patients receive a reference standard? Yes 
Did patients receive the same reference standard? Yes 
Were all patients included in the analysis? No 
Could the patient flow have introduced bias? RISK: High 
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APPENDIX 4: TABLE OF EXCLUDED STUDIES WITH RATIONALE 
To be included in the review studies had to fulfil the following criteria: 
Population: ĚƵůƚƐ  ?A? ? ?ǇƌƐ ? ƉƌĞƐĞŶƚŝŶŐ ǁŝƚŚ ĂĐƵƚĞ  ‘ƉĂŝŶ ? ĚŝƐĐŽŵĨŽƌƚ Žƌ ƉƌĞƐƐƵƌĞ ŝŶ ƚŚĞ
chest, epigastrium, neck, jaw, or upper limb without an apparent non-
cardiac ƐŽƵƌĐĞ ?ĚƵĞƚŽĂƐƵƐƉĞĐƚĞĚ ?ďƵƚŶŽƚƉƌŽǀĞŶ ?D/Žƌ^ 
Setting:  Secondary or tertiary care 
Index Test:  Abbott ARCHITECT (STAT hs-cTnI); Beckman Coulter Access and Unicel DxI 
(accuTnI+3); Roche Elecsys (cTnT-hs or cTnT-hs STAT); results available within 
3 hours 
Reference Standard:  Universal definition of AMI, including measurement of troponin T or I (using 
any method not defined as a hs-cTn test) on presentation and 10-12 hours 
after the onset of symptomƐ ŝŶ A? ? ?A? ŽĨ ƚŚĞ ƉŽƉƵůĂƚŝŽŶ Žƌ ŽĐĐƵƌƌĞŶĐĞ ŽĨ
MACE (any definition used in identified studies) during 30 day follow-up 
Outcome:  Sufficient data to construct 2x2 table of test performance 
The table below summarises studies which were screened for inclusion based on full text publication 
but did not fulfil one or more of the above criteria.  Studies were assessed sequentially against 
criteria; as soon as a study had failed based on one of the criteria it was not assessed against 
subsequent criteria.  The tablĞƐŚŽǁƐǁŚŝĐŚŽĨƚŚĞĐƌŝƚĞƌŝĂĞĂĐŚƐƚƵĚǇĨƵůĨŝůůĞĚ ? “zĞƐ ? ?ĂŶĚŽŶǁŚŝĐŚ
ŝƚĞŵŝƚĨĂŝůĞĚ ? “EŽ ? ? ? 
Study Details Primary 
study 
Population Setting Index Test Reference 
Standard 
Outcome 
Ahmed(2013)
113
 Yes Yes Yes Yes No  
Aldous(2010)
114
 Yes Yes Yes Yes Unclear No 
Aldous(2010)
115
 Yes Yes Yes Yes Unclear No 
Aldous(2012)
116
 No      
Aldous(2010)
117
 Yes Yes Yes Unclear No  
Aldous(2012)
118
 Yes Yes Yes Unclear Yes No 
Aldous(2012)
119
 Yes Yes Yes No   
Aldous(2012)
120
 No      
Aldous(2012)
121
 No      
Alexandra(2013)
122
 Yes Yes Yes No   
Arenja(2010)
123
 Yes Yes Yes Yes No  
Bahrmann(2012)
124
 Yes No     
Bahrmann(2013)
125
 Yes No     
Bahrmann(2013)
126
 Yes No     
Bahrmann(2012)
127
 Yes Yes Yes Yes No  
Balmelli(2013)
128
 Yes Yes Yes Yes Unclear No 
Balmelli(2011)
129
 Yes Yes Yes Yes Unclear No 
Beyrau(2009)
130
 Yes No     
Bhardwaj(2011)
131
 Yes Yes Yes No   
Bhardwaj(2011)
132
 Yes Yes Yes No   
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Study Details Primary 
study 
Population Setting Index Test Reference 
Standard 
Outcome 
Biasillo(2010)
133
 Yes Yes Yes Unclear No  
Biasucci(2010)
134
 Yes Yes Yes Yes No  
Biasucci(2010)
135
 Yes Yes Yes Yes No  
Biasucci(2010)
136
 Yes Yes Yes Yes No  
Biasucci(2010)
137
 Yes Yes Yes Yes No  
Biasucci(2011)
138
 Yes Yes Yes Yes No  
Biener(2013)
139
 Yes Unclear Yes Unclear Unclear No 
Biener(2012)
140
 Yes Yes Yes Unclear Unclear No 
Biener(2013)
141
 Yes No     
Biener(2013)
142
 Yes Yes Yes No   
Biosite(2006)
143
 Yes Yes Yes No   
Body(2012)
144
 Yes Yes Yes Unclear Unclear No 
Body(2012)
145
 Yes Yes Yes Yes Yes No 
Body(2012)
146
 No      
Braga(2011)
147
 Yes Yes Yes Yes Yes No 
Braga(2011)
148
 Yes Yes Yes Yes Yes No 
Bronze(2012)
149
 Yes Yes Yes Yes No  
Brown(2007)
150
 Yes Yes Yes No   
Buccelletti(2012)
151
 Yes Yes Yes Yes No  
Buhl(2011)
152
 Yes No     
Cardillo(2012)
153
 Yes Yes Yes Yes Yes No 
Carmo(2013)
154
 No      
Ceriani(2012)
155
 No      
Charpentier(2011)
156
 Yes Yes Yes No   
Chenevier-
Gobeaux(2013)
157
 
No      
Collinson(2012)
158
 Yes Yes Yes No   
Collinson(2012)
159
 Yes Yes Yes No   
Collinson(2012)
160
 Yes Yes Yes No   
Collinson(2006)
161
 Yes Yes Yes No   
Collinson(2010)
162
 Yes Yes Yes No   
Costabel(2013)
163
 No      
Cullen(2011)
164
 Yes Yes Yes No   
Dawson(2013)
165
 Yes No     
Diercks(2012)
166
 Yes Yes Yes No   
Drexler(2011)
167
 Yes Yes Yes Unclear Unclear No 
Engel(2007)
168
 Yes Yes Yes No   
Escabi-Mendoza(2010)
169
 Yes Yes Yes No   
Figiel(2008)
170
 Yes No     
Fitzgerald(2011)
81
 Yes Yes Yes No   
Freund(2011)
171
 Yes Yes Yes Unclear Unclear No 
Freund(2011)
172
 Yes Yes Yes Unclear Unclear No 
Giannitsis(2010)
112
 Yes No     
Giannitsis(2011)
173
 Yes Yes Yes Unclear Unclear No 
Giavarina(2012)
174
 No      
Giavarina(2011)
175
 Yes Yes Yes No   
Gimenez(2012)
176
 Yes Yes Yes No   
Gimenez(2012)
177
 Yes Yes Yes No   
Goodacre(2011)
99
 Yes Yes Yes No   
Goodacre(2013)
7
 No      
Goodacre(2011)
85
 Yes Yes Yes No   
Gustapane(2012)
178
 Yes Yes Yes Unclear No  
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Study Details Primary 
study 
Population Setting Index Test Reference 
Standard 
Outcome 
Gustapane(2012)
179
 Yes Yes Yes Unclear No  
Haaf(2011)
180
 Yes Yes Yes Unclear Unclear No 
Haaf(2011)
181
 Yes Yes Yes Unclear Unclear No 
Haaf(2013)
182
 No      
Haaf(2012)
183
 Yes Yes Yes Yes No  
Haaf(2012)
184
 Yes Yes Yes Yes No  
Haltern(2010)
185
 Yes Yes Yes No   
Heinisch(2010)
186
 Yes Yes Yes Unclear Unclear No 
Hochholzer(2011)
187
 Yes Yes Yes Yes No  
Hochholzer(2010)
188
 Yes Yes Yes Yes No  
Hoeller(2012)
189
 Yes Yes Yes Yes No  
Hoeller(2012)
190
 Yes Yes Yes Yes No  
Ilva(2009)
191
 Yes Yes No    
Inoue(2011)
192
 Yes Yes Yes Yes No  
Irfan(2011)
193
 Yes Yes Yes Unclear Unclear No 
Irfan(2011)
194
 Yes Yes Yes Unclear No  
Irfan(2013)
195
 Yes Yes Yes Yes Unclear No 
Irfan(2013)
196
 Yes Yes Yes Yes Unclear No 
Jairam(2011)
197
 Yes No     
Januzzi(2010)
198
 Yes Yes Yes No   
Januzzi(2009)
199
 Yes Yes Yes Yes No  
Januzzi(2013)
200
 Yes Yes Yes No   
Jia(2009)
201
 Yes Yes Yes No   
Kagawa(2013)
202
 Yes Yes Yes No   
Karakas(2011)
203
 Yes Yes Yes Yes No  
Kavsak(2012)
204
 Yes Yes Yes Unclear Unclear No 
Kavsak(2007)
205
 Yes Yes Yes No   
Kavsak(2013)
206
 Yes Yes Yes Unclear No  
Kavsak(2005)
207
 Yes Yes Yes No   
Kavsak(2012)
208
 Yes Yes Yes Yes Unclear No 
Kavsak(2008)
209
 Yes No     
Kavsak(2011)
210
 Yes Yes Yes Yes No  
Kavsak(2010)
211
 Yes Yes Yes Yes Yes No 
Keene(2012)
212
 Yes Yes Yes Yes No  
Keller(2011)
213
 Yes Yes Yes Yes Unclear No 
Keller(2011)
214
 Yes Yes Yes Yes Unclear No 
Keller(2009)
215
 Yes Yes Yes No   
Keller(2010)
216
 Yes Yes Yes No   
Keller(2009)
217
 Yes Yes Yes No   
Kelly(2011)
218
 Yes Yes Yes No   
Khan(2011)
219
 Yes Yes Yes Yes No  
Khoo(2008)
220
 Yes Unclear Yes No   
Kitamura(2012)
221
 Yes Yes Yes No   
Kobayashi(2011)
222
 Yes Yes Yes Unclear No  
Kobayashi(2011)
223
 Yes Yes Yes Yes No  
Koenig(2008)
224
 Yes Yes Yes Yes No  
Lacnak(2007)
225
 Yes Yes Yes Unclear No  
Lee(2011)
226
 Yes Yes Yes Unclear No  
Lindahl(2009)
227
 Yes No     
Lippi(2013)
228
 No      
Lippi(2012)
229
 No      
Lippi(2013)
230
 No      
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Study Details Primary 
study 
Population Setting Index Test Reference 
Standard 
Outcome 
Lotze(2011)
231
 Yes Yes Yes No   
Lotze(2011)
232
 Yes Yes Yes Yes No  
Macrae(2006)
233
 Yes Yes Yes No   
Mair(2011)
234
 Yes No     
Mair(2011)
235
 Yes No     
Matsui(2011)
236
 Yes Yes Yes Unclear Unclear No 
Mazhar(2011)
237
 Yes Yes Yes Unclear No  
Melanson(2008)
238
 Yes Yes Yes No   
Melki(2011)
239
 Yes Yes Yes Yes No  
Melki(2011)
240
 Yes Yes Yes No   
Melki(2012)
241
 Yes Yes Yes Yes No  
Menhofer(2013)
242
 Yes No     
Meune(2011)
243
 Yes Yes Yes Yes Yes No 
Meune(2011)
244
 Yes Yes Yes Yes Yes No 
Meune(2013)
245
 Yes Yes Yes Yes No  
Meune(2011)
246
 Yes Yes Yes Yes No  
Mikkel(2013)
247
 Yes Yes Yes Yes Unclear No 
Mikkel(2013)
248
 Yes Yes Yes No   
Mikkel(2013)
249
 Yes Yes Yes No   
Mills(2010)
250
 Yes Yes Yes Unclear No  
Mills(2010)
251
 Yes Yes Yes Unclear No  
Mills(2012)
252
 Yes Yes Yes Yes No  
Mingels(2012)
253
 Yes No     
Moehring(2012)
254
 Yes Yes Yes Yes No  
Moehring(2012)
255
 Yes Yes Yes Yes Unclear No 
Montagnana(2012)
256
 Yes Yes Yes Yes Yes No 
Morrow(2009)
257
 No      
Nagurney(2005)
258
 Yes Yes Yes No   
Nanosphere(2010)
259
 Yes Yes Yes Unclear Yes No 
Naroo(2009)
260
 Yes Yes Yes No   
Ngan(2010)
261
 Yes Yes Yes Yes Yes No 
Noad(2010)
262
 Yes Yes Yes Unclear Unclear No 
Normann(2012)
263
 Yes Yes Yes Yes No  
Nusier(2006)
264
 Yes Yes Yes No   
Olivieri(2012)
265
 Yes Yes Yes No   
Orsborne(2012)
266
 No      
Paoloni(2010)
267
 Yes Yes Yes Unclear No  
Perego(2011)
268
 Yes      
Plebani(2009)
269
 Yes Yes Yes No   
Ploner(2011)
270
 Yes No No    
Popp(2010)
271
 Yes Yes Yes Yes No  
Potocki(2011)
272
 Yes Yes Yes No   
Pracon(2012)
273
 Yes Yes Yes No   
Rajdl(2011)
274
 Yes Yes Yes Yes Unclear No 
Ray(2011)
275
 Yes Yes Yes Unclear Unclear No 
Reichlin(2012)
276
 No      
Reichlin(2011)
277
 Yes Yes Yes Unclear Unclear No 
Reichlin(2012)
278
 Yes Yes Yes Yes No  
Reichlin(2010)
279
 Yes Yes Yes Unclear No  
Reichlin(2010)
280
 Yes Yes Yes Unclear No  
Reichlin(2012)
281
 Yes Yes Yes Yes No  
Rubini Gimenez(2012)
282
 Yes Yes Yes Yes Unclear No 
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Standard 
Outcome 
Rudolph(2011)
283
 Yes Yes Yes Unclear Unclear No 
Rudolph(2011)
284
 Yes Yes Yes Unclear Unclear No 
Rudolph(2012)
285
 Yes Yes Yes No   
Samaraie(2010)
286
 Yes Yes Yes Unclear No  
Scharnhorst(2011)
287
 Yes Yes Yes No   
Schaub(2012)
288
 Yes Yes Yes Yes Yes No 
Schoos(2013)
289
 Yes Yes Yes Yes Unclear No 
Schoos(2013)
290
 Yes Yes Yes Yes Unclear No 
Schreiber(2012)
291
 Yes Yes Yes No   
Sethi(2013)
292
 No      
Shand(2012)
293
 Yes Yes Unclear Unclear No  
Shortt(2013)
294
 No      
Spanuth(2011)
295
 Yes Yes Yes Unclear Unclear No 
Spasic-Obradovic(2011)
296
 Yes Yes Yes Yes No  
Stengaard(2012)
297
 Yes Yes Yes Unclear Unclear No 
Tajsic(2013)
298
 Yes Yes Yes Unclear Unclear No 
Tajsic(2013)
299
 Yes Yes Yes Unclear Unclear No 
Tajsic(2012)
300
 Yes Yes Yes Unclear No  
Tajsic(2013)
301
 Yes Yes Yes Unclear Unclear No 
Tamimi(2010)
302
 Yes Yes Yes No   
Tanaka(2006)
303
 Yes Yes Yes No   
Than(2012)
304
 Yes Yes Yes No   
Thelin(2013)
305
 Yes Yes Yes Yes No  
Thomas(2007)
306
 Yes No     
Thomas(2007)
307
 Yes No     
Truong(2012)
308
 Yes Yes Yes No   
Truong(2011)
309
 Yes Yes No Unclear Unclear No 
Twerenbold(2010)
310
 Yes Yes Yes Yes Unclear No 
Twerenbold(2010)
311
 Yes Yes Yes Yes Unclear No 
Twerenbold(2010)
312
 Yes Yes Yes Yes Unclear No 
Twerenbold(2011)
313
 Yes Yes Yes No   
Twerenbold(2012)
314
 Yes Yes Yes Yes No  
University of Edinburgh 
(2013)
315
 
Yes Yes Yes Unclear No  
University of Erlangen 
(2013)
316
 
Yes Yes Yes Unclear Unclear  
van Wijk(2012)
317
 Yes Yes Yes Yes No  
Vasikaran(2012)
318
 No      
Veljkovic (2012)
319
 Yes Yes Yes Yes Unclear No 
Venge(2008)
320
 Yes No     
Venge(2009)
321
 Yes No     
Venge(2010)
322
 Yes No     
Weber(2011)
323
 Yes No     
Weber(2009)
324
 Yes No     
Wildi(2012)
325
 Yes Yes Yes No   
Wong(2010)
326
 Yes No Yes No   
Worster(2013)
327
 Yes No Yes Yes No No 
Zahid(2009)
328
 Yes Yes Yes Unclear Unclear No 
Zahid(2008)
329
 Yes Yes Yes No   
Zellweger(2012)
330
 Yes Yes Yes Yes No  
Zuily(2011)
331
 Yes Yes Yes Yes No  
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APPENDIX 5: SENSITIVITY ANALYSES (BASE CASE) 
Deterministic base case: 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.734 -£440 -0.015 £28,870     
Roche 99th centile £2,301 11.740 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,327 11.743 -£370 -0.006 £58,988 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,426 11.744 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.748 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £2,697 11.749    Abbott strategy £204 0.002 £124,391 
 
Increased re-infarction & mortality risk for no treatment (vs treated) = lifetime (instead of only during the first year after presentation at ED) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.677 -£440 -0.072 £6,112     
Roche 99th centile £2,301 11.704 -£396 -0.045 £8,731 Abbott 99th centile £44 0.027 Extendedly dominated 
Beckman 99th centile £2,327 11.720 -£370 -0.030 £12,493 Abbott 99th centile £69 0.042 £1,642 
Roche strategy £2,426 11.723 -£271 -0.026 £10,284 Beckman 99th centile £99 0.003 Extendedly dominated 
Abbott strategy £2,493 11.741 -£204 -0.008 £26,352 Beckman 99th centile £167 0.022 £7,602 
Standard troponin £2,697 11.749    Abbott strategy £204 0.008 £26,352 
 
No doctor on demand, but average waiting time before doctor becomes available is increased with 1, 2 or 3 hours 
Waiting time for doctor / decision pending delay = 1 hour(s) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,285 11.734 -£440 -0.015 £28,869     
Roche 99th centile £2,329 11.740 -£396 -0.010 £41,232 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,355 11.743 -£370 -0.006 £58,987 Abbott 99th centile £70 0.009 £7,776 
Roche strategy £2,470 11.744 -£255 -0.006 £45,643 Beckman 99th centile £115 0.001 Extendedly dominated 
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Abbott strategy £2,541 11.748 -£184 -0.002 £112,580 Beckman 99th centile £186 0.005 £40,072 
Standard troponin £2,725 11.749    Abbott strategy £184 0.002 £112,580 
          
Waiting time for doctor / decision pending delay = 2 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,313 11.734 -£440 -0.015 £28,868     
Roche 99th centile £2,357 11.740 -£396 -0.010 £41,231 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,383 11.743 -£370 -0.006 £58,987 Abbott 99th centile £70 0.009 £7,776 
Roche strategy £2,515 11.744 -£239 -0.006 £42,727 Beckman 99th centile £132 0.001 Extendedly dominated 
Abbott strategy £2,588 11.748 -£165 -0.002 £100,769 Beckman 99th centile £205 0.005 £44,240 
Standard troponin £2,754 11.749    Abbott strategy £165 0.002 £100,769 
          
Waiting time for doctor / decision pending delay = 3 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,342 11.734 -£440 -0.015 £28,868     
Roche 99th centile £2,386 11.740 -£396 -0.010 £41,231 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,411 11.743 -£370 -0.006 £58,986 Abbott 99th centile £70 0.009 £7,775 
Roche strategy £2,559 11.744 -£223 -0.006 £39,811 Beckman 99th centile £148 0.001 Extendedly dominated 
Abbott strategy £2,636 11.748 -£146 -0.002 £88,957 Beckman 99th centile £225 0.005 £48,408 
Standard troponin £2,782 11.749    Abbott strategy £146 0.002 £88,957 
 
Doctor on demand at ED, but average waiting time before doctor becomes available in the general ward is increased with 1, 2 or 3 hours (discharge to 
general ward after 4 hours after presenting at ED) 
Waiting time for doctor / decision pending delay = 1 hour(s) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,258 11.734 -£468 -0.015 £30,665     
Roche 99th centile £2,302 11.740 -£424 -0.010 £44,080 Abbott 99th centile £44 0.006 £7,776 
Beckman 99th centile £2,327 11.743 -£398 -0.006 £63,347 Roche 99th centile £26 0.003 £7,776 
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Roche strategy £2,443 11.744 -£282 -0.006 £50,541 Beckman 99th centile £115 0.001 Extendedly dominated 
Abbott strategy £2,513 11.748 -£212 -0.002 £129,290 Beckman 99th centile £186 0.005 £40,072 
Standard troponin £2,725 11.749    Abbott strategy £212 0.002 £129,290 
          
Waiting time for doctor / decision pending delay = 2 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,259 11.734 -£495 -0.015 £32,459     
Roche 99th centile £2,302 11.740 -£451 -0.010 £46,927 Abbott 99th centile £44 0.006 £7,776 
Beckman 99th centile £2,328 11.743 -£425 -0.006 £67,705 Roche 99th centile £26 0.003 £7,776 
Roche strategy £2,460 11.744 -£294 -0.006 £52,522 Beckman 99th centile £132 0.001 Extendedly dominated 
Abbott strategy £2,534 11.748 -£220 -0.002 £134,189 Beckman 99th centile £205 0.005 £44,240 
Standard troponin £2,754 11.749    Abbott strategy £220 0.002 £134,189 
          
Waiting time for doctor / decision pending delay = 3 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,260 11.734 -£522 -0.015 £34,254     
Roche 99th centile £2,303 11.740 -£478 -0.010 £49,774 Abbott 99th centile £44 0.006 £7,775 
Beckman 99th centile £2,329 11.743 -£453 -0.006 £72,064 Roche 99th centile £26 0.003 £7,775 
Roche strategy £2,477 11.744 -£305 -0.006 £54,504 Beckman 99th centile £148 0.001 Extendedly dominated 
Abbott strategy £2,554 11.748 -£228 -0.002 £139,089 Beckman 99th centile £225 0.005 £48,408 
Standard troponin £2,782 11.749    Abbott strategy £228 0.002 £139,089 
 
Total delay of 1.5 hours 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,214 11.734 -£440 -0.015 £28,871     
Roche 99th centile £2,258 11.740 -£396 -0.010 £41,234 Abbott 99th centile £44 0.006 £7,778 
Beckman 99th centile £2,284 11.743 -£370 -0.006 £58,989 Roche 99th centile £26 0.003 £7,778 
Roche strategy £2,359 11.744 -£296 -0.006 £52,933 Beckman 99th centile £75 0.001 Extendedly dominated 
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Abbott strategy £2,422 11.748 -£233 -0.002 £142,108 Beckman 99th centile £138 0.005 £29,653 
Standard troponin £2,655 11.749    Abbott strategy £233 0.002 £142,108 
MI treatment costs added for patients that were tested false positive 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,456 11.734 -£241 -0.015 £15,824     
Abbott strategy £2,671 11.748 -£26 -0.002 £16,050 Abbott 99th centile £215 0.014 £15,797 
Standard troponin £2,697 11.749    Abbott strategy £26 0.002 £16,050 
Roche 99th centile £2,760 11.740 £63 -0.010 Dominated Standard troponin £63 -0.010 Dominated 
Roche strategy £2,947 11.744 £251 -0.006 Dominated Standard troponin £251 -0.006 Dominated 
Beckman 99th centile £3,038 11.743 £341 -0.006 Dominated Standard troponin £341 -0.006 Dominated 
MI treatment costs added to first year of UA 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,703 11.734 -£440 -0.015 £28,870     
Roche 99th centile £2,747 11.740 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,773 11.743 -£370 -0.006 £58,988 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,872 11.744 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,940 11.748 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £3,144 11.749    Abbott strategy £204 0.002 £124,391 
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Test costs 
Test costs = £5          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,240 11.734 -£425 -0.015 £27,856     
Roche 99th centile £2,284 11.740 -£381 -0.010 £39,624 Abbott 99th centile £44 0.006 £7,778 
Beckman 99th centile £2,310 11.743 -£355 -0.006 £56,526 Roche 99th centile £26 0.003 £7,778 
Roche strategy £2,400 11.744 -£265 -0.006 £47,439 Beckman 99th centile £90 0.001 Extendedly dominated 
Abbott strategy £2,466 11.748 -£199 -0.002 £121,624 Beckman 99th centile £156 0.005 £33,550 
Standard troponin £2,665 11.749    Abbott strategy £199 0.002 £121,624 
          
Test costs = £40          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,278 11.734 -£460 -0.015 £30,150     
Roche 99th centile £2,322 11.740 -£416 -0.010 £43,264 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,348 11.743 -£390 -0.006 £62,097 Abbott 99th centile £70 0.009 £7,776 
Roche strategy £2,458 11.744 -£279 -0.006 £49,972 Beckman 99th centile £111 0.001 Extendedly dominated 
Abbott strategy £2,528 11.748 -£210 -0.002 £127,886 Beckman 99th centile £180 0.005 £38,878 
Standard troponin £2,737 11.749    Abbott strategy £210 0.002 £127,886 
          
 
AMI treatment costs 
AMI treatment costs = £2,577          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,119 11.734 -£415 -0.015 £27,188     
Roche 99th centile £2,154 11.740 -£380 -0.010 £39,551 Abbott 99th centile £34 0.006 Extendedly dominated 
Beckmann 99th centile £2,174 11.743 -£360 -0.006 £57,307 Abbott 99th centile £55 0.009 £6,096 
Roche strategy £2,272 11.744 -£262 -0.006 £46,877 Beckmann 99th centile £98 0.001 Extendedly dominated 
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Abbott strategy £2,333 11.748 -£201 -0.002 £122,710 Beckmann 99th centile £159 0.005 £34,223 
Standard troponin £2,534 11.749    Roche strategy £201 0.002 £122,710 
          
AMI treatment costs = £4,295          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,394 11.734 -£466 -0.015 £30,551 Abbott 99th centile £53 0.006 £9,458 
Roche 99th centile £2,448 11.740 -£413 -0.010 £42,914 Roche 99th centile £32 0.003 £9,458 
Beckmann 99th centile £2,479 11.743 -£381 -0.006 £60,669 Beckmann 99th centile £100 0.001 Extendedly dominated 
Roche strategy £2,579 11.744 -£281 -0.006 £50,240 Beckmann 99th centile £174 0.005 £37,586 
Abbott strategy £2,654 11.748 -£207 -0.002 £126,073 Roche strategy £207 0.002 £126,073 
Standard troponin £2,860 11.749        
 
Post-MI health state costs 
Post-MI health state costs (1st year) = £6,791 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,393 11.734 -£443 -0.015 £29,024     
Roche 99th centile £2,438 11.740 -£398 -0.010 £41,387 Abbott 99th centile £45 0.006 £7,931 
Beckman 99th centile £2,464 11.743 -£371 -0.006 £59,142 Roche 99th centile £26 0.003 £7,931 
Roche strategy £2,563 11.744 -£272 -0.006 £48,713 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,632 11.748 -£204 -0.002 £124,545 Beckman 99th centile £167 0.005 £36,059 
Standard troponin £2,836 11.749    Abbott strategy £204 0.002 £124,545 
          
Post-MI health state costs (1st year) = £4,879 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,121 11.734 -£438 -0.015 £28,715     
Roche 99th centile £2,164 11.740 -£395 -0.010 £41,078 Abbott 99th centile £43 0.006 £7,623 
Beckman 99th centile £2,189 11.743 -£369 -0.006 £58,834 Roche 99th centile £25 0.003 £7,623 
Roche strategy £2,288 11.744 -£271 -0.006 £48,405 Beckman 99th centile £99 0.001 Extendedly dominated 
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Abbott strategy £2,355 11.748 -£204 -0.002 £124,237 Beckman 99th centile £166 0.005 £35,750 
Standard troponin £2,558 11.749    Abbott strategy £204 0.002 £124,237 
 
Utility difference between UA and AMI 
Utility difference between UA and AMI = 0.12 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.779 -£440 -0.015 £28,870     
Roche 99th centile £2,301 11.785 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,327 11.788 -£370 -0.006 £58,988 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,426 11.789 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.793 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £2,697 11.794    Abbott strategy £204 0.002 £124,391 
          
Utility difference between UA and AMI = -0.10 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.581 -£440 -0.015 £28,870     
Roche 99th centile £2,301 11.587 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,327 11.590 -£370 -0.006 £58,988 Abbott 99th centile £70 0.009 £7,777 
Roche strategy £2,426 11.591 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.595 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £2,697 11.597    Abbott strategy £204 0.002 £124,391 
 
MI disutility 
MI disutility = -0.059 (age = 45); -0.050 (age = 55); -0.024 (age = 65); -0.006 (age = 75+) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.735 -£440 -0.015 £28,832     
Roche 99th centile £2,301 11.741 -£396 -0.010 £41,178 Abbott 99th centile £44 0.006 £7,767 
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Beckman 99th centile £2,327 11.744 -£370 -0.006 £58,910 Roche 99th centile £26 0.003 £7,767 
Roche strategy £2,426 11.745 -£271 -0.006 £48,495 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.749 -£204 -0.002 £124,227 Beckman 99th centile £167 0.005 £35,857 
Standard troponin £2,697 11.751    Abbott strategy £204 0.002 £124,227 
          
MI disutility = -0.061(age = 45); -0.052 (age = 55); -0.026 (age = 65); -0.008 (age = 75+) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.733 -£440 -0.015 £28,908     
Roche 99th centile £2,301 11.738 -£396 -0.010 £41,287 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,327 11.742 -£370 -0.006 £59,066 Abbott 99th centile £70 0.009 £7,787 
Roche strategy £2,426 11.742 -£271 -0.006 £48,623 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.746 -£204 -0.002 £124,556 Beckman 99th centile £167 0.005 £35,952 
Standard troponin £2,697 11.748    Abbott strategy £204 0.002 £124,556 
 
Mortality (30-day) treated AMI (decision tree) 
Mortality (30-day) treated AMI = 0.120 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,219 11.710 -£432 -0.010 £41,819     
Roche 99th centile £2,260 11.714 -£391 -0.007 £60,062 Abbott 99th centile £41 0.004 £10,692 
Beckman 99th centile £2,284 11.716 -£367 -0.004 £86,264 Roche 99th centile £24 0.002 £10,692 
Roche strategy £2,383 11.717 -£268 -0.004 £70,874 Beckman 99th centile £99 0.000 Extendedly dominated 
Abbott strategy £2,448 11.719 -£203 -0.001 £182,781 Beckman 99th centile £164 0.003 £52,200 
Standard troponin £2,651 11.721    Abbott strategy £203 0.001 £182,781 
          
Mortality (30-day) treated AMI = 0.074 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,295 11.758 -£448 -0.020 £22,206     
Roche 99th centile £2,342 11.765 -£401 -0.013 £31,543 Abbott 99th centile £47 0.007 Extendedly dominated 
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Beckman 99th centile £2,369 11.770 -£374 -0.008 £44,952 Abbott 99th centile £75 0.012 £6,277 
Roche strategy £2,469 11.771 -£274 -0.007 £37,076 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,538 11.776 -£205 -0.002 £94,345 Beckman 99th centile £169 0.006 £27,519 
Standard troponin £2,743 11.778    Abbott strategy £205 0.002 £94,345 
 
Mortality (30-day) untreated AMI (decision tree) 
Mortality (30-day) untreated AMI = 0.240 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,227 11.707 -£470 -0.042 £11,153     
Roche 99th centile £2,282 11.723 -£415 -0.027 £15,623 Abbott 99th centile £55 0.016 Extendedly dominated 
Beckman 99th centile £2,314 11.732 -£383 -0.017 £22,042 Abbott 99th centile £88 0.025 £3,528 
Roche strategy £2,414 11.734 -£282 -0.015 £18,271 Beckman 99th centile £100 0.002 Extendedly dominated 
Abbott strategy £2,490 11.745 -£207 -0.005 £45,686 Beckman 99th centile £176 0.013 £13,697 
Standard troponin £2,697 11.749    Abbott strategy £207 0.005 £45,686 
          
Mortality (30-day) untreated AMI = 0.000 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,280 11.755 -£417 0.006 Dominant     
Roche 99th centile £2,316 11.753 -£381 0.004 Dominant Abbott 99th centile £35 -0.002 Dominated 
Beckman 99th centile £2,336 11.752 -£361 0.002 Dominant Abbott 99th centile £56 -0.003 Dominated 
Roche strategy £2,434 11.751 -£263 0.002 Dominant Abbott 99th centile £154 -0.004 Dominated 
Abbott strategy £2,496 11.750 -£201 0.001 Dominant Abbott 99th centile £215 -0.005 Dominated 
Standard troponin £2,697 11.749    Abbott 99th centile £417 -0.006 Dominated 
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Annual re-infarction probability (after initial AMI) 
Annual re-infarction (after initial AMI) = 0.26 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,286 11.722 -£440 -0.015 £28,543     
Roche 99th centile £2,330 11.728 -£397 -0.010 £40,757 Abbott 99th centile £44 0.006 £7,704 
Beckman 99th centile £2,356 11.731 -£371 -0.006 £58,299 Roche 99th centile £26 0.003 £7,704 
Roche strategy £2,455 11.732 -£272 -0.006 £47,995 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,523 11.736 -£204 -0.002 £122,916 Beckman 99th centile £167 0.005 £35,493 
Standard troponin £2,727 11.737    Abbott strategy £204 0.002 £122,916 
Annual re-infarction (after initial AMI) = 0.19 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,227 11.746 -£440 -0.015 £29,218     
Roche 99th centile £2,270 11.752 -£396 -0.009 £41,738 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,296 11.755 -£370 -0.006 £59,719 Abbott 99th centile £70 0.009 £7,856 
Roche strategy £2,395 11.756 -£271 -0.006 £49,157 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,463 11.760 -£204 -0.002 £125,955 Beckman 99th centile £167 0.005 £36,342 
Standard troponin £2,666 11.761    Abbott strategy £204 0.002 £125,955 
RR re-infarction (untreated versus treated) 
RR re-infarction (untreated versus treated) = 5.15 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,259 11.730 -£438 -0.019 £22,555     
Roche 99th centile £2,302 11.737 -£395 -0.012 £32,258 Abbott 99th centile £43 0.007 £5,999 
Beckman 99th centile £2,327 11.741 -£370 -0.008 £46,195 Roche 99th centile £25 0.004 £5,999 
Roche strategy £2,426 11.742 -£271 -0.007 £38,009 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.747 -£204 -0.002 £97,530 Beckman 99th centile £166 0.006 £28,076 
Standard troponin £2,697 11.749    Abbott strategy £204 0.002 £97,530 
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RR re-infarction (untreated versus treated) = 1.28 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,256 11.736 -£441 -0.013 £33,518     
Roche 99th centile £2,300 11.741 -£397 -0.008 £47,838 Abbott 99th centile £44 0.005 Extendedly dominated 
Beckman 99th centile £2,326 11.744 -£371 -0.005 £68,404 Abbott 99th centile £70 0.008 £9,086 
Roche strategy £2,425 11.744 -£272 -0.005 £56,324 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.748 -£204 -0.001 £144,162 Beckman 99th centile £167 0.004 £41,666 
Standard troponin £2,697 11.749    Abbott strategy £204 0.001 £144,162 
Annual post-MI mortality 
Annual post-MI mortality = 0.068 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,248 11.715 -£440 -0.015 £28,843     
Roche 99th centile £2,292 11.721 -£396 -0.010 £41,191 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,318 11.724 -£370 -0.006 £58,924 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,417 11.725 -£271 -0.006 £48,508 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,485 11.729 -£204 -0.002 £124,247 Beckman 99th centile £167 0.005 £35,869 
Standard troponin £2,688 11.731    Abbott strategy £204 0.002 £124,247 
          
Annual post-MI mortality = 0.065 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,266 11.753 -£440 -0.015 £28,897     
Roche 99th centile £2,309 11.758 -£396 -0.010 £41,275 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,335 11.762 -£370 -0.006 £59,053 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,434 11.762 -£271 -0.006 £48,610 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,502 11.766 -£204 -0.002 £124,538 Beckman 99th centile £167 0.005 £35,940 
Standard troponin £2,706 11.768    Abbott strategy £204 0.002 £124,538 
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Annual mortality post-MI after re-infarction 
Annual mortality post-MI with re-infarction = 0.137 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,258 11.737 -£440 -0.015 £28,946     
Roche 99th centile £2,302 11.742 -£396 -0.010 £41,341 Abbott 99th centile £44 0.006 £7,797 
Beckman 99th centile £2,328 11.746 -£370 -0.006 £59,144 Roche 99th centile £26 0.003 £7,797 
Roche strategy £2,427 11.746 -£271 -0.006 £48,687 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,494 11.750 -£204 -0.002 £124,721 Beckman 99th centile £167 0.005 £35,999 
Standard troponin £2,698 11.752    Abbott strategy £204 0.002 £124,721 
Annual mortality post-MI with re-infarction = 0.146 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,256 11.731 -£440 -0.015 £28,795     
Roche 99th centile £2,300 11.737 -£396 -0.010 £41,126 Abbott 99th centile £44 0.006 £7,758 
Beckman 99th centile £2,325 11.740 -£370 -0.006 £58,835 Roche 99th centile £26 0.003 £7,758 
Roche strategy £2,424 11.741 -£271 -0.006 £48,433 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,492 11.745 -£204 -0.002 £124,067 Beckman 99th centile £167 0.005 £35,812 
Standard troponin £2,696 11.746    Abbott strategy £204 0.002 £124,067 
 
HR mortality (UA versus NSTEMI) 
HR mortality (UA versus NSTEMI) = 1.053 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,205 11.558 -£440 -0.015 £28,870     
Roche 99th centile £2,249 11.564 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 Extendedly dominated 
Beckman 99th centile £2,274 11.567 -£370 -0.006 £58,988 Abbott 99th centile £70 0.009 £7,777 
Roche strategy £2,374 11.568 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
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Abbott strategy £2,441 11.572 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £2,645 11.573    Abbott strategy £204 0.002 £124,391 
          
HR mortality (UA versus NSTEMI) = 0.581 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,306 11.898 -£440 -0.015 £28,870     
Roche 99th centile £2,349 11.904 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,375 11.907 -£370 -0.006 £58,988 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,474 11.908 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,542 11.912 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £2,746 11.913    Abbott strategy £204 0.002 £124,391 
 
RR mortality (untreated versus treated AMI) 
RR mortality (untreated versus treated AMI) = 3.908 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,224 11.709 -£472 -0.040 £11,771     
Roche 99th centile £2,280 11.724 -£417 -0.025 £16,467 Abbott 99th centile £56 0.015 £3,759 
Beckman 99th centile £2,313 11.733 -£384 -0.017 £23,212 Roche 99th centile £33 0.009 £3,759 
Roche strategy £2,414 11.734 -£283 -0.015 £19,250 Beckman 99th centile £100 0.002 Extendedly dominated 
Abbott strategy £2,490 11.745 -£207 -0.004 £48,054 Beckman 99th centile £176 0.012 £14,443 
Standard troponin £2,697 11.749    Abbott strategy £207 0.004 £48,054 
          
RR mortality (untreated versus treated AMI) = 0.901 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,272 11.746 -£425 -0.003 £128,875     
Roche 99th centile £2,310 11.747 -£387 -0.002 £186,080 Abbott 99th centile £38 0.001 Extendedly dominated 
Beckman 99th centile £2,333 11.748 -£364 -0.001 £268,237 Abbott 99th centile £61 0.002 £31,275 
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Roche strategy £2,431 11.748 -£266 -0.001 £219,979 Beckman 99th centile £98 0.000 Extendedly dominated 
Abbott strategy £2,495 11.749 -£202 0.000 £570,869 Beckman 99th centile £162 0.001 £161,425 
Standard troponin £2,697 11.749    Abbott strategy £202 0.000 £570,869 
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APPENDIX 6: SENSITIVITY ANALYSES (SECONDARY ANALYSIS) 
Deterministic secondary analysis: 
Deterministic secondary analysis         
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.530 -£276 0.036 Dominant     
Roche 99th centile £2,832 11.532 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,858 11.532 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,957 11.535 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,025 11.543 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,047 
Standard troponin £3,064 11.493    Abbott strategy £39 -0.050 Dominated 
 
Increased re-infarction & mortality risk for no treatment (vs treated) = lifetime (instead of only during the first year after presentation at ED) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.473 -£286 0.089 Dominant     
Roche 99th centile £2,833 11.496 -£242 0.113 Dominant Abbott 99th centile £43 0.023 £1,853 
Beckman 99th centile £2,858 11.509 -£217 0.126 Dominant Roche 99th centile £26 0.013 £2,017 
Roche strategy £2,957 11.515 -£118 0.131 Dominant Beckman 99th centile £99 0.006 Extendedly dominated 
Abbott strategy £3,025 11.537 -£50 0.154 Dominant Beckman 99th centile £167 0.028 £5,889 
Standard troponin £3,075 11.383    Abbott strategy £50 -0.154 Dominated 
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No doctor on demand, but average waiting time before doctor becomes available is increased with 1, 2 or 3 hours 
Waiting time for doctor / decision pending delay = 1 hour(s) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚs A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,817 11.530 -£275 0.036 Dominant     
Roche 99th centile £2,861 11.532 -£232 0.039 Dominant Abbott 99th centile £44 0.002 £17,587 
Beckman 99th centile £2,887 11.532 -£206 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £3,002 11.535 -£91 0.042 Dominant Roche 99th centile £141 0.003 Extendedly dominated 
Abbott strategy £3,073 11.543 -£20 0.050 Dominant Roche 99th centile £212 0.011 £18,628 
Standard troponin £3,093 11.493    Abbott strategy £20 -0.050 Dominated 
          
Waiting time for doctor / decision pending delay = 2 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,846 11.530 -£275 0.036 Dominant     
Roche 99th centile £2,890 11.532 -£232 0.039 Dominant Abbott 99th centile £44 0.002 £17,586 
Beckman 99th centile £2,915 11.532 -£206 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £3,047 11.535 -£74 0.042 Dominant Roche 99th centile £157 0.003 Extendedly dominated 
Abbott strategy £3,121 11.543 £0 0.050 Dominant Roche 99th centile £232 0.011 £20,326 
Standard troponin £3,121 11.493    Abbott strategy £0 -0.050 Dominated 
          
Waiting time for doctor / decision pending delay = 3 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,875 11.530 -£275 0.036 Dominant     
Roche 99th centile £2,918 11.532 -£231 0.039 Dominant Abbott 99th centile £44 0.002 £17,584 
Beckman 99th centile £2,944 11.532 -£206 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £3,092 11.535 -£58 0.042 Dominant Roche 99th centile £174 0.003 Extendedly dominated 
Standard troponin £3,149 11.493    Roche 99th centile £231 -0.039 Dominated 
Abbott strategy £3,169 11.543 £20 0.050 £390 Roche 99th centile £251 0.011 £22,024 
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Doctor on demand at ED, but average waiting time before doctor becomes available in the general ward is increased with 1, 2 or 3 hours (discharge to 
general ward after 4 hours after presenting at ED) 
Waiting time for doctor / decision pending delay = 1 hour(s) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,790 11.530 -£303 0.036 Dominant     
Roche 99th centile £2,834 11.532 -£259 0.039 Dominant Abbott 99th centile £44 0.002 £17,587 
Beckman 99th centile £2,859 11.532 -£234 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £2,975 11.535 -£118 0.042 Dominant Roche 99th centile £141 0.003 Extendedly dominated 
Abbott strategy £3,046 11.543 -£47 0.050 Dominant Roche 99th centile £212 0.011 £18,628 
Standard troponin £3,093 11.493    Abbott strategy £47 -0.050 Dominated 
          
Waiting time for doctor / decision pending delay = 2 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,791 11.530 -£330 0.036 Dominant     
Roche 99th centile £2,835 11.532 -£286 0.039 Dominant Abbott 99th centile £44 0.002 £17,586 
Beckman 99th centile £2,860 11.532 -£261 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £2,992 11.535 -£129 0.042 Dominant Roche 99th centile £157 0.003 Extendedly dominated 
Abbott strategy £3,066 11.543 -£55 0.050 Dominant Roche 99th centile £232 0.011 £20,326 
Standard troponin £3,121 11.493    Abbott strategy £55 -0.050 Dominated 
          
Waiting time for doctor / decision pending delay = 3 hour(s) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,792 11.530 -£357 0.036 Dominant     
Roche 99th centile £2,836 11.532 -£313 0.039 Dominant Abbott 99th centile £44 0.002 £17,584 
Beckman 99th centile £2,862 11.532 -£288 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £3,010 11.535 -£140 0.042 Dominant Roche 99th centile £174 0.003 Extendedly dominated 
Abbott strategy £3,087 11.543 -£63 0.050 Dominant Roche 99th centile £251 0.011 £22,024 
Standard troponin £3,149 11.493    Abbott strategy £63 -0.050 Dominated 
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Total delay of 1.5 hours 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,746 11.530 -£276 0.036 Dominant     
Roche 99th centile £2,790 11.532 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,815 11.532 -£207 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,890 11.535 -£132 0.042 Dominant Abbott 99th centile £144 0.006 Extendedly dominated 
Abbott strategy £2,953 11.543 -£69 0.050 Dominant Abbott 99th centile £207 0.014 £14,956 
Standard troponin £3,022 11.493    Abbott strategy £69 -0.050 Dominated 
 
MI treatment costs added for patients that were tested false positive 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,841 11.530 -£224 0.036 Dominant     
Abbott strategy  £3,056 11.543 -£9 0.050 Dominant Abbott 99th centile £215 0.014 £15,507 
Standard troponin £3,064 11.493 £0 0.000  Abbott strategy £9 -0.050 Dominated 
Roche 99th centile £3,144 11.532 £80 0.039 £2,065 Abbott strategy £89 -0.011 Dominated 
Roche strategy £3,331 11.535 £267 0.042 £6,360 Abbott strategy £275 -0.008 Dominated 
Beckman 99th centile £3,421 11.532 £356 0.039 £9,142 Abbott strategy £365 -0.011 Dominated 
MI treatment costs added to first year of UA 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £3,212 11.530 -£275 0.036 Dominant     
Roche 99th centile £3,256 11.532 -£231 0.039 Dominant Abbott 99th centile £43 0.002 Extendedly dominated 
Beckman 99th centile £3,281 11.532 -£205 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £3,381 11.535 -£106 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,449 11.543 -£38 0.050 Dominant Abbott 99th centile £236 0.014 £17,048 
Standard troponin £3,487 11.493    Abbott strategy £38 -0.050 Dominated 
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Test costs 
Test costs = £5          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,772 11.530 -£260 0.036 Dominant     
Roche 99th centile £2,816 11.532 -£217 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,841 11.532 -£191 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,931 11.535 -£101 0.042 Dominant Abbott 99th centile £159 0.006 Extendedly dominated 
Abbott strategy £2,997 11.543 -£35 0.050 Dominant Abbott 99th centile £225 0.014 £16,260 
Standard troponin £3,032 11.493    Abbott strategy £35 -0.050 Dominated 
          
Test costs = £40          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,810 11.530 -£295 0.036 Dominant     
Roche 99th centile £2,854 11.532 -£252 0.039 Dominant Abbott 99th centile £44 0.002 £17,586 
Beckman 99th centile £2,879 11.532 -£226 0.039 Dominant Roche 99th centile £26 0.000 Extendedly dominated 
Roche strategy £2,990 11.535 -£115 0.042 Dominant Roche 99th centile £137 0.003 Extendedly dominated 
Abbott strategy £3,060 11.543 -£45 0.050 Dominant Roche 99th centile £207 0.011 £18,141 
Standard troponin £3,105 11.493    Abbott strategy £45 -0.050 Dominated 
AMI treatment costs 
AMI treatment costs = £2,577          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,607 11.530 -£286 0.036 Dominant     
Roche 99th centile £2,641 11.532 -£252 0.039 Dominant Abbott 99th centile £34 0.002 £13,770 
Beckmann 99th centile £2,661 11.532 -£232 0.039 Dominant Roche 99th centile £20 0.000 Extendedly dominated 
Roche strategy £2,759 11.535 -£134 0.042 Dominant Roche 99th centile £118 0.003 Extendedly dominated 
Abbott strategy £2,820 11.543 -£73 0.050 Dominant Roche 99th centile £179 0.011 £15,751 
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Standard troponin £2,893 11.493    Abbott strategy £73 -0.050 Dominated 
          
AMI treatment costs = £4,295          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,971 11.530 -£265 0.036 Dominant     
Roche 99th centile £3,024 11.532 -£212 0.039 Dominant Abbott 99th centile £53 0.002 Extendedly dominated 
Beckmann 99th centile £3,055 11.532 -£181 0.039 Dominant Abbott 99th centile £84 0.003 Extendedly dominated 
Roche strategy £3,155 11.535 -£81 0.042 Dominant Abbott 99th centile £185 0.006 Extendedly dominated 
Abbott strategy £3,230 11.543 -£6 0.050 Dominant Abbott 99th centile £259 0.014 £18,698 
Standard troponin £3,236 11.493    Abbott strategy £6 -0.050 Dominated 
Post-MI health state costs 
Post-MI health state costs (1st year) = £6,791 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,970 11.530 -£276 0.036 Dominant     
Roche 99th centile £3,014 11.532 -£231 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £3,040 11.532 -£205 0.039 Dominant Abbott 99th centile £71 0.003 Extendedly dominated 
Roche strategy £3,139 11.535 -£106 0.042 Dominant Abbott 99th centile £170 0.006 Extendedly dominated 
Abbott strategy £3,208 11.543 -£37 0.050 Dominant Abbott 99th centile £239 0.014 £17,199 
Standard troponin £3,245 11.493    Abbott strategy £37 -0.050 Dominated 
          
Post-MI health state costs (1st year) = £4,879 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,608 11.530 -£275 0.036 Dominant     
Roche 99th centile £2,651 11.532 -£233 0.039 Dominant Abbott 99th centile £43 0.002 Extendedly dominated 
Beckman 99th centile £2,676 11.532 -£207 0.039 Dominant Abbott 99th centile £68 0.003 Extendedly dominated 
Roche strategy £2,775 11.535 -£108 0.042 Dominant Abbott 99th centile £167 0.006 Extendedly dominated 
Abbott strategy £2,842 11.543 -£41 0.050 Dominant Abbott 99th centile £234 0.014 £16,896 
Standard troponin £2,883 11.493    Abbott strategy £41 -0.050 Dominated 
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Utility difference between UA and AMI 
Utility difference between UA and AMI = 0.12 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.572 -£276 0.036 Dominant     
Roche 99th centile £2,832 11.575 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,858 11.575 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,957 11.578 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,025 11.586 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,046 
Standard troponin £3,064 11.536    Abbott strategy £39 -0.050 Dominated 
Utility difference between UA and AMI = -0.10 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.385 -£276 0.036 Dominant     
Roche 99th centile £2,832 11.387 -£232 0.038 Dominant Abbott 99th centile £44 0.003 Extendedly dominated 
Beckman 99th centile £2,858 11.388 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,957 11.391 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,025 11.399 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,051 
Standard troponin £3,064 11.349    Abbott strategy £39 -0.050 Dominated 
 
MI disutility 
MI disutility = -0.059 (age = 45); -0.050 (age = 55); -0.024 (age = 65); -0.006 (age = 75+) 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.531 -£276 0.036 Dominant     
Roche 99th centile £2,832 11.534 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,858 11.534 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,957 11.537 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,025 11.545 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,025 
Standard troponin £3,064 11.495    Abbott strategy £39 -0.050 Dominated 
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MI disutility = -0.061(age = 45); -0.052 (age = 55); -0.026 (age = 65); -0.008 (age = 75+) 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.528 -£276 0.036 Dominant     
Roche 99th centile £2,832 11.530 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,858 11.531 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,957 11.534 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,025 11.542 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,070 
Standard troponin £3,064 11.492    Abbott strategy £39 -0.050 Dominated 
 
Mortality (30-day) treated AMI (decision tree) 
Mortality (30-day) treated AMI = 0.120 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,750 11.504 -£269 0.039 Dominant     
Roche 99th centile £2,790 11.504 -£228 0.039 Dominant Abbott 99th centile £41 0.000 Dominated 
Beckman 99th centile £2,814 11.502 -£205 0.038 Dominant Abbott 99th centile £64 -0.002 Dominated 
Roche strategy £2,913 11.506 -£106 0.041 Dominant Abbott 99th centile £163 0.002 Extendedly dominated 
Abbott strategy £2,979 11.514 -£40 0.049 Dominant Abbott 99th centile £229 0.010 £24,010 
Standard troponin £3,019 11.465    Abbott strategy £40 -0.049 Dominated 
          
Mortality (30-day) treated AMI = 0.074 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,828 11.555 -£282 0.033 Dominant     
Roche 99th centile £2,875 11.560 -£236 0.038 Dominant Abbott 99th centile £47 0.005 £9,175 
Beckman 99th centile £2,902 11.562 -£208 0.040 Dominant Roche 99th centile £28 0.002 £12,967 
Roche strategy £3,002 11.565 -£109 0.043 Dominant Beckman 99th centile £100 0.003 Extendedly dominated 
Abbott strategy £3,072 11.574 -£39 0.051 Dominant Beckman 99th centile £170 0.011 £15,399 
Standard troponin £3,111 11.522    Abbott strategy £39 -0.051 Dominated 
CONFIDENTIAL UNTIL PUBLISHED 
228 
Mortality (30-day) untreated AMI (decision tree) 
Mortality (30-day) untreated AMI = 0.240 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,759 11.503 -£294 0.066 Dominant     
Roche 99th centile £2,813 11.515 -£239 0.079 Dominant Abbott 99th centile £55 0.012 £4,404 
Beckman 99th centile £2,846 11.521 -£207 0.085 Dominant Roche 99th centile £32 0.006 £5,228 
Roche strategy £2,946 11.525 -£106 0.089 Dominant Beckman 99th centile £101 0.004 Extendedly dominated 
Abbott strategy £3,022 11.541 -£30 0.104 Dominant Beckman 99th centile £176 0.019 £9,139 
Standard troponin £3,052 11.436    Abbott strategy £30 -0.104 Dominated 
Mortality (30-day) untreated AMI = 0.000 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,813 11.551 -£262 0.013 Dominant     
Roche 99th centile £2,847 11.545 -£227 0.007 Dominant Abbott 99th centile £35 -0.005 Dominated 
Beckman 99th centile £2,868 11.541 -£206 0.003 Dominant Abbott 99th centile £55 -0.010 Dominated 
Roche strategy £2,966 11.543 -£108 0.005 Dominant Abbott 99th centile £153 -0.008 Dominated 
Abbott strategy £3,028 11.546 -£46 0.008 Dominant Abbott 99th centile £215 -0.005 Dominated 
Standard troponin £3,074 11.538    Abbott 99th centile £262 -0.013 Dominated 
 
Annual re-infarction probability (after initial AMI)  
Annual re-infarction (after initial AMI) = 0.26 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,830 11.515 -£275 0.036 Dominant     
Roche 99th centile £2,873 11.517 -£232 0.039 Dominant Abbott 99th centile £44 0.003 Extendedly dominated 
Beckman 99th centile £2,899 11.517 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,998 11.520 -£107 0.042 Dominant Abbott 99th centile £169 0.006 Extendedly dominated 
Abbott strategy £3,066 11.529 -£39 0.050 Dominant Abbott 99th centile £237 0.014 £16,867 
Standard troponin £3,105 11.478    Abbott strategy £39 -0.050 Dominated 
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Annual re-infarction (after initial AMI) = 0.19 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,747 11.545 -£276 0.036 Dominant     
Roche 99th centile £2,791 11.547 -£233 0.038 Dominant Abbott 99th centile £43 0.002 Extendedly dominated 
Beckman 99th centile £2,817 11.548 -£207 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,916 11.551 -£108 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £2,984 11.559 -£40 0.050 Dominant Abbott 99th centile £236 0.014 £17,241 
Standard troponin £3,023 11.509    Abbott strategy £40 -0.050 Dominated 
RR re-infarction (untreated versus treated) 
RR re-infarction (untreated versus treated) = 5.15 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,791 11.525 -£277 0.036 Dominant     
Roche 99th centile £2,834 11.529 -£234 0.041 Dominant Abbott 99th centile £43 0.004 £10,647 
Beckman 99th centile £2,859 11.531 -£209 0.042 Dominant Roche 99th centile £25 0.001 Extendedly dominated 
Roche strategy £2,958 11.534 -£110 0.045 Dominant Roche 99th centile £124 0.004 Extendedly dominated 
Abbott strategy £3,025 11.543 -£43 0.054 Dominant Roche 99th centile £192 0.014 £14,126 
Standard troponin £3,068 11.489    Abbott strategy £43 -0.054 Dominated 
          
RR re-infarction (untreated versus treated) = 1.28 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,788 11.532 -£275 0.036 Dominant     
Roche 99th centile £2,832 11.533 -£231 0.038 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,858 11.533 -£205 0.038 Dominant Abbott 99th centile £70 0.002 Dominated 
Roche strategy £2,957 11.536 -£106 0.040 Dominant Abbott 99th centile £169 0.004 Extendedly dominated 
Abbott strategy £3,025 11.544 -£38 0.048 Dominant Abbott 99th centile £237 0.012 £19,764 
Standard troponin £3,063 11.496    Abbott strategy £38 -0.048 Dominated 
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Annual post-MI mortality 
Annual post-MI mortality = 0.068 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,779 11.509 -£276 0.036 Dominant     
Roche 99th centile £2,822 11.511 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,848 11.512 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,947 11.514 -£107 0.042 Dominant Abbott 99th centile £169 0.006 Extendedly dominated 
Abbott strategy £3,015 11.523 -£39 0.050 Dominant Abbott 99th centile £237 0.014 £17,036 
Standard troponin £3,054 11.472    Abbott strategy £39 -0.050 Dominated 
Annual post-MI mortality = 0.065 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,799 11.551 -£276 0.036 Dominant     
Roche 99th centile £2,843 11.553 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,868 11.553 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,968 11.556 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,035 11.565 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,059 
Standard troponin £3,075 11.515    Abbott strategy £39 -0.050 Dominated 
 
Annual mortality post-MI after re-infarction 
Annual mortality post-MI with re-infarction = 0.137 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,790 11.532 -£276 0.036 Dominant     
Roche 99th centile £2,834 11.535 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,859 11.535 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,958 11.538 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,026 11.546 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,091 
Standard troponin £3,066 11.496    Abbott strategy £39 -0.050 Dominated 
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Annual mortality post-MI with re-infarction = 0.146 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,788 11.527 -£276 0.036 Dominant     
Roche 99th centile £2,831 11.529 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,857 11.530 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,956 11.533 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,024 11.541 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,005 
Standard troponin £3,063 11.491    Abbott strategy £39 -0.050 Dominated 
 
HR mortality (UA versus NSTEMI) 
HR mortality (UA versus NSTEMI) = 1.053 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,740 11.363 -£276 0.036 Dominant     
Roche 99th centile £2,783 11.365 -£232 0.038 Dominant Abbott 99th centile £44 0.003 Extendedly dominated 
Beckman 99th centile £2,809 11.366 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,908 11.369 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £2,976 11.377 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,051 
Standard troponin £3,015 11.327    Abbott strategy £39 -0.050 Dominated 
HR mortality (UA versus NSTEMI) = 0.581 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,835 11.685 -£275 0.037 Dominant     
Roche 99th centile £2,879 11.688 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,904 11.688 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £3,003 11.691 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,071 11.699 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,044 
Standard troponin £3,111 11.649    Abbott strategy £39 -0.050 Dominated 
RR mortality (untreated versus treated AMI) 
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RR mortality (untreated versus treated AMI) = 3.908 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,757 11.505 -£274 0.042 Dominant     
Roche 99th centile £2,812 11.516 -£219 0.053 Dominant Abbott 99th centile £56 0.012 £4,755 
Beckman 99th centile £2,845 11.522 -£186 0.059 Dominant Roche 99th centile £33 0.006 £5,714 
Roche strategy £2,945 11.526 -£85 0.063 Dominant Beckman 99th centile £101 0.004 Extendedly dominated 
Abbott strategy £3,022 11.541 -£9 0.078 Dominant Beckman 99th centile £177 0.019 £9,476 
Standard troponin £3,031 11.463    Abbott strategy £9 -0.078 Dominated 
          
RR mortality (untreated versus treated AMI) = 0.901 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,804 11.542 -£276 0.034 Dominant     
Roche 99th centile £2,842 11.540 -£238 0.032 Dominant Abbott 99th centile £38 -0.002 Dominated 
Beckman 99th centile £2,865 11.537 -£216 0.029 Dominant Abbott 99th centile £60 -0.004 Dominated 
Roche strategy £2,963 11.540 -£118 0.032 Dominant Abbott 99th centile £159 -0.002 Dominated 
Abbott strategy £3,027 11.545 -£54 0.037 Dominant Abbott 99th centile £223 0.003 £69,543 
Standard troponin £3,081 11.508    Abbott strategy £54 -0.037 Dominated 
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APPENDIX 7: SUBGROUP ANALYSES (BASE CASE) 
Deterministic base case: 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,257 11.734 -£440 -0.015 £28,870     
Roche 99th centile £2,301 11.740 -£396 -0.010 £41,233 Abbott 99th centile £44 0.006 £7,777 
Beckman 99th centile £2,327 11.743 -£370 -0.006 £58,988 Roche 99th centile £26 0.003 £7,777 
Roche strategy £2,426 11.744 -£271 -0.006 £48,559 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,493 11.748 -£204 -0.002 £124,391 Beckman 99th centile £167 0.005 £35,904 
Standard troponin £2,697 11.749    Abbott strategy £204 0.002 £124,391 
 
Age and gender subgroups: 
Females          
Age = 45          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,087 12.853 -£443 -0.016 £27,038     
Roche 99th centile £2,132 12.859 -£398 -0.010 £38,540 Abbott 99th centile £45 0.006 £7,414 
Beckman 99th centile £2,158 12.863 -£372 -0.007 £55,060 Roche 99th centile £27 0.004 £7,414 
Roche strategy £2,258 12.864 -£272 -0.006 £45,357 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,326 12.868 -£204 -0.002 £115,910 Beckman 99th centile £168 0.005 £33,583 
Standard troponin £2,530 12.870    Abbott strategy £204 0.002 £115,910 
          
Age = 55          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,093 10.615 -£443 -0.016 £28,189     
Roche 99th centile £2,138 10.620 -£398 -0.010 £40,181 Abbott 99th centile £45 0.006 Extendedly dominated 
Beckman 99th centile £2,164 10.624 -£372 -0.006 £57,405 Abbott 99th centile £71 0.009 £7,728 
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Roche strategy £2,263 10.624 -£272 -0.006 £47,288 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,332 10.629 -£204 -0.002 £120,850 Beckman 99th centile £168 0.005 £35,013 
Standard troponin £2,536 10.630    Abbott strategy £204 0.002 £120,850 
          
Age = 65          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,087 8.193 -£443 -0.015 £29,368     
Roche 99th centile £2,132 8.199 -£398 -0.010 £41,866 Abbott 99th centile £45 0.006 Extendedly dominated 
Beckman 99th centile £2,158 8.202 -£372 -0.006 £59,816 Abbott 99th centile £71 0.009 £8,044 
Roche strategy £2,258 8.203 -£272 -0.006 £49,272 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,326 8.207 -£204 -0.002 £125,935 Beckman 99th centile £167 0.005 £36,479 
Standard troponin £2,530 8.208    Abbott strategy £204 0.002 £125,935 
          
Age = 75          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,037 5.640 -£442 -0.013 £32,776     
Roche 99th centile £2,082 5.645 -£398 -0.009 £46,745 Abbott 99th centile £45 0.005 Extendedly dominated 
Beckman 99th centile £2,108 5.648 -£371 -0.006 £66,808 Abbott 99th centile £71 0.008 £8,942 
Roche strategy £2,207 5.649 -£272 -0.005 £55,024 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,276 5.652 -£204 -0.001 £140,710 Beckman 99th centile £167 0.004 £40,725 
Standard troponin £2,480 5.654    Abbott strategy £204 0.001 £140,710 
          
Age = 85          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £1,826 3.107 -£437 -0.007 £59,890     
Roche 99th centile £1,869 3.110 -£394 -0.005 £85,736 Abbott 99th centile £43 0.003 Extendedly dominated 
Beckman 99th centile £1,894 3.112 -£369 -0.003 £122,857 Abbott 99th centile £68 0.004 £15,793 
Roche strategy £1,993 3.112 -£270 -0.003 £101,053 Beckman 99th centile £99 0.000 Extendedly dominated 
Abbott strategy £2,059 3.114 -£203 -0.001 £259,592 Beckman 99th centile £166 0.002 £74,597 
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Standard troponin £2,263 3.115    Abbott strategy £203 0.001 £259,592 
          
Males          
Age = 45          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,404 14.047 -£438 -0.015 £28,815     
Roche 99th centile £2,447 14.053 -£395 -0.010 £41,214 Abbott 99th centile £43 0.006 £7,660 
Beckman 99th centile £2,472 14.056 -£370 -0.006 £59,021 Roche 99th centile £25 0.003 £7,660 
Roche strategy £2,571 14.057 -£271 -0.006 £48,561 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,638 14.061 -£204 -0.002 £124,616 Beckman 99th centile £166 0.005 £35,870 
Standard troponin £2,842 14.062    Abbott strategy £204 0.002 £124,616 
          
Age = 55          
 Costs QALYs A?osts A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,407 11.852 -£438 -0.014 £30,338     
Roche 99th centile £2,450 11.857 -£395 -0.009 £43,396 Abbott 99th centile £43 0.005 Extendedly dominated 
Beckman 99th centile £2,476 11.860 -£370 -0.006 £62,149 Abbott 99th centile £68 0.008 £8,059 
Roche strategy £2,575 11.861 -£271 -0.005 £51,134 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,642 11.865 -£204 -0.002 £131,231 Beckman 99th centile £166 0.004 £37,768 
Standard troponin £2,845 11.866    Abbott strategy £204 0.002 £131,231 
          
Age = 65          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,371 9.384 -£438 -0.013 £32,627     
Roche 99th centile £2,413 9.389 -£395 -0.008 £46,682 Abbott 99th centile £43 0.005 Extendedly dominated 
Beckman 99th centile £2,439 9.392 -£369 -0.006 £66,867 Abbott 99th centile £68 0.008 £8,647 
Roche strategy £2,538 9.392 -£270 -0.005 £55,011 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,605 9.396 -£203 -0.001 £141,222 Beckman 99th centile £166 0.004 £40,624 
Standard troponin £2,808 9.397    Abbott strategy £203 0.001 £141,222 
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Age = 75          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,253 6.574 -£437 -0.011 £39,186     
Roche 99th centile £2,295 6.578 -£394 -0.007 £56,106 Abbott 99th centile £42 0.004 Extendedly dominated 
Beckman 99th centile £2,320 6.581 -£369 -0.005 £80,406 Abbott 99th centile £68 0.007 £10,317 
Roche strategy £2,419 6.581 -£270 -0.004 £66,133 Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,486 6.584 -£203 -0.001 £169,919 Beckman 99th centile £166 0.003 £48,814 
Standard troponin £2,689 6.585    Abbott strategy £203 0.001 £169,919 
          
Age = 85          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £1,940 3.634 -£429 -0.004 £114,585     
Roche 99th centile £1,980 3.635 -£389 -0.002 £164,917 Abbott 99th centile £40 0.001 Extendedly dominated 
Beckman 99th centile £2,004 3.636 -£366 -0.002 £237,203 Abbott 99th centile £63 0.002 £28,711 
Roche strategy £2,102 3.636 -£267 -0.001 £194,744 Beckman 99th centile £99 0.000 Extendedly dominated 
Abbott strategy £2,167 3.637 -£203 0.000 £503,476 Beckman 99th centile £163 0.001 £143,225 
Standard troponin £2,369 3.638    Abbott strategy £203 0.000 £503,476 
 
Subgroup with history of previous NSTEMIa 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £4,643 5.764 -£472 -0.019 £25,031     
Roche 99th centile £4,699 5.771 -£417 -0.012 £35,017 Abbott 99th centile £56 0.007 Extendedly dominated 
Beckman 99th centile £4,732 5.775 -£384 -0.008 £49,358 Abbott 99th centile £89 0.011 £7,994 
Roche strategy £4,834 5.776 -£281 -0.007 £40,639 Beckman 99th centile £103 0.001 Extendedly dominated 
Abbott strategy £4,910 5.781 -£205 -0.002 £101,225 Beckman 99th centile £178 0.006 £31,052 
Standard troponin £5,115 5.783    Abbott strategy £205 0.002 £101,225 
a
 Based on an AMI prevalence of 20% (see Appendix 9) 
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MI prevalence 
MI prevalence = 1%          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £576 12.891 -£439 -0.005 £96,456     
Abbott 99th centile £687 12.894 -£329 -0.001 £366,354 No testing £111 0.004 Extendedly dominated 
Roche 99th centile £690 12.895 -£326 -0.001 £576,522 No testing £113 0.004 Extendedly dominated 
Beckman 99th centile £691 12.895 -£324 0.000 £878,364 No testing £115 0.004 £27,409 
Roche strategy £774 12.895 -£241 0.000 £734,155 Beckman 99th centile £83 0.000 Extendedly dominated 
Abbott strategy £813 12.895 -£202 0.000 £2,097,914 Beckman 99th centile £122 0.000 £447,934 
Standard troponin £1,016 12.895    Abbott strategy £202 0.000 £2,097,914 
          
MI prevalence = 5%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £855 12.586 -£581 -0.023 £25,513     
Abbott 99th centile £1,079 12.604 -£356 -0.004 £79,492 No testing £224 0.018 Extendedly dominated 
Roche 99th centile £1,092 12.606 -£344 -0.003 £121,526 No testing £237 0.020 Extendedly dominated 
Beckman 99th centile £1,100 12.607 -£336 -0.002 £181,894 No testing £245 0.021 £11,703 
Roche strategy £1,187 12.607 -£249 -0.002 £151,398 Beckman 99th centile £87 0.000 Extendedly dominated 
Abbott strategy £1,233 12.608 -£203 0.000 £420,420 Beckman 99th centile £133 0.001 £97,709 
Standard troponin £1,436 12.609    Abbott strategy £203 0.000 £420,420 
          
MI prevalence = 10%          
 Costs QALYs A?osts A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £1,204 12.205 -£758 -0.046 £16,645     
Abbott 99th centile £1,570 12.242 -£391 -0.009 £43,635 No testing £366 0.037 Extendedly dominated 
Roche 99th centile £1,596 12.245 -£366 -0.006 £64,651 No testing £392 0.040 Extendedly dominated 
Beckman 99th centile £1,611 12.247 -£350 -0.004 £94,836 No testing £407 0.042 £9,740 
Roche strategy £1,703 12.247 -£258 -0.003 £78,554 Beckman 99th centile £92 0.000 Extendedly dominated 
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Abbott strategy £1,758 12.250 -£203 -0.001 £210,733 Beckman 99th centile £147 0.003 £53,931 
Standard troponin £1,961 12.251    Abbott strategy £203 0.001 £210,733 
          
MI prevalence = 20%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?Costs A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £1,900 11.443 -£1,112 -0.091 £12,211     
Abbott 99th centile £2,551 11.516 -£461 -0.018 £25,706 No testing £651 0.073 Extendedly dominated 
Roche 99th centile £2,603 11.523 -£410 -0.011 £36,214 No testing £702 0.080 Extendedly dominated 
Beckman 99th centile £2,633 11.527 -£379 -0.007 £51,306 No testing £733 0.084 £8,759 
Roche strategy £2,735 11.528 -£277 -0.007 £42,131 Beckman 99th centile £102 0.001 Extendedly dominated 
Abbott strategy £2,808 11.532 -£204 -0.002 £105,889 Beckman 99th centile £175 0.005 £32,042 
Standard troponin £3,012 11.534    Abbott strategy £204 0.002 £105,889 
          
MI prevalence = 30%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £2,597 10.681 -£1,466 -0.137 £10,733     
Abbott 99th centile £3,532 10.791 -£531 -0.027 £19,730 No testing £935 0.110 Extendedly dominated 
Roche 99th centile £3,610 10.801 -£454 -0.017 £26,735 No testing £1,012 0.120 Extendedly dominated 
Beckman 99th centile £3,655 10.807 -£408 -0.011 £36,797 No testing £1,058 0.125 £8,431 
Roche strategy £3,767 10.808 -£296 -0.010 £29,991 Beckman 99th centile £112 0.001 Extendedly dominated 
Abbott strategy £3,858 10.815 -£205 -0.003 £70,942 Beckman 99th centile £203 0.008 £24,745 
Standard troponin £4,063 10.818    Abbott strategy £205 0.003 £70,942 
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APPENDIX 8: SUBGROUP ANALYSES (SECONDARY ANALYSIS) 
Deterministic secondary analysis: 
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,789 11.530 -£276 0.036 Dominant     
Roche 99th centile £2,832 11.532 -£232 0.039 Dominant Abbott 99th centile £44 0.002 Extendedly dominated 
Beckman 99th centile £2,858 11.532 -£206 0.039 Dominant Abbott 99th centile £69 0.003 Extendedly dominated 
Roche strategy £2,957 11.535 -£107 0.042 Dominant Abbott 99th centile £168 0.006 Extendedly dominated 
Abbott strategy £3,025 11.543 -£39 0.050 Dominant Abbott 99th centile £236 0.014 £17,047 
Standard troponin £3,064 11.493    Abbott strategy £39 -0.050 Dominated 
 
Age and gender subgroups: 
Females          
Age = 45          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?Costs A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,602 12.547 -£276 0.042 Dominant     
Roche 99th centile £2,647 12.549 -£231 0.044 Dominant Abbott 99th centile £45 0.003 Extendedly dominated 
Beckman 99th centile £2,673 12.550 -£205 0.044 Dominant Abbott 99th centile £71 0.003 Extendedly dominated 
Roche strategy £2,773 12.553 -£105 0.048 Dominant Abbott 99th centile £170 0.006 Extendedly dominated 
Abbott strategy £2,841 12.562 -£37 0.057 Dominant Abbott 99th centile £239 0.015 £16,023 
Standard troponin £2,878 12.505    Abbott strategy £37 -0.057 Dominated 
          
Age = 55          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,605 10.407 -£276 0.034 Dominant     
Roche 99th centile £2,650 10.410 -£231 0.037 Dominant Abbott 99th centile £45 0.003 £15,224 
Beckman 99th centile £2,676 10.410 -£205 0.038 Dominant Roche 99th centile £26 0.001 Extendedly dominated 
Roche strategy £2,776 10.413 -£105 0.040 Dominant Roche 99th centile £126 0.003 Extendedly dominated 
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Abbott strategy £2,844 10.421 -£37 0.048 Dominant Roche 99th centile £194 0.011 £17,150 
Standard troponin £2,881 10.373    Abbott strategy £37 -0.048 Dominated 
          
Age = 65          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,592 8.089 -£276 0.025 Dominant     
Roche 99th centile £2,637 8.092 -£232 0.029 Dominant Abbott 99th centile £45 0.003 £13,064 
Beckman 99th centile £2,663 8.094 -£205 0.030 Dominant Roche 99th centile £26 0.001 Extendedly dominated 
Roche strategy £2,762 8.096 -£106 0.032 Dominant Roche 99th centile £126 0.003 Extendedly dominated 
Abbott strategy £2,831 8.103 -£37 0.039 Dominant Roche 99th centile £194 0.010 £18,999 
Standard troponin £2,868 8.064    Abbott strategy £37 -0.039 Dominated 
          
Age = 75          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,521 5.618 -£278 0.015 Dominant     
Roche 99th centile £2,565 5.621 -£234 0.019 Dominant Abbott 99th centile £44 0.004 £12,392 
Beckman 99th centile £2,592 5.623 -£207 0.021 Dominant Roche 99th centile £26 0.002 £16,407 
Roche strategy £2,691 5.625 -£108 0.022 Dominant Beckman 99th centile £99 0.002 Extendedly dominated 
Abbott strategy £2,759 5.630 -£40 0.028 Dominant Beckman 99th centile £168 0.007 £24,020 
Standard troponin £2,799 5.602    Abbott strategy £40 -0.028 Dominated 
          
Age = 85          
 Costs QALYs A?ŽƐƚƐ A?Y>Ys A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,250 3.104 -£289 0.002 Dominant     
Roche 99th centile £2,292 3.106 -£247 0.004 Dominant Abbott 99th centile £42 0.002 £21,140 
Beckman 99th centile £2,317 3.107 -£222 0.005 Dominant Roche 99th centile £25 0.001 £26,911 
Roche strategy £2,416 3.108 -£123 0.006 Dominant Beckman 99th centile £99 0.001 Extendedly dominated 
Abbott strategy £2,483 3.111 -£56 0.009 Dominant Beckman 99th centile £166 0.004 £45,709 
Standard troponin £2,539 3.102    Abbott strategy £56 -0.009 Dominated 
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Males          
Age = 45          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,958 13.801 -£275 0.042 Dominant     
Roche 99th centile £3,000 13.803 -£233 0.044 Dominant Abbott 99th centile £43 0.002 Extendedly dominated 
Beckman 99th centile £3,026 13.803 -£207 0.044 Dominant Abbott 99th centile £68 0.002 Dominated 
Roche strategy £3,125 13.806 -£108 0.047 Dominant Abbott 99th centile £167 0.005 Extendedly dominated 
Abbott strategy £3,192 13.815 -£41 0.056 Dominant Abbott 99th centile £235 0.014 £16,897 
Standard troponin £3,233 13.759    Abbott strategy £41 -0.056 Dominated 
          
Age = 55          
 Costs QALYs A?ŽƐƚƐ A?QALYs A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,954 11.689 -£276 0.035 Dominant     
Roche 99th centile £2,997 11.691 -£233 0.037 Dominant Abbott 99th centile £43 0.002 Extendedly dominated 
Beckman 99th centile £3,022 11.691 -£208 0.037 Dominant Abbott 99th centile £68 0.002 Dominated 
Roche strategy £3,121 11.694 -£109 0.040 Dominant Abbott 99th centile £167 0.005 Extendedly dominated 
Abbott strategy £3,188 11.702 -£41 0.048 Dominant Abbott 99th centile £234 0.013 £17,836 
Standard troponin £3,230 11.654    Abbott strategy £41 -0.048 Dominated 
          
Age = 65          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,902 9.306 -£276 0.026 Dominant     
Roche 99th centile £2,945 9.309 -£234 0.029 Dominant Abbott 99th centile £43 0.003 £16,877 
Beckman 99th centile £2,970 9.310 -£209 0.029 Dominant Roche 99th centile £25 0.001 Extendedly dominated 
Roche strategy £3,069 9.312 -£110 0.032 Dominant Roche 99th centile £124 0.003 Extendedly dominated 
Abbott strategy £3,136 9.319 -£42 0.039 Dominant Roche 99th centile £191 0.010 £19,851 
Standard troponin £3,179 9.280    Abbott strategy £42 -0.039 Dominated 
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Age = 75          
 Costs QALYs A?ŽƐƚƐ A?Y>Ys A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,752 6.560 -£278 0.017 Dominant     
Roche 99th centile £2,795 6.563 -£236 0.019 Dominant Abbott 99th centile £42 0.002 £16,994 
Beckman 99th centile £2,819 6.563 -£211 0.020 Dominant Roche 99th centile £25 0.001 Extendedly dominated 
Roche strategy £2,918 6.565 -£112 0.022 Dominant Roche 99th centile £124 0.003 Extendedly dominated 
Abbott strategy £2,985 6.570 -£45 0.027 Dominant Roche 99th centile £191 0.008 £25,149 
Standard troponin £3,030 6.543    Abbott strategy £45 -0.027 Dominated 
          
Age = 85          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Abbott 99th centile £2,374 3.631 -£283 0.006 Dominant     
Roche 99th centile £2,414 3.631 -£244 0.007 Dominant Abbott 99th centile £40 0.001 Extendedly dominated 
Beckman 99th centile £2,437 3.631 -£220 0.007 Dominant Abbott 99th centile £63 0.001 Extendedly dominated 
Roche strategy £2,536 3.632 -£122 0.007 Dominant Abbott 99th centile £162 0.001 Extendedly dominated 
Abbott strategy £2,601 3.634 -£57 0.010 Dominant Abbott 99th centile £227 0.003 £66,418 
Standard troponin £2,657 3.624    Abbott strategy £57 -0.010 Dominated 
 
MI prevalence 
MI prevalence = 1%          
Strategy   Compared to Standard troponin Compared to next best strategy 
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £1,072 12.546 -£439 -0.005 £96,456     
Abbott 99th centile £1,405 12.619 -£106 0.068 Dominant No testing £333 0.073 £4,563 
Roche 99th centile £1,407 12.615 -£104 0.064 Dominant Abbott 99th centile £2 -0.004 Dominated 
Beckman 99th centile £1,408 12.611 -£103 0.061 Dominant Abbott 99th centile £3 -0.008 Dominated 
Roche strategy £1,492 12.614 -£20 0.064 Dominant Abbott 99th centile £87 -0.005 Dominated 
Standard troponin £1,511 12.550    Abbott 99th centile £106 -0.068 Dominated 
Abbott strategy £1,531 12.620 £20 0.070 £290 Abbott 99th centile £126 0.001 £109,991 
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MI prevalence = 5%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £1,316 12.265 -£581 -0.023 £25,513     
Abbott 99th centile £1,747 12.348 -£150 0.060 Dominant No testing £431 0.083 £5,209 
Roche 99th centile £1,759 12.346 -£137 0.058 Dominant Abbott 99th centile £13 -0.002 Dominated 
Beckman 99th centile £1,766 12.343 -£130 0.055 Dominant Abbott 99th centile £20 -0.005 Dominated 
Roche strategy £1,854 12.346 -£43 0.058 Dominant Abbott 99th centile £107 -0.002 Dominated 
Standard troponin £1,897 12.288    Abbott 99th centile £150 -0.060 Dominated 
Abbott strategy £1,900 12.352 £4 0.064 £61 Abbott 99th centile £154 0.004 £35,574 
          
MI prevalence = 10%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £1,623 11.913 -£758 -0.046 £16,645     
Abbott 99th centile £2,178 12.008 -£203 0.050 Dominant No testing £554 0.095 £5,820 
Roche 99th centile £2,203 12.008 -£178 0.049 Dominant Abbott 99th centile £25 0.000 Dominated 
Beckman 99th centile £2,218 12.006 -£163 0.048 Dominant Abbott 99th centile £40 -0.002 Dominated 
Roche strategy £2,311 12.009 -£71 0.051 Dominant Abbott 99th centile £133 0.001 Extendedly dominated 
Abbott strategy £2,366 12.017 -£15 0.058 Dominant Abbott 99th centile £188 0.008 £22,684 
Standard troponin £2,381 11.958    Abbott strategy £15 -0.058 Dominated 
          
MI prevalence = 20%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £2,247 11.202 -£1,112 -0.091 £12,211     
Abbott 99th centile £3,053 11.324 -£306 0.031 Dominant No testing £806 0.122 £6,625 
Roche 99th centile £3,104 11.327 -£255 0.034 Dominant Abbott 99th centile £51 0.004 £14,063 
Beckman 99th centile £3,135 11.328 -£224 0.035 Dominant Roche 99th centile £30 0.001 Extendedly dominated 
Roche strategy £3,237 11.331 -£122 0.038 Dominant Roche 99th centile £132 0.004 Extendedly dominated 
Abbott strategy £3,310 11.340 -£49 0.047 Dominant Roche 99th centile £206 0.013 £16,319 
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Standard troponin £3,359 11.293    Abbott strategy £49 -0.047 Dominated 
          
MI prevalence = 30%          
 Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ Comparator A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
No testing £2,880 10.484 -£1,466 -0.137 £10,733     
Abbott 99th centile £3,942 10.634 -£404 0.013 Dominant No testing £1,062 0.149 £7,109 
Roche 99th centile £4,019 10.641 -£327 0.020 Dominant Abbott 99th centile £77 0.008 £10,278 
Beckman 99th centile £4,065 10.645 -£281 0.024 Dominant Roche 99th centile £46 0.004 £12,899 
Roche strategy £4,177 10.648 -£169 0.027 Dominant Beckman 99th centile £112 0.003 Extendedly dominated 
Abbott strategy £4,268 10.658 -£78 0.037 Dominant Beckman 99th centile £203 0.013 £15,410 
Standard troponin £4,346 10.621    Abbott strategy £78 -0.037 Dominated 
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APPENDIX 9: SUBGROUP ANALYSES BASED ON ACCURACY AND AMI PREVALENCE (ONLY AVAILABLE FOR THE ROCHE 99TH CENTILE TEST) 
Base case MI prevalence Roche 99th centile Standard troponin Increments 
  Costs QALYs Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Base case 17% £2,301 11.740 £2,697 11.749 -£396 -0.010 £41,233 
ŐĞA? ? ?b 28% £3,411 10.946 £3,853 10.961 -£442 -0.015 £28,633 
Age >70
c
 10% £1,550 6.274 £1,880 6.275 -£330 -0.001 £355,571 
With pre-existing CAD 20% £2,641 11.528 £3,012 11.534 -£371 -0.006 £58,509 
Without pre-existing CAD 16% £2,236 11.816 £2,592 11.821 -£356 -0.004 £80,454 
Symptom onset < 3 hours 22% £2,726 11.369 £3,222 11.391 -£496 -0.022 £22,111 
Symptom onset > 3 hours 13% £1,929 12.032 £2,277 12.036 -£348 -0.003 £103,107 
Symptom onset < 3 hours 17% £2,241 11.732 £2,697 11.749 -£456 -0.017 £26,327 
Symptom onset > 3 hours 17% £2,341 11.745 £2,697 11.749 -£356 -0.004 £80,677 
     
Secondary analysis MI prevalence Roche 99th centile Standard troponin Increments 
  Costs QALYs Costs QALYs A?ŽƐƚƐ A?Y>zƐ A?ŽƐƚƐ ?A?Y>zƐ 
Base case 17% £2,832 11.532 £3,064 11.493 -£232 0.039 Dominant 
ŐĞA? ? ?b 28% £3,839 10.780 £4,148 10.756 -£310 0.024 Dominant 
Age >70
c
 10% £2,111 6.245 £2,259 6.222 -£148 0.023 Dominant 
With pre-existing CAD 20% £3,142 11.325 £3,359 11.293 -£217 0.031 Dominant 
Without pre-existing CAD 16% £2,778 11.604 £2,967 11.560 -£189 0.044 Dominant 
Symptom onset < 3 hours 22% £3,209 11.180 £3,556 11.159 -£347 0.021 Dominant 
Symptom onset > 3 hours 13% £2,503 11.806 £2,673 11.760 -£171 0.046 Dominant 
Symptom onset < 3 hours 17% £2,772 11.524 £3,064 11.493 -£292 0.031 Dominant 
Symptom onset > 3 hours 17% £2,873 11.535 £3,064 11.493 -£192 0.042 Dominant 
a
 The two studies presenting data on subgroups 
67, 75
 were both conducted in patients in whom NSTEMI had not been excluded. They were not at specifically high or low risk of AMI. We 
calibrated the prevalence (obtained from these studies) in the subgroup to be adapted to a population with a prevalence of 17% (see below). 
b
 Average age = 53 (base case value) 
c
 Average age = 75  
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AMI prevalence in subgroups 
Subgroup 
Prevalence of AMI (x) 
Prevalence of AMI in whole 
population from subgroups 
were derived (y) 
Prevalence assuming population 
prevalence of 17% (multiple 
x*y/17) 
Source 
Age<70 years 24% 15% 28% APACE
52, 75
 
Age>70 years 9% 15% 10% APACE
52, 75
 
Patients with CAD 18% 16% 20% APACE 
46, 75
 
Patients without CAD 14% 16% 16% APACE 
46, 75
 
<3 hours from symptoms
67
 24% 18% 22% APACE,
75
Body (2011)
67
 
>3 hours from symptoms
67
 14% 18% 13% APACE,
75
Body (2011)
67
 
<3 hours from symptoms
75
 21% 21% 17% APACE,
75
Body (2011)
67
 
>3 hours from symptoms
75
 21% 21% 17% APACE,
75
Body (2011)
67
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APPENDIX 10: NICE GUIDANCE RELEVANT TO THE MANAGEMENT OF SUPECTED ACS 
MI  W secondary prevention: secondary prevention in primary and secondary for patients following a 
myocardial infarction. NICE clinical guideline CG172 (2013). Available from: 
http://guidance.nice.org.uk/CG172. Date for review: not stated 
Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of 
suspected cardiac origin. NICE clinical Guideline CG95 (2010). Available from: 
http://www.nice.org.uk/guidance/CG95. Reviewed March 2013, review recommended.  
Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-
elevation myocardial infarction. NICE clinical guideline CG94 (2010).  Available from: 
http://www.nice.org.uk/guidance/CG94. Last modified November 2013.  
BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain. NICE 
medical technology guidance MTG4 (2011). Available from: http://guidance.nice.org.uk/MTG4. Date 
for review: not stated. 
Myocardial Infarction with ST-segment elevation: the acute management of myocardial infarction 
with ST-segment elevation. NICE clinical guideline CG167 (2013). Available from: 
http://guidance.nice.org.uk/CG167. Date for review: not stated. 
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APPENDIX 11: PRISMA CHECK LIST 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  pg 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
Executive summary (pg 12-16) 
PROSPERO registration (pg 2) 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Background (Section 2, pg 19-26) 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
Objectives (Section 1, pg 18) 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
PROSPERO: CRD42013005939 
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Table 2 (pg 30) 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
Section 3.1.1 (pg 27-29) 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
Appendix 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Section 3.1.3 (pg 31) 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
Section 3.1.3 (pg 31) 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
Section 3.1.3 (pg 31) 
Full data extraction tables: 
Appendix 2 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
Section 3.1.4 (pg 31) 
Full QUADAS-2 tables: Appendix 3 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Section 3.1.5 (pg 31-33) 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
Section 3.1.5 (pg 31-33) 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
NA 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
Section 3.1.5 (pg 31-33) 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Figure 1 (pg 34) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
Section 3.2.3.1 (pg 38), section 
3.2.4.1 (pg 51), section 3.2.5.1 (pg 
56). 
Full data extraction tables: 
Appendix 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Section 3.2.2 (pg 35-37) 
Full QUADAS-2 tables: Appendix 3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Appendix 2, Table c 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figures 3-5 (pg 39-40), Table 4 (pg 
47), Table 5 (pg 54), Table 6 (pg 58) 
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Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  NA 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
Table 4 (pg 47), Table 5 (pg 54), 
Table 6 (pg 58) 
DISCUSSION   
Summary of evidence  24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Section 5.1 (pg 102-107) 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
Sections 5.2 and 5.3 (pg 107-114) 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
Section 6 (pg 115-116) 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
pg 2 
  
 
 
 
 
 
 
 
